



Universiteit  
Leiden  
The Netherlands

## 2023 ESC Guidelines for the management of endocarditis

Delgado, V.; Marsan, N.; Waha, S. de; Bonaros, N.; Brida, M.; Burri, H.; ... ; ESC Sci Document Grp

### Citation

Delgado, V., Marsan, N., Waha, S. de, Bonaros, N., Brida, M., Burri, H., ... Borger, M. A. (2023). 2023 ESC Guidelines for the management of endocarditis. *European Heart Journal*, 44(39), 3948-4042. doi:10.1093/eurheartj/ehad193

Version: Publisher's Version

License: [Licensed under Article 25fa Copyright Act/Law \(Amendment Taverne\)](#)

Downloaded from: <https://hdl.handle.net/1887/3722059>

**Note:** To cite this publication please use the final published version (if applicable).

# 2023 ESC Guidelines for the management of endocarditis

Developed by the task force on the management of endocarditis of the European Society of Cardiology (ESC)

Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Nuclear Medicine (EANM)

**Authors/Task Force Members:** Victoria Delgado  \*<sup>†</sup>, (Chairperson) (Spain), Nina Ajmone Marsan  <sup>‡</sup>, (Task Force Co-ordinator) (Netherlands), Suzanne de Waha <sup>‡</sup>, (Task Force Co-ordinator) (Germany), Nikolaos Bonaros  (Austria), Margarita Brida  (Croatia), Haran Burri  (Switzerland), Stefano Caselli  (Switzerland), Torsten Doenst  (Germany), Stephane Ederhy  (France), Paola Anna Erba  <sup>1</sup> (Italy), Dan Foldager (Denmark), Emil L. Fosbøl  (Denmark), Jan Kovac (United Kingdom), Carlos A. Mestres  (South Africa), Owen I. Miller  (United Kingdom), Jose M. Miro  <sup>2</sup> (Spain), Michal Pazdernik  (Czech Republic), Maria Nazarena Pizzi  (Spain), Eduard Quintana  <sup>3</sup> (Spain), Trine Bernholdt Rasmussen  (Denmark), Arsen D. Ristić  (Serbia), Josep Rodés-Cabau (Canada), Alessandro Sionis  (Spain), Liesl Joanna Zühlke  (South Africa), Michael A. Borger  \*<sup>†</sup>, (Chairperson) (Germany), and ESC Scientific Document Group

\* Corresponding authors: Victoria Delgado, Cardiology, Hospital University Germans Trias i Pujol, Badalona, Spain, and Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain. Tel: +34 934 65 12 00, E-mail: videlga@gmail.com; and Michael A. Borger, University Department of Cardiac Surgery, Leipzig Heart Center, Leipzig, Germany. Tel: +49-341-865-0, E-mail: Michael.Borger@helios-gesundheit.de

<sup>†</sup> The two Chairpersons contributed equally to the document and are joint corresponding authors.

<sup>‡</sup> The two Task Force Co-ordinators contributed equally to the document.

**Author/Task Force Member affiliations are listed in author information.**

<sup>1</sup> Representing the European Association of Nuclear Medicine (EANM)

<sup>2</sup> Representing the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

<sup>3</sup> Representing the European Association for Cardio-Thoracic Surgery (EACTS)

**ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.**

**ESC subspecialty communities having participated in the development of this document:**

**Associations:** Association of Cardiovascular Nursing & Allied Professions (ACNAP), Association for Acute CardioVascular Care (ACVCC), European Association of Cardiovascular Imaging (EACVI), European Association of Preventive Cardiology (EAPC), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), and Heart Failure Association (HFA).

**Councils:** Council for Cardiology Practice, Council on Stroke.

**Working Groups:** Adult Congenital Heart Disease, Cardiovascular Surgery.

**Patient Forum**

The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford University Press, the publisher of the *European Heart Journal* and the party authorized to handle such permissions on behalf of the ESC ([journals.permissions@oup.com](mailto:journals.permissions@oup.com)).

© The European Society of Cardiology 2023. All rights reserved. For permissions please e-mail: [journals.permissions@oup.com](mailto:journals.permissions@oup.com).

**Document Reviewers:** Bernard Lung, (CPG Review Co-ordinator) (France), Bernard Prendergast, (CPG Review Co-ordinator) (United Kingdom), Magdy Abdelhamid (Egypt), Marianna Adamo (Italy), Riccardo Asteggiano (Italy), Larry M. Baddour (United States of America), Jelena Čelutkienė (Lithuania), John Chambers (United Kingdom), Jean-Claude Deharo (France), Wolfram Doehner (Germany), Laura Dos Subira (Spain), Xavier Duval (France), Volkmar Falk (Germany), Laurent Fauchier (France), Nuria Fernandez-Hidalgo (Spain), Christian Giske<sup>2</sup> (Sweden), Anežka Gombošová (Czechia), Gilbert Habib (France), Borja Ibanez (Spain), Tiny Jaarsma (Sweden), Lars Køber (Denmark), Konstantinos C. Koskinas (Switzerland), Dipak Kotecha (United Kingdom), Ulf Landmesser (Germany), Sandra B. Lauck (Canada), Basil S. Lewis (Israel), Maja-Lisa Løchen (Norway), John William McEvoy (Ireland), Borislava Mihaylova (United Kingdom), Richard Mindham (United Kingdom), Lis Neubeck (United Kingdom), Jens Cosedis Nielsen (Denmark), Jean-François Obadia (France), Agnes A. Pasquet (Belgium), Steffen Petersen (United Kingdom), Eva Prescott (Denmark), Susanna Price (United Kingdom), Amina Rakisheva (Kazakhstan), Archana Rao (United Kingdom), François Rouzet (France), Jonathan Sandoe (United Kingdom), Renate B. Schnabel (Germany), Christine Selton-Suty (France), Lars Sondergaard (Denmark), Martin Thornhill (United Kingdom), Konstantinos Toutouzas (Greece), Nico Van de Veire (Belgium), Isidre Vilacosta (Spain), Christiaan Vrints (Belgium), and Olaf Wendler (United Kingdom)

All experts involved in the development of these guidelines have submitted declarations of interest. These have been compiled in a report and simultaneously published in a supplementary document to the guidelines. The report is also available on the ESC website [www.escardio.org/Guidelines](http://www.escardio.org/Guidelines)

**SD** See the *European Heart Journal* online for supplementary documents that include background information and evidence tables.

## Keywords

Guidelines • Antibiotics • Cardiac imaging • Cardiac implantable electronic device • Cardiac surgery • Complications • Computed tomography • Congenital heart disease • Diagnosis • Echocardiography • Endocarditis • Infection • Nuclear imaging • Positron emission tomography • Prevention • Prognosis • Prosthetic heart valve • Valve disease

## Table of contents

1. Preamble .....	3953	5.3.1. Blood culture-positive infective endocarditis .....	3966
2. Introduction .....	3955	5.3.2. Blood culture-negative infective endocarditis .....	3966
2.1. What is new .....	3955	5.3.3. Proposed strategy for a microbiological diagnostic algorithm in suspected infective endocarditis .....	3967
3. Prevention .....	3959	5.4. Imaging techniques .....	3967
3.1. Rationale .....	3959	5.4.1. Echocardiography .....	3967
3.2. Populations at risk of infective endocarditis .....	3960	5.4.2. Computed tomography .....	3969
3.3. Situations and procedures at risk .....	3961	5.4.3. Magnetic resonance imaging .....	3969
3.3.1. Dental procedures .....	3961	5.4.4. Nuclear imaging positron emission tomography/ computed tomography (angiography) and single photon emission tomography/computed tomography .....	3970
3.3.2. Non-dental procedures .....	3961	5.5. Diagnostic criteria .....	3971
3.3.3. Cardiac or vascular interventions .....	3962	5.5.1. Modifications for the diagnosis of infective endocarditis .....	3971
3.4. Patient education .....	3962	5.5.1.1. Major criteria – microbiology .....	3973
4. The Endocarditis Team .....	3963	5.5.1.2. Major criteria – imaging .....	3973
5. Diagnosis .....	3965	5.5.1.3. Minor criteria .....	3974
5.1. Clinical features .....	3965	5.5.1.4. Microbiological criteria .....	3974
5.2. Laboratory findings .....	3966	5.5.1.5. Infective endocarditis classification .....	3975
5.3. Microbiological diagnosis .....	3966		

**Disclaimer.** The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular, in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with that patient and, where appropriate and/or necessary, the patient's caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient's case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional's responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.

5.5.2. The new 2023 European Society of Cardiology diagnostic algorithms .....	3975	9.5. Heart rhythm and conduction disturbances .....	3993
<b>6. Prognostic assessment at admission .....</b>	<b>3975</b>	9.6. Musculoskeletal manifestations .....	3993
<b>7. Antimicrobial therapy: principles and methods .....</b>	<b>3975</b>	9.6.1. Osteoarticular infective endocarditis-related infections .....	3993
7.1. General principles .....	3975	9.6.2. Rheumatological manifestations .....	3994
7.2. Penicillin-susceptible oral streptococci and <i>Streptococcus gallolyticus</i> group .....	3977	9.7. Acute renal failure .....	3994
7.3. Oral streptococci and <i>Streptococcus gallolyticus</i> group susceptible, increased exposure or resistant to penicillin .....	3977	<b>10. Surgical therapy: principles and methods .....</b>	<b>3994</b>
7.4. <i>Streptococcus pneumoniae</i> , $\beta$ -haemolytic streptococci (groups A, B, C, and G) .....	3979	10.1. Pre-operative and peri-operative management .....	3994
7.5. <i>Granulicatella</i> and <i>Abiotrophia</i> (formerly nutritionally variant streptococci) .....	3979	10.1.1. Coronary angiography .....	3994
7.6. <i>Staphylococcus aureus</i> and coagulase-negative staphylococci .....	3979	10.1.2. Extracardiac infection .....	3995
7.7. Methicillin-resistant staphylococci .....	3979	10.1.3. Intra-operative echocardiography .....	3995
7.8. <i>Enterococcus</i> spp. ....	3982	10.2. Other intra-operative considerations .....	3995
7.9. Gram-negative bacteria .....	3983	10.3. Surgical approach and techniques .....	3995
7.9.1. <i>Haemophilus</i> , <i>Aggregatibacter</i> , <i>Cardiobacterium</i> , <i>Eikenella</i> , and <i>Kingella</i> -related species .....	3983	10.3.1. Choice of valve prosthesis .....	3996
7.9.2. <i>Non-Haemophilus</i> , <i>Aggregatibacter</i> , <i>Cardiobacterium</i> , <i>Eikenella</i> , and <i>Kingella</i> species .....	3984	10.4. Timing of surgery after ischaemic and haemorrhagic stroke .....	3997
7.10. Blood culture-negative infective endocarditis .....	3984	10.5. Post-operative complications .....	3997
7.11. Fungi .....	3984	10.6. Management of antithrombotic therapy after surgery .....	3998
7.12. Empirical therapy .....	3984	<b>11. Outcome after discharge: follow-up and long-term prognosis ..</b>	<b>3998</b>
7.13. Outpatient parenteral or oral antibiotic therapy for infective endocarditis .....	3985	11.1. Recurrences: relapses and reinfections .....	3998
7.13.1. Parenteral and oral step-down antibiotic treatment ...	3986	11.2. First year follow-up .....	3999
7.13.2. Other considerations for outpatient oral or parenteral antimicrobial therapy .....	3986	11.3. Long-term prognosis .....	3999
<b>8. Indications for surgery and management of main infective endocarditis complications .....</b>	<b>3987</b>	<b>12. Management of specific situations .....</b>	<b>3999</b>
8.1. Pre-operative risk assessment .....	3987	12.1. Prosthetic valve endocarditis .....	3999
8.2. Heart failure .....	3987	12.1.1. Definition and pathophysiology .....	4000
8.2.1. Heart failure in infective endocarditis .....	3987	12.1.2. Diagnosis .....	4000
8.2.2. Indications and timing of surgery in the presence of heart failure in infective endocarditis .....	3989	12.1.3. Prognosis and treatment .....	4000
8.3. Uncontrolled infection .....	3989	12.2. Endocarditis in the elderly .....	4000
8.3.1. Septic shock and persistent infection .....	3989	12.3. Transcatheter prosthetic valve endocarditis .....	4001
8.3.2. Locally uncontrolled infection .....	3989	12.3.1. Endocarditis following transcatheter aortic valve implantation .....	4001
8.3.3. Indications and timing of surgery in the presence of uncontrolled infection .....	3990	12.3.1.1. Diagnosis .....	4001
8.3.3.1. Persistent infection .....	3990	12.3.1.2. Prognosis and treatment .....	4001
8.3.3.2. Locally uncontrolled infection .....	3990	12.3.2. Endocarditis following transcatheter pulmonary valve implantation .....	4001
8.3.3.3. Infection with resistant or virulent organisms .....	3990	12.3.2.1. Diagnosis .....	4002
8.4. Prevention of systemic embolism .....	3990	12.3.2.2. Prognosis and treatment .....	4002
8.4.1. Incidence of embolic events in infective endocarditis ....	3990	12.4. Infective endocarditis affecting cardiac implantable electronic devices .....	4002
8.4.2. Predicting the risk of embolism .....	3990	12.4.1. Definitions of cardiac device infections .....	4002
8.4.3. Indications and timing of surgery to prevent embolism in infective endocarditis .....	3990	12.4.2. Pathophysiology and microbiology .....	4002
<b>9. Other complications of infective endocarditis .....</b>	<b>3991</b>	12.4.3. Risk factors .....	4002
9.1. Neurological complications .....	3991	12.4.4. Prophylaxis .....	4002
9.1.1. The role of cerebral imaging in infective endocarditis ...	3992	12.4.5. Diagnosis .....	4002
9.2. Infective aneurysms .....	3992	12.4.6. Antimicrobial therapy .....	4004
9.3. Splenic complications .....	3992	12.4.7. Device extraction .....	4004
9.4. Myocarditis and pericarditis .....	3993	12.4.8. Device reimplantation .....	4004
		12.5. Infective endocarditis in patients admitted to intensive care units .....	4005
		12.5.1. Causative microorganisms .....	4005
		12.5.2. Diagnosis .....	4005
		12.5.3. Management .....	4005
		12.6. Right-sided infective endocarditis .....	4005
		12.6.1. Diagnosis and complications .....	4006
		12.6.2. Endocarditis in people who inject drugs .....	4006
		12.6.3. Prognosis and treatment .....	4006
		12.6.3.1. Antimicrobial therapy .....	4006

12.6.3.2. Surgery .....	4006
12.7. Infective endocarditis in congenital heart disease .....	4007
12.8. Infective endocarditis in rheumatic heart disease .....	4008
12.9. Infective endocarditis during pregnancy .....	4008
12.10. Infective endocarditis in immunocompromised patients .....	4008
12.10.1. Solid organ transplant recipients .....	4008
12.10.2. Patients with human immunodeficiency virus .....	4008
12.10.3. Patients with neutropaenia .....	4009
12.11. Antithrombotic and anticoagulant therapy in infective endocarditis .....	4009
12.12. Non-bacterial thrombotic endocarditis .....	4009
12.13. Infective endocarditis and malignancy .....	4010
<b>13. Patient-centred care and shared decision-making in infective endocarditis .....</b>	<b>4010</b>
13.1. What is patient-centred care and shared decision-making and why is it important? .....	4010
13.2. Patient-centred care and shared decision-making in infective endocarditis .....	4010
<b>14. Sex differences .....</b>	<b>4011</b>
<b>15. Key messages .....</b>	<b>4012</b>
<b>16. Gaps in evidence .....</b>	<b>4013</b>
<b>17. 'What to do' and 'What not to do' messages from the Guidelines .....</b>	<b>4020</b>
<b>18. Supplementary data .....</b>	<b>4021</b>
<b>19. Data availability .....</b>	<b>4021</b>
<b>20. Author information .....</b>	<b>4021</b>
<b>21. Appendix .....</b>	<b>4021</b>
<b>22. References .....</b>	<b>4022</b>

## Tables of Recommendations

Recommendation Table 1 — Recommendations for antibiotic prophylaxis in patients with cardiovascular diseases undergoing oro-dental procedures at increased risk for infective endocarditis .....	3961
Recommendation Table 2 — Recommendations for infective endocarditis prevention in high-risk patients .....	3963
Recommendation Table 3 — Recommendations for infective endocarditis prevention in cardiac procedures .....	3963
Recommendation Table 4 — Recommendations for the Endocarditis Team .....	3965
Recommendation Table 5 — Recommendations for the role of echocardiography in infective endocarditis .....	3969
Recommendation Table 6 — Recommendations for the role of computed tomography, nuclear imaging, and magnetic resonance in infective endocarditis .....	3970
Recommendation Table 7 — Recommendations for antibiotic treatment of infective endocarditis due to oral streptococci and <i>Streptococcus gallolyticus</i> group .....	3977
Recommendation Table 8 — Recommendations for antibiotic treatment of infective endocarditis due to <i>Staphylococcus</i> spp. ....	3980
Recommendation Table 9 — Recommendations for antibiotic treatment of infective endocarditis due to <i>Enterococcus</i> spp. ....	3982
Recommendation Table 10 — Recommendations for antibiotic regimens for initial empirical treatment of infective endocarditis (before pathogen identification) .....	3985
Recommendation Table 11 — Recommendations for outpatient antibiotic treatment of infective endocarditis .....	3987

Recommendation Table 12 — Recommendations for the main indications of surgery in infective endocarditis (native valve endocarditis and prosthetic valve endocarditis) .....	3991
Recommendation Table 13 — Recommendations for the treatment of neurological complications of infective endocarditis .....	3992
Recommendation Table 14 — Recommendations for pacemaker implantation in patients with complete atrioventricular block and infective endocarditis .....	3993
Recommendation Table 15 — Recommendations for patients with musculoskeletal manifestations of infective endocarditis .....	3994
Recommendation Table 16 — Recommendations for pre-operative coronary anatomy assessment in patients requiring surgery for infective endocarditis .....	3995
Recommendation Table 17 — Indications and timing of cardiac surgery after neurological complications in active infective endocarditis .....	3997
Recommendation Table 18 — Recommendations for post-discharge follow-up .....	3999
Recommendation Table 19 — Recommendations for prosthetic valve endocarditis .....	4000
Recommendation Table 20 — Recommendations for cardiovascular implanted electronic device-related infective endocarditis .....	4004
Recommendation Table 21 — Recommendations for the surgical treatment of right-sided infective endocarditis .....	4007
Recommendation Table 22 — Recommendations for the use of antithrombotic therapy in infective endocarditis .....	4009

## List of tables

Table 1 Classes of recommendations .....	3953
Table 2 Levels of evidence .....	3953
Table 3 New recommendations .....	3955
Table 4 Revised recommendations .....	3957
Table 5 General prevention measures to be followed in patients at high and intermediate risk of infective endocarditis .....	3960
Table 6 Prophylactic antibiotic regime for high-risk dental procedures .....	3961
Table 7 Members of the Endocarditis Team .....	3963
Table 8 Cardiac and non-cardiac risk factors .....	3965
Table 9 Investigation of rare causes of blood culture-negative infective endocarditis .....	3967
Table 10 Definitions of the 2023 European Society of Cardiology modified diagnostic criteria of infective endocarditis .....	3971
Table 11 Antibiotic treatment of blood culture-negative infective endocarditis .....	3984
Table 12 Features favouring a non-mechanical valve substitute in the setting of surgery for acute infective endocarditis .....	3997
Table 13 Factors associated with an increased rate of relapse of infective endocarditis .....	3999
Table 14 'What to do' and 'What not to do' .....	4014

## List of figures

Figure 1 Management of patients with infective endocarditis .....	3954
Figure 2 Education of high-risk patients to prevent infective endocarditis .....	3962
Figure 3 Management of patients with infective endocarditis: positioning of the Endocarditis Team .....	3964

Figure 4 Microbiological diagnostic algorithm in culture-positive and culture-negative infective endocarditis .....	3968
Figure 5 European Society of Cardiology 2023 algorithm for diagnosis of native valve infective endocarditis .....	3972
Figure 6 European Society of Cardiology 2023 algorithm for diagnosis of prosthetic valve infective endocarditis .....	3973
Figure 7 European Society of Cardiology 2023 algorithm for diagnosis of cardiac device-related infective endocarditis .....	3974
Figure 8 Phases of antibiotic treatment for infective endocarditis in relation to outpatient parenteral antibiotic therapy and partial oral endocarditis treatment .....	3976
Figure 9 Flowchart to assess clinical stability based on the Partial Oral Treatment of Endocarditis trial .....	3986
Figure 10 Proposed surgical timing for infective endocarditis .....	3988
Figure 11 Surgery for infective endocarditis following stroke .....	3996
Figure 12 Algorithm differentiating relapse from reinfection .....	3998
Figure 13 Management of cardiovascular implanted electronic device-related infective endocarditis .....	4003
Figure 14 Concept of patient-centred care in infective endocarditis .....	4011

## Abbreviations and acronyms

[18F]FDG	<sup>18</sup> F-fluorodeoxyglucose
<sup>99m</sup> Tc-HMPAO	<sup>99m</sup> Technetium-hexamethylpropyleneamine oxime
AIDS	Acquired immune deficiency syndrome
AEPEI	Association for the Study and Prevention of Infective Endocarditis Study
ANCLA	Anaemia, NYHA class IV, critical state, large intracardiac destruction, surgery of thoracic aorta
APLs	Antiphospholipid syndrome
AUC	Area under the curve
AVB	Atrioventricular block
AVN	Atrioventricular node
BCNIE	Blood culture-negative infective endocarditis
BMI	Body mass index
CAD	Coronary artery disease
CHD	Congenital heart disease
CI	Confidence interval
CIED	Cardiovascular implanted electronic device
CNS	Central nervous system
CoNS	Coagulase-negative staphylococci
CPB	Cardio-pulmonary bypass
CRT	Cardiac resynchronization therapy
CT	Computed tomography
CTA	Computed tomography angiography
DIC	Disseminated intravascular coagulation
DNA	Deoxyribonucleic acid
DSA	Digital subtraction angiography
ECG	Electrocardiogram
EHRA	European Heart Rhythm Association
ESC	European Society of Cardiology
EUCAST	European Committee on Antimicrobial Susceptibility Testing
EURO-ENDO	European Infective Endocarditis Registry

HACEK	<i>Haemophilus</i> , <i>Aggregatibacter</i> , <i>Cardiobacterium</i> , <i>Eikenella</i> , and <i>Kingella</i>
HF	Heart failure
HIV	Human immunodeficiency virus
HLAR	High-level aminoglycoside resistance
i.m.	Intramuscular
i.v.	Intravenous
ICD	Implantable cardioverter defibrillator
ICE-PCS	International Collaboration on Endocarditis-Pro prospective Cohort Study
ICU	Intensive care unit
IE	Infective endocarditis
Ig	Immunoglobulin
MALDI-TOF MS	Matrix-assisted laser desorption ionization time-of-flight mass spectrometry
MIC	Minimum inhibitory concentration
MRA	Magnetic resonance angiography
MRI	Magnetic resonance imaging
MRSA	Methicillin-resistant <i>Staphylococcus aureus</i>
MSSA	Methicillin-susceptible <i>Staphylococcus aureus</i>
NBTE	Non-bacterial thrombotic endocarditis
NIHSS	National Institutes of Health Stroke Scale Score
NVE	Native valve endocarditis
NYHA	New York Heart Association
OPAT	Outpatient parenteral antibiotic therapy
PADIT	Previous procedure on same pocket; Age; Depressed renal function; Immunocompromised; Type of procedure
PALSUSE	Prosthetic valve, age $\geq 70$ , large intracardiac destruction, <i>Staphylococcus</i> spp., urgent surgery, sex (female), EuroSCORE $\geq 10$
PBP	Penicillin-binding protein
PCR	Polymerase chain reaction
PET/CT	Positron emission tomography/computed tomography
POET	Partial Oral Treatment of Endocarditis (trial)
PPV	Positive predictive value
PVE	Prosthetic valve endocarditis
PWID	People who inject drugs
RCT	Randomized clinical trial
RHD	Rheumatic heart disease
rRNA	Ribosomal ribonucleic acid
SAPS	Simplified Acute Physiology Score
SLE	Systemic lupus erythematosus
SOT	Solid organ transplantation
SPECT/CT	Single photon emission tomography/computed tomography
STS	Society of Thoracic Surgeons
TAVI	Transcatheter aortic valve implantation
TOE	Transoesophageal echocardiography
TPVI	Transcatheter pulmonary valve implantation
TTE	Transthoracic echocardiography
WBC	White blood cell
WRAP-IT	Worldwide Randomized Antibiotic Envelope Infection Prevention Trial

## 1. Preamble

Guidelines evaluate and summarize available evidence, with the aim of assisting health professionals in proposing the best diagnostic or therapeutic approach for an individual patient with a given condition. Guidelines are intended for use by health professionals and the European Society of Cardiology (ESC) makes its Guidelines freely available.

ESC Guidelines do not override the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with that patient or

the patient's caregiver where appropriate and/or necessary. It is also the health professional's responsibility to verify the rules and regulations applicable in each country to drugs and devices at the time of prescription, and, where appropriate, to respect the ethical rules of their profession.

ESC Guidelines represent the official position of the ESC on a given topic and are regularly updated. ESC Policies and Procedures for formulating and issuing ESC Guidelines can be found on the ESC website (<https://www.escardio.org/Guidelines>).

The Members of this Task Force were selected by the ESC to represent professionals involved with the medical care of patients with this

**Table 1** Classes of recommendations


	Definition	Wording to use	
Classes of recommendations	<b>Class I</b>	Evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective.	Is recommended or is indicated
	<b>Class II</b>	Conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of the given treatment or procedure.	
	Class IIa	Weight of evidence/opinion is in favour of usefulness/efficacy.	Should be considered
	Class IIb	Usefulness/efficacy is less well established by evidence/opinion.	May be considered
	<b>Class III</b>	Evidence or general agreement that the given treatment or procedure is not useful/effective, and in some cases may be harmful.	Is not recommended

©ESC 2023

**Table 2** Levels of evidence

Level of evidence A	Data derived from multiple randomized clinical trials or meta-analyses.
Level of evidence B	Data derived from a single randomized clinical trial or large non-randomized studies.
Level of evidence C	Consensus of opinion of the experts and/or small studies, retrospective studies, registries.

©ESC 2023



Downloaded from <https://academic.oup.com/eurheartj/article/44/39/3948/7243107> by Universiteit Leiden - LUMC user on 14 March 2024

**Figure 1** Management of patients with infective endocarditis. i.v., intravenous; OPAT, outpatient parenteral antibiotic therapy.



pathology. The selection procedure aimed to include members from across the whole of the ESC region and from relevant ESC Subspecialty Communities. Consideration was given to diversity and inclusion, notably with respect to gender and country of origin. The Task Force performed a critical evaluation of diagnostic and therapeutic approaches, including assessment of the risk-benefit ratio. The strength of every recommendation and the level of evidence supporting them were weighed and scored according to predefined scales as outlined below. The Task Force followed ESC voting procedures, and all approved recommendations were subject to a vote and achieved at least 75% agreement among voting members.

The experts of the writing and reviewing panels provided declaration of interest forms for all relationships that might be perceived as real or potential sources of conflicts of interest. Their declarations of interest were reviewed according to the ESC declaration of interest rules and can be found on the ESC website (<http://www.escardio.org/Guidelines>) and have been compiled in a report published in a supplementary document with the guidelines. The Task Force received its entire financial support from the ESC without any involvement from the healthcare industry.

The ESC Clinical Practice Guidelines (CPG) Committee supervises and co-ordinates the preparation of new guidelines and is responsible for the approval process. ESC Guidelines undergo extensive review by the CPG Committee and external experts, including members from across the whole of the ESC region and from relevant ESC Subspecialty Communities and National Cardiac Societies. After appropriate revisions, the guidelines are signed off by all the experts involved in the Task Force. The finalized document is signed off by the CPG Committee for publication in the *European Heart Journal*. The guidelines were developed after careful consideration of the scientific and medical knowledge and the evidence available at the time of their writing. Tables of evidence summarizing the findings of studies informing development of the guidelines are included. The ESC warns readers that the technical language may be misinterpreted and declines any responsibility in this respect.

Off-label use of medication may be presented in this guideline if a sufficient level of evidence shows that it can be considered medically appropriate for a given condition. However, the final decisions concerning an individual patient must be made by the responsible health professional giving special consideration to:

- The specific situation of the patient. Unless otherwise provided for by national regulations, off-label use of medication should be limited to situations where it is in the patient's interest with regard to the quality, safety, and efficacy of care, and only after the patient has been informed and has provided consent.
- Country-specific health regulations, indications by governmental drug regulatory agencies, and the ethical rules to which health professionals are subject, where applicable.

## 2. Introduction

Infective endocarditis (IE) is a major public health challenge.<sup>1</sup> In 2019, the estimated incidence of IE was 13.8 cases per 100 000 subjects per year, and IE accounted for 66 300 deaths worldwide.<sup>2</sup> Due to the associated high morbidity and mortality (1723.59 disability-adjusted life years and 0.87 death cases per 100 000 population, respectively), identification of the best preventive strategies has been the focus of research.<sup>2,3</sup> Since the publication of the *2015 ESC Guidelines for the management of infective endocarditis*,<sup>4</sup> important new data have been published mandating an update of recommendations. First, the population at risk of IE has increased and new data on IE in different clinical scenarios have arisen.<sup>5–11</sup> Furthermore, the emerging and increasing antibiotic resistance among oral streptococci is

of concern. The rate of resistance to azithromycin and clarithromycin is higher than that to penicillin.<sup>12</sup> Whether changes in national guidelines on the use of antibiotic prophylaxis have resulted in an increase in the incidence of IE remains unclear.<sup>13–18</sup> It is likely that the increased use of diagnostic tools to diagnose IE is an important contributor to the increase in the incidence of IE. The use of echocardiography has probably increased in patients with positive blood cultures for *Enterococcus faecalis*, *Staphylococcus aureus*, or streptococci due to the associated increased risk of IE.<sup>19</sup> In addition, computed tomography (CT) and nuclear imaging techniques have increased the number of definite IE cases particularly among patients with prosthetic valves and implantable cardiac devices.<sup>20–22</sup>

Data on the contemporary characterization of patients with IE have been taken into consideration to update the recommendations on the diagnosis and management of patients with IE.<sup>5,19,23–41</sup> Furthermore, the recommendations on antibiotic therapy have been updated based on the susceptibility of various microorganisms defined by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints.<sup>42</sup> Recommendations on outpatient parenteral antibiotic therapy (OPAT) or oral antibiotic treatment have been included based on the results of the Partial Oral Treatment of Endocarditis (POET) randomized trial and other trials.<sup>43–46</sup>

The main objective of the current Task Force was to provide clear and simple recommendations, assisting healthcare providers in their clinical decision-making. These recommendations were obtained by expert consensus after thorough review of the available literature (see [Supplementary data, evidence tables online](#)). An evidence-based scoring system was used, based on a classification of the strength of recommendations and the levels of evidence.

### 2.1. What is new

**Table 3** New recommendations

Recommendation	Class	Level
<b>Section 3. Recommendation Table 1 — Recommendations for antibiotic prophylaxis in patients with cardiovascular diseases undergoing oro-dental procedures at increased risk of infective endocarditis</b>		
General prevention measures are recommended in individuals at high and intermediate risk of IE.	I	C
Antibiotic prophylaxis is recommended in patients with ventricular assist devices.	I	C
Antibiotic prophylaxis may be considered in recipients of heart transplant.	IIb	C
<b>Section 3. Recommendation Table 2 — Recommendations for infective endocarditis prevention in high-risk patients</b>		
Systemic antibiotic prophylaxis may be considered for high-risk patients undergoing an invasive diagnostic or therapeutic procedure of the respiratory, gastrointestinal, genitourinary tract, skin, or musculoskeletal systems.	IIb	C
<b>Section 3. Recommendation Table 3 — Recommendations for infective endocarditis prevention in cardiac procedures</b>		
Optimal pre-procedural aseptic measures of the site of implantation is recommended to prevent CIED infections.	I	B

Continued

Surgical standard aseptic measures are recommended during the insertion and manipulation of catheters in the catheterization laboratory environment.	I	C
Antibiotic prophylaxis covering for common skin flora including <i>Enterococcus</i> spp. and <i>S. aureus</i> should be considered before TAVI and other transcatheter valvular procedures.	IIa	C
<b>Section 5. Recommendation Table 5 — Recommendations for the role of echocardiography in infective endocarditis</b>		
TOE is recommended when the patient is stable before switching from intravenous to oral antibiotic therapy.	I	B
<b>Section 5. Recommendation Table 6 — Recommendations for the role of computed tomography, nuclear imaging, and magnetic resonance in infective endocarditis</b>		
Cardiac CTA is recommended in patients with possible NVE to detect valvular lesions and confirm the diagnosis of IE.	I	B
[18F]FDG-PET/CT(A) and cardiac CTA are recommended in possible PVE to detect valvular lesions and confirm the diagnosis of IE.	I	B
[18F]FDG-PET/CT(A) may be considered in possible CIED-related IE to confirm the diagnosis of IE.	IIb	B
Cardiac CTA is recommended in NVE and PVE to diagnose paravalvular or periprosthetic complications if echocardiography is inconclusive.	I	B
Brain and whole-body imaging (CT, [18F]FDG-PET/CT, and/or MRI) are recommended in symptomatic patients with NVE and PVE to detect peripheral lesions or add minor diagnostic criteria.	I	B
WBC SPECT/CT should be considered in patients with high clinical suspicion of PVE when echocardiography is negative or inconclusive and when PET/CT is unavailable.	IIa	C
Brain and whole-body imaging (CT, [18F]FDG-PET/CT, and MRI) in NVE and PVE may be considered for screening of peripheral lesions in asymptomatic patients.	IIb	B
<b>Section 7. Recommendation Table 11 — Recommendations for outpatient antibiotic treatment of infective endocarditis</b>		
Outpatient parenteral antibiotic treatment should be considered in patients with left-sided IE caused by <i>Streptococcus</i> spp., <i>E. faecalis</i> , <i>S. aureus</i> , or CoNS who were receiving appropriate i.v. antibiotic treatment for at least 10 days (or at least 7 days after cardiac surgery), are clinically stable, and who do not show signs of abscess formation or valve abnormalities requiring surgery on TOE.	IIa	A
Outpatient parenteral antibiotic treatment is not recommended in patients with IE caused by highly difficult-to-treat microorganisms, liver cirrhosis (Child–Pugh B or C), severe cerebral nervous system emboli, untreated large extracardiac abscesses, heart valve complications, or other severe conditions requiring surgery, severe post-surgical complications, and in PWID-related IE.	III	C

Continued

<b>Section 9. Recommendation Table 13 — Recommendations for the treatment of neurological complications of infective endocarditis</b>		
In embolic stroke, mechanical thrombectomy may be considered if the expertise is available in a timely manner.	IIb	C
Thrombolytic therapy is not recommended in embolic stroke due to IE.	III	C
<b>Section 9. Recommendation Table 14 — Recommendations for pacemaker implantation in patients with complete atrioventricular block and infective endocarditis</b>		
Immediate epicardial pacemaker implantation should be considered in patients undergoing surgery for valvular IE and complete AVB if one of the following predictors of persistent AVB is present: pre-operative conduction abnormality, <i>S. aureus</i> infection, aortic root abscess, tricuspid valve involvement, or previous valvular surgery.	IIa	C
<b>Section 9. Recommendation Table 15 — Recommendations for patients with musculoskeletal manifestations of infective endocarditis</b>		
MRI or PET/CT is recommended in patients with suspected spondylodiscitis and vertebral osteomyelitis complicating IE.	I	C
TTE/TOE is recommended to rule out IE in patients with spondylodiscitis and/or septic arthritis with positive blood cultures for typical IE microorganisms.	I	C
More than 6-week antibiotic therapy should be considered in patients with osteoarticular IE-related lesions caused by difficult-to-treat microorganisms, such as <i>S. aureus</i> or <i>Candida</i> spp., and/or complicated with severe vertebral destruction or abscesses.	IIa	C
<b>Section 10. Recommendation Table 16 — Recommendations for pre-operative coronary anatomy assessment in patients requiring surgery for infective endocarditis</b>		
In haemodynamically stable patients with aortic valve vegetations who require cardiac surgery and are high risk of CAD, a high-resolution multislice coronary CTA is recommended.	I	B
Invasive coronary angiography is recommended in patients requiring heart surgery who are high risk of CAD, in the absence of aortic valve vegetations.	I	C
In emergency situations, valvular surgery without pre-operative coronary anatomy assessment regardless of CAD risk should be considered.	IIa	C
Invasive coronary angiography may be considered despite the presence of aortic valve vegetations in selected patients with known CAD or at high risk of significant obstructive CAD.	IIb	C
<b>Section 10. Recommendation Table 17 — Indications and timing of cardiac surgery after neurological complications in active infective endocarditis</b>		
In patients with intracranial haemorrhage and unstable clinical status due to HF, uncontrolled infection, or persistent high embolic risk, urgent or emergency surgery should be considered weighing the likelihood of a meaningful neurological outcome.	IIa	C

Continued

Section 11. Recommendation Table 18 — Recommendations for post-discharge follow-up		
Patient education on the risk of recurrence and preventive measures, with emphasis on dental health, and based on the individual risk profile, is recommended during follow-up.	I	C
Addiction treatment for patients following PWID-related IE is recommended.	I	C
Cardiac rehabilitation including physical exercise training should be considered in clinically stable patients based on an individual assessment.	IIa	C
Psychosocial support may be considered to be integrated in follow-up care, including screening for anxiety and depression, and referral to relevant psychological treatment.	IIb	C
Section 12. Recommendation Table 19 — Recommendations for prosthetic valve endocarditis		
Surgery is recommended for early PVE (within 6 months of valve surgery) with new valve replacement and complete debridement.	I	C
Section 12. Recommendation Table 20 — Recommendations for cardiovascular implanted electronic device-related infective endocarditis		
Complete system extraction without delay is recommended in patients with definite CIED-related IE under initial empirical antibiotic therapy.	I	B
Extension of antibiotic treatment of CIED-related endocarditis to (4–)6 weeks following device extraction should be considered in the presence of septic emboli or prosthetic valves.	IIa	C
Use of an antibiotic envelope may be considered in select high-risk patients undergoing CIED reimplantation to reduce risk of infection.	IIb	B

Continued

In non- <i>S. aureus</i> CIED-related endocarditis without valve involvement or lead vegetations, and if follow-up blood cultures are negative without septic emboli, 2 weeks of antibiotic treatment may be considered following device extraction.	IIb	C
Removal of CIED after a single positive blood culture, with no other clinical evidence of infection, is not recommended.	III	C
Section 12. Recommendation Table 21 — Recommendations for the surgical treatment of right-sided infective endocarditis		
Tricuspid valve repair should be considered instead of valve replacement, when possible.	IIa	B
Surgery should be considered in patients with right-sided IE who are receiving appropriate antibiotic therapy and present persistent bacteraemia/sepsis after at least 1 week of appropriate antibiotic therapy.	IIa	C
Prophylactic placement of an epicardial pacing lead should be considered at the time of tricuspid valve surgical procedures.	IIa	C
Debulking of right intra-atrial septic masses by aspiration may be considered in select patients who are high risk of surgery.	IIb	C

[18F]FDG-PET, <sup>18</sup>F-fluorodeoxyglucose positron emission tomography; AVB, atrioventricular block; CAD, coronary artery disease; CIED, cardiovascular implanted electronic device; CoNS, coagulase-negative staphylococci; CT, computed tomography; CTA, computed tomography angiography; HF, heart failure; IE, infective endocarditis; i.v., intravenous; MRI, magnetic resonance imaging; NVE, native valve endocarditis; PET, positron emission tomography; PVE, prosthetic valve endocarditis; PWID, people who inject drugs; TAVI, transcatheter aortic valve implantation; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography; WBC SPECT/CT, white blood cell single photon emission tomography/computed tomography.

Downloaded from https://academic.oup.com/eurheartj/article/44/39/3948/7243107 by Universiteit Leiden - LUMC user on 14 March 2024 © ESC 2023

**Table 4** Revised recommendations

Recommendations in 2015 version	Class	Level	Recommendations in 2023 version	Class	Level
Section 3. Recommendation Table 1 — Recommendations for antibiotic prophylaxis in patients with cardiovascular diseases undergoing oro-dental procedures at increased risk of infective endocarditis					
Antibiotic prophylaxis should be considered for patients at highest risk of IE:	IIa	C	Antibiotic prophylaxis is recommended in patients with previous IE.	I	B
(1) Patients with any prosthetic valve, including a transcatheter valve, or those in whom any prosthetic material was used for cardiac valve repair.			I	C	
(2) Patients with a previous episode of IE.			I	C	
(3) Patients with CHD:			I	C	
(a) Any type of cyanotic CHD.	IIa	C	Antibiotic prophylaxis should be considered in patients with transcatheter mitral and tricuspid valve repair.	IIa	C
(b) Any type of CHD repaired with a prosthetic material, whether placed surgically or by percutaneous techniques, up to 6 months after the procedure or lifelong if residual shunt.					

Continued

			Antibiotic prophylaxis is recommended in patients with untreated cyanotic CHD, and patients treated with surgery or transcatheter procedures with post-operative palliative shunts, conduits, or other prostheses. After surgical repair, in the absence of residual defects or valve prostheses, antibiotic prophylaxis is recommended only for the first 6 months after the procedure.	<b>I</b>	<b>C</b>
<b>Section 4. Recommendation Table 4 — Recommendations for the Endocarditis Team</b>					
Patients with complicated IE should be evaluated and managed at an early stage in a reference centre, with immediate surgical facilities and the presence of a multidisciplinary 'Endocarditis Team', including an infectious disease specialist, a microbiologist, a cardiologist, imaging specialists, a cardiac surgeon and, if needed, a specialist in CHD.	<b>Ila</b>	<b>B</b>	Diagnosis and management of patients with complicated IE are recommended to be performed at an early stage in a Heart Valve Centre, with immediate surgical facilities and an 'Endocarditis Team' to improve the outcomes.	<b>I</b>	<b>B</b>
For patients with uncomplicated IE managed in a non-reference centre, early and regular communication with the reference centre and, when needed, visits to the reference centre should be made.	<b>Ila</b>	<b>B</b>	For patients with uncomplicated IE managed in a Referring Centre, early and regular communication between the local and the Heart Valve Centre Endocarditis Teams is recommended to improve the outcomes of the patients.	<b>I</b>	<b>B</b>
<b>Section 5. Recommendation Table 5 — Recommendations for the role of echocardiography in infective endocarditis</b>					
TOE should be considered in patients with suspected IE, even in cases with positive TTE, except in isolated right-sided native valve IE with good quality TTE examination and unequivocal echocardiographic finding.	<b>Ila</b>	<b>C</b>	TOE is recommended in patients with suspected IE, even in cases with positive TTE, except in isolated right-sided native valve IE with good quality TTE examination and unequivocal echocardiographic findings.	<b>I</b>	<b>C</b>
<b>Section 8. Recommendation Table 12 — Recommendations for the main indications of surgery in infective endocarditis (native valve endocarditis and prosthetic valve endocarditis)</b>					
Aortic or mitral NVE with vegetations >10 mm, associated with severe valve stenosis or regurgitation, and low operative risk (urgent surgery should be considered).	<b>Ila</b>	<b>B</b>	Urgent surgery is recommended in IE with vegetation ≥10 mm and other indications for surgery.	<b>I</b>	<b>C</b>
Aortic or mitral NVE or PVE with isolated large vegetations (>15 mm) and no other indication for surgery (urgent surgery may be considered).	<b>Ilb</b>	<b>C</b>	Urgent surgery may be considered in aortic or mitral IE with vegetation ≥10 mm and without severe valve dysfunction or without clinical evidence of embolism and low surgical risk.	<b>Ilb</b>	<b>B</b>
<b>Section 9. Recommendation Table 13 — Recommendations for the treatment of neurological complications of infective endocarditis</b>					
Intracranial infectious aneurysms should be looked for in patients with IE and neurological symptoms. CT or MRA should be considered for diagnosis. If non-invasive techniques are negative and the suspicion of intracranial aneurysm remains, conventional angiography should be considered.	<b>Ila</b>	<b>B</b>	Brain CT or MRA is recommended in patients with IE and suspected infective cerebral aneurysms.	<b>I</b>	<b>B</b>
			If non-invasive techniques are negative and the suspicion of infective aneurysm remains, invasive angiography should be considered.	<b>Ila</b>	<b>B</b>
<b>Section 12. Recommendation Table 20 — Recommendations for cardiovascular implanted electronic device-related infective endocarditis</b>					
Routine antibiotic prophylaxis is recommended before device implantation.	<b>I</b>	<b>B</b>	Antibiotic prophylaxis covering <i>S. aureus</i> is recommended for CIED implantation.	<b>I</b>	<b>A</b>
TOE is recommended in patients with suspected cardiac device-related infective endocarditis with positive or negative blood cultures, independent of the results of TTE, to evaluate lead-related endocarditis and heart valve infection.	<b>I</b>	<b>C</b>	TTE and TOE are both recommended in case of suspected CIED-related IE to identify vegetations.	<b>I</b>	<b>B</b>
In patients with NVE or PVE and an intracardiac device with no evidence of associated device infection, complete hardware extraction may be considered.	<b>Ilb</b>	<b>C</b>	Complete CIED extraction should be considered in case of valvular IE, even without definite lead involvement, taking into account the identified pathogen and requirement for valve surgery.	<b>Ila</b>	<b>C</b>

Continued

Complete hardware removal should be considered on the basis of occult infection without another apparent source of infection.	IIa	C	In cases of possible CIED-related IE or occult Gram-positive bacteraemia or fungaemia, complete system removal should be considered in case bacteraemia/fungaemia persists after a course of antimicrobial therapy.	IIa	C
			In cases of possible CIED-related IE with occult Gram-negative bacteraemia, complete system removal may be considered in case of persistent/relapsing bacteraemia after a course of antimicrobial therapy.	IIb	C
When indicated, definite reimplantation should be postponed if possible, to allow a few days or weeks of antibiotic therapy.	IIa	C	If CIED reimplantation is indicated after extraction for CIED-related IE, it is recommended to be performed at a site distant from the previous generator, as late as possible, once signs and symptoms of infection have abated and until blood cultures are negative for at least 72 h in the absence of vegetations, and negative for at least 2 weeks if vegetations were visualized.	I	C

**Section 12. Recommendation Table 21 — Recommendations for the surgical treatment of right-sided infective endocarditis**

Surgical treatment should be considered in the following scenarios:		Surgery is recommended in patients with right-sided IE who are receiving appropriate antibiotic therapy for the following scenarios:			
<ul style="list-style-type: none"> <li>• Microorganisms difficult to eradicate (e.g. persistent fungi) or bacteraemia for &gt;7 days (e.g. <i>S. aureus</i>, <i>P. aeruginosa</i>) despite adequate antimicrobial therapy; or</li> <li>• Persistent tricuspid valve vegetations &gt;20 mm after recurrent pulmonary emboli with or without concomitant right HF; or</li> <li>• Right HF secondary to severe tricuspid regurgitation with poor response to diuretic therapy.</li> </ul>	IIa	C	Right ventricular dysfunction secondary to acute severe tricuspid regurgitation non-responsive to diuretics.	I	B
			Persistent vegetation with respiratory insufficiency requiring ventilatory support after recurrent pulmonary emboli.	I	B
			Large residual tricuspid vegetations (>20 mm) after recurrent septic pulmonary emboli.	I	C
			Patients with simultaneous involvement of left-heart structures.	I	C

**Section 12. Recommendation Table 22 — Recommendations for the use of antithrombotic therapy in infective endocarditis**

Interruption of antiplatelet therapy is recommended in the presence of major bleeding.	I	B	Interruption of antiplatelet or anticoagulant therapy is recommended in the presence of major bleeding (including intracranial haemorrhage).	I	C
--	---	---	--	---	---

CHD, congenital heart disease; CIED, cardiovascular implanted electronic device; CT, computed tomography; HF, heart failure; IE, infective endocarditis; MRA, magnetic resonance angiography; NVE, native valve endocarditis; PVE, prosthetic valve endocarditis; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography.

### 3. Prevention

#### 3.1. Rationale

The development of IE usually requires several conditions, including the presence of predisposing risk factors (i.e. a surface/structure that could be colonized by bacteria), pathogens entering the bloodstream, and the competence of the host's immune response. The role of predisposing risk factors has been recently underscored by Thornhill *et al.*<sup>47</sup> Predisposing risk factors conveying a moderate and high risk of IE had an incidence of 280 and 497 cases per 100 000 subjects per year, respectively.<sup>47</sup>

The portals of entry of bacteria/fungi are variable and include: (i) infections of the skin, oral cavity, gastrointestinal, or genitourinary system; (ii) direct inoculation in people who inject drugs (PWID), or by any unsafe or unprotected vascular puncture; (iii) healthcare exposure (including a variety of invasive diagnostic or therapeutic procedures, such as transcatheter or surgical techniques).<sup>6,11,48–50</sup>

The oral cavity is colonized by relevant commensal flora, including oral group streptococci, and represents an important entry port. Oral surgery procedures (including all extractions, periodontal surgery,

implant surgery, and oral biopsies) and dental procedures that involve manipulation of the gingival or periapical region of the teeth are considered at high risk of causing bacteraemia.<sup>11,48,49,51</sup>

Successful antibiotic prophylaxis assumes that reducing the bacteraemia associated with medical procedures will lead to a reduced risk of IE. This concept was supported by a few animal models and observational studies that led to the recommendation for antibiotic prophylaxis in a large number of patients with predisposing cardiac conditions undergoing a wide range of procedures.<sup>4,14,52–60</sup>

However, systematic use of antibiotic prophylaxis has been questioned based on several considerations, the most important being the lack of randomized clinical trials (RCTs) demonstrating the efficacy of antibiotic prophylaxis prior to medical procedures in preventing IE. Such trials would entail enrolment of a very large number of individuals and prolonged follow-up, making the feasibility of such studies improbable. Furthermore, since the standard of care for high-risk individuals is antibiotic prophylaxis (to date, mostly before invasive oro-dental procedures), there may not be sufficient equipoise to perform such RCTs. Finally, the costs of performing such trials have been considered unacceptable.<sup>61</sup> To overcome these limitations, population-based studies

have evaluated the efficacy of antibiotic prophylaxis using bacteraemia as a surrogate of IE.<sup>16–18,52,62</sup> However, the relationship between bacteraemia and IE is not straightforward. Bacteraemia may be caused by daily activities such as tooth brushing, flossing, and chewing, and although these constitute low-level bacteraemia, they occur repetitively and may therefore outweigh the risk of bacteraemia associated with dental procedures.<sup>48,49</sup> A meta-analysis of 36 studies, including 21 trials that investigated the effect of antibiotic prophylaxis on the incidence of bacteraemia following dental procedures, demonstrated that antibiotic prophylaxis is effective in reducing the incidence of bacteraemia, but did not lead to a statistically significant protective effect against IE in case-control studies.<sup>52</sup> Additionally, the potential risk of anaphylaxis,<sup>63</sup> or other adverse side effects in a small minority of patients, and the fact that a widespread use of antibiotics may be associated with antibiotic resistance, are areas of concern.<sup>57,58,64–67</sup> While some studies did not demonstrate significant increases in IE-related hospitalizations and death rates after scaling down antibiotic prophylaxis indications,<sup>68–77</sup> others showed an increase in the incidence of IE among individuals at moderate and high risk of IE.<sup>13,26,59,78–81</sup> A meta-analysis including 16 studies reporting over 1.3 million cases of IE has shown that restricting antibiotic prophylaxis to only high-risk individuals has not resulted in an increase in the incidence of streptococcal IE in a North American population (despite the fact that it was unable to draw that conclusion for other populations).<sup>18</sup> In contrast, a systematic review including multiple nationwide population-based studies in Europe has shown a 4% per year rise in the incidence of IE.<sup>82</sup> These contrasting results may be explained by differences in the methodology of the studies (retrospective, population- or health-system-based studies that relied on claims data or epidemiological observations to estimate the incidence of IE), greater disease diagnosis with the use of newer imaging technologies, lack of microbiological data, and the lack of specific International Classification of Diseases codes for oral streptococci.<sup>83</sup> Recently, it has been shown that antibiotic prophylaxis in high-risk individuals was associated with a significant reduction of IE after invasive dental procedures (particularly extractions and oral surgical procedures).<sup>11,51</sup> After careful consideration of all the new studies published after 2015, the present Task Force decided to revise and update the risk categories for IE, strengthening the recommendation of antibiotic prophylaxis, clarifying the definition of the population at risk, and considering the advances in transcatheter valve interventions.

### 3.2. Populations at risk of infective endocarditis

The groups of individuals at high risk of IE in whom antibiotic prophylaxis is recommended or should be considered include the following:

- (i) Patients with previous IE: the highest risk of IE is observed in patients with previous history of IE who have an ominous prognosis during IE-related hospitalization. Patients with recurrent IE more frequently have prosthetic valves or prosthetic material, are more commonly PWID, or have staphylococcal IE.<sup>47,84–86</sup>
- (ii) Patients with surgically implanted prosthetic valves, with transcatheter implanted prosthetic valves, and with any material used for cardiac valve repair: the increased risk of IE in these patients, combined with the ominous outcomes as compared with patients with native IE (NVE), make antibiotic prophylaxis advisable in this patient group. Patients with prosthetic valve endocarditis (PVE) have an in-hospital mortality rate that is twice as high with more complications (e.g. heart failure [HF], conduction disturbances) as compared with patients with NVE, regardless of the

- pathogen.<sup>87,88</sup> Furthermore, mitral and aortic bioprostheses may be associated with increased risk of IE as compared with mechanical prostheses,<sup>89,90</sup> and bioprostheses are being implanted in an ever-increasing proportion of patients requiring valve replacement therapy. The indication for prophylaxis also expands to transcatheter aortic and pulmonic prosthetic valves, since IE is also associated with a high risk of morbidity and mortality in these patients.<sup>91–94</sup> In terms of transcatheter mitral and tricuspid valve interventions, the data on the risk of IE are limited.<sup>95</sup> Patients with septal defect closure devices, left atrial appendage closure devices, vascular grafts, vena cava filters, and central venous system ventriculo-atrial shunts are considered within this risk category in the first 6 months after implantation.<sup>96</sup>
- (iii) Patients with congenital heart disease (CHD) (not including isolated congenital valve abnormalities) are at increased risk of IE.<sup>8,47,97–99</sup> The cumulative incidence over time is influenced strongly by the improved long-term survival of children with CHD into adulthood.<sup>98</sup> Indeed, there are now more adults living with CHD than children with CHD.<sup>100</sup> The overall incidence rate of IE among adult patients with CHD is 27–44 times that reported for contemporary adults of the general population (1.33 cases per 1000 persons per year)<sup>8</sup> while in children with CHD the incidence of IE is 0.41 cases per 1000 persons per year.<sup>101</sup> CHD groups at increased risk include those with untreated cyanotic CHD, and those whose surgery includes prosthetic material, including valved conduits or systemic to pulmonary shunts.<sup>8,47,97</sup> The risk of post-operative IE for CHD patients undergoing transcatheter atrial or ventricular septal defect closure with devices or surgery with non-valve-related prosthetic material is also increased, but predominantly for the first 6 months after surgery.<sup>8</sup>
  - (iv) Patients with ventricular assist devices as destination therapy are also considered at high risk because of associated morbidity and mortality, and prophylaxis is also recommended in such patients.<sup>102</sup>

Patients at intermediate risk of IE include those with: (i) rheumatic heart disease (RHD); (ii) non-rheumatic degenerative valve disease; (iii) congenital valve abnormalities including bicuspid aortic valve disease; (iv) cardiovascular implanted electronic devices (CIEDs); and (v) hypertrophic cardiomyopathy.<sup>47,103,104</sup> Some epidemiological data suggest that certain conditions stratified as intermediate risk are associated

**Table 5** General prevention measures to be followed in patients at high and intermediate risk of infective endocarditis

Patients should be encouraged to maintain twice daily tooth cleaning and to seek professional dental cleaning and follow-up at least twice yearly for high-risk patients and yearly for others.
Strict cutaneous hygiene, including optimized treatment of chronic skin conditions.
Disinfection of wounds.
Curative antibiotics for any focus of bacterial infection.
No self-medication with antibiotics.
Strict infection control measures for any at-risk procedure.
Discouragement of piercing and tattooing.
Limitation of infusion catheters and invasive procedures, when possible.
Strict adherence to care bundles for central and peripheral cannulae should be performed.

with a higher risk of IE compared with the background population,<sup>47,90,103</sup> but further studies are required. In patients at intermediate risk of IE, antibiotic prophylaxis is not routinely recommended and may be considered on an individual basis. However, prevention measures (Table 5) are strongly encouraged in these patients.<sup>7</sup>

Most of the IE in recipients of solid organ transplant is nosocomial. A recent systematic review of patient-level data including 57 heart transplant patients has shown that IE occurs frequently during the first year post-transplant, and the most common pathogen is *S. aureus* followed by *Aspergillus fumigatus*.<sup>105</sup> Oral streptococci are a very infrequent cause of IE, making the value of antibiotic prophylaxis after invasive orodental procedures questionable. However, IE in this group of patients is associated with very high mortality, particularly in patients with fungal IE. In contrast, other series that include a larger proportion of non-cardiac solid organ transplant patients have shown that the pathogens are more frequently from the *Staphylococcus* spp. and the mortality seems to be similar to that of patients without solid organ transplant.<sup>106,107</sup>

### Recommendation Table 1 — Recommendations for antibiotic prophylaxis in patients with cardiovascular diseases undergoing oro-dental procedures at increased risk for infective endocarditis

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>
General prevention measures are recommended in individuals at high and intermediate risk for IE.	I	C
Antibiotic prophylaxis is recommended in patients with previous IE. <sup>47,84,86</sup>	I	B
Antibiotic prophylaxis is recommended in patients with surgically implanted prosthetic valves and with any material used for surgical cardiac valve repair. <sup>47,87–89</sup>	I	C
Antibiotic prophylaxis is recommended in patients with transcatheter implanted aortic and pulmonary valvular prostheses. <sup>91–94</sup>	I	C
Antibiotic prophylaxis is recommended in patients with untreated cyanotic CHD, and patients treated with surgery or transcatheter procedures with post-operative palliative shunts, conduits, or other prostheses. After surgical repair, in the absence of residual defects or valve prostheses, antibiotic prophylaxis is recommended only for the first 6 months after the procedure. <sup>8,47,97,101</sup>	I	C
Antibiotic prophylaxis is recommended in patients with ventricular assist devices. <sup>102</sup>	I	C
Antibiotic prophylaxis should be considered in patients with transcatheter mitral and tricuspid valve repair. <sup>95</sup>	IIa	C
Antibiotic prophylaxis may be considered in recipients of heart transplant. <sup>105–107</sup>	IIb	C
Antibiotic prophylaxis is not recommended in other patients at low risk for IE. <sup>11,51</sup>	III	C

CHD, congenital heart disease; IE, infective endocarditis.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

## 3.3. Situations and procedures at risk

### 3.3.1. Dental procedures

Antibiotic prophylaxis is recommended in patients at high risk of IE undergoing at-risk dental procedures and is not currently recommended in other situations. At-risk dental procedures include dental extractions, oral surgery procedures (including periodontal surgery, implant surgery, and oral biopsies), and dental procedures involving manipulation of the gingival or periapical region of the teeth (including scaling and root canal procedures).<sup>49,108</sup> The use of dental implants raises concerns about potential risk due to foreign material at the interface between the buccal cavity and blood, but available data remain very limited.<sup>109</sup> So far there is no evidence to contraindicate implants in all patients at risk and the indication should be discussed on an individual basis. Implant placement procedures, and invasive dental procedures on established implants, however, should be covered by antibiotic prophylaxis in those at high risk of IE. Once dental implants are placed in high-risk patients, professional dental hygiene and follow-up should be performed at least twice yearly under antibiotic cover, when indicated.

The main target for antibiotic prophylaxis is oral streptococci. Table 6 summarizes the main regimens of antibiotic prophylaxis recommended before dental procedures. The risk of adverse fatal/non-fatal events appear to be extremely low for amoxicillin but high for clindamycin (mainly related to *Clostridioides difficile* infections).<sup>63,110–112</sup> Accordingly, this Task Force does not recommend the use of clindamycin for antibiotic prophylaxis.

**Table 6** Prophylactic antibiotic regime for high-risk dental procedures

Situation	Antibiotic	Single-dose 30–60 min before procedure	
		Adults	Children
No allergy to penicillin or ampicillin	Amoxicillin	2 g orally	50 mg/kg orally
	Ampicillin	2 g i.m. or i.v.	50 mg/kg i.v. or i.m.
	Cefazolin or ceftriaxone	1 g i.m. or i.v.	50 mg/kg i.v. or i.m.
Allergy to penicillin or ampicillin	Cephalexin <sup>a,b</sup>	2 g orally	50 mg/kg orally
	Azithromycin or clarithromycin	500 mg orally	15 mg/kg orally
	Doxycycline	100 mg orally	<45 kg, 2.2 mg/kg orally >45 kg, 100 mg orally
	Cefazolin or ceftriaxone <sup>b</sup>	1 g i.m. or i.v.	50 mg/kg i.v. or i.m.

i.m., intramuscular; i.v., intravenous.

<sup>a</sup>Or other first- or second-generation oral cephalosporin in equivalent adult or paediatric dosing.

<sup>b</sup>Cephalosporins should not be used in an individual with a history of anaphylaxis, angioedema, or urticarial with penicillin or ampicillin.

### 3.3.2. Non-dental procedures

No convincing evidence has been brought forward on the relationship between bacteraemia resulting from a non-dental procedure and risk of subsequent IE. However, observational studies reported that, compared with patients with IE not undergoing an invasive procedure,

several invasive non-dental medical procedures were associated with increased risk of IE, including cardiovascular interventions, skin procedures and wound management, transfusion, dialysis, bone marrow puncture, and endoscopic procedures.<sup>6,11,51</sup> For this reason, an aseptic operational environment should be ensured during all these procedures to minimize the risk of IE. As previously indicated, it is very unlikely that an RCT on antibiotic prophylaxis for IE will be performed in the foreseeable future. However, at-risk patients have longer survival due to the advent of newer medical and device-based medical therapies. In addition, the ageing general population with their accumulating number of co-morbidities has an increased risk of surgical therapy, if IE occurs. For these reasons, this Task Force no longer felt that a class III recommendation for antibiotic prophylaxis in high-risk patients undergoing non-dental medical procedures (see Recommendation Table 2) was appropriate, despite the limitations of observational data used to support this class IIb recommendation.

### 3.3.3. Cardiac or vascular interventions

In all patients undergoing implantation of a prosthetic valve, any type of prosthetic graft/occluder device or CIED, peri-operative antibiotic

prophylaxis is recommended due to the increased risk and adverse outcome of an infection.<sup>6</sup> The most frequent microorganisms underlying early (1 year after surgery) surgical PVE are coagulase-negative staphylococci (CoNS) and *S. aureus*. Pre-operative screening of nasal carriage for *S. aureus* is recommended before elective cardiac surgery or transcatheter valve implantation to treat carriers using local mupirocin and chlorhexidine.<sup>113,114</sup> Rapid identification techniques using gene amplification are useful to avoid delaying urgent surgery. Systematic local treatment without screening is not recommended. It is strongly recommended that potential sources of dental sepsis should be eliminated at least 2 weeks before implantation of a prosthetic valve or other intracardiac or intravascular foreign material unless the latter procedure is urgent. For specific prophylactic measures in other cardiac and vascular interventions (i.e. CIED, transcatheter aortic valve implantation [TAVI]), please see the [Supplementary data online, Section S1.1](#).

### 3.4. Patient education

Preventing IE also depends on preventive measures other than antibiotic prophylaxis. People at risk should be educated to maintain good dental and skin hygiene, to look out for signs of infection and, when

## Education of high-risk patients to prevent infective endocarditis

Maintain good dental hygiene

Use dental floss daily

Brush teeth morning and evening

See your dentist for regular check-ups

Maintain good skin hygiene

Minimize risk of skin lesions

In case of lesions, observe for signs of infection (redness, swelling, tenderness, puss)

Avoid tattoos and piercings

Be mindful of infections

If experiencing fever for no obvious reason, contact your doctor, and discuss appropriate action based on your risk of endocarditis

Do not self prescribe antibiotics

Show this card to your doctors before any interventions

ESC

**Figure 2** Education of high-risk patients to prevent infective endocarditis.

experiencing fever of unknown origin, report to their physician that they are at risk, in which case clinicians should consider screening for IE before initiating antibiotics.

Use of non-medical language, visual aids, digital tools, repetition, and teach back methods all aid the patients' comprehension and is encouraged.<sup>115</sup> National cardiology societies should be encouraged to develop specific IE cards for patient awareness (Figure 2).

**Recommendation Table 2 — Recommendations for infective endocarditis prevention in high-risk patients**

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>
Antibiotic prophylaxis is recommended in dental extractions, oral surgery procedures, and procedures requiring manipulation of the gingival or periapical region of the teeth. <sup>11,49,51,108</sup>	I	B
Systemic antibiotic prophylaxis may be considered for high-risk <sup>c</sup> patients undergoing an invasive diagnostic or therapeutic procedure of the respiratory, gastrointestinal, genitourinary tract, skin, or musculoskeletal systems. <sup>6,11</sup>	IIb	C

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

<sup>c</sup>This recommendation does not apply to patients with intermediate risk for IE or to the general population.

**Recommendation Table 3 — Recommendations for infective endocarditis prevention in cardiac procedures**

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>
Pre-operative screening for nasal carriage of <i>S. aureus</i> is recommended before elective cardiac surgery or transcatheter valve implantation to treat carriers. <sup>113,114</sup>	I	A
Peri-operative antibiotic prophylaxis is recommended before placement of a CIED. <sup>116–118</sup>	I	A
Optimal pre-procedural aseptic measures of the site of implantation is recommended to prevent CIED infections. <sup>119</sup>	I	B
Periprocedural antibiotic prophylaxis is recommended in patients undergoing surgical or transcatheter implantation of a prosthetic valve, intravascular prosthetic, or other foreign material. <sup>120</sup>	I	B
Surgical standard aseptic measures are recommended during the insertion and manipulation of catheters in the catheterization laboratory environment.	I	C
Elimination of potential sources of sepsis (including of dental origin) should be considered ≥2 weeks before implantation of a prosthetic valve or other intracardiac or intravascular foreign material, except in urgent procedures.	IIa	C

Continued

Antibiotic prophylaxis covering for common skin flora including <i>Enterococcus</i> spp. and <i>S. aureus</i> should be considered before TAVI and other transcatheter valvular procedures. <sup>121</sup>	IIa	C
Systematic skin or nasal decolonization without screening for <i>S. aureus</i> is not recommended.	III	C

CIED, cardiac implantable electronic device; TAVI, transcatheter aortic valve implantation.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

**4. The Endocarditis Team**


The importance of an Endocarditis Team in the diagnosis, management, and clinical outcomes of patients with IE has been demonstrated in several observational studies.<sup>36–41,122–126</sup> Establishing multidisciplinary endocarditis teams according to the European Society of Cardiology (ESC) and the American College of Cardiology/American Heart Association Guidelines<sup>4,127,128</sup> has resulted in earlier and more accurate diagnosis of the primary disease and its complications,<sup>5,22,31,40,129</sup> uniform antibiotic treatment,<sup>36,40,123</sup> and optimized timing for surgical intervention.<sup>36,37,40,123</sup> A variety of scenarios of patients presenting with IE justifies a multidisciplinary approach.<sup>5,25,27,28,130–135</sup>

Furthermore, the clinical presentation may vary significantly depending on the characteristics of the host and virulence of the microorganism. Accordingly, the concept of the Endocarditis Team needs to embrace a multidisciplinary approach that must adapt according to the patient's clinical needs and the local epidemiology to ensure prompt diagnosis and treatment.

The members of the Endocarditis Team should include the specialists with direct involvement in the diagnostic and therapeutic processes (Table 7), and may vary depending on the type of centre. In the

**Table 7 Members of the Endocarditis Team**

	Heart Valve Centre
<b>Core members</b>	<ul style="list-style-type: none"> <li>• Cardiologists.</li> <li>• Cardiac imaging experts.</li> <li>• Cardiovascular surgeons.</li> <li>• Infectious disease specialist (or internal medicine specialist with expertise in infectious diseases).</li> <li>• Microbiologist.</li> <li>• Specialist in outpatient parenteral antibiotic treatment.</li> </ul>
<b>Adjunct specialities</b>	<ul style="list-style-type: none"> <li>• Radiologist and nuclear medicine specialist.</li> <li>• Pharmacologist.</li> <li>• Neurologist and neurosurgeon.</li> <li>• Nephrologist.</li> <li>• Anaesthesiologists.</li> <li>• Critical care.</li> <li>• Multidisciplinary addiction medicine teams.</li> <li>• Geriatricians.</li> <li>• Social worker.</li> <li>• Nurses.</li> <li>• Pathologist.</li> </ul>



**Figure 3** Management of patients with infective endocarditis: positioning of the Endocarditis Team. CIED, cardiovascular implanted electronic device; ESC, European Society of Cardiology.

Heart Valve Centre, a centre having all diagnostic and therapeutic resources to treat IE, the core members of the Endocarditis Team should include cardiologists, cardiovascular surgeons, infectious disease specialists (or internal medicine specialists with expertise in infectious diseases), and microbiologists. Furthermore, for specific clinical questions, cardiologists/surgeons with expertise in CIED extraction, HF, and CHD; pathologists; critical care specialists; cardiac anaesthesiologists; interventional cardiologists; neurologists and neurosurgeons; pharmacologists; radiologists and nuclear medicine specialists;

nephrologists; geriatricians; and multidisciplinary addiction medicine teams (psychiatrists, nurses, and social work specialists providing counselling) are crucial adjuncts that should be available onsite for consultation. Specific subgroups of complex and high-risk patients are frequently assessed by the Endocarditis Team. The decision-making process may involve difficult decisions regarding continuation of therapy, and legal counsel may therefore be required.

Cardiovascular imaging has achieved such an advanced sophistication in the diagnosis of IE that the cardiologists with expertise in

multimodality imaging are key in the Endocarditis Team. In addition, radiology and nuclear medicine specialists with expertise on clinical cardiovascular imaging should be available whenever indicated.<sup>22,31,129</sup> The Endocarditis Team must meet on a frequent basis and work with standard operating procedures and the clinical governance arrangements defined locally.<sup>128,136</sup> Although the decision of timing is left to the discretion of the local team, a weekly meeting is to be considered.

In Referring Centres, i.e. those without a cardiovascular surgical team, the treating physician diagnosing IE should consult with a specialist in infectious diseases (or an internal medicine specialist with expertise in infectious diseases) and the microbiologist.<sup>136</sup> In addition, a cardiologist with expertise in valvular heart disease and cardiac imaging should be present to provide the initial and subsequent evaluations with echocardiography. Information of the strains of the isolated microorganisms, usually kept for 7–15 days, should be provided to the Heart Valve Centre if requested.

Communication between Referring Centres and the Heart Valve Centres should be facilitated with digital solutions that enable reliable data sharing. Early referral to the Heart Valve Centre for further diagnostic testing and clinical management should be available when deemed necessary (Figure 3). When there is evidence of failure to respond to the antibiotic therapy or there are complications related to valvular tissue destruction, the Referring Centre should consult the Heart Valve Centre. The Endocarditis Team of the Heart Valve Centre should share protocols with the physicians from the referring hospitals and should facilitate their continuing education.<sup>136</sup>

A critical aspect of the Endocarditis Team decision-making process is defining when a patient must be transferred to a Heart Valve Centre to expedite advanced diagnostics and therapy. The indications for transfer are comprehensive, to facilitate interhospital communication and avoid delaying therapy to improve prognosis.

**Recommendation Table 4 — Recommendations for the Endocarditis Team**

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>
Diagnosis and management of patients with complicated IE are recommended to be performed at an early stage in a Heart Valve Centre, with immediate surgical facilities and an 'Endocarditis Team' to improve the outcomes. <sup>36–41,122,123,125,126</sup>	I	B
For patients with uncomplicated IE managed in a Referring Centre, early and regular communication between the local and the Heart Valve Centre endocarditis teams is recommended to improve the outcomes of the patients. <sup>36–41,122,123,125,126</sup>	I	B

© ESC 2023

IE, infective endocarditis.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

## 5. Diagnosis

The diagnosis of IE is based on a clinical suspicion supported by consistent microbiological data and the documentation of IE-related cardiac lesions by imaging techniques. Evidence of involvement of cardiac valves (native or prosthetic) or prosthetic intracardiac material is a major diagnostic criterion of IE. Echocardiography is the first-line diagnostic

imaging technique. Other imaging modalities such as CT, nuclear imaging, and magnetic resonance imaging (MRI) are currently part of the diagnostic strategy of suspected IE, given their ability to provide key information to confirm IE diagnosis, to assess local IE complications as well as IE-related distant lesions, and to identify the original source of bacteraemia in patients who develop secondary IE.<sup>137</sup> Beyond diagnosis of IE, imaging findings also have prognostic implications.

### 5.1. Clinical features

Infective endocarditis remains a diagnostic challenge due to its variable clinical presentation. In general, a diagnosis of IE should be considered in all patients with sepsis or fever of unknown origin in the presence of risk factors. Infective endocarditis may present as an acute, rapidly progressive infection, but also as a subacute or chronic disease with low-grade, or even no fever, and non-specific symptoms that may mislead or confuse initial assessment. Infective endocarditis can also present with a complication mimicking a wide range of medical conditions that may prompt evaluation of other diseases, such as rheumatological, neurological, and autoimmune disorders, or even malignancy, before reaching a diagnosis of IE. Therefore, high suspicion for IE is generally driven by fever and positive blood cultures in the absence of an alternative focus of infection, especially in patients with one or more risk factors. Early involvement of the Endocarditis Team to guide management is highly recommended.

The initial clinical assessment should include evaluation of cardiac and non-cardiac risk factors (Table 8), supportive clinical context, and physical examination findings including potential portals of entry. Physical examination may reveal a variety of clinical signs. However, the absence of clinical signs alone should not exclude IE since the overall sensitivity and specificity of the clinical signs are low.

In the European Infective Endocarditis Registry (EURO-ENDO), fever (77.7%), cardiac murmur (64.5%), and congestive HF (27.2%) were the most frequent clinical presentations.<sup>5</sup> Embolic complications were detected in 25.3% of patients and cardiac conduction abnormalities were found in 11.5%. Some classical signs, such as peripheral stigmata, are less frequently observed, but may still be observed in severe infections caused by *S. aureus* and in cases of subacute endocarditis (mainly caused by *Streptococcus* spp.). However, vascular and immunological phenomena, such as splinter haemorrhages,<sup>138</sup> Roth spots, and

**Table 8 Cardiac and non-cardiac risk factors**

Cardiac risk factors
Previous infective endocarditis
Valvular heart disease
Prosthetic heart valve
Central venous or arterial catheter
Transvenous cardiac implantable electronic device
Congenital heart disease
Non-cardiac risk factors
Central venous catheter
People who inject drugs
Immunosuppression
Recent dental or surgical procedures
Recent hospitalization
Haemodialysis

Downloaded from https://academic.oup.com/eurheartj/article/44/39/3948/7243107 by Universiteit Leiden - LUMC user on 14 March 2024

© ESC 2023

glomerulonephritis, remain common. The main symptoms and signs observed in the EURO-ENDO registry are shown in the [Supplementary data online, Table S1](#). Atypical presentation is common in elderly or immunocompromised patients.<sup>139–141</sup> A high index of suspicion and low threshold for investigation are therefore essential to exclude IE or avoid delays in diagnosis in these and other high-risk groups, such as those with CHD or prosthetic valves.<sup>142</sup> It is important to inform those patients about the risk of IE who should be aware of compatible symptoms to ask for advice in referral centres.

## 5.2. Laboratory findings

Laboratory investigations and biomarkers typically yield non-specific results. A large number of potential biomarkers have been proposed, reflecting the complex pathophysiology of the pro- and anti-inflammatory processes, humoral and cellular reactions, and both circulatory and end-organ abnormalities involved in IE.<sup>143</sup> The degree of anaemia, leucocytosis/leucopaenia, the number of immature white cell forms, concentrations of C-reactive protein and procalcitonin, erythrocyte sedimentation rate, and markers of end-organ dysfunction (serum lactate, serum creatinine, bilirubin, thrombocytopenia, cardiac troponin, and natriuretic brain peptides) can be used to estimate the severity of sepsis, but none is diagnostic of IE. C-reactive protein and procalcitonin are the most widely evaluated biomarkers in RCTs of antibiotic stewardship. Furthermore, several of these biomarkers are included in scores used for risk stratification in critically ill patients. Unfortunately, no biomarker has sufficient accuracy for the diagnosis of sepsis or specificity for IE.<sup>144</sup> Therefore, the main role of biomarkers is to facilitate initial risk stratification and monitor the response to antibiotic therapy.

## 5.3. Microbiological diagnosis

The aetiology of IE is described in the EURO-ENDO registry<sup>5</sup> and the International Collaboration on Endocarditis-Prospective Cohort Study (ICE-PCS).<sup>145</sup> In 2009, the ICE-PCS showed that the most frequent microorganisms causing IE were *S. aureus* (31%), followed by oral streptococci (17%), and CoNS (11%).<sup>145</sup> Similar results were reported in the EURO-ENDO registry.<sup>5,145</sup> Other registries have highlighted the increasing incidence of IE caused by *E. faecalis* and CoNS, particularly in the elderly.<sup>146–149</sup> However, the results of these registries should be carefully interpreted due to inherent biases (type of participating centres, geographical differences, lack of complete granular data, etc.).

### 5.3.1. Blood culture-positive infective endocarditis

Positive blood cultures remain the cornerstone of IE diagnosis and provide live bacteria for both identification and susceptibility testing. At least three sets of blood cultures should be obtained at 30-minute intervals prior to antibiotic therapy, each containing 10 mL of blood, and should be incubated in both aerobic and anaerobic atmospheres.<sup>150,151</sup> Sampling should be obtained from a peripheral vein rather than from a central venous catheter (because of the risk of contamination and misleading interpretation), using a meticulous sterile technique. In the absence of previous antimicrobial therapy, this is virtually always sufficient to identify the usual causative microorganisms. The need for culture before antibiotic administration is self-evident. In IE, bacteraemia is almost constant and has two implications: (i) there is no rationale for delaying blood sampling to coincide with peaks of

fever; and (ii) nearly all blood cultures are positive during bacteraemia. As a result, a single positive blood culture should be regarded cautiously for establishing IE diagnosis. The microbiology laboratory should be aware of the clinical suspicion of IE. Automated machines perform continuous monitoring of bacterial growth, which ensures quick provision of reports to physicians. When a positive blood culture is identified, presumptive identification is based on Gram staining. This information is immediately given to clinicians in order to adapt empirical antibiotic therapy. Complete identification is routinely achieved the same day or the following day with current methodology (e.g. matrix-assisted laser desorption ionization time-of-flight mass spectrometry [MALDI-TOF MS]), but may require a longer time for fastidious or atypical organisms. Since there is a long delay between blood culture sampling and definitive identification of the organism responsible for the bacteraemia and antibiotic susceptibility testing, many improvements have been proposed to speed up the process of detection and identification. One of the most recent procedures for rapid bacterial identification is based on peptide spectra obtained by MALDI-TOF MS.<sup>152</sup> However, despite technical developments and the progress toward rapid susceptibility testing using MALDI-TOF MS, the gold standard for susceptibility testing is still the determination of the minimal inhibitory concentrations (MICs) to select appropriate antibiotic therapy, which needs to be performed following validated, standardized methodology.<sup>153</sup>

### 5.3.2. Blood culture-negative infective endocarditis

Blood culture-negative infective endocarditis (BCNIE) refers to IE in which no causative microorganism can be grown using the usual blood culture methods. The frequency of BCNIE as the cause of IE is highly variable and often poses considerable diagnostic and therapeutic dilemmas.<sup>154,155</sup> Blood culture-negative IE most commonly arises as a consequence of previous antibiotic administration, underlying the importance of performing blood cultures prior to antibiotic therapy, particularly in patients with known risk factors for IE. Withdrawal of antibiotics and repeating blood cultures may be required in stable patients with subacute symptoms, no evidence of local or distant complications, and receiving a very short course of antibiotics. Blood culture-negative IE can also be caused by fungi or fastidious bacteria, notably obligatory intracellular bacteria. Isolation of these microorganisms requires culturing on specialized media, and their growth is relatively slow. Depending on local epidemiology,<sup>156</sup> systematic serological testing for *Coxiella burnetii*, *Bartonella* spp., *Aspergillus* spp., *Mycoplasma pneumoniae*, *Brucella* spp., and *Legionella pneumophila* should be proposed,<sup>157</sup> followed by specific polymerase chain reaction (PCR) assays for *Tropheryma whipplei*, *Bartonella* spp., and fungi (*Candida* spp., *Aspergillus* spp.) from blood and the tissue (Table 9).<sup>158</sup>

In addition, 16S and 18S ribosomal ribonucleic acid (rRNA) sequencing from tissue is routinely performed in most laboratories and may provide a microorganism diagnosis in BCNIE. For patients with prosthetic valve BCNIE, molecular imaging technique fluorescence *in situ* hybridization combined with 16S rRNA-gene PCR and sequencing improved the conventional cultural diagnostic methods in 30% of cases.<sup>159</sup> Next-generation sequencing of plasma microbial cell-free deoxyribonucleic acid (DNA) may facilitate a rapid diagnosis of IE in the future.<sup>160</sup>

When all microbiological assays are negative, the diagnosis of non-bacterial endocarditis should systematically be considered and assays

**Table 9 Investigation of rare causes of blood culture-negative infective endocarditis**

Pathogen	Diagnostic procedures
<i>Brucella</i> spp.	Serology, blood cultures, tissue culture, immunohistology, and 16S rRNA sequencing of tissue
<i>C. burnetii</i>	Serology (IgG phase I >1:800), tissue culture, immunohistology, and 16S rRNA sequencing of tissue
<i>Bartonella</i> spp.	Serology (IgG phase I >1:800), blood cultures, tissue culture, immunohistology, and 16S rRNA sequencing of tissue
<i>T. whipplei</i>	Histology and 16S rRNA sequencing of tissue
<i>Mycoplasma</i> spp.	Serology, tissue culture, immunohistology, and 16S rRNA sequencing of tissue
<i>Legionella</i> spp.	Serology, blood cultures, tissue culture, immunohistology, and 16S rRNA sequencing of tissue
Fungi	Serology, blood cultures, 18S rRNA sequencing of tissue
Mycobacteria (including <i>Mycobacterium chimaera</i> )	Specific blood cultures, 16S rRNA sequencing of tissue

© ESC 2023

Ig, immunoglobulin; rRNA, ribosomal ribonucleic acid.

for antinuclear antibodies as well as antiphospholipid syndrome (APLs) (anticardiolipin antibodies [immunoglobulin (Ig)G] and anti- $\beta_2$ -glycoprotein 1 antibodies [IgG and IgM]) should be performed (although these antibodies may also be present in patients with proven IE).<sup>161,162</sup> Pathological examination of resected tissue or embolic fragments remains the gold standard for IE diagnosis. All tissue samples that are excised during surgical valve debridement/resection must be collected in a sterile container without fixative or culture medium. Samples should be sent to the pathology department and the microbiology laboratory for the identification of microorganisms. On histological examination of excised valve tissue, patterns, and degrees of inflammation will vary depending on the infecting organism. Stains for bacteria, mycobacteria, and fungi may identify the microorganisms, and organism-specific immunohistochemical stains can be very useful for the final diagnosis. Importantly, histopathological analysis may facilitate the diagnosis of non-infectious causes of endocarditis, such as neoplastic and autoimmune causes.<sup>160</sup>

### 5.3.3. Proposed strategy for a microbiological diagnostic algorithm in suspected infective endocarditis

A proposed diagnostic scheme is provided in [Figure 4](#). When there is clinical suspicion of IE and blood cultures remain negative at 48 h, consultation with the microbiologist is necessary.<sup>156,160</sup> A suggested strategy is the use of a diagnostic kit including blood cultures for the suspected microorganism and when negative, systematic serological


testing for *C. burnetii*, *Bartonella* spp., *Aspergillus* spp., *L. pneumophila*, *Brucella* spp., and *M. pneumoniae*, as well as rheumatoid factor, serological tests for APLs (anticardiolipin [IgG] and anti- $\beta_2$ -glycoprotein 1 [IgG and IgM]), antinuclear antibodies, and anti-pork antibodies. Serological testing should be performed taking into consideration the clinical characteristics of the patients (i.e. *Aspergillus* spp. in severe immunocompromised patients), the local epidemiology, and being aware of the specificity of the tests. In addition, tissue or prosthetic material obtained at surgery must be subjected to systematic culture, histological examination, and 16S or 18S rRNA sequencing aimed at documenting the presence of organisms.

## 5.4. Imaging techniques

Evidence of lesions characteristic of IE are major diagnostic criterion. Echocardiography is the first-line imaging technique to diagnose IE and to assess the structural and functional damage of cardiac structures. Echocardiographic findings have prognostic implications, and help to guide decision-making and patient follow-up while receiving antibiotic therapy and during the peri-operative and post-operative periods.<sup>163</sup> In some clinical scenarios, other imaging modalities, such as CT, nuclear imaging, and MRI, are needed to confirm or exclude the diagnosis of IE, to characterize the extent of the cardiac lesions, and to diagnose extracardiac complications. They can also provide additional useful information for patient management.<sup>137</sup> Each of these techniques has its diagnostic strengths and weaknesses (see [Supplementary data online, Table S2](#)). The use of an optimal imaging strategy depends on the availability of, and expertise in, each technique, but when indicated a multimodality imaging approach is essential for patients with suspected IE and should be strongly encouraged by the Endocarditis Team.<sup>21</sup>

### 5.4.1. Echocardiography

Transthoracic echocardiography (TTE) and transoesophageal echocardiography (TOE) are the first and key imaging techniques used to diagnose IE. Although echocardiography is widely accessible, significant variation in the use of TOE still exists.<sup>164</sup> Three-dimensional TOE and intracardiac echocardiography have also been shown to be useful for the diagnosis of IE and its complications.<sup>165</sup> However, the availability of intracardiac echocardiography is limited. Vegetation characteristics and size, perivalvular complications (abscess, pseudoaneurysm, new partial dehiscence of prosthetic valve), intracardiac fistula, and leaflet perforation are the main echocardiographic findings for the diagnosis and evaluation of local complications of IE (see [Supplementary data online, Table S3](#)). Importantly, vegetation size is a key metric that guides surgical indication, and vegetation size is defined as the maximal length of the vegetation.<sup>166</sup> When evaluating IE on native or prosthetic valves, TTE had low sensitivity but good specificity as compared with TOE.<sup>166</sup> TOE is helpful in a wide range of clinical scenarios, due to limitations of TTE to diagnose perivalvular complications, small vegetations, PVE, and vegetations associated with CIED. TOE is strongly recommended in patients with an inconclusive TTE, in patients with a negative TTE and a high suspicion of IE, as well as in patients with a positive TTE, in order to document local complications. Repeating TTE and/or TOE should be considered during follow-up of uncomplicated IE, in order to detect new silent complications and monitor vegetation size. The timing and mode (TTE or TOE) of repeated examination depend on the initial findings, type of microorganism, and initial response to therapy.



**Figure 4** Microbiological diagnostic algorithm in culture-positive and culture-negative infective endocarditis. BCNIE, blood cultures negative endocarditis; IE, infective endocarditis; MALDI-TOF MS, matrix-assisted laser desorption ionization time-of-flight mass spectrometry; PCR, polymerase chain reaction. <sup>a</sup>Qualified microbiological laboratory. <sup>b</sup>Immunological laboratory.

Echocardiographic imaging should be performed as soon as the IE diagnosis is suspected. The degree of valvular damage, the rate of peripheral embolic events, and the need for valve surgery increase with increasing time to initial echocardiographic assessment.<sup>167</sup> Echocardiography should be repeated 5–7 days after an initial normal or inconclusive echocardiography, if the suspicion of IE remains high, and in patients with diagnosed IE at high risk of complications (e.g. aggressive microorganisms, prosthetic valves).<sup>22,165,168,169</sup>

There is uncertainty regarding whether echocardiography should be systematically performed in patients with bloodstream infections due to different bacterial species, or if there are strategies (microbiological or imaging) that allow the identification of patients at higher risk of IE.

Scoring systems have been developed to help in the appropriate indication to perform echocardiography when bacteraemia of different microorganisms occurs (see [Supplementary data online, Table S4](#)).<sup>60,170–173</sup> The combination of microbiological parameters (type of microorganism and number of positive blood culture bottles) and cardiac-related risk factors (native valve disease, previous IE, prosthetic valve, and cardiac devices) may help identify the patients in whom echocardiography (TTE+TOE) is needed.<sup>19,174</sup> Three risk scores were recently developed to identify patients at high risk of IE caused by *S. aureus*, and those who should be evaluated with echocardiography (see [Supplementary data online, Section S2.2.1](#)).<sup>170–173,175–178</sup> The cut-off values of the various scores are provided in [Supplementary data online, Table S4](#).

### Recommendation Table 5 — Recommendations for the role of echocardiography in infective endocarditis

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>
<b>A. Diagnosis</b>		
TTE is recommended as the first-line imaging modality in suspected IE. <sup>166,179</sup>	I	B
TOE is recommended in all patients with clinical suspicion of IE and a negative or non-diagnostic TTE. <sup>166,178,179</sup>	I	B
TOE is recommended in patients with clinical suspicion of IE, when a prosthetic heart valve or an intracardiac device is present. <sup>166,178,179</sup>	I	B
Repeating TTE and/or TOE within 5–7 days is recommended in cases of initially negative or inconclusive examination when clinical suspicion of IE remains high. <sup>178</sup>	I	C
TOE is recommended in patients with suspected IE, even in cases with positive TTE, except in isolated right-sided native valve IE with good quality TTE examination and unequivocal echocardiographic findings. <sup>165,166,179</sup>	I	C
Performing an echocardiography should be considered in <i>S. aureus</i> , <i>E. faecalis</i> , and some <i>Streptococcus</i> spp. bacteraemia. <sup>19,149,174</sup>	IIa	B
<b>B. Follow-up under medical therapy</b>		
Repeating TTE and/or TOE is recommended as soon as a new complication of IE is suspected (new murmur, embolism, persisting fever and bacteraemia, HF, abscess, AVB). <sup>165,166,179</sup>	I	B
TOE is recommended when patient is stable before switching from intravenous to oral antibiotic therapy. <sup>43,180</sup>	I	B
During follow-up of uncomplicated IE, repeat TTE and/or TOE should be considered to detect new silent complications. The timing of repeat TTE and/or TOE depends on the initial findings, type of microorganism, and initial response to therapy. <sup>165,166,179</sup>	IIa	B
<b>C. Intra-operative echocardiography</b>		
Intra-operative echocardiography is recommended in all cases of IE requiring surgery. <sup>181</sup>	I	C
<b>D. Following completion of therapy</b>		
TTE and/or TOE are recommended at completion of antibiotic therapy for evaluation of cardiac and valve morphology and function in patients with IE who did not undergo heart valve surgery. <sup>182–184</sup>	I	C

AVB, atrioventricular block; HF, heart failure; IE, infective endocarditis; PVE, prosthetic valve endocarditis; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

#### 5.4.2. Computed tomography

The indications for CT in patients with suspected or diagnosed IE include:

- (i) Diagnosis of IE and cardiac complications. Cardiac CT is more accurate than TOE for diagnosing perivalvular and periprosthetic complications of IE (abscesses, pseudoaneurysms, and fistulae) and is recommended in both NVE and PVE if TOE is not conclusive or not feasible.<sup>33,168,169</sup> In addition, cardiac CT can significantly influence subsequent surgical decision-making.<sup>20,185,186</sup> Echocardiography continues to be superior for detecting valvular lesions, particularly small vegetations (<10 mm) which remain underdiagnosed by CT, but also leaflet perforations and fistulae (see [Supplementary data online, Table S3](#)).<sup>35,168,169</sup> Cardiac CT should be acquired according to the recommendations of cardiac CT guidelines to ensure high diagnostic accuracy, and can be performed alone or in combination with PET.<sup>187</sup>
- (ii) Detection of distant lesions and sources of bacteraemia. Whole-body and brain CT are useful for assessing IE systemic complications, including septic emboli. The detection of distant lesions adds a minor diagnostic criterion leading to a more conclusive diagnosis of definite or rejected IE, and can be relevant for decision-making.<sup>188</sup> CT angiography can detect mycotic arterial aneurysms complicating IE in almost any site of the vascular tree,<sup>189,190</sup> including the central nervous system (CNS). Although MRI is superior to CT for diagnosing neurological complications,<sup>191</sup> CT may be more feasible in an emergency setting and is an acceptable alternative for the detection of neurological complications, with a sensitivity of 90% and specificity of 86% in the detection of ischaemic and haemorrhagic lesions.<sup>192</sup> Finally, CT can also detect the extracardiac sources of the bacteraemia, including early neoplastic lesions, that may be important for patient management, and which need to be ideally addressed prior to undergoing heart valve surgery. However, CT does not replace the specific test indicated for the diagnosis of the extracardiac source of bacteraemia (i.e. colonoscopy in colon neoplasms).
- (iii) Pre-operative assessment. Cardiac CT is a valuable alternative for non-invasive assessment of coronary artery disease (CAD) before cardiac surgery in patients with IE.<sup>193</sup>
- (iv) Alternative diagnosis. In patients in whom IE is ruled out, or even in doubtful patients with possible IE, an alternative diagnosis can be reached by whole-body CT, as it can help to detect alternative infectious foci. However, in these circumstances, an [18]FDG positron emission tomography/computed tomography (PET/CT) is the preferred imaging technique.<sup>194</sup>

#### 5.4.3. Magnetic resonance imaging

The roles of MRI in the diagnostic work-up of IE include:

- (i) Diagnosis of IE and cardiac complications. The role of cardiac MRI to diagnose IE is limited by the low spatial resolution (as compared with cardiac CT) and the signal void generated by some prostheses impairing the assessment of prosthetic valve anatomy and function.<sup>195,196</sup>
- (ii) Diagnosis of neurological IE-related complications. MRI has higher sensitivity than CT for the diagnosis of neurological lesions and, hence, increases the likelihood of detecting neurological complications in patients with IE. Patients with IE might present CNS lesions in up to 60–80% of cases,<sup>197</sup> most of them corresponding to ischaemic lesions (50–80% of patients) that are often small and asymptomatic and do not impact on the decision-making.<sup>198</sup> Other lesions that may influence the decision-making, such as parenchymal or subarachnoid haemorrhages, abscesses, or mycotic aneurysms, are found in <10% of patients.<sup>198–201</sup> The systematic performance of brain MRI has shown to directly impact the

- diagnosis of IE, as it can add a minor diagnostic criterion in patients without neurological symptoms with non-definitive IE diagnosis. Brain MRI can reclassify 25% of patients with an initially inconclusive diagnosis for IE to a more conclusive diagnosis, thereby leading to an earlier diagnosis.<sup>151</sup> Cerebral microbleeds, found in 50–60% of patients with IE, are detected at gradient echo T2\* sequences.<sup>200,202</sup> Cerebral microbleeds should not be considered a minor criterion because there is no concordance with ischaemic lesions.<sup>203–205</sup>
- (iii) Diagnosis of spine lesions. MRI is the diagnostic modality of choice of spondylodiscitis and vertebral osteomyelitis with a diagnostic accuracy of 89–94%. MRI findings include vertebrae and disc oedema, paravertebral/epidural inflammation or abscess, bone erosion, and gadolinium enhancement of vertebrae and discs.<sup>32,206</sup> It should be acknowledged that when MRI is performed too early, the rate of false-negative increases.<sup>207</sup>

#### 5.4.4. Nuclear imaging positron emission tomography/computed tomography (angiography) and single photon emission tomography/computed tomography

Technical specifications of these imaging techniques are in the [Supplementary data online, Section S2.2.2](#). The roles of nuclear imaging techniques in the diagnostic work-up of IE include:

- (i) Diagnosis of IE and cardiac complications. [18F]FDG-PET/CT and white blood cell (WBC) single photon emission computed tomography (SPECT)/CT are recommended in suspected PVE in cases of inconclusive echocardiography. The most recent meta-analysis showed 86% sensitivity and 84% specificity for [18F]FDG-PET/CT in PVE.<sup>129</sup> Additional evidence demonstrating the incremental diagnostic value of [18F]FDG-PET/CT and WBC SPECT/CT is summarized in the [Supplementary data online, Section S2.2.2; Table S5](#).<sup>22,208–212</sup>

White blood cell SPECT/CT is an alternative nuclear imaging technique for the diagnosis of IE, when PET/CT is unavailable and inexperienced centres. The sensitivity of WBC SPECT/CT has been reported as 64–90% and the specificity as 36–100%; diagnostic ability significantly increases with the presence of periprosthetic abscesses.<sup>213–215</sup> <sup>99m</sup>Tc-hexamethylpropyleneamine oxime (99mTc-HMPAO)-SPECT/CT helped to reduce the number of misdiagnosed IE cases classified in the ‘possible IE’ category by the modified Duke criteria by 27%.<sup>216</sup>

In cases of NVE, the sensitivity of PET/CT and SPECT/CT is low (about 31%) but with a higher specificity (around 98%).<sup>211</sup> In NVE, the diagnosis of IE cannot be excluded in the absence of abnormal [18F]FDG uptake.<sup>217</sup> The more frequent presence of valve vegetations in comparison with paravalvular involvement in NVE compared with PVE leads to reduced inflammatory response and subsequently lower [18F]FDG and WBC uptake. The lower sensitivity of [18F]FDG-PET/CT is offset by other strengths of the technique, such as its ability to identify septic emboli when suspected.<sup>211,218–220</sup> Electrocardiogram (ECG)-gated PET may further improve the diagnostic accuracy.<sup>221</sup>

Combining PET/CT acquisition with a CT angiography (PET/CTA) allows the detection of metabolic findings ([18F]FDG uptake distribution and intensity) and anatomical findings (IE-related lesions) within a single imaging procedure, resulting in the clinical clarification of indeterminate findings and change in the management of the patients.<sup>22,211</sup> Such investigations may be particularly helpful in complex settings, such as patients with CHD<sup>222,223</sup> and/or aortic grafts.<sup>22,224</sup>

- (ii) Detection of distant lesions and sources of bacteraemia. Whole-body [18F]FDG-PET/CT imaging is particularly useful in patients with a suspicion or proven IE to identify distant lesions, mycotic aneurysms, and the portal of entry of the infection.<sup>225,226</sup> Septic emboli are typically located in the spleen, lungs (in right-sided IE), and kidneys, and metastatic infections in the intervertebral discs and/or the vertebral bone (spondylodiscitis) as well as in muscles and joints (septic arthritis) and liver.<sup>211,227,228</sup> [18F]FDG-PET/CT is less suited to detect cerebral septic embolism and mycotic aneurysms of intracerebral arteries due to the high physiological uptake of [18F]FDG in the brain.
- (iii) Monitoring response to antimicrobial treatment with [18F]FDG-PET/CT in patients with established IE and indication for surgery but who cannot be operated on due to unacceptable high risk and remain with long-term suppressive antibiotic treatment.<sup>137,184,229–236</sup>

#### Recommendation Table 6 — Recommendations for the role of computed tomography, nuclear imaging, and magnetic resonance in infective endocarditis

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>
Cardiac CTA is recommended in patients with possible NVE to detect valvular lesions and confirm the diagnosis of IE. <sup>33,168,169</sup>	I	B
[18F]FDG-PET/CT(A) and cardiac CTA are recommended in possible PVE to detect valvular lesions and confirm the diagnosis of IE. <sup>22,129,209,210,237–239</sup>	I	B
Cardiac CTA is recommended in NVE and PVE to diagnose paravalvular or periprosthetic complications if echocardiography is inconclusive. <sup>20,168,169,185,186</sup>	I	B
Brain and whole-body imaging (CT, [18F]FDG-PET/CT, and/or MRI) are recommended in symptomatic <sup>c</sup> patients with NVE and PVE to detect peripheral lesions or add minor diagnostic criteria. <sup>22,197–200,210,213,240,241</sup>	I	B
WBC SPECT/CT should be considered in patients with high clinical suspicion of PVE when echocardiography is negative or inconclusive and when PET/CT is unavailable. <sup>213–216</sup>	IIa	C
[18F]FDG-PET/CT(A) may be considered in possible CIED-related IE to confirm the diagnosis of IE. <sup>22,129,209,210,237,238</sup>	IIb	B
Brain and whole-body imaging (CT, [18F]FDG-PET/CT, and MRI) in NVE and PVE may be considered for screening of peripheral lesions in asymptomatic patients. <sup>188,197–201</sup>	IIb	B

[18F]FDG-PET/CT, <sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomography; CAD, coronary artery disease; CT, computed tomography; CTA, computed tomography angiography; IE, infective endocarditis; MRI, magnetic resonance imaging; NVE, native valve endocarditis; PVE, prosthetic valve endocarditis; WBC SPECT/CT, white blood cell single photon emission tomography/computed tomography.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

<sup>c</sup>Symptomatic: symptoms suggesting septic embolic complications.

## 5.5. Diagnostic criteria

Since 2000, clinical, microbiological, and imaging findings have been integrated in the modified Duke criteria (see [Supplementary data online, Table S6](#)), which have demonstrated an overall sensitivity of 80% for IE.<sup>151</sup> However, the clinical presentation of IE can be highly variable and some major limitations of the modified Duke criteria have become clear, particularly when prosthetic material is present (PVE, aortic grafts, cardiac devices, CHD). In these situations, echocardiography can be normal or inconclusive in up to 30% of cases despite the presence of IE.<sup>242–244</sup> Therefore, the 2015 ESC diagnostic criteria introduced a

multimodality imaging approach (echocardiography, cardiac/whole-body CT, cerebral MRI, [18F]FDG-PET/CT, and WBC SPECT/CT) to improve the diagnostic yield. This new approach has shown to be superior over the traditional diagnostic criteria.<sup>36–41,122,123,125,126,212</sup>

### 5.5.1. Modifications for the diagnosis of infective endocarditis

The current 2023 ESC Guidelines for the management of endocarditis introduce the following modifications for IE diagnosis:


- (i) Changes to the major and minor diagnostic criteria ([Table 10](#)).

**Table 10** Definitions of the 2023 European Society of Cardiology modified diagnostic criteria of infective endocarditis

Major criteria
<p><b>(i) Blood cultures positive for IE</b></p> <p>(a) Typical microorganisms consistent with IE from two separate blood cultures: Oral streptococci, <i>Streptococcus gallolyticus</i> (formerly <i>S. bovis</i>), HACEK group, <i>S. aureus</i>, <i>E. faecalis</i></p> <p>(b) Microorganisms consistent with IE from continuously positive blood cultures:</p> <ul style="list-style-type: none"> <li>• ≥2 positive blood cultures of blood samples drawn &gt;12 h apart.</li> <li>• All of 3 or a majority of ≥4 separate cultures of blood (with first and last samples drawn ≥1 h apart).</li> </ul> <p>(c) Single positive blood culture for <i>C. burnetii</i> or phase I IgG antibody titre &gt;1:800.</p> <p><b>(ii) Imaging positive for IE:</b> Valvular, perivalvular/periprosthetic and foreign material anatomic and metabolic lesions characteristic of IE detected by any of the following imaging techniques:</p> <ul style="list-style-type: none"> <li>• Echocardiography (TTE and TOE).</li> <li>• Cardiac CT.</li> <li>• [18F]-FDG-PET/CT(A).</li> <li>• WBC SPECT/CT.</li> </ul>
Minor criteria
<p><b>(i) Predisposing conditions (i.e. predisposing heart condition at high or intermediate risk of IE or PWIDs)<sup>a</sup></b></p> <p><b>(ii) Fever defined as temperature &gt;38°C</b></p> <p><b>(iii) Embolic vascular dissemination (including those asymptomatic detected by imaging only):</b></p> <ul style="list-style-type: none"> <li>• Major systemic and pulmonary emboli/infarcts and abscesses.</li> <li>• Haematogenous osteoarticular septic complications (i.e. spondylodiscitis).</li> <li>• Mycotic aneurysms.</li> <li>• Intracranial ischaemic/haemorrhagic lesions.</li> <li>• Conjunctival haemorrhages.</li> <li>• Janeway's lesions.</li> </ul> <p><b>(IV) Immunological phenomena:</b></p> <ul style="list-style-type: none"> <li>• Glomerulonephritis.</li> <li>• Osler nodes and Roth spots.</li> <li>• Rheumatoid factor.</li> </ul> <p><b>(V) Microbiological evidence:</b></p> <ul style="list-style-type: none"> <li>• Positive blood culture but does not meet a major criterion as noted above.</li> <li>• Serological evidence of active infection with organism consistent with IE.</li> </ul>
IE Classification (at admission and during follow-up)
<p><b>Definite:</b></p> <ul style="list-style-type: none"> <li>• 2 major criteria.</li> <li>• 1 major criterion and at least 3 minor criteria.</li> <li>• 5 minor criteria.</li> </ul> <p><b>Possible:</b></p> <ul style="list-style-type: none"> <li>• 1 major criterion and 1 or 2 minor criteria.</li> <li>• 3–4 minor criteria.</li> </ul> <p><b>Rejected:</b></p> <ul style="list-style-type: none"> <li>• Does not meet criteria for definite or possible at admission with or without a firm alternative diagnosis.</li> </ul>

[18F]-FDG-PET/CT, <sup>18</sup>F-fluorodeoxyglucose positron emission tomography; CT(A), computed tomography (angiography); HACEK, *Haemophilus*, *Aggregatibacter*, *Cardiobacterium*, *Eikenella*, and *Kingella*; IE, infective endocarditis; Ig, immunoglobulin; PWID, people who inject drugs; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography; WBC SPECT/CT, white blood cell single photon emission tomography/computed tomography.


<sup>a</sup>For detailed explanation of predisposing conditions, please see [Section 3](#).



**Figure 5** European Society of Cardiology 2023 algorithm for diagnosis of native valve infective endocarditis. [18F]FDG, <sup>18</sup>F-fluorodeoxyglucose; CT, computed tomography; CTA, computed tomography angiography; ESC, European Society of Cardiology; IE, infective endocarditis; MRI, magnetic resonance imaging; NVE, native valve endocarditis; PET, positron emission tomography; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography; WBC SPECT, white blood cell single photon emission tomography. <sup>a</sup>TOE for diagnosis and to detect perivalvular complications in all cases (unless right-sided NVE when TTE is good quality and conclusive).

- (ii) Specific diagnostic algorithms to support decision-making, especially in the recommended sequence of imaging techniques (Figures 5–7).
- (iii) CIED-related IE is considered a right-sided endocarditis for diagnostic purposes and is included in the diagnostic algorithms, but

its definitions and recommendations for management can be found in Section 12 and are in accordance with the specific European Heart Rhythm Association (EHRA) consensus on CIED infections.<sup>130</sup>



**Figure 6** European Society of Cardiology 2023 algorithm for diagnosis of prosthetic valve infective endocarditis. [18F]FDG, <sup>18</sup>F-fluorodeoxyglucose; CT, computed tomography; CTA, computed tomography angiography; ESC, European Society of Cardiology; IE, infective endocarditis; MRI, magnetic resonance imaging; PET, positron emission tomography; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography; WBC SPECT, white blood cell single photon emission tomography. <sup>a</sup>TOE for diagnosis and to detect perivalvular complications in all cases (unless right-sided NVE when TTE is good quality and conclusive).

The reasons to justify the changes in the diagnostic criteria include:


**5.5.1.1. Major criteria – microbiology**

*Enterococcus faecalis* should be acknowledged as a typical endocarditis bacterium, regardless of the place of acquisition or the source of infection. Currently, the modified Duke criteria fail to identify 30% of *E. faecalis* definite IE. Using data from a prospective study of 344 patients with *E. faecalis* bacteraemia evaluated with echocardiography,

Dahl *et al.* demonstrated that designating *E. faecalis* as a ‘typical’ endocarditis pathogen significantly improved the sensitivity to correctly identify definite IE, from 70% to 96%.<sup>245</sup>

**5.5.1.2. Major criteria – imaging**

(i) Diagnosis based on the presence of lesions characteristics of IE. Anatomic lesions and increased [18F]FDG uptake or WBC accumulation can be depicted by nuclear imaging techniques and add



**Figure 7** European Society of Cardiology 2023 algorithm for diagnosis of cardiac device-related infective endocarditis. CIED, cardiovascular implanted electronic device; CT, computed tomography; CTA, computed tomography angiography; ESC, European Society of Cardiology; IE, infective endocarditis; PET, positron emission tomography; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography; WBC SPECT, white blood cell single photon emission tomography.

a major diagnostic criterion. Definitions of the anatomic and metabolic features of the infective lesions can be found in the [Supplementary data online, Table S5](#).

- (ii) Abnormal prosthetic or periprosthetic uptake (intense focal or heterogeneous) detected by [18F]FDG-PET/CT or WBC SPECT/CT should be considered a major criterion for PVE, irrespective of the interval from surgery (see [Supplementary data online, Figure S1](#)). Published data support that intense focal or heterogeneous patterns is associated with a final diagnosis of infection, while post-operative inflammatory changes can be persistent more than 3 months after surgery, as noted in the previous guidelines. However, these inflammatory changes can be differentiated from infection even after recent valve implantation.<sup>246</sup> Therefore, a consensus of experts has concluded that the need for a time interval prior to investigation is questionable,

but accurate imaging interpretation by proper interpretation criteria is mandatory.<sup>233,236</sup>

#### 5.5.1.3. Minor criteria

Distant IE-related lesions include all lesions that can result from embolic events and from haematogenous seeding of bacteria. These lesions can be suspected due to specific symptoms or can be incidentally detected on imaging techniques. Spondylodiscitis is the most frequent osteoarticular infective complication in patients with IE.<sup>247,248</sup>

#### 5.5.1.4. Microbiological criteria

Molecular biology (16S/18S rRNA PCR sequencing) in cardiac tissue or embolic material has increased the diagnostic performance of IE with negative blood culture. The sensitivity ranges between 41% and 96% and the specificity is very high, ranging between 90% and 100%.<sup>249</sup>

### 5.5.1.5. Infective endocarditis classification

Infective endocarditis classification has been added to the 2023 ESC criteria. Possible IE cases include the combination of 1 major and 1 or 2 minor criteria. Infective endocarditis classification should be applied by the Endocarditis Team at admission and later at follow-up, taking into account the complete clinical, microbiology, imaging, and surgical information to establish the final diagnosis.

It is important to acknowledge that these new criteria should be prospectively validated.

### 5.5.2. The new 2023 European Society of Cardiology diagnostic algorithms

The diagnosis of IE is based on clinical suspicion, blood cultures, and imaging findings. Echocardiography is usually the first imaging technique to diagnose IE, although the use of other techniques, either for the diagnosis of cardiac involvement (cardiac CT, [18F]FDG-PET/CT, or WBC SPECT/CT), or for the diagnosis of distant lesions (cerebral MRI, whole-body CT, and/or PET/CT), is encouraged. In the presence of prosthetic valves and CIED, echocardiography is particularly limited and the aforementioned imaging techniques are strongly recommended. Adapted diagnostic algorithms for suspected IE in NVE, PVE, and CIED are displayed in [Figures 5–7](#), respectively.

## 6. Prognostic assessment at admission

The in-hospital mortality rate of patients with IE has remained largely unchanged over the past two decades, ranging from 15% to 30%.<sup>5,145,250,251</sup> Several patient characteristics, often occurring simultaneously, have been shown to confer an increased risk of death in IE. The rapid identification of patients at the highest risk may offer the opportunity to change the course of the disease (i.e. with urgent or emergency surgery) and improve prognosis. Predictors of poor outcome on admission of patients with IE are specified in the [Supplementary data online, Section S3.1; Table S7](#).

## 7. Antimicrobial therapy: principles and methods

### 7.1. General principles

Successful treatment of IE relies on microbial eradication by antimicrobial drugs. Surgery contributes by removing infected material. Bactericidal regimens are more effective than bacteriostatic therapy, both in animal experiments and in humans.<sup>252–254</sup> Aminoglycosides synergize with cell wall inhibitors (i.e. beta-lactams and glycopeptides) for bactericidal activity and are useful for shortening the duration of therapy (e.g. oral streptococci) and eradicating problematic organisms. However, the side effects of aminoglycosides should be taken into consideration and currently the combination of ampicillin with ceftriaxone has demonstrated effective in treating IE caused by *E. faecalis* irrespective of the presence of high-level aminoglycoside resistance (HLAR) and minimizing the risk of nephrotoxicity.<sup>255,256</sup>

One major hindrance to drug-induced killing is bacterial antibiotic tolerance. Tolerant microbes are not resistant (i.e. they are still susceptible to growth inhibition by the drug) but escape drug-induced killing and may resume growth after treatment discontinuation. Slow-growing and dormant microbes display phenotypic tolerance

towards most antimicrobials (except rifampin to some extent). They are present in vegetations and biofilms (complex communities of bacteria residing within an exopolysaccharide matrix that adheres to a surface, e.g. in PVE),<sup>257</sup> and justify the need for prolonged therapy to fully sterilize infected heart valves. Some bacteria carry mutations rendering them tolerant during both active growth and stationary (dormant) phases.<sup>258,259</sup> Bactericidal drug combinations are preferred to monotherapy against tolerant organisms (e.g. the combination of ampicillin and ceftriaxone in IE caused by *E. faecalis*).

Drug treatment of PVE should last longer (≥6 weeks) than that of NVE (2–6 weeks) but is otherwise similar. In staphylococcal PVE, the regimen should include rifampin whenever the strain is susceptible, even if some recent data have shown no differences in outcomes between patients with PVE treated with rifampin vs. those treated without.<sup>260,261</sup>

In NVE needing valve replacement by a prosthesis during antibiotic therapy, the post-operative antibiotic regimen should be that recommended for NVE, not for PVE. In both NVE and PVE, the duration of treatment is based on the first day of effective antibiotic therapy (negative blood culture in the case of initial positive blood culture), not on the day of surgery. A new full course of treatment should only start if valve cultures are positive.

Finally, there are important considerations in these recommendations:

- (i) Only published antibiotic efficacy data from clinical trials and cohort studies in patients with IE (or bacteraemia if there are no IE data) have been considered in these guidelines. Data from experimental IE models have not been taken into account. A recent systematic review evaluating the existing evidence about clinical benefits and harms of different antibiotic regimens used to treat patients with IE has shown that there is limited and low- to very low-quality evidence to make strong conclusions on the comparative effects of different antibiotic regimens on cure rates or other relevant clinical outcomes and, therefore, there is not enough evidence to support or reject any regimen of antibiotic therapy for the treatment of IE.<sup>262,263</sup>
- (ii) These guidelines have adopted the MIC breakpoints included in the 2022 EUCAST clinical breakpoint tables.<sup>42</sup> The EUCAST breakpoints are used to categorize results into three susceptibility categories:
  - Susceptible, standard dosing regimen: a microorganism is categorized as such, when there is a high likelihood of therapeutic success using a standard dosing regimen of the agent.
  - Susceptible, increased exposure: a microorganism is categorized as such when there is a high likelihood of therapeutic success because exposure to the agent is increased by adjusting the dosing regimen or by its concentration at the site of infection.
  - Resistant: a microorganism is categorized as such when there is a high likelihood of therapeutic failure even when there is increased exposure.


The term exposure is defined as a function of how the mode of administration, dose, dosing interval, infusion time, as well as distribution and excretion of the antimicrobial agent, will influence the infecting organism at the site of infection. The local laboratories are responsible for the use of appropriate methods and interpretative criteria and quality control of the test results (MIC) while the clinicians are responsible for adjusting the level of exposure by modifying the dosing strategy

(individual dose, frequency of dosing, mode of administration [oral or intravenous (i.v.)]).<sup>42</sup>

- (iii) Oral antimicrobial therapy. The POET trial has changed the paradigm of i.v. antibiotic treatment for IE.<sup>43</sup> For more than 60 years it had been considered that antibiotics should always be given intravenously. The POET trial has shown that after an initial phase of i.v. treatment, up to 20% of patients could complete the treatment by oral antibiotic therapy (see [Section 7.13.1](#)).<sup>43</sup> Therefore, as indicated in [Figure 8](#), the antibiotic treatment of IE has two phases. The first phase can last up to 2 weeks of hospital i.v. treatment using combinations of rapidly bactericidal antibiotics to destroy planktonic bacteria.<sup>257</sup> In this initial phase, cardiac surgery should be performed if indicated, infected foreign bodies should be removed, and cardiac as well as extracardiac abscesses should be drained. After this period, clinically stable patients can end the antibiotic treatment at home with i.v. (OPAT) or oral antibiotic regimens for up to 6 weeks in order to eliminate the dormant (resting) bacteria and prevent relapses.
- (iv) Aminoglycosides are not recommended in staphylococcal NVE because their clinical benefits have not been demonstrated, but they

can increase renal toxicity.<sup>255,264</sup> When they are indicated in other conditions (e.g. resistant oral streptococci),<sup>265</sup> aminoglycosides should be given for no longer than 2 weeks to reduce nephrotoxicity.<sup>266</sup>

- (v) Rifampin should be used only in foreign body infections such as PVE after 3–5 days of effective antibiotic therapy, once the bacteraemia has been cleared. The rationale supporting this recommendation is based on the likely antagonistic effect of the antibiotic combinations with rifampin against planktonic/replicating bacteria,<sup>267</sup> and the synergy seen against dormant bacteria within the biofilms and prevention of rifampin-resistant variants.<sup>268</sup> New evidence based on a small, retrospective study has questioned this approach and needs further validation.<sup>260</sup>
- (vi) Daptomycin has been recommended for treating staphylococcal and enterococcal endocarditis.<sup>269</sup> When daptomycin is indicated, it must be given at high doses (10 mg/kg once daily)<sup>270</sup> and combined with a second antibiotic (beta-lactams or fosfomycin in beta-lactam allergic patients) to increase activity and avoid the development of resistance.<sup>271</sup> It should be noted the use of fosfomycin is associated with increased risk of acute HF and renal failure due to the high load of sodium while the use of daptomycin has been associated with eosinophilic syndromes in up to 15% of patients.<sup>272,273</sup>



**Figure 8** Phases of antibiotic treatment for infective endocarditis in relation to outpatient parenteral antibiotic therapy and partial oral endocarditis treatment. i.v., intravenous; OPAT, outpatient parenteral antibiotic treatment; TOE, transoesophageal echocardiography. <sup>a</sup>Criteria for switching to OPAT or partial oral treatment of endocarditis are given in the [Supplementary data online, Table S8](#).

- (vii) The antibiotic regimens need to adapt to the local circumstances and the availability of antibiotics.
- (viii) Data on the efficacy of long-term antibiotic suppressive therapy in patients with IE who do not undergo cardiac surgery are limited to small and heterogeneous series with various antibiotic regimens.<sup>184,274</sup> In a small series of Gram-positive bloodstream infections and IE, dalbavancin (500 mg weekly or 1000 mg biweekly regimens) has been shown effective.<sup>274,275</sup> Relapses are not infrequent.<sup>184</sup>

## 7.2. Penicillin-susceptible oral streptococci and *Streptococcus gallolyticus* group

Oral streptococci include the groups *mitis*, *sanguinis*, *anginosus*, *salivarius*, *downei*, and *mutans* (see [Supplementary data online, Figure S2](#)).<sup>276</sup> The remaining streptococci isolated outside of the oral cavity are classified into either the *Streptococcus gallolyticus* (former *bovis*) or pyogenic groups. Recommended regimens against susceptible (susceptible standard dosing regimen and increased exposure) streptococci are summarized in Recommendation Table 7.<sup>4,277–279</sup> The cure rate is expected to be >95%. In uncomplicated cases of NVE, short-term 2-week therapy can be administered by combining penicillin or ceftriaxone with gentamicin or netilmicin.<sup>280,281</sup> Gentamicin and netilmicin can be given once daily in patients with IE due to susceptible streptococci and normal renal function. When outpatient antibiotic therapy is feasible, ceftriaxone alone or combined with gentamicin or netilmicin given once a day is particularly convenient.<sup>280–282</sup> In patients with documented allergy to penicillin, desensitization is recommended. If desensitization cannot be performed, patients allergic to beta-lactam should receive

cephalosporins (in non-anaphylactic reaction) or vancomycin, keeping in mind that a beta-lactam is superior to glycopeptides. Teicoplanin has been proposed as an alternative,<sup>4</sup> starting with loading doses (6 mg/kg/12 h for 3 days) and followed by 6–10 mg/kg/day. Loading is critical because the drug is highly bound ( $\geq 98\%$ ) to serum proteins and penetrates slowly into vegetations.<sup>283</sup> However, only limited retrospective studies have assessed its efficacy in streptococcal IE.<sup>284</sup> After 10–14 days of therapy, OPAT or outpatient oral antibiotic therapy should be considered.

## 7.3. Oral streptococci and *Streptococcus gallolyticus* group susceptible, increased exposure or resistant to penicillin

The incidence of these resistant streptococci is increasing. Large strain collections have reported >30% of resistant *S. mitis* and *Streptococcus oralis*.<sup>285</sup>

Retrospective series provide the evidence for the recommendations on antibiotic treatment of IE caused by penicillin-resistant oral streptococci and *S. gallolyticus*. Compiling four of them, 47 of 60 patients (78%) were treated with penicillin or ceftriaxone, mostly combined with aminoglycosides.<sup>285–290</sup> In penicillin-resistant cases, aminoglycoside treatment must be given for  $\geq 2$  weeks and short-term therapy regimens are not recommended. There is very limited experience with daptomycin in IE caused by resistant isolates.<sup>265,291</sup> After 10–14 days of therapy, OPAT or outpatient oral antibiotic therapy should be considered if clinically stable (see [Section 7.13](#)).

**Recommendation Table 7 — Recommendations for antibiotic treatment of infective endocarditis due to oral streptococci and *Streptococcus gallolyticus* group**

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>	
<b>Penicillin-susceptible oral streptococci and <i>Streptococcus gallolyticus</i> group</b>			
<b>Standard treatment: 4-week duration in NVE or 6-week duration in PVE</b>			
In patients with IE due to oral streptococci and <i>S. gallolyticus</i> group, penicillin G, amoxicillin, or ceftriaxone are recommended for 4 (in NVE) or 6 weeks (in PVE), using the following doses. <sup>277,278</sup>	I	B	
<i>Adult antibiotic dosage and route</i>			
Penicillin G			12–18 million <sup>c</sup> U/day i.v. either in 4–6 doses or continuously
Amoxicillin			100–200 mg/kg/day i.v. in 4–6 doses
Ceftriaxone			2 g/day i.v. in 1 dose
<i>Paediatric antibiotic dosage and route</i>			
Penicillin G			200 000 U/kg/day i.v. in 4–6 divided doses
Amoxicillin			100–200 <sup>c</sup> mg/kg/day i.v. in 4–6 doses
Ceftriaxone			100 mg/kg/day i.v. in 1 dose
<b>Standard treatment: 2-week duration (not applicable to PVE)</b>			
2-week treatment with penicillin G, amoxicillin, ceftriaxone combined with gentamicin is recommended only for the treatment of non-complicated NVE due to oral streptococci and <i>S. gallolyticus</i> in patients with normal renal function using the following doses. <sup>277,278</sup>	I	B	
<i>Adult antibiotic dosage and route</i>			
Penicillin G			12–18 million <sup>c</sup> U/day i.v. either in 4–6 doses or continuously
Amoxicillin			100–200 mg/kg/day i.v. in 4–6 doses
Ceftriaxone			2 g/day i.v. in 1 dose
Gentamicin <sup>d</sup>			3 mg/kg/day i.v. or i.m. in 1 dose <sup>d</sup>

Continued

<b>Paediatric antibiotic dosage and route</b>			
Penicillin G	200 000 U/kg/day i.v. in 4–6 divided doses		
Amoxicillin	100–200 mg/kg/day <sup>c</sup> i.v. in 4–6 doses		
Ceftriaxone	100 mg/kg i.v. in 1 dose		
Gentamicin <sup>d</sup>	3 mg/kg/day i.v. or i.m. in 1 dose or 3 equally divided doses <sup>d</sup>		
<b>Allergy to beta-lactams</b>		<b>I</b>	<b>C</b>
In patients allergic to beta-lactams and with IE due to oral streptococci and <i>S. gallolyticus</i> , vancomycin for 4 weeks in NVE or for 6 weeks in PVE is recommended using the following doses: <sup>292</sup>			
<b>Adult antibiotic dosage and route</b>			
Vancomycin <sup>e</sup>	30 mg/kg/day i.v. in 2 doses <sup>e</sup>	<b>I</b>	<b>C</b>
<b>Paediatric antibiotic dosage and route</b>			
Vancomycin <sup>e</sup>	30 mg/kg/day i.v. in 2 or 3 equally divided doses <sup>e</sup>		
<b>Oral streptococci and Streptococcus gallolyticus group susceptible, increased exposure or resistant to penicillin</b>		<b>I</b>	<b>B</b>
In patients with NVE due to oral streptococci and <i>S. gallolyticus</i> , penicillin G, amoxicillin, or ceftriaxone for 4 weeks in combination with gentamicin for 2 weeks is recommended using the following doses: <sup>285–290</sup>			
<b>Adult antibiotic dosage and route</b>			
Penicillin G	24 million U/day i.v. either in 4–6 doses or continuously		
Amoxicillin	12 g/day i.v. in 6 doses		
Ceftriaxone	2 g/day i.v. in 1 dose		
Gentamicin	3 mg/kg/day i.v. or i.m. in 1 dose <sup>d</sup>	<b>I</b>	<b>B</b>
In patients with PVE due to oral streptococci and <i>S. gallolyticus</i> , penicillin G, amoxicillin, or ceftriaxone for 6 weeks combined with gentamicin for 2 weeks is recommended using the following doses: <sup>285–290</sup>			
<b>Adult antibiotic dosage and route</b>			
Penicillin G	24 million U/day i.v. either in 4–6 doses or continuously		
Amoxicillin	12 g/day i.v. in 6 doses		
Ceftriaxone	2 g/day i.v. in 1 dose		
Gentamicin <sup>d</sup>	3 mg/kg/day i.v. or i.m. in 1 dose <sup>d</sup>	<b>I</b>	<b>C</b>
<b>Allergy to beta-lactams</b>			
In patients with NVE due to oral streptococci and <i>S. gallolyticus</i> and who are allergic to beta-lactams, vancomycin for 4 weeks is recommended using the following doses:			
<b>Adult antibiotic dosage and route</b>		<b>I</b>	<b>C</b>
Vancomycin <sup>e</sup>	30 mg/kg/day i.v. in 2 doses <sup>e</sup>		
<b>Paediatric antibiotic dosage and route</b>			
Vancomycin <sup>e</sup>	30 mg/kg/day i.v. in 2 doses <sup>e</sup>	<b>I</b>	<b>C</b>
In patients with PVE due to oral streptococci and <i>S. gallolyticus</i> and who are allergic to beta-lactams, vancomycin for 6 weeks combined with gentamicin for 2 weeks is recommended using the following doses:			
<b>Adult antibiotic dosage and route</b>			
Vancomycin <sup>e</sup>	30 mg/kg/day i.v. in 2 doses <sup>e</sup>		
Gentamicin <sup>d</sup>	3 mg/kg/day i.v. or i.m. in 1 dose <sup>d</sup>		
<b>Paediatric antibiotic dosage and route</b>		<b>I</b>	<b>C</b>
Vancomycin <sup>e</sup>	30 mg/kg/day i.v. in 2 doses <sup>e</sup>		
Gentamicin <sup>d</sup>	3 mg/kg/day i.v. or i.m. in 1 dose <sup>d</sup>		

IE, infective endocarditis; i.m., intramuscular; i.v., intravenous; NVE, native valve endocarditis; PVE, prosthetic valve endocarditis; U, units.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

<sup>c</sup>The starting recommended doses are the lower doses which can be scalable to the highest doses.

<sup>d</sup>Maximum doses 240 mg/day. High doses are associated with increased risk of nephrotoxicity. Renal function and serum gentamicin concentrations should be monitored once a week. When given in a single daily dose, pre-dose (trough) concentrations should be <1 mg/L and post-dose (peak; 1 h after injection) serum concentrations should be ~10–12 mg/L.

<sup>e</sup>Serum vancomycin concentrations should achieve 10–15 mg/L at pre-dose (trough) level, although some experts recommend to increase the dose of vancomycin to 45–60 mg/kg/day i.v. in 2 or 3 divided doses to reach serum trough vancomycin levels ( $C_{min}$ ) of 15–20 mg/L as in staphylococcal endocarditis. However, vancomycin dose should not exceed 2 g/day unless serum levels are monitored and can be adjusted to obtain a peak plasma concentration of 30–45 µg/mL 1 h after completion of the i.v. infusion of the antibiotic.

## 7.4. *Streptococcus pneumoniae*, $\beta$ -haemolytic streptococci (groups A, B, C, and G)

Infective endocarditis due to *Streptococcus pneumoniae* has become rare. It is associated with meningitis and pneumonia in up to 30% of cases,<sup>293–296</sup> which requires special consideration in cases with penicillin resistance. Treatment of penicillin-susceptible strains is similar to that of oral streptococci (see Recommendation Table 7), except for the use of short-term 2-week therapy, which has not been thoroughly investigated. The same holds true for penicillin-susceptible increased exposure or resistant strains without meningitis, although for resistant strains some authors recommend high doses of cephalosporins (e.g. cefotaxime or ceftriaxone) or vancomycin.<sup>295</sup> In cases with meningitis, penicillin must be avoided because of its poor penetration into the cerebrospinal fluid, and should be replaced with ceftriaxone or cefotaxime alone, or in association with vancomycin according to the antibiotic susceptibility pattern.<sup>297,298</sup> After 10–14 days of therapy and when meningitis is not associated, OPAT or outpatient oral antibiotic therapy should be considered if clinically stable (see Section 7.13).

Infective endocarditis due to group A, B, C, or G streptococci, including the *Streptococcus anginosus* group (*S. constellatus*, *S. anginosus*, and *S. intermedius*) is relatively rare.<sup>299,300</sup> Group A streptococci are uniformly susceptible to beta-lactams, whereas other serogroups may display some degree of resistance. Infective endocarditis due to group B streptococci was once associated with the peripartum period, but it now occurs in all adults, especially the elderly. Groups B, C, and G streptococci and *S. anginosus* induce abscesses that require adjunctive surgery.<sup>300</sup> Mortality from group B PVE is very high and cardiac surgery is recommended.<sup>301</sup> Antibiotic treatment is similar to that of oral streptococci (see Recommendation Table 7), except that short-term (2 weeks) therapy is not recommended and gentamicin should be given for 2 weeks.

## 7.5. *Granulicatella* and *Abiotrophia* (formerly nutritionally variant streptococci)

*Granulicatella* and *Abiotrophia* induce IE with a prolonged course and are associated with large vegetations (>10 mm), and consequently with high rates of complications and valve replacement (around 50%).<sup>302,303</sup> This is possibly due to delayed diagnosis and treatment. Antibiotic recommendations include penicillin G, ceftriaxone, or vancomycin for 6 weeks, combined with an aminoglycoside for at least the first 2 weeks in case of PVE (for doses, please see Recommendation Table 7).<sup>302–304</sup>

## 7.6. *Staphylococcus aureus* and coagulase-negative staphylococci

*Staphylococcus aureus* is usually responsible for acute and destructive IE,<sup>305</sup> whereas CoNS can induce more protracted valve infections.<sup>306,307</sup> Of note, the addition of an aminoglycoside in staphylococcal NVE is no longer recommended because it increases renal toxicity.<sup>264,308</sup> Short-term (2-week) and oral treatments have been proposed for uncomplicated right-sided native valve methicillin-susceptible *S. aureus* (MSSA) IE (see also Section 12.4.2), but these regimens cannot be applied to left-sided IE. For penicillin-allergic patients with MSSA IE, penicillin desensitization can be attempted in stable patients or cefazolin can be used since vancomycin is inferior to beta-lactams.<sup>309</sup> If beta-lactams cannot be given, where available, daptomycin

should be chosen and given in combination with another effective anti-staphylococcal drug to increase activity and avoid the development of resistance.<sup>310</sup> *Staphylococcus lugdunensis* is mostly methicillin-susceptible and can be treated with cloxacillin.

*Staphylococcus aureus* PVE carries a very high risk of mortality (>45%),<sup>305,312,313</sup> and often requires early valve replacement. Other differences in comparison with NVE include the overall duration of therapy, the use of aminoglycosides, and the addition of rifampin after 3–5 days of effective antibiotic therapy once the bacteraemia has been cleared.<sup>264,314–318</sup> The rationale supporting this recommendation is based on the antagonistic effect of the antibiotic combinations with rifampin against planktonic/replicating bacteria as has been demonstrated in foreign body infection models and clinically in prosthetic orthopaedic and vascular infections.<sup>319</sup> However, a recent study has shown that the addition of aminoglycosides to a regimen containing vancomycin or cloxacillin plus rifampin in *S. aureus* PVE was not associated with a better outcome.<sup>320</sup> In addition, the risk of nephrotoxicity associated with the use of aminoglycosides should be taken into consideration. Adding rifampin to the treatment of staphylococcal PVE is standard practice despite the weak evidence.<sup>261,321</sup> The potential side effects and drug interactions of rifampin should also be considered. In patients with PVE who are allergic to penicillin, daptomycin can be given combined with ceftaroline or fosfomycin or with gentamicin (for 2 weeks) plus rifampin for at least 6 weeks. After 10–14 days of therapy, OPAT or outpatient oral antibiotic therapy should be considered if clinically stable (see Section 7.13).

## 7.7. Methicillin-resistant staphylococci

Methicillin-resistant *S. aureus* (MRSA) produces low-affinity penicillin-binding proteins (PBPs), which confer cross-resistance to most beta-lactams. Methicillin-resistant *S. aureus* is usually resistant to multiple antibiotics, leaving vancomycin, daptomycin, ceftaroline, and dalbavancin to treat severe infections.<sup>322–324</sup> However, it should be noted that subpopulations susceptible with increased exposure and resistant to vancomycin have emerged worldwide and are associated with IE treatment failures.<sup>325–328</sup> The prevalence of MRSA causing IE that is susceptible with increased exposure or resistant to vancomycin ranges between 19% and 34%. In addition, among patients with IE caused by MRSA, those isolates with a population analysis profile MIC  $\geq 4$  mg/L were associated with treatment failure defined by persistent bacteraemia for  $\geq 7$  days or MRSA-attributable mortality.<sup>325</sup> Nephrotoxicity is of concern when using trough monitoring of levels of vancomycin as a surrogate marker of the area under the curve relative to the MIC (AUC/MIC). Therefore, it is recommended to use a target of AUC/MIC between 400 and 600 mg\*h/L (assuming an MIC of 1 mg/L) that should be achieved with 48 h of therapy.<sup>329</sup> When the MIC is >1 mg/L, the probability of achieving an AUC/MIC  $\geq 400$  is unlikely. In that clinical scenario, changing therapy should be considered due to the high risk of nephrotoxicity with higher doses of vancomycin. Daptomycin is a lipopeptide antibiotic approved for *S. aureus* bacteraemia and right-sided IE.<sup>330</sup> Cohort studies of *S. aureus* and CoNS IE have shown that daptomycin is at least as effective as vancomycin,<sup>327,328</sup> and, in two cohort studies of MRSA bacteraemia with high vancomycin MICs (>1 mg/L),<sup>331,332</sup> daptomycin was associated with better outcomes (including survival) compared with vancomycin. Importantly, daptomycin needs to be administered in appropriate doses and combined with other antibiotics to avoid further resistance in patients with IE.<sup>330,333</sup> Therefore, daptomycin should be given at high doses (10 mg/kg), and most experts recommend its combination with beta-lactams<sup>334</sup> or fosfomycin<sup>335</sup> (beta-lactams [and probably fosfomycin] increase membrane

daptomycin binding by decreasing the positive surface charge) for NVE, and with gentamicin and rifampin for PVE.<sup>326–328</sup> However, in a randomized trial including 352 patients with MRSA bacteraemia, daptomycin or vancomycin combined with i.v. flucloxacillin, cloxacillin, or cefazolin did not result in a significant reduction of the primary composite endpoint of mortality, persistent bacteraemia, relapse, or treatment failure as compared with daptomycin or vancomycin alone.<sup>328</sup> The study was stopped prematurely before recruiting the target number of patients ( $n = 440$ ) due to increased incidence of acute kidney injury in the

combination therapy arm and, therefore, the results should be interpreted with caution.

Other alternatives include fosfomycin plus imipenem,<sup>336</sup> ceftaroline,<sup>337</sup> quinupristin–dalfopristin with or without beta-lactams,<sup>338,339</sup> beta-lactams plus oxazolidinones (linezolid),<sup>340</sup> beta-lactams plus vancomycin,<sup>341</sup> and high doses of trimethoprim/sulfamethoxazole and clindamycin.<sup>342,343</sup> These clinical and therapeutic scenarios warrant collaborative management with the Endocarditis Team including an infectious disease specialist, since the evidence is based on very small populations.

### Recommendation Table 8 — Recommendations for antibiotic treatment of infective endocarditis due to *Staphylococcus* spp.

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>
<b>IE caused by methicillin-susceptible staphylococci</b>		
In patients with NVE due to methicillin-susceptible staphylococci, (flu)cloxacillin or cefazolin is recommended for 4–6 weeks using the following doses: <sup>264,314,316–318</sup>		
<i>Adult antibiotic dosage and route</i>		
(Flu)cloxacillin <sup>c</sup>	I	B
Cefazolin <sup>e</sup>		
<i>Paediatric antibiotic dosage and route</i>		
(Flu)cloxacillin <sup>c</sup>	I	B
Cefazolin <sup>e</sup>		
In patients with PVE due to methicillin-susceptible staphylococci, (flu)cloxacillin or cefazolin with rifampin for at least 6 weeks and gentamicin for 2 weeks is recommended using the following doses: <sup>264,314,316–318,320</sup>		
<i>Adult antibiotic dosage and route</i>		
(Flu)cloxacillin <sup>c</sup>	I	B
Cefazolin		
Rifampin		
Gentamicin <sup>d</sup>		
<i>Paediatric antibiotic dosage and route</i>		
(Flu)cloxacillin <sup>c</sup>	I	B
Cefazolin		
Rifampin		
Gentamicin <sup>d</sup>		
<b>Allergy to beta-lactams</b>		
In patients with NVE due to methicillin-susceptible staphylococci who are allergic to penicillin, cefazolin for 4–6 weeks is recommended using the following doses: <sup>322–327</sup>		
<i>Adult antibiotic dosage and route</i>		
Cefazolin <sup>e</sup>	I	B
Cefazolin <sup>e</sup>		
<i>Paediatric antibiotic dosage and route</i>		
Cefazolin <sup>e</sup>	I	B
Cefazolin <sup>e</sup>		
Rifampin		
Gentamicin <sup>d</sup>		
<i>Paediatric antibiotic dosage and route</i>		
Cefazolin <sup>e</sup>	I	B
Cefazolin <sup>e</sup>		
Rifampin		
Gentamicin <sup>d</sup>		

Continued

In patients with NVE due to methicillin-susceptible staphylococci who are allergic to penicillin, daptomycin combined with ceftaroline or fosfomycin may be considered. <sup>322–327</sup>		IIb	C
<i>Adult antibiotic dosage and route</i>			
Daptomycin	10 mg/kg/day i.v. in 1 dose		
Ceftaroline <sup>f</sup>	1800 mg/day i.v. in 3 doses	IIb	C
OR	OR		
Fosfomycin <sup>g</sup>	8–12 g/day i.v. in 4 doses		
In patients with PVE due to methicillin-susceptible staphylococci who are allergic to penicillin, daptomycin combined with ceftaroline or fosfomycin or gentamicin with rifampin for at least 6 weeks and gentamicin for 2 weeks may be considered using the following doses: <sup>344</sup>		IIb	C
<i>Adult antibiotic dosage and route</i>			
Daptomycin	10 mg/kg/day i.v. in 1 dose		
Ceftaroline <sup>f</sup>	1800 mg/day i.v. in 3 doses		
OR	OR		
Fosfomycin <sup>g</sup>	8–12 g/day i.v. in 4 doses		
Rifampin	900 mg/day i.v. or orally in 3 equally divided doses	IIb	C
Gentamicin <sup>d</sup>	3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses		
<b>IE caused by methicillin-resistant staphylococci</b>			
In patients with NVE due to methicillin-resistant staphylococci, vancomycin is recommended for 4–6 weeks using the following doses: <sup>345</sup>		I	B
<i>Adult antibiotic dosage and route</i>			
Vancomycin <sup>h</sup>	30–60 mg/kg/day i.v. in 2–3 doses	I	B
<i>Paediatric antibiotic dosage and route</i>			
Vancomycin <sup>h</sup>	30 mg/kg/day i.v. in 2–3 equally divided doses		
In patients with PVE due to methicillin-resistant staphylococci, vancomycin with rifampin for at least 6 weeks and gentamicin for 2 weeks is recommended using the following doses:		I	B
<i>Adult antibiotic dosage and route</i>			
Vancomycin <sup>h</sup>	30–60 mg/kg/day i.v. in 2–3 doses		
Rifampin	900–1200 mg/day i.v. or orally in 2 or 3 divided doses		
Gentamicin <sup>d</sup>	3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses		
<i>Paediatric antibiotic dosage and route</i>			
Vancomycin <sup>h</sup>	30 mg/kg/day i.v. in 2–3 equally divided doses	I	B
Rifampin	20 mg/kg/day i.v. or orally in 2 or 3 divided doses		
Gentamicin <sup>d</sup>	3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses		
In patients with NVE due to methicillin-resistant staphylococci, daptomycin combined with cloxacillin, ceftaroline or fosfomycin may be considered using the following doses: <sup>335,345–349</sup>		IIb	C
<i>Adult antibiotic dosage and route</i>			
Daptomycin	10 mg/kg/day i.v. in 1 dose		
Cloxacillin <sup>c</sup>	12 g/day i.v. in 6 doses		
OR	OR		
Ceftaroline <sup>f</sup>	1800 mg/day i.v. in 3 doses		
OR	OR	IIb	C
Fosfomycin <sup>g</sup>	8–12 g/day i.v. in 4 doses		

IE, infective endocarditis; i.m., intramuscular; i.v., intravenous; NVE, native valve endocarditis; PVE, prosthetic valve endocarditis; U, units.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

<sup>c</sup>Cloxacillin is not recommended if the patient has penicillin allergy.

<sup>d</sup>Maximum doses 240 mg/day. High doses are associated with increased risk of nephrotoxicity. Renal function and serum gentamicin concentrations should be monitored once a week. When given in a single daily dose, pre-dose (trough) concentrations should be <1 mg/L and post-dose (peak; 1 h after injection) serum concentrations should be ~10–12 mg/L.

<sup>e</sup>Cefazolin can replace cloxacillin only in patients with non-immediate-type hypersensitivity reactions to penicillin.

<sup>f</sup>High doses of ceftaroline may be associated with risk of leucopaenia after 2 weeks. Ceftaroline can replace cloxacillin only in patients with non-immediate-type hypersensitivity reactions to penicillin.

<sup>g</sup>In patients with heart failure, the high load of sodium associated with the use of fosfomycin can lead to acute heart failure.

<sup>h</sup>Serum vancomycin concentrations should achieve 10–15 mg/L at pre-dose (trough) level, although some experts recommend to increase the dose of vancomycin to 45–60 mg/kg/day i.v. in 2 or 3 divided doses to reach serum trough vancomycin levels (C<sub>min</sub>) of 15–20 mg/L as in staphylococcal endocarditis. However, vancomycin dose should not exceed 2 g/d unless serum levels are monitored and can be adjusted to obtain a peak plasma concentration of 30–45 µg/mL 1 h after completion of the i.v. infusion of the antibiotic.

## 7.8. *Enterococcus* spp.

Enterococcal IE is primarily caused by *E. faecalis* (90% of cases) and less often by *Enterococcus faecium* (5% of cases), or other species.<sup>350</sup> Enterococcal IE poses two major problems. First, enterococci are highly resistant to antibiotic-induced killing, and eradication requires prolonged administration (up to 6 weeks) of synergistic bactericidal combinations of two cell wall inhibitors (ampicillin plus ceftriaxone, which synergize by inhibiting complementary PBPs), or one cell wall inhibitor with aminoglycosides.<sup>351–353</sup> Second, they may be resistant to multiple drugs, including aminoglycosides (HLAR), beta-lactams (via PBP 5 modification and sometimes beta-lactamases), and vancomycin.<sup>351–357</sup>

Penicillin-susceptible strains are treated with penicillin G or ampicillin (or amoxicillin) combined with gentamicin. However, ampicillin (or amoxicillin) is preferred since the MIC is two to four times lower than that of penicillin G. Gentamicin resistance is frequent in both *E. faecalis* and *E. faecium* (up to 75%).<sup>358,359</sup> An aminoglycoside MIC >128 mg/L (HLAR) is associated with the loss of bactericidal synergism with cell wall inhibitors, and aminoglycosides should not be used in such conditions.

There have been two important advances in recent years. First, in several cohort studies of *E. faecalis* IE including hundreds of cases, it was observed that ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for non-HLAR *E. faecalis* IE. The combination of ampicillin

plus ceftriaxone was also associated with a beneficial safety profile, due to the lack of nephrotoxicity.<sup>355,360,361</sup> Therefore, this is the combination of choice for treating NVE and PVE caused by HLAR *E. faecalis*. This double beta-lactam therapy is not effective against *E. faecium* and the experience in the treatment of other enterococcal species is very limited. Second, the total daily dose of gentamicin can be given in a single daily dose instead of the 2 or 3 divided doses previously recommended, and the length of the treatment with gentamicin for non-HLAR *E. faecalis* IE may be safely shortened from 4–6 weeks to 2 weeks, reducing the rates of nephrotoxicity to very low levels.<sup>266,362,363</sup> After 10–14 days of therapy, OPAT or outpatient oral antibiotic therapy should be considered if the patient is clinically stable (see [Section 7.13](#)).<sup>364–367</sup>

Beta-lactam or vancomycin resistance is mainly observed in *E. faecium*. Since dual resistance is rare, beta-lactam might be used against vancomycin-resistant strains and vice versa. Varying results have been reported with quinupristin–dalfopristin (not active against *E. faecalis*), linezolid, daptomycin, teicoplanin, and tigecycline.<sup>353,365,368</sup> Daptomycin 10–12 mg/kg/24 h, always combined with beta-lactams (ampicillin, ertapenem, or ceftaroline) or fosfomycin in order to prevent the development of daptomycin resistance, is the best option for treating multidrug- and vancomycin-resistant enterococcal IE.<sup>369</sup>

**Recommendation Table 9 — Recommendations for antibiotic treatment of infective endocarditis due to *Enterococcus* spp.**

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>
<b>Beta-lactam and gentamicin-susceptible strains</b>		
In patients with NVE due to non-HLAR <i>Enterococcus</i> spp., the combination of ampicillin or amoxicillin with ceftriaxone for 6 weeks or with gentamicin for 2 weeks is recommended using the following doses: <sup>355,360,361</sup>	I	B
<i>Adult antibiotic dosage and route</i>		
Amoxicillin 200 mg/kg/day i.v. in 4–6 doses		
Ampicillin 12 g/day i.v. in 4–6 doses		
Ceftriaxone 4 g/day i.v. in 2 doses		
Gentamicin <sup>c</sup> 3 mg/kg/day i.v. or i.m. in 1 dose		
<i>Paediatric antibiotic dosage and route</i>		
Ampicillin 300 mg/kg/day i.v. in 4–6 equally divided doses		
Ceftriaxone 100 mg/kg i.v. in 2 doses		
Gentamicin <sup>c</sup> 3 mg/kg/day i.v. or i.m. in 3 equally divided doses		
In patients with PVE and patients with complicated NVE or >3 months of symptoms due to non-HLAR <i>Enterococcus</i> spp., the combination of ampicillin or amoxicillin with ceftriaxone for 6 weeks or with gentamicin for 2 weeks is recommended using the following doses: <sup>355,360,361</sup>	I	B
<i>Adult antibiotic dosage and route</i>		
Amoxicillin 200 mg/kg/day i.v. in 4–6 doses		
Ampicillin 12 g/day i.v. in 4–6 doses		
Ceftriaxone 4 g/day i.v. in 2 doses		
Gentamicin <sup>c</sup> 3 mg/kg/day i.v. or i.m. in 1 dose		
<i>Paediatric antibiotic dosage and route</i>		
Ampicillin 300 mg/kg/day i.v. in 4–6 equally divided doses		
Amoxicillin 100–200 mg/kg/day i.v. in 4–6 doses		
Ceftriaxone 100 mg/kg/day i.v. in 2 doses		
Gentamicin <sup>c</sup> 3 mg/kg/day i.v. or i.m. in 3 equally divided doses		

Continued

High-level aminoglycoside resistance <sup>d</sup>		I	B		
In patients with NVE or PVE due to HLAR <i>Enterococcus</i> spp., the combination of ampicillin or amoxicillin and ceftriaxone for 6 weeks is recommended using the following doses: <sup>355,360,361</sup>					
Adult antibiotic dosage and route					
Ampicillin	12 g/day i.v. in 4–6 doses				
Amoxicillin	200 mg/kg/day i.v. in 4–6 doses				
Ceftriaxone	4 g/day i.v. or i.m. in 2 doses				
Paediatric antibiotic dosage and route					
Ampicillin	300 mg/kg/day i.v. in 4–6 equally divided doses				
Amoxicillin	100–200 mg/kg/day i.v. in 4–6 doses				
Ceftriaxone	100 mg/kg i.v. or i.m. in 2 doses				
Beta-lactam resistant <i>Enterococcus</i> spp. ( <i>E. faecium</i> ) <sup>e</sup>		I	C		
In patients with IE due to beta-lactam resistant <i>Enterococcus</i> spp. ( <i>E. faecium</i> ), vancomycin for 6 weeks combined with gentamicin for 2 weeks is recommended using the following doses: <sup>358,359,369</sup>					
Adult antibiotic dosage and route					
Vancomycin	30 mg/kg/day i.v. in 2 doses				
Gentamicin	3 mg/kg/day i.v. or i.m. in 1 dose				
Paediatric antibiotic dosage and route					
Vancomycin	30 mg/kg/day i.v. in 2–3 equally divided doses				
Gentamicin	3 mg/kg/day i.v. or i.m. in 1 dose				
Vancomycin-resistant <i>Enterococcus</i> spp. <sup>f</sup>				I	C
In patients with IE due to vancomycin-resistant <i>Enterococcus</i> spp., daptomycin combined with beta-lactams (ampicillin, ertapenem, or ceftaroline) or fosfomycin is recommended using the following doses: <sup>369</sup>					
Adult antibiotic dosage and route					
Daptomycin	10–12 mg/kg/day i.v. in 1 dose				
Ampicillin	300 mg/kg/day i.v. in 4–6 equally divided doses				
Fosfomycin	12 g/day i.v. in 4 doses				
Ceftaroline	1800 mg/day i.v. in 3 doses				
Ertapenem <sup>g</sup>	2 g/day i.v. or i.m. in 1 dose				
Paediatric antibiotic dosage and route					
Daptomycin	10–12 mg/kg/day i.v. in 1 dose (age-adjusted)				
Ampicillin	300 mg/kg/day i.v. in 4–6 equally divided doses				
Fosfomycin	2–3 g/day i.v. in 1 dose				
Ceftaroline	24–36 mg/kg/day in 3 doses				
Ertapenem <sup>g</sup>	1 g/day i.v. or i.m. in 1 dose [if younger than 12 years, 15 mg/kg/dose (to a maximum of 500 mg) twice daily]				

HLAR, high-level aminoglycoside resistance; IE, Infective endocarditis; i.m., intramuscular; i.v., intravenous; NVE, native valve endocarditis; PBP, Penicillin-binding protein; PVE, prosthetic valve endocarditis.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

<sup>c</sup>Maximum doses 240 mg/day. High doses are associated with increased risk of nephrotoxicity. Renal function and serum gentamicin concentrations should be monitored once a week. When given in a single daily dose, pre-dose (trough) concentrations should be <1 mg/L and post-dose (peak; 1 h after injection) serum concentrations should be ~10–12 mg/L.

<sup>d</sup>High-level resistance to gentamicin: if susceptible to streptomycin, replace gentamicin with streptomycin 15 mg/kg/day in two equally divided doses.

<sup>e</sup>Beta-lactam resistance: (i) if due to beta-lactamase production, replace ampicillin with ampicillin–sulbactam or amoxicillin with amoxicillin–clavulanate; (ii) if due to PBP5 alteration, use vancomycin-based regimens.

<sup>f</sup>Multiresistance to aminoglycosides, beta-lactams and vancomycin: suggested alternatives are (i) daptomycin 10 mg/kg/day plus either ampicillin 200 mg/kg/day i.v. in four to six doses, ertapenem (2 g/day i.v.), ceftaroline (600 mg/8 h i.v.), or fosfomycin (3 g/6 h i.v.); (ii) linezolid 2 × 600 mg/day i.v. or orally for ≥8 weeks (monitor haematological toxicity); (iii) quinupristin–dalfopristin 3 × 7.5 mg/kg/day for ≥8 weeks. Quinupristin–dalfopristin is not active against *E. faecalis*; (iv) for other combinations (daptomycin plus ertapenem or ceftaroline or fosfomycin), consult infectious disease specialists.

<sup>g</sup>High doses of ertapenem are associated with seizures.

## 7.9. Gram-negative bacteria

### 7.9.1. *Haemophilus*, *Aggregatibacter*, *Cardiobacterium*, *Eikenella*, and *Kingella*-related species

*Haemophilus*, *Aggregatibacter* (previously *Actinobacillus*), *Cardiobacterium*, *Eikenella*, and *Kingella* (HACEK) Gram-negative bacilli are fastidious organisms that require special investigations when they are the suspected cause of IE (see also Section 5). Because they grow slowly, standard MIC tests may

be difficult to interpret. Some HACEK group bacilli produce beta-lactamases, and therefore ampicillin is no longer the first-line option. Conversely, they are susceptible to ceftriaxone, other third-generation cephalosporins, and fluoroquinolones. The standard treatment is ceftriaxone 2 g/day for 4 weeks in NVE and for 6 weeks in PVE. If they do not produce beta-lactamase, ampicillin (12 g/day i.v. in 4 or 6 doses) for 4–6 weeks plus gentamicin (3 mg/kg/day divided into 2 or 3 doses) for 2 weeks is an

option.<sup>370</sup> Ciprofloxacin (400 mg every 8–12 h i.v. or 750 mg every 12 h orally) is a less well-validated alternative.<sup>370–373</sup>

### 7.9.2. Non-Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, and Kingella species

The ICE cohort reported non-HACEK Gram-negative bacteria in 49 of 2761 (1.8%) IE cases.<sup>279,374</sup> Recommended treatment is early surgery plus prolonged (6 weeks) therapy with bactericidal combinations of beta-lactams and aminoglycosides, sometimes with additional quinolones or cotrimoxazole.<sup>375,376</sup> *In vitro* bactericidal tests and monitoring of serum antibiotic concentrations may be helpful. Because of their rarity and severity, these conditions should be discussed by the Endocarditis Team.

**Table 11 Antibiotic treatment of blood culture-negative infective endocarditis**

Pathogens	Proposed therapy <sup>a</sup>	Treatment outcome
<i>Brucella</i> spp.	Doxycycline (200 mg/24 h) plus cotrimoxazole (960 mg/12 h) plus rifampin (300–600 mg/24 h) for ≥3–6 months <sup>b</sup> orally	Treatment success defined as an antibody titre <1:60. Some authors recommend adding gentamicin for the first 3 weeks
<i>C. burnetii</i> (Q fever agent)	Doxycycline (200 mg/24 h) plus hydroxychloroquine (200–600 mg/24 h) <sup>c</sup> orally (>18 months of treatment)	Treatment success defined as anti-phase I IgG titre <1:400, and IgA and IgM titres <1:50
<i>Bartonella</i> spp. <sup>d</sup>	Doxycycline 100 mg/12 h orally for 4 weeks plus gentamicin (3 mg/24 h) i.v. for 2 weeks	Treatment success expected in ≥90%
<i>Legionella</i> spp.	Levofloxacin (500 mg/12 h) i.v. or orally for ≥6 weeks or clarithromycin (500 mg/12 h) i.v. for 2 weeks, then orally for 4 weeks plus rifampin (300–1200 mg/24 h)	Optimal treatment unknown
<i>Mycoplasma</i> spp.	Levofloxacin (500 mg/12 h) i.v. or orally for ≥6 months <sup>e</sup>	Optimal treatment unknown
<i>T. whipplei</i> (Whipple's disease agent) <sup>f</sup>	Doxycycline (200 mg/24 h) plus hydroxychloroquine (200–600 mg/24 h) <sup>c</sup> orally for ≥18 months	Long-term treatment, optimal duration unknown

© ESC 2023

IE, infective endocarditis; Ig, immunoglobulin; i.v., intravenous.

Adapted from Brouqui et al.<sup>383</sup>

<sup>a</sup>Owing to the lack of large series, the optimal duration of treatment of IE due to these pathogens is unknown. The presented durations are based on selected case reports. Consultation with an infectious disease specialist is recommended.

<sup>b</sup>Addition of streptomycin (15 mg/kg/24 h in 2 doses) for the first few weeks is optional.

<sup>c</sup>Doxycycline plus hydroxychloroquine (with monitoring of serum hydroxychloroquine levels) is significantly superior to doxycycline.<sup>385</sup>

<sup>d</sup>Several therapeutic regimens have been reported, including ampicillin or amoxicillin, (12 g/24 h i.v.) or cephalosporins (ceftriaxone 2 g/24 h i.v.) combined with aminoglycosides (gentamicin or netilmicin).<sup>381</sup> Dosages are as for streptococcal and enterococcal IE.<sup>379,380</sup>

<sup>e</sup>Newer fluoroquinolones (levofloxacin, moxifloxacin) are more potent than ciprofloxacin against intracellular pathogens such as *Mycoplasma* spp., *Legionella* spp., and *Chlamydia* spp.

<sup>f</sup>Treatment of Whipple's IE remains highly empirical. In the case of central nervous system involvement, sulfadiazine 1.5 g/6 h orally must be added to doxycycline. An alternative therapy is ceftriaxone (2 g/24 h i.v.) for 2–4 weeks or penicillin G (2 million U/4 h) and streptomycin (1 g/24 h) i.v. for 2–4 weeks followed by cotrimoxazole (800 mg/12 h) orally. Trimethoprim is not active against *T. whipplei*. Successes have been reported with long-term therapy (1 year).

## 7.10. Blood culture-negative infective endocarditis

The main causes of BCNIE are summarized in Section 5.3.2.<sup>377,378</sup>

Treatment options are summarized in Table 11.<sup>379–383</sup> Treatment of Whipple's IE remains highly empirical. Successes have been reported with long-term therapy (>1 year).<sup>384</sup> In cases of CNS involvement, sulfadiazine 1.5 g/6 h orally must be added to doxycycline. An alternative therapy is ceftriaxone (2 g/24 h i.v.) for 2–4 weeks or penicillin G (2 million U/4 h) and streptomycin (1 g/24 h) i.v. for 2–4 weeks followed by cotrimoxazole (800 mg/12 h) orally. Trimethoprim is not active against *T. whipplei*. Consultation with the Endocarditis Team, including an infectious disease specialist, is recommended.

## 7.11. Fungi

Fungi are most frequently observed in PVE and in IE affecting PWID or immunocompromised patients.<sup>386</sup> *Candida* and *Aspergillus* spp. predominate, the latter resulting in BCNIE.<sup>387,388</sup> Mortality is very high (>50%), and treatment necessitates combined antifungal administration and with a low threshold for surgery.<sup>278,387,388</sup> Antifungal therapy for *Candida* IE includes an echinocandin at high doses or liposomal amphotericin B (or other lipid formulations) with or without flucytosine. for *Aspergillus* IE, voriconazole is the drug of choice. Some experts recommend the addition of an echinocandin or amphotericin B.<sup>278,387–390</sup> Suppressive long-term treatment with oral azoles (fluconazole and voriconazole) is recommended, sometimes lifelong.<sup>278,388,389</sup> Consultation with the Endocarditis Team including an infectious disease specialist is recommended.

## 7.12. Empirical therapy

Treatment of IE should be started promptly. Three sets of blood cultures should be drawn at 30-minute intervals before initiation of antibiotics.<sup>391</sup>

The initial choice of empirical treatment depends on several considerations:

- Previous antibiotic therapy.
- IE in a native valve or a prosthesis (and if so, when surgery was performed [early vs. late PVE]).
- The place of the infection (community, nosocomial, or non-nosocomial healthcare-associated IE) and knowledge of the local epidemiology, especially for antibiotic resistance and specific genuine culture-negative pathogens.
- Cloxacillin/cefazolin administration is associated with lower mortality rates than other beta-lactams, including amoxicillin/clavulanic acid or ampicillin/sulbactam,<sup>392</sup> and vancomycin for empirically treating MSSA bacteraemia/endocarditis.<sup>309,393</sup> However, recently amoxicillin/clavulanic acid or ampicillin/sulbactam might be an effective empirical treatment for MSSA bacteraemia when de-escalated to cloxacillin or cefazolin within 96 h from the index blood culture.<sup>394</sup>

Native valve endocarditis and late PVE regimens should cover staphylococci, streptococci, and enterococci. If the patient was receiving antibiotic therapy, the empirical therapy should include different antibiotics. CoNS should be empirically covered in PVE but not in NVE. Early PVE or healthcare-associated IE regimens should cover methicillin-resistant staphylococci, enterococci and, ideally, non-HACEK Gram-negative pathogens. Once the pathogen is identified (usually within 24 h), the antibiotic treatment must be adapted to its antimicrobial susceptibility pattern. It should be emphasized that the empirical treatment should be changed to targeted therapy once the organism is identified within 24–48 h.

**Recommendation Table 10 — Recommendations for antibiotic regimens for initial empirical treatment of infective endocarditis (before pathogen identification)<sup>a</sup>**

Recommendations	Class <sup>b</sup>	Level <sup>c</sup>	
In patients with community-acquired NVE or late PVE (≥12 months post-surgery), ampicillin in combination with ceftriaxone or with (flu)cloxacillin and gentamicin should be considered using the following doses: <sup>255</sup>	IIa	C	
<i>Adult antibiotic dosage and route</i>			
Ampicillin			12 g/day i.v. in 4–6 doses
Ceftriaxone			4 g/day i.v. or i.m. in 2 doses
(Flu)cloxacillin			12 g/day i.v. in 4–6 doses
Gentamicin <sup>d</sup>			3 mg/kg/day i.v. or i.m. in 1 dose
<i>Paediatric antibiotic dosage and route</i>			
Ampicillin			300 mg/kg/day i.v. in 4–6 equally divided doses
Ceftriaxone			100 mg/kg i.v. or i.m. in 1 dose
(Flu)cloxacillin			200–300 mg/kg/day i.v. in 4–6 equally divided doses
Gentamicin <sup>d</sup>	3 mg/kg/day i.v. or i.m. in 3 equally divided doses		
In patients with early PVE (<12 months post-surgery) or nosocomial and non-nosocomial healthcare-associated IE, vancomycin or daptomycin combined with gentamicin and rifampin may be considered using the following doses: <sup>395</sup>	IIb	C	
<i>Adult antibiotic dosage and route</i>			
Vancomycin <sup>e</sup>			30 mg/kg/day i.v. in 2 doses
Daptomycin			10 mg/kg/day i.v. in 1 dose
Gentamicin <sup>d</sup>			3 mg/kg/day i.v. or i.m. in 1 dose
Rifampin			900–1200 mg i.v. or orally in 2 or 3 doses
<i>Paediatric antibiotic dosage and route</i>			
Vancomycin <sup>e</sup>			40 mg/kg/day i.v. in 2–3 equally divided doses
Gentamicin <sup>d</sup>			3 mg/kg/day i.v. or i.m. in 3 equally divided doses
Rifampin			20 mg/kg/day i.v. or orally in 3 equally divided doses
<b>Allergy to beta-lactams</b>			
In patients with community-acquired NVE or late PVE (≥12 months post-surgery) who are allergic to penicillin, cefazolin, or vancomycin in combination with gentamicin may be considered using the following doses:	IIb	C	
<i>Adult antibiotic dosage and route</i>			
Cefazolin			6 g/day i.v. in 3 doses
Vancomycin <sup>e</sup>			30 mg/kg/day i.v. in 2 doses
Gentamicin <sup>d</sup>			3 mg/kg/day i.v. or i.m. in 1 dose

Continued

Paediatric antibiotic dosage and route	
Cefazolin	6 g/day i.v. in 3 doses
Vancomycin <sup>e</sup>	40 mg/kg/day i.v. in 2–3 equally divided doses
Gentamicin <sup>d</sup>	3 mg/kg/day i.v. or i.m. in 3 equally divided doses

© ESC 2023

BCNIE, blood culture-negative infective endocarditis; IE, infective endocarditis; i.m., intramuscular; i.v., intravenous; NVE, native valve endocarditis; PVE, prosthetic valve endocarditis.

<sup>a</sup>If initial blood cultures are negative and there is no clinical response, BCNIE aetiology (see Section 7.10) and the extension of the antibiotic spectrum to blood culture-negative pathogens should be considered. If cardiac surgery is indicated, molecular diagnosis can be performed.

<sup>b</sup>Class of recommendation.

<sup>c</sup>Level of evidence.

<sup>d</sup>Maximum doses 240 mg/day. High doses are associated with increased risk of nephrotoxicity. Renal function and serum gentamicin concentrations should be monitored once a week. When given in a single daily dose, pre-dose (trough) concentrations should be <1 mg/L and post-dose (peak; 1 h after injection) serum concentrations should be ~10–12 mg/L.


<sup>e</sup>Serum vancomycin concentrations should achieve 10–15 mg/L at pre-dose (trough) level, although some experts recommend to increase the dose of vancomycin to 45–60 mg/kg/day i.v. in 2 or 3 divided doses to reach serum trough vancomycin levels (C<sub>min</sub>) of 15–20 mg/L as in staphylococcal endocarditis. However, vancomycin dose should not exceed 2 g/d unless serum levels are monitored and can be adjusted to obtain a peak plasma concentration of 30–45 µg/mL 1 h after completion of the i.v. infusion of the antibiotic.

### 7.13. Outpatient parenteral or oral antibiotic therapy for infective endocarditis

Outpatient parenteral antibiotic treatment or step-down outpatient oral antibiotic treatment is used to consolidate antimicrobial therapy once critical infection-related complications are under control (e.g. perivalvular abscesses, acute HF, septic emboli, and stroke) and the patient is clinically stable.<sup>43,396–399</sup> When feasible, early hospital discharge and OPAT helps to alleviate the effects of infection and prolonged hospitalization especially in the elderly.<sup>400</sup> In the initial phase of IE treatment, standard i.v. treatment is administered according to recommendations for specific microorganisms. Once the clinical condition of the patient is stable, OPAT or step-down outpatient oral antibiotic treatment is a safe alternative to in-hospital i.v. treatment in selected patients.<sup>43,399</sup> Patients may reach such stability at various points in their disease course but, when criteria for stability are reached, the patient may then be switched to OPAT or alternatively to an oral therapy at hospital discharge. The OPAT regime consists of the same antibiotic combinations administered in the acute phase if possible. The 5-year outcomes from the POET trial showed continued effectiveness of oral antibiotic therapy as compared with i.v. antibiotic therapy for IE in selected patients.<sup>401</sup> Hence, clinical stability will then differentiate IE courses into two phases:

- (i) Critical phase where at least 10 days of i.v. treatment is required: at this time point, OPAT has a restricted indication.
- (ii) Continuation phase (beyond 10 days of therapy and 7 days post-surgery), where OPAT/step-down oral therapy may be feasible.

Supplementary data online, Table S8 summarizes the salient questions to address when considering OPAT/step-down oral therapy for IE.



**Figure 9** Flowchart to assess clinical stability based on the Partial Oral Treatment of Endocarditis trial. BMI, body mass index; CoNS, coagulase-negative staphylococci; CRP, C-reactive protein; i.v., intravenous; TOE, transoesophageal echocardiography. Adapted with permission from Iversen *et al.*<sup>43</sup>

In addition to the patient being medically stable, general considerations for suitability for OPAT include assessment of the patient's home environment and self-care capabilities. Adherence to treatment and follow-up visits are also crucial for a beneficial outcome of outpatient treatment and the healthcare provider–patient relationship is important for ensuring proper and continued treatment and maintenance of infection control.

### 7.13.1. Parenteral and oral step-down antibiotic treatment

Stability criteria are essential and timing in the clinical planning the patient's course, especially TOE, becomes key (Figure 9). Stability criteria include blood samples, clinical parameters, and TOE.<sup>43</sup>

OPAT has been shown to be a safe treatment in IE for stable patients who are suitable for home treatment.

The patient, and preferably also a caregiver, should be educated carefully in the disease and how to monitor/observe for signs of infection,

including daily temperature and other signs of disease progression or complications. In addition, regular post-discharge evaluation is required (nurse once per day, responsible physician 1–3 times per week). For patients receiving OPAT, regular i.v. catheter inspection and care by a healthcare professional should be provided. If the patient is not sufficiently able to self-monitor, and has no close caregivers, added surveillance is required by involved staff and home treatment should generally be carefully considered in such cases.

Certain combinations of two oral antibiotics should be used for oral step-down treatment (see [Supplementary data online, Table S9](#)).

### 7.13.2. Other considerations for outpatient oral or parenteral antimicrobial therapy

In the OPAT programme, patients continue with the same antibiotics that are administered in the acute phase in once-daily regimens, or with infusion pumps if antibiotics should be administered intermittently,

or in continuous infusion. Dalbavancin is a glycopeptide antibiotic with a very long half-life that can be administered weekly. There is previous positive experience in sensitive Gram-positive IE, although the most effective administration schedule is not clear.<sup>274,402</sup> The recommended prescription is 1.5 g as a loading dose followed by 0.5–1 g weekly until completing 6 weeks of antibiotic treatment.

Although the evidence is weak, another option (in addition to the combinations listed in the [Supplementary data online, Table S9](#)) for staphylococcal IE is the combination of i.v. cotrimoxazole (sulfamethoxazole 4800 mg/day and trimethoprim 960 mg/day in 4–6 doses) plus i.v. clindamycin (1800 mg/day in 3 doses) during the first week followed by only oral cotrimoxazole for 5 weeks.<sup>343</sup>

### Recommendation Table 11 — Recommendations for outpatient antibiotic treatment of infective endocarditis

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>
Outpatient parenteral or oral antibiotic treatment should be considered in patients with left-sided IE caused by <i>Streptococcus</i> spp., <i>E. faecalis</i> , <i>S. aureus</i> , or CoNS who were receiving appropriate i.v. antibiotic treatment for at least 10 days (or at least 7 days after cardiac surgery), are clinically stable, and who do not show signs of abscess formation or valve abnormalities requiring surgery on TOE. <sup>43,401</sup>	IIa	A
Outpatient parenteral antibiotic treatment is not recommended in patients with IE caused by highly difficult-to-treat microorganisms, <sup>c</sup> liver cirrhosis (Child-Pugh B or C), severe cerebral nervous system emboli, untreated large extracardiac abscesses, heart valve complications, or other severe conditions requiring surgery, severe post-surgical complications, and PWID-related IE.	III	C

© ESC 2023

CoNS, coagulase-negative staphylococci; IE, infective endocarditis; i.v., intravenous; TOE, transoesophageal echocardiography; PWID, people who inject drugs.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

<sup>c</sup>Highly difficult-to-treat microorganism: microorganisms requiring i.v. antibiotic combinations that cannot be administered by means of outpatient parenteral antibiotic treatment or that require strict monitoring of drug levels either in blood or in other fluids owing to their potential toxicity or narrow therapeutic index (e.g. MRSA or vancomycin-resistant enterococci also resistant to alternative drugs such as daptomycin and linezolid, multidrug- or extensively drug-resistant Gram-negative rods, highly penicillin-resistant oral streptococci, fungi other than *Candida*).

## 8. Indications for surgery and management of main infective endocarditis complications

Infective endocarditis is associated with certain risks and complications that can only be controlled with surgical intervention. Despite the risks of surgery in these patients, current evidence suggests that surgical treatment may generate a survival advantage of up to 20% in the first year.<sup>403,404</sup> There are three main reasons to undergo surgery in the setting of acute IE: HF, uncontrolled infection, and prevention of septic embolization (in particular, to the CNS) ([Figure 10](#)).

A significant proportion of surgical procedures for IE are performed on an urgent basis. The Task Force has defined urgent surgery as that requiring intervention within 3–5 days, although unnecessary delays should be avoided once the indication for urgent surgery is established. Some cases require emergency surgery (within 24 h), irrespective of the pre-operative duration of antibiotic treatment. A third group requires surgery non-urgently, i.e. within the same hospital admission. In cases where the infective component can be completely healed with antibiotic treatment alone, both timing and indications for treatment of residual valve dysfunction follow the conventional guidelines for valve treatment.<sup>128</sup>

### 8.1. Pre-operative risk assessment

The risk of surgical therapy during the active phase of IE can be significant. It is heavily influenced by pre-existing co-morbidities and current organ function, but should not be limited by one risk factor alone (e.g. age or liver function).<sup>405,406</sup> The decision to operate should therefore be made by the Endocarditis Team (see [Section 4](#)),<sup>167</sup> considering urgency of the patient's clinical condition, peri-operative risk, the potential to recover from the infection, and the patient's associated long-term prognosis.<sup>403,404</sup>


There are several scoring systems that predict mortality after general (i.e. non-IE) cardiac surgery and which are in routine clinical use.<sup>407,408</sup> Other scoring systems were designed specifically for the setting of IE including the AEPEI (Association for the Study and Prevention of Infective Endocarditis Study) score, the STS (Society of Thoracic Surgeons) IE score, the PALSUSE (prosthetic valve, age  $\geq 70$ , large intracardiac destruction, *Staphylococcus* spp., urgent surgery, sex [female], EuroSCORE  $\geq 10$ ) score, the de Feo score, and the ANCLA (anaemia, NYHA [New York Heart Association] class IV, critical state, large intracardiac destruction, surgery of thoracic aorta) score, among others.<sup>256,409–414</sup> Some of these scoring systems are web-based and free of charge (e.g. the AEPEI risk calculator <https://www.endocardite.org/index.php/calculateurs/score-de-mortalite-post-chirurgie-aepei>). Such scoring systems have been developed based on retrospective data and their performance is variable.<sup>250,256,415–417</sup> In addition, none of these scoring systems are used in daily clinical routine. Therefore, prospective surgical scoring systems with better precision need to be developed, particularly for determining operative suitability in prohibitively high-risk patients.

A significant proportion of patients with clear indications for surgery for IE may have multiple risk factors or other reasons that lead to surgery not being performed, and these patients have the worst prognosis.<sup>184,403</sup> Conversely, high-risk but salvageable patients may not be offered life-saving operations on the basis of perceived unacceptable risk, and this is especially true in the elderly (see [Section 12.2](#)). The complex decision of not offering surgery when indicated should therefore be made in the setting of an Endocarditis Team with experienced surgical input.<sup>418</sup> Determining when operative management for a specific patient is futile requires compassionate multidisciplinary insight along with consideration of the patient's and family's wills (see [Section 13.2](#)).

### 8.2. Heart failure

#### 8.2.1. Heart failure in infective endocarditis

Heart failure is the most frequent complication of IE and the main indication for urgent and emergency surgery for IE.<sup>419</sup> The prevalence of HF with left-sided IE is variable and inconsistently defined between reported series, ranging between 19% and 73%.<sup>420–425</sup> Clinical symptoms



**Figure 10** Proposed surgical timing for infective endocarditis. HACEK, *Haemophilus*, *Aggregatibacter*, *Cardiobacterium*, *Eikenella*, and *Kingella*; PVE, prosthetic valve endocarditis. Surgery timing: emergency, within 24 h. Urgent, within 3–5 days. Non-urgent, within same hospital admission. <sup>a</sup>Despite appropriate antibiotic therapy for >1 week and control of septic embolic foci. <sup>b</sup>E.g. patients with significant valvular dysfunction that is, or is not, a direct result of endocarditis process. <sup>c</sup>*S. aureus* (methicillin resistant and non-methicillin resistant), vancomycin-resistant enterococci, non-HACEK Gram-negative bacteria and fungi. <sup>d</sup>Urgent for *S. aureus*, non-urgent for others.

are mainly caused by congestion and may vary from mild dyspnoea to severe and rapidly worsening dyspnoea, orthopnoea, pulmonary oedema, and cardiogenic shock. Factors associated with increased risk of HF complicating the course of IE include older age, presence of NVE with aortic valve involvement, and high comorbidity.<sup>420–425</sup>

Leaflet perforation and rupture, as well as mitral chordal rupture, lead to new severe valvular regurgitation or worsening of pre-existent valvular regurgitation and subsequent acute HF. Other less common causes of HF include intracardiac fistulae, interference of the vegetation mass with leaflet opening and closure, or myocardial infarction from vegetations embolizing into the coronary arteries. Patients with right-sided IE complicated by HF present with symptoms of right heart congestion, as discussed in [Section 12.6](#).

New-onset HF is the predominant clinical presentation in IE patients, whereas worsening of pre-existing HF is less frequent. Cardiogenic shock can be the first presentation in up to 5% of cases, of which half of such patients develop cardiogenic shock within 72 h of admission for IE.<sup>424</sup> On imaging tests, patients with IE complicated by HF present more frequently with lower left ventricular ejection fraction, larger vegetation size, perivalvular abscesses, pseudoaneurysms, and valvular regurgitation secondary to leaflet perforation or rupture.<sup>420–425</sup>

Heart failure complicating IE is independently associated with poor in-hospital and 1-year survival, and surgical treatment is the only effective treatment that is associated with improved survival.<sup>420,421,424,426–430</sup>

Even though in-hospital mortality rates increase with the severity of HF presentation, the survival benefit of surgical treatment vs. medical therapy is more pronounced among patients with NYHA functional class III–IV symptoms.<sup>420</sup> TTE provides important information on the severity of the haemodynamic consequences of valve dysfunction. New onset of elevated filling pressures, pulmonary hypertension, and/or pericardial effusion may lead to urgent or emergency recommendation for surgery.<sup>163</sup> Biomarkers such as B-type natriuretic peptide and troponin have been associated with poor prognosis in IE.<sup>431,432</sup>

Patients who are discharged after treatment of IE require subsequent follow-up (see [Section 11](#)). Heart failure is more likely to develop during follow-up in IE patients who are discharged with valvular regurgitation than in those without regurgitation, particularly if mitral regurgitation is present.<sup>433</sup>

### 8.2.2. Indications and timing of surgery in the presence of heart failure in infective endocarditis

Timing of surgical intervention in patients with IE ([Figure 10](#)) complicated by HF should be decided by the Endocarditis Team, although surgery should not be delayed by Endocarditis Team discussions in patients requiring emergency operations. The presence of HF leads to recommendation for surgery in the majority of patients and is the principal indication for urgent surgery in IE patients.<sup>429,434</sup> Emergency surgery should be performed in patients with new-onset NYHA class IV HF symptoms, pulmonary oedema, and/or cardiogenic shock, irrespective of the status of infection or length of antibiotic treatment and when considered non-futile intervention. Urgent surgery is indicated in patients with milder forms of HF (NYHA class II–III) and severe valve regurgitation or echocardiographic signs of haemodynamic compromise (elevated end-diastolic left ventricular pressure, high left atrial pressure, or moderate and severe pulmonary hypertension), or large vegetations. In patients without haemodynamic compromise, i.v. antibiotic therapy and strict clinical and echocardiographic observation are first indicated, and surgery can be temporarily delayed. However, it should be

emphasized that early surgery is a good option for patients with surgical indications and low risk of surgery.<sup>403,404</sup>

## 8.3. Uncontrolled infection

Uncontrolled infection is one of the most common complications of IE and is the second most frequent indication for surgery.<sup>5</sup> Uncontrolled infection is considered to be present when there is: (i) persistent infection or sepsis despite antibiotic therapy; (ii) signs of local infection that do not respond to antibiotic therapy; or (iii) infection with resistant or very virulent organisms.

### 8.3.1. Septic shock and persistent infection

Septic shock, defined as vasopressor requirement to maintain a mean arterial pressure of 65 mmHg or greater and serum lactate level greater than 2 mmol/L in the absence of hypovolaemia,<sup>435</sup> is a highly lethal complication of IE and occurs in ~5–10% of patients.<sup>425,436</sup> Risk factors for septic shock include *S. aureus* and Gram-negative bacteria, persistent bacteraemia, nosocomial acquisition, acute renal failure, diabetes mellitus, CNS emboli, and large vegetations.<sup>147,436</sup> Surgery is associated with a significant reduction in early and 1-year mortality for patients with IE and septic shock.<sup>425,436</sup> Urgent surgery is therefore recommended in patients with IE and persistent sepsis or septic shock despite adequate antibiotic therapy, in which surgery is non-futile.

The definition of persistent infection is somewhat arbitrary and consists of fever and persistent positive cultures after 7 days of appropriate antibiotic treatment. It has been demonstrated that persistent blood cultures 48–72 h after initiation of antibiotics are an independent risk factor for hospital mortality.<sup>437</sup> In many cases of persistent infection, antibiotics alone are insufficient to eradicate the infection. Surgery is therefore indicated for persistent infection when extracardiac abscesses (splenic, vertebral, cerebral, or renal) and other potential causes of positive cultures and fever (infected lines and embolic complications) have been excluded. Persistent fever may also be caused as an adverse reaction to antibiotics.<sup>438</sup>

### 8.3.2. Locally uncontrolled infection

Signs of locally uncontrolled infection include increasing vegetation size, abscess formation, the creation of pseudoaneurysms and/or fistulae, and new atrioventricular block (AVB). The incidence of perivalvular extension ranges from 10% to 30% in NVE with higher incidences found in patients with PVE.<sup>5,439</sup> Perivalvular complications and abscess formation are more frequent in aortic valve than mitral valve IE, and may be higher in patients with bicuspid vs. tricuspid aortic valves.<sup>440</sup> In aortic valve IE, perivalvular extension occurs most frequently in the mitral-aortic intervalvular fibrosa,<sup>441</sup> whereas perivalvular abscesses are usually located posteriorly or laterally in mitral valve IE.<sup>442</sup> Persistent fever and infection, new AVB, chest pain, new heart murmur, recurrent embolism, or HF may indicate perivalvular extension. The diagnosis should be confirmed by TOE, which is more sensitive and specific than TTE.<sup>443</sup> However, mitral annular calcification may obscure small regions of mitral perivalvular extension, particularly in the posterior aspects of the mitral annulus. Cardiac CT has been shown to be an accurate alternative imaging procedure for the evaluation of perivalvular extension of infection, and PET/CT imaging may be particularly helpful in cases of PVE (see [Section 5.4.4](#)).

### 8.3.3 Indications and timing of surgery in the presence of uncontrolled infection

Surgery should be considered for uncontrolled infection when antibiotic therapy is ineffective and extracardiac sources are ruled out. Reports in the literature demonstrate that surgery for uncontrolled infection in IE has the potential to improve 1-year survival by 15–20%.<sup>403,429,444</sup>

#### 8.3.3.1. Persistent infection

Uncontrolled infection is present in the form of persistent infection when blood cultures remain positive for >1 week or persistent sepsis despite appropriate antimicrobial therapy and when other causes of bacteraemia have been excluded. Not performing surgery for uncontrolled infection is associated with significantly increased mortality.<sup>444</sup>

#### 8.3.3.2. Locally uncontrolled infection

Uncontrolled infection is also present if signs of local progression, i.e. increasing vegetation size or perivalvular involvement, are observed during follow-up imaging.<sup>5,420,421,445,446</sup> Surgery should be performed urgently (within 3–5 days) in such cases. Rarely, when there are no other reasons for surgery and fever is easily controlled with antibiotics, small abscesses or pseudoaneurysms can be treated conservatively under close clinical and echocardiographic follow-up.<sup>429,444</sup>

#### 8.3.3.3. Infection with resistant or virulent organisms

Microorganisms causing endocarditis that are unlikely to be controlled with current antimicrobial therapy include fungi,<sup>447,448</sup> multiresistant bacteria (e.g. MRSA or vancomycin-resistant enterococci) and, in rare cases, non-HACEK Gram-negative bacteria. *S. aureus* should also be included in this group due to its fast progression and ability to cause local tissue destruction and abscess formation,<sup>5,449</sup> specifically, if a favourable early response to antibiotics is not achieved.<sup>305,312,449</sup> The presence of these organisms should lead to discussions within the Endocarditis Team and urgent surgery.<sup>385,450</sup>

## 8.4. Prevention of systemic embolism

### 8.4.1. Incidence of embolic events in infective endocarditis

Embolic events are frequent and potentially life-threatening complications of IE related to the migration of cardiac vegetations.<sup>451,452</sup> The brain and spleen are the most frequent sites of embolism for left-sided IE, while pulmonary embolism is frequent in right-sided and pacemaker lead IE (see [Section 12](#)). Stroke may be the first clinical manifestation of IE, and is a severe complication that is associated with increased morbidity and mortality.<sup>451,453,454</sup> Embolic events may be clinically silent in up to 50% of patients with IE.<sup>198</sup> Emboli affecting the splenic or cerebral circulation are frequently asymptomatic, and are diagnosed by non-invasive imaging.<sup>197,200</sup> Although whole-body CT imaging (i.e. chest, abdomen, and pelvis) is frequently performed during the work-up for surgery, diagnosis and management of patients is infrequently altered as a result of these investigations.<sup>194</sup> However, cerebral CT may affect clinical decision-making and outcomes when surgery is considered.<sup>452</sup>

Embolic risk in IE is high, with 20–50% of patients being affected.<sup>452,455</sup> The highest incidence of embolic strokes can be observed in the days around the initial diagnosis of IE,<sup>456</sup> and embolic events are often what leads to the initial diagnosis of IE. Embolic risk is highest the day after therapy initiation, and is 10–20 times higher on the day before

and after the start of antibiotic treatment compared with 2 weeks before and after.<sup>456</sup> Thus, embolic events occurring after the initiation of antibiotic therapy continuously drop in incidence within the first 2 weeks of antibiotic treatment.<sup>429,455–457</sup> The benefits of surgery to prevent embolism may therefore be greatest during the early stages of therapy, when embolic risk is at its highest.

### 8.4.2. Predicting the risk of embolism

Predicting the risks of embolization is important for decision-making in IE. Echocardiography plays a key role in identifying potentially embolic structures in the heart,<sup>429,455,456,458</sup> although predicting the time point of embolization remains difficult. Several factors are associated with increased risk of embolism including the size and mobility of vegetations,<sup>455,456,458–460</sup> the location of the vegetation on the mitral valve,<sup>455</sup> the increasing or decreasing size of the vegetation under antibiotic therapy,<sup>455</sup> particular microorganisms (especially *S. aureus*,<sup>455</sup> *S. gallolyticus*,<sup>461</sup> and *Candida* spp.<sup>450</sup>), previous embolism,<sup>455</sup> multivalvular involvement,<sup>458</sup> and biological markers.<sup>462</sup> Among these, the size and mobility of the vegetations are the most important independent predictors of new embolic events.<sup>459,460,463</sup> A recent study, however, demonstrated that vegetation size was predictive of worse outcomes only when present with other indications for surgery (i.e. HF or uncontrolled infection).<sup>464</sup> Staphylococcal endocarditis is also a risk factor for embolization,<sup>465–468</sup> which is particularly important because the incidence of *S. aureus* IE is increasing.<sup>78,469</sup> Risk of neurological complications is particularly high in patients with very large vegetations (>30 mm in length).<sup>451</sup>

Additional factors may need to be taken into account and it may be helpful to use an embolic risk calculator.<sup>470</sup> *S. aureus* infection, previous embolism, vegetation length, age, diabetes, and the presence of atrial fibrillation have been identified as specific risk factors for embolism.<sup>470</sup>

### 8.4.3. Indications and timing of surgery to prevent embolism in infective endocarditis

Surgical removal of potentially embolic material from the heart may prevent new or additional embolic events. Given the imminent risk and high rates of embolization in patients with mobile and large vegetations,<sup>5,451,455–457,460,471</sup> surgery should be considered urgently (within 3–5 days) in such patients. A prospective randomized trial in young, low-risk patients assessed the effects of early surgery in patients with large vegetations and streptococcal IE.<sup>471</sup> Although there was no difference in all-cause mortality at 6 months between the early surgery and conventional treatment groups, the risk of embolization was significantly reduced with early surgery. Non-randomized observational analyses including patients at higher risk also suggest that early surgery may be beneficial in patients with a high likelihood of embolization,<sup>428,459,472,473</sup> and that initial conservative treatment is associated with increased mortality.<sup>474,475</sup> However, prosthetic dehiscence has also been associated with early surgery in patients with *S. aureus* IE.<sup>429</sup> Individualized decision-making is required to balance the risk of surgery, which is also influenced by pre-operative neurological events or other co-morbidities.<sup>5,453</sup>

The main indications and the timing of surgery to prevent embolism based on the currently available literature are given in Recommendation Table 12 and [Figure 10](#).

### Recommendation Table 12 — Recommendations for the main indications of surgery in infective endocarditis (native valve endocarditis and prosthetic valve endocarditis)<sup>a</sup>

Recommendations	Class <sup>b</sup>	Level <sup>c</sup>
<b>(i) Heart failure</b>		
Emergency <sup>d</sup> surgery is recommended in aortic or mitral NVE or PVE with severe acute regurgitation, obstruction, or fistula causing refractory pulmonary oedema or cardiogenic shock. <sup>420,423,424,429,476,477</sup>	I	B
Urgent <sup>d</sup> surgery is recommended in aortic or mitral NVE or PVE with severe acute regurgitation or obstruction causing symptoms of HF or echocardiographic signs of poor haemodynamic tolerance. <sup>5,420–422,429</sup>	I	B
<b>(ii) Uncontrolled infection</b>		
Urgent <sup>d</sup> surgery is recommended in locally uncontrolled infection (abscess, false aneurysm, fistula, enlarging vegetation, prosthetic dehiscence, new AVB). <sup>5,420,421,429,445</sup>	I	B
Urgent <sup>d</sup> or non-urgent surgery is recommended in IE caused by fungi or multiresistant organisms according to the haemodynamic condition of the patient. <sup>420</sup>	I	C
Urgent <sup>d</sup> surgery should be considered in IE with persistently positive blood cultures >1 week or persistent sepsis despite appropriate antibiotic therapy and adequate control of metastatic foci. <sup>436,437</sup>	IIa	B
Urgent <sup>d</sup> surgery should be considered in PVE caused by <i>S. aureus</i> or non-HACEK Gram-negative bacteria. <sup>5,385,449</sup>	IIa	C
<b>(iii) Prevention of embolism</b>		
Urgent <sup>d</sup> surgery is recommended in aortic or mitral NVE or PVE with persistent vegetations ≥10 mm after one or more embolic episodes despite appropriate antibiotic therapy. <sup>451,455,457,471,478</sup>	I	B
Urgent <sup>d</sup> surgery is recommended in IE with vegetation ≥10 mm and other indications for surgery. <sup>5,460,465,466,471,478</sup>	I	C
Urgent <sup>d</sup> surgery may be considered in aortic or mitral IE with vegetation ≥10 mm and without severe valve dysfunction or without clinical evidence of embolism and low surgical risk. <sup>460,463,465,473,478</sup>	IIb	B

AVB, atrioventricular block; HACEK, *Haemophilus*, *Aggregatibacter*, *Cardiobacterium*, *Eikenella*, *Kingella*; HF, heart failure; IE, infective endocarditis; NVE, native valve endocarditis; PVE, prosthetic valve endocarditis.

<sup>a</sup>For right-sided endocarditis, please refer to [Section 12](#).

<sup>b</sup>Class of recommendation.

<sup>c</sup>Level of evidence.

<sup>d</sup>Emergency, within 24 h. Urgent, within 3–5 days. Non-urgent, within same hospital admission.

## 9. Other complications of infective endocarditis

### 9.1. Neurological complications

Neurological manifestations may occur before or after the diagnosis of IE is established and recurrent events can also take place later in the course of IE.<sup>451</sup> The possibility of IE should be considered in patients who present with stroke, meningitis, or brain abscess. Unexplained fever accompanying a stroke in a patient with valvular disease should trigger the suspicion of IE with blood cultures taken prior to empirical antibiotic therapy.

Symptomatic cerebrovascular complications occur in up to 35% of patients with IE,<sup>145,198,451,452</sup> whereas silent cerebrovascular complications (including ischaemia and microhaemorrhage) occur in up to 80% of patients.<sup>200,204,403</sup> Clinical presentation is variable, but ischaemic stroke and transient ischaemic attack are the most common presentations.<sup>479</sup> Other manifestations include haemorrhage (intracerebral, subarachnoid), meningitis, brain abscess, encephalopathy, and infectious aneurysms. Focal neurological symptoms are present in ~40% of affected patients, and non-focal presentations occur in approximately one-third.

*S. aureus* IE is more frequently associated with neurological complications compared with IE caused by other microorganisms. Vegetation size and mobility also correlate with embolic risk.

Neurological complications are associated with excess mortality, as well as long-term morbidity, particularly in the case of stroke.<sup>480</sup> Prompt diagnosis of IE and early initiation of the antibiotic therapy are pivotal to preventing neurological complications. Early cardiac surgery in high-risk patients is key to preventing embolization of vegetations.<sup>471,481</sup> In contrast, antithrombotic/thrombolytic medical therapies are not beneficial.<sup>481–483</sup>

Mechanical thrombectomy may be considered within time limits in selected cases.<sup>484</sup> If mechanical thrombectomy is performed, the retrieved embolic material must be sent off for pathological and microbiological analyses. Neurosurgery or endovascular therapy is recommended for large infective aneurysms, especially when a continuous growth, despite optimal antibiotic therapy or ruptured intracranial infective aneurysms, is observed.<sup>485</sup>

The use of anticoagulation in patients with left-sided IE does not seem to have an effect on the risk of stroke, cerebrovascular haemorrhage, or mortality at 10 weeks and, therefore, continuation of anticoagulation in patients with left-sided IE and with a pre-existing indication for the use of anticoagulants is recommended in the absence of other contraindications.<sup>486</sup> Substitution from oral anticoagulation to heparin in such patients is generally preferred in case of cerebral bleeding or indication for early surgery.

Following a neurological event, the indication for cardiac surgery must be balanced against the peri-operative risk and post-operative prognosis of the patient. Randomized studies are impractical and cohort studies suffer from bias that can only be partially compensated for by statistical methods. The majority of publications demonstrate lower risk of secondary haemorrhagic conversion of uncomplicated ischaemic lesions than the risk of recurrent embolism under antibiotic treatment. Therefore, the available evidence supports early surgery in such patients (see [Section 10.4](#)).

Recommendation Table 13 summarizes the recommended management of neurological complications in IE; considerations for cardiac surgery after neurological complications are discussed in [Section 10.4](#).

### 9.1.1. The role of cerebral imaging in infective endocarditis

Cerebral imaging is mandatory when neurological complications of IE are suspected. Evaluation should include MRI with and without gadolinium, or CT with and without contrast if MRI is not possible.<sup>487</sup> Vascular imaging should not be performed routinely, and CTA or magnetic resonance angiography (MRA) is probably sufficient for screening when infective aneurysm is suspected. Catheter angiography should be performed in patients in whom an infective aneurysm was diagnosed on CTA or MRA, in patients with an acute brain haemorrhage, or if the suspicion of aneurysm remains despite negative non-invasive techniques, and if mechanical thrombectomy is considered.<sup>488</sup>

In patients without neurological symptoms, cerebral MRI often detects 'silent' lesions such as microbleeds.<sup>204</sup> The lack of association with parenchymal haemorrhage and the absence of post-operative neurological complications in patients with microbleeds suggest that microbleeds should not postpone surgery when indicated.<sup>489</sup>

#### Recommendation Table 13 — Recommendations for the treatment of neurological complications of infective endocarditis

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>
Brain CT or MRA is recommended in patients with IE and suspected infective cerebral aneurysms. <sup>490</sup>	I	B
Neurosurgery or endovascular therapy is recommended for large aneurysms, those with continuous growth despite optimal antibiotic therapy, and ruptured intracranial infective cerebral aneurysms. <sup>485</sup>	I	C
If non-invasive techniques are negative and the suspicion of infective aneurysm remains, invasive angiography should be considered. <sup>488</sup>	IIa	B
In embolic stroke, mechanical thrombectomy may be considered if the expertise is available in a timely manner. <sup>484</sup>	IIb	C
Thrombolytic therapy is not recommended in embolic stroke due to IE. <sup>481,491</sup>	III	C

© ESC 2023

CT, computed tomography; IE, infective endocarditis; MRA, magnetic resonance angiography.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

## 9.2. Infective aneurysms

An infective (mycotic) aneurysm is a rare but potentially devastating complication of IE. Infective cerebral aneurysms may be asymptomatic, cause headaches, seizures, or focal symptoms, and may progress to a potentially lethal rupture. They are associated with subarachnoid, intracerebral, and intracranial haemorrhage,<sup>201</sup> particularly when the patient is anticoagulated. The true incidence of infective cerebral aneurysms may be underdiagnosed as vascular imaging modalities are not systematically performed in asymptomatic patients. In 168 patients who underwent cerebral angiography with a diagnosis of IE or infected left ventricular assist device were retrospectively reviewed and infective aneurysms were present in 9% of patients.<sup>488</sup> Another series using CTA identified infective aneurysms in up to 32% of patients with left-sided IE.<sup>492</sup>

Digital subtraction angiography (DSA) remains the gold standard diagnostic test for the detection of infective aneurysms.<sup>487</sup> The sensitivity of CTA and MRA progressively increases with the size of the aneurysm. In a large study including 142 patients, the sensitivity for detection of infective aneurysms smaller than 5 mm was 57% for CTA and 35% for MRA, compared with respective 94% and 86% sensitivities for the detection of aneurysms of 5 mm or larger.<sup>493</sup> Compared with the sensitivity of DSA, the sensitivities of CTA and MRA for detecting infective aneurysms are inferior.<sup>488,490</sup> Therefore, in patients with IE and high suspicion of infective aneurysms in whom CTA or MRA are negative, DSA may be considered.<sup>490,494</sup>

Treatment options of infective cerebral aneurysms consist of anti-biotic treatment with or without endovascular or surgical therapy, although evidence is limited to case reports and retrospective studies.<sup>495–498</sup> Therefore, management should be discussed among the members of the Endocarditis Team and tailored to individual clinical situations. Shi *et al.*<sup>496</sup> reported that in patients with unruptured infective cerebral aneurysms, antibiotic treatment may have similar outcomes to invasive treatment. However, interventional treatment should be considered in cases of ruptured infective aneurysms or unruptured infective aneurysms that do not respond to antibiotic therapy.<sup>485,495</sup>

Endovascular therapy is highly successful and associated with low morbidity compared with microsurgical and medical management.<sup>487,499</sup> A systematic review including 499 patients with infective cerebral aneurysms reported a 36% rate of aneurysm rupture.<sup>495</sup> Endovascular surgical and conservative therapies were performed in an approximately equal number of patients. Among patients undergoing valve surgery in this series, only 15% underwent cardiac surgery before aneurysm treatment whereas 85% underwent cardiac surgery after aneurysm treatment.<sup>495</sup>

Urgency of cardiac surgery plays a pivotal role in decision-making regarding the type of invasive treatment. Compared with neurosurgical clipping that requires a craniotomy and often at least 2-week delay prior to procedure, cardiovascular surgery can be performed on the same day as endovascular treatment.<sup>485,487,496,499</sup> Finally, endovascular treatment of infective cerebral aneurysms prior to heart valve surgery may be considered, even if no rupture is documented.<sup>499</sup>

## 9.3. Splenic complications

Splenic complications associated with IE range from asymptomatic infarction<sup>500</sup> and abscess formation<sup>501</sup> through to splenic rupture and cardiovascular collapse.<sup>502</sup> Splenic infarcts are common (~20% of patients in the EURO-ENDO registry) and very often asymptomatic.<sup>5</sup> Up to 5% of splenic infarcts can progress to abscess formation.<sup>503</sup> Persistent or recurrent fever, abdominal pain, and persistent bacteraemia are suggestive for the presence of such complications. Patients with suspected splenic complications should be evaluated with ultrasound, abdominal CT, MRI, or PET/CT.<sup>504</sup>

Treatment of splenic complications includes conservative medical therapy with appropriate antibiotics for splenic infarction or for antibiotic-responsive abscesses, although antibiotic penetration may be poor in these circumstances. When an abscess is large, splenectomy may be considered, but the timing of splenectomy in relation to heart valve surgery needs careful assessment.<sup>505</sup> Splenectomy and heart valve surgery are seldom performed in the same operative episode.<sup>506</sup> Splenectomy is usually performed prior to valve surgery due to concerns of dissemination and reinfection of the heart valve.

Nevertheless, one case series reported that it is safe to address the splenic abscess with splenectomy after valve repair.<sup>502</sup> Alternatives to open splenectomy, i.e. percutaneous drainage<sup>507</sup> and/or laparoscopic surgery,<sup>508</sup> may be considered in patients with high surgical risk. After splenectomy, vaccination against encapsulated microorganisms (*S. pneumoniae*, *N. meningitidis*, and *Haemophilus* spp.) is recommended.

## 9.4. Myocarditis and pericarditis

The actual prevalence of acute myocarditis in the setting of IE is unknown. Myocarditis will usually present in the form of acute HF and/or ventricular arrhythmias indicating myocardial involvement in the inflammatory process most likely mediated by an immune mechanism. Differential diagnosis and exclusion of other potential complications are best assessed using echocardiography and cardiac MRI.<sup>509–511</sup>

Pericarditis is an infrequent complication of IE. In one retrospective series of 95 patients with aortic valve IE, 19% developed pericarditis usually related to ring abscess formation. The same authors also described a 12% rate of pericarditis associated with mitral valve IE.<sup>512,513</sup> The pathophysiological mechanisms most commonly involved in IE-related pericarditis are the extension of inflammation from an infective aneurysm of the aortic root or valve ring abscess, an embolus in an extramural coronary artery, or the rupture of an infective aneurysm. In a recent large series of NVE, pericardial effusion was observed in 7.8% of patients and was associated with a higher risk of HF during admission. After adjusting for possible confounders, patients did not have a higher rate of surgery, and the presence of pericardial effusion was not associated with a higher in-hospital or 1-year mortality.<sup>513</sup>

## 9.5. Heart rhythm and conduction disturbances

Due to the critical anatomical relationship between heart valves and the conduction system, AVB may complicate the clinical presentation of IE. The atrioventricular node (AVN) and His bundle lie in close proximity to the insertion of the septal leaflet of the tricuspid valve, the aortic root (below the non-coronary and right coronary cusps), and the mitral annulus.<sup>514</sup> A paravalvular abscess of these valves, especially of the aortic valve, may lead to AVB, and new electrocardiographic AVN conduction abnormalities are indicative of a paravalvular extension of the infection. In the EURO-ENDO registry, conduction abnormalities were observed at diagnosis in 11.5% of patients, including first-degree AVB in 8.1%, second-degree AVB in 0.6%, and third-degree AVB in 2.8% of cases.<sup>5</sup> New-onset AVB caused by local extension of IE (i.e. abscess) is an indication for urgent cardiac surgery.

Atrioventricular block may not only occur as a complication of paravalvular extension of the infection, but it may also develop as a consequence of valve surgery. In a series of 444 patients who survived cardiac surgery for IE,<sup>515</sup> 12.8% of patients required pacemaker implantation for AVB. Multivariable analysis identified that prolonged pre-operative PR and QRS intervals, *S. aureus* infection, presence of aortic root abscess, tricuspid valve involvement, and prior valvular surgery were independently associated with the need for post-operative pacemaker implantation.

Pacemaker implantation should be considered in patients with surgery for valvular endocarditis and complete AVB if one or more of these risk factors is present.<sup>515</sup>

## Recommendation Table 14 — Recommendations for pacemaker implantation in patients with complete atrioventricular block and infective endocarditis

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>
Immediate epicardial pacemaker implantation should be considered in patients undergoing surgery for valvular IE and complete AVB if one of the following predictors of persistent AVB is present: pre-operative conduction abnormality, <i>S. aureus</i> infection, aortic root abscess, tricuspid valve involvement, or previous valvular surgery. <sup>515</sup>	IIa	C

AVB, atrioventricular block; IE, infective endocarditis.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

## 9.6. Musculoskeletal manifestations

### 9.6.1. Osteoarticular infective endocarditis-related infections

Metastatic bone or joint IE-related lesions are relatively frequent due to the spread of the pathogen through the bloodstream and its subsequent tissue implantation. Although these lesions are considered an IE-related distal lesion or complication because infected valves are a continuous source of bacteraemia, it is often impossible to determine whether the primary infection is the valve or the osteoarticular infection. Overall, the incidence of osteoarticular infection among patients with IE is 6–8%, including bones, joints, and vertebral discs.<sup>5,145,247,516</sup>

The prevalence of spondylodiscitis ranges from 2% to 10% in patients with IE, including symptomatic and asymptomatic cases,<sup>248,517</sup> while series of spontaneous spondylodiscitis have reported co-existing IE in up to 20–30% of patients.<sup>518–520</sup> In general, the rate of IE is 10 times higher in patients with known spondylodiscitis. Therefore, in patients with a definite diagnosis of pyogenic spondylodiscitis and positive blood cultures, TTE/TOE is recommended to rule out IE.<sup>521</sup>

The most frequent microorganisms associated with spondylodiscitis are *S. aureus*, followed by *Streptococcus* spp., CoNS, and *Enterococcus* spp.<sup>247,248,305,517–523</sup>

The most common symptom of spondylodiscitis is back pain, although only 4% of patients with IE and back pain have spondylodiscitis.<sup>32,522</sup> An MRI should be performed to accurately diagnose spondylodiscitis. Computed tomography can detect indirect signs of spondylodiscitis: loss of disc height, erosion/destruction of the endplates and vertebral bodies, and paravertebral soft tissue phlegmonous changes or abscess.<sup>206</sup> Whole-body [18F]FDG-PET/CT can also identify spondylodiscitis.<sup>30,32,524</sup> Indeed, spondylodiscitis is frequently detected as an incidental finding when PET/CT is performed for the diagnosis of PVE. Imaging techniques can also be helpful in guiding biopsies to obtain material for cultures in cases of suspected IE with negative blood cultures.<sup>206</sup>

Antibiotic treatment adapted to the antimicrobial susceptibility pattern is appropriate for most cases of spondylodiscitis. The outcome is usually favourable with the 4- to 6-week IE treatment course. Prolonged therapy is necessary in patients with IE caused by difficult-to-treat microorganisms, such as *S. aureus* or *Candida* spp., or in those with epidural or perivertebral abscesses.<sup>523,525</sup> In patients with neurological deficits or severe spinal instability, the indication for

surgical spinal treatment should be considered.<sup>526</sup> In patients with urgent indication for cardiac surgery, the presence of these lesions does not contraindicate the cardiac intervention. Spondylodiscitis does not appear to worsen the prognosis of patients with IE but delaying the diagnosis of IE in patients with spondylodiscitis is associated with poor prognosis.<sup>248,517–520</sup>

### 9.6.2. Rheumatological manifestations

The pathogenesis of rheumatological manifestations and musculoskeletal symptoms in IE is not well established. The probable immunological-inflammatory aetiology of this clinical presentation is supported by a variety of antibodies and laboratory markers, the sterility of the synovial fluid, and the rapid resolution without sequelae.<sup>527</sup> Myalgia and back pain are reported in 12–15% of cases. Arthralgia occurs in ~10% of patients, sometimes sequentially affecting several joints. Slightly less often are symptoms of peripheral arthritis preferentially involving the major and proximal joints at the lower extremities.<sup>5,145,182,516</sup>

Sacroiliitis is less frequently observed (1% of cases) as well as polymyalgia rheumatic-like syndrome with pain and morning stiffness of the shoulders and hips, proximal muscle weakness (0.9% of cases), and cutaneous leucocytoclastic vasculitis (purpuric skin lesions, 3.6% of cases).<sup>182,527,528</sup> Rheumatological manifestations and musculoskeletal symptoms show rapid and complete resolution with antibiotics and their presence does not impact on the prognosis of IE.<sup>182,529</sup>

#### Recommendation Table 15 — Recommendations for patients with musculoskeletal manifestations of infective endocarditis

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>
MRI or PET/CT is recommended in patients with suspected spondylodiscitis and vertebral osteomyelitis complicating IE. <sup>30,32,206,524</sup>	I	C
TTE/TOE is recommended to rule out IE in patients with spondylodiscitis and/or septic arthritis with positive blood cultures for typical IE microorganisms. <sup>247,248,517–521,523</sup>	I	C
More than 6-week antibiotic therapy should be considered in patients with osteoarticular IE-related lesions caused by difficult-to-treat microorganisms, such as <i>S. aureus</i> or <i>Candida</i> spp., and/or complicated with severe vertebral destruction or abscesses. <sup>523,525,530</sup>	IIa	C

IE, infective endocarditis; MRI, magnetic resonance imaging; PET/CT, positron emission tomography/computed tomography; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

### 9.7. Acute renal failure

Acute renal failure is a common complication of IE and is associated with increased morbidity and mortality as well as significant increase in length and cost of hospitalization.<sup>5,531–534</sup> Additionally, renal failure is an independent predictor of poor outcome after cardiac surgery.<sup>417</sup> However, acute renal failure should not be a reason to delay cardiac surgery. The EURO-ENDO registry reported that in patients with IE, acute renal failure was the second most common complication with an incidence of almost 18%.<sup>5</sup> Some single-centre studies that specifically

reported on the incidence of acute renal failure (using standardized criteria) in patients with IE reported that any degree of acute renal failure from mild to severe might be observed in 40–69% of cases.<sup>532,535,536</sup> Severe renal failure requiring haemodialysis has been reported in 6% of patients with IE and it is associated with a very high risk of mortality (40%).<sup>537</sup>

Several factors may be responsible for the onset or worsening of renal dysfunction: (i) immune complex and vasculitic glomerulonephritis; (ii) renal infarction due to septic emboli;<sup>538,539</sup> (iii) haemodynamic impairment in patients with HF; (iv) antibiotic and other drug toxicity (notably related to aminoglycosides, vancomycin, nafcillin, amoxicillin, oxacillin, concomitant use of non-steroidal anti-inflammatories, and/or high dose loop diuretics); and (v) nephrotoxicity of contrast agents used for diagnostic imaging techniques.<sup>417,531,534,535,537,540</sup>

To reduce the incidence of acute renal failure, nephrotoxic antibiotics should be avoided if possible or, if not possible, serum levels (aminoglycosides and vancomycin) as well as creatinine should be closely monitored, and the optimal dose of medication should be periodically re-evaluated and discussed with the Endocarditis Team and a pharmacologist.<sup>536</sup> Loop diuretics should also be used cautiously and other potentially nephrotoxic drugs, such as non-steroidal anti-inflammatories, should be avoided.<sup>536</sup> Similarly, the use of nephrotoxic contrast agents for diagnostic imaging techniques should be carefully evaluated and avoided when possible.

In patients with IE and a reduced glomerular filtration rate, contrast enhanced abdominal ultrasound or MRI are reasonable tests to diagnose embolization as cause of renal function impairment.<sup>541</sup>

## 10. Surgical therapy: principles and methods

Surgery has been demonstrated to be an independent predictor of survival in many retrospective studies of IE patients under various clinical conditions and offers a potential curative therapy to select patient groups.<sup>5,250,403,404,421,436</sup> Optimal management of such patients may lead to lower peri-operative complication rates and further potential benefits of surgical therapy.

### 10.1. Pre-operative and peri-operative management

#### 10.1.1. Coronary angiography

When cardiac surgery becomes necessary in IE, assessment of coronary anatomy is recommended (see Recommendation Table 16). Classically, pre-operative coronary angiography is recommended for men >40 years, post-menopausal women, and in those with one or more cardiovascular risk factors or history of CAD.<sup>128</sup> The presence of aortic valve vegetations may preclude invasive coronary angiography due to the risk of iatrogenic embolization.<sup>542,543</sup> However, some studies have demonstrated the safety of performing invasive coronary angiography in the presence of aortic valve vegetations, particularly in patients without very large and mobile vegetations.<sup>193,544</sup> Alternatively, coronary CTA can be used to rule out significant coronary obstructions. Furthermore, surgery may need to be conducted without detailed information on coronary anatomy in certain clinical conditions, particularly emergencies. Of note, a recent study questioned the need for coronary artery bypass grafting of non-critical lesions at the time of surgery for IE and suggested that such concomitant intervention may have a negative impact on peri-operative outcomes.<sup>545</sup>

### Recommendation Table 16 — Recommendations for pre-operative coronary anatomy assessment in patients requiring surgery for infective endocarditis

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>
In haemodynamically stable patients with aortic valve vegetations who require cardiac surgery and are high risk for CAD, a high-resolution multislice coronary CTA is recommended. <sup>185,546</sup>	I	B
Invasive coronary angiography is recommended in patients requiring heart surgery who are high risk for CAD, in the absence of aortic valve vegetations.	I	C
In emergency situations, valvular surgery without pre-operative coronary anatomy assessment regardless of CAD risk should be considered. <sup>543,545</sup>	IIa	C
Invasive coronary angiography may be considered despite the presence of aortic valve vegetations in selected patients with known CAD or at high risk of significant obstructive CAD. <sup>193,543,544</sup>	IIb	C

© ESC 2023

CAD, coronary artery disease, CTA, computed tomography angiography.

<sup>a</sup>Class of recommendation.<sup>b</sup>Level of evidence.

#### 10.1.2. Extracardiac infection

Extracardiac foci may be treated prior to valve surgery, during the valve operation, or post-operatively, dependent on the urgency of cardiac surgery. Regardless of the timing of intervention, infective foci need to be eradicated before completion of antibiotic therapy in order to avoid cardiac valve reinfection.

#### 10.1.3. Intra-operative echocardiography

Intra-operative TOE provides contemporaneous assessment of the extent of infection prior to valve repair/replacement. Extent of infection, stability of known vegetations, re-assessment of previously uninvolved heart valves, and biventricular function are routinely performed with intra-operative TOE. Intra-operative TOE post-surgical repair is mandatory to determine the immediate result and establish a baseline for follow-up comparisons.<sup>547</sup>

### 10.2. Other intra-operative considerations

Specific peri-operative management considerations are necessary in all IE patients undergoing valve surgery, particularly in those following stroke (see Section 10.3). Pre-operative antibiotic therapy must be continued intra-operatively, and doses may need to be repeated in case of prolonged operations or major bleeding. Although the pharmacokinetics of antibiotic therapy is altered during cardio-pulmonary bypass (CPB), adjustment of doses is rarely required.<sup>548</sup> In general, ongoing IE antibiotic treatment offers appropriate surgical site infection prophylaxis. However, when the antibiotic treatment for IE does not fully cover normal surgical prophylactic treatment, conventional prophylaxis should be added. Intra-operative bleeding management is often complicated by marked coagulopathy in patients with IE, particularly those undergoing surgery during persistent sepsis. The management of hypotension and vasoplegia is particularly challenging in patients presenting with septic shock, and accompanying vasoplegia tends to worsen significantly during CPB. Norepinephrine is frequently used as first-line therapy for septic shock, followed by vasopressin or terlipressin in cases

of resistant vasoplegia.<sup>549</sup> Methylene blue may be used as a rescue agent in patients who are unresponsive to these measures, but mortality rates are high for such patients.<sup>550</sup>

Retrospective studies have suggested that the use of haemoadsorbent filters during CPB may decrease the negative effects associated with cytokine cascade activation.<sup>551</sup> A recent RCT of haemoadsorption during cardiac surgery in IE patients, however, failed to demonstrate any beneficial effects with regards to adverse events or end-organ function.<sup>552</sup>

### 10.3. Surgical approach and techniques


Surgery for IE aims to remove infected structures followed by re-establishment of anatomy and haemodynamic function. With regards to the involved heart valve(s), repair or replacement is carried out based on the extent of destruction, acuity of disease, and patient characteristics.<sup>553</sup> Appropriate collection and labelling of tissue samples for pathological, microbiological, and molecular biological analyses are necessary to help guide antibiotic treatment.

Aortic valve replacement is usually required for aortic IE. Aortic valve repair is very uncommon in the acute situation but may be performed for isolated aortic regurgitation after healed endocarditis. In mitral IE, leaflet perforations with preserved free margin and chordae tendinae may be treated with patch repair, particularly in the setting of subacute or healed IE. Although mitral valve repair is feasible in more complex mitral IE involving the annuli, the leaflet free edge, and/or chordae, evidence showing the feasibility and durability of such repair techniques is scarce.<sup>554,555</sup> A large registry on mitral repair vs. replacement in IE was limited by the lack of information on severity of IE, different patient group profiles, and significantly higher incidence of staphylococcal endocarditis in the mitral valve replacement group.<sup>556</sup> Therefore, it cannot be concluded that mitral valve repair is superior to replacement due to the high probability of selection bias. Valve preservation in acute IE should only be attempted if a durable repair is anticipated and complete eradication of infected tissue can be achieved. However, valve repair may be necessary in children, where valve replacement options are more limited.

Invasion of the aortic annuli may create shallow defects (very limited abscess or small pseudoaneurysms) that are still amenable to conventional valve replacement surgery. When disease progresses into an extensive aortic root abscess or periannular destruction, aortic root replacement is usually required. In experienced centres, the use of allografts has been preferred as they have the advantage of adapting to irregular surfaces and provide haemostatic advantages with very good haemodynamic function and low thrombo-embolic risk, and can be used to repair concomitant lesions of the anterior mitral valve leaflet.<sup>557,558</sup> Additionally, allografts and stentless bioprostheses can be beneficial in small aortic roots and are associated with low reinfection rates. However, experience is generally limited to single-centre case series and there is no clear evidence of superiority of one valve substitute over the other.<sup>559</sup> In very selected patients and children in particular, the Ross operation (pulmonary valve autotransplantation) may be considered for aortic root IE.<sup>128</sup>

The use of patches to cover abscess cavities and prevent extensive resection and reconstruction is discouraged in aortic root IE as it may be associated with recurrences, periprosthetic leaks, and pseudoaneurysm formation. After exclusion from the circulation, abscess and pseudoaneurysm cavities are left to drain into the pericardial cavity.

When periannular infection of the aortic root extends into the inter-valvular fibrosa body, complex surgical reconstructions are required and are frequently the only option to achieve patient survival. The reported



**Figure 11** Surgery for infective endocarditis following stroke. NIHSS, National Institutes of Health Stroke Scale Score. Surgery timing: emergency, within 24 h. Urgent, within 48–72 h. Non-urgent, within same hospital admission. <sup>a</sup>Glasgow Coma Scale  $\leq 4$  or NIHSS  $> 18$ . <sup>b</sup>Intracranial haemorrhage volume  $< 30$  mL or NIHSS  $< 12$ .

pooled peri-operative survival rate of such surgical technique is 84%.<sup>560</sup> Even more extensive repairs may be required for cases involving the intervalvular fibrosa, central fibrous body, and mitral valve, with or without fistulation to the right-side chambers. These operations are technically complex and require a surgeon who is very experienced in IE, which may not be available in every cardiovascular surgery department.

Exceptionally, heart transplantation has been utilized for carefully selected patients without other surgical options.<sup>561</sup>

### 10.3.1. Choice of valve prosthesis

Many patient characteristics are taken into account when deciding the type of valve prosthesis to implant in a given patient with IE. The studies published to date evaluating various valve prostheses in the setting of IE, however, suffer from numerous biases.<sup>90,559,562–566</sup>

Beyond the patient characteristics that apply in the non-IE setting,<sup>128</sup> valve selection in IE is influenced by the presence of recent stroke, risk of new-onset bleeding, complexity of expected post-operative course,

**Table 12** Features favouring a non-mechanical valve substitute in the setting of surgery for acute infective endocarditis

Early surgery after a recent ischaemic stroke
Evidence of intracranial bleeding
Woman of childbearing age
High likelihood of prolonged mechanical circulatory support
Advanced age or frailty
Poor or unknown medical compliance
Expected complicated and prolonged post-operative course
Patient preference

© ESC 2023

and the ability of the patient to participate in decision-making, especially for emergency surgery (Table 12). In the absence of specific contraindications for a particular valve substitute, patient preferences should determine the final decision.

## 10.4. Timing of surgery after ischaemic and haemorrhagic stroke

There is a general trend of offering early surgery in IE in light of the improved operative outcomes and survival benefits observed with operative management.<sup>451,567</sup> For patients who have suffered a neurological injury, however, the optimal timing of surgery remains to be defined.<sup>568</sup> There are no RCTs specifically assessing this clinically relevant issue and contemporary evidence arises from observational studies.<sup>415,454,473,569,570</sup>

Neurological exacerbation may occur during surgery or early post-operatively due to the altered physiology conditions during and immediately after cardiac repair.<sup>571</sup> Several peri-operative variables should be addressed in order to lower the risk of neurological deterioration and haemorrhagic transformation post-stroke (see [Supplementary data online, Table S10](#)).

The risk of neurological exacerbation during surgery needs to be balanced against that of delaying a cardiac operation. When haemodynamic disturbances are present, surgery should be pursued without delay (see [Figure 11](#) and Recommendation Table 17).<sup>451,468,473,567,568,570–578</sup> A more common situation occurs when surgery is considered for the prevention of recurrent embolism after stroke, due to the presence of large vegetations (>10 mm). In patients that have suffered a transient ischaemic attack, the risk of surgery is usually low and surgery should be performed without delay. For patients with ischaemic stroke, multiple observational data exist supporting a non-delayed (urgent) intervention, unless the neurological status is poor (i.e. coma or extensive damage leading to poor functional prognosis).<sup>573,578</sup> Involvement of an expert neurology/neurosurgical specialist will help in risk assessment discussions.

The risk of post-operative haemorrhagic conversion after pre-operative stroke is reported in the range of 2–7%.<sup>453,579</sup> Remarkably, bleeding transformation after cardiac surgery can also occur in patients with silent pre-operative cerebral embolisms, with similar frequency as in patients with overt neurological deficits. Unfortunately, these events cannot currently be accurately predicted prior to surgery. When haemorrhagic transformation occurs, it is associated with high mortality (40%) and may require rescue neurointerventional or neurosurgical treatment to control bleeding or allow cerebral decompression by means of craniectomy.<sup>577,580</sup>

Several retrospective studies report benefits of early surgery (within 2 weeks) after haemorrhagic stroke without further compromising

neurological outcomes.<sup>574,581,582</sup> Decisions should be taken on a case-by-case basis by the Endocarditis Team, including a neurologist, and should be adapted to the mechanism of intracranial haemorrhage and its severity including intracranial haemorrhage volume measurement and National Institutes of Health Stroke Scale Score (NIHSS) score (see [Figure 11](#)).<sup>495</sup> In patients in whom surgery is delayed, repeat CT or MRI imaging should be performed 1–2 weeks following intracranial haemorrhage (or earlier in the case of clinical deterioration) in order to assess stability of the cerebral finding and potentially re-assess timing of surgery. The timing of surgery after intracranial haemorrhage is controversial and an area where further evidence is urgently required.

## Recommendation Table 17 — Indications and timing of cardiac surgery after neurological complications in active infective endocarditis

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>
After a transient ischaemic attack, cardiac surgery, if indicated, is recommended without delay. <sup>454,468</sup>	I	B
After a stroke, surgery is recommended without any delay in the presence of HF, uncontrolled infection, abscess, or persistent high embolic risk, as long as coma is absent and the presence of cerebral haemorrhage has been excluded by cranial CT or MRI. <sup>451,468,473,567,568,570–578</sup>	I	B
Following intracranial haemorrhage, delaying cardiac surgery >1 month, if possible, with frequent re-assessment of the patient's clinical condition and imaging should be considered. <sup>571</sup>	IIa	C
In patients with intracranial haemorrhage and unstable clinical status due to HF, uncontrolled infection or persistent high embolic risk, urgent or emergency surgery should be considered weighing the likelihood of a meaningful neurological outcome. <sup>199,581–584</sup>	IIa	C

CT, computed tomography; HF, heart failure; MRI, magnetic resonance imaging.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

## 10.5. Post-operative complications

Post-operative management of patients with IE may be challenging due to pre-operative multiorgan involvement and often complex surgical procedures. The risk of in-hospital mortality associated with IE surgery remains high (10–20%), particularly in patients >75 years of age, usually due to co-morbidities and complications of IE. Further research should focus on methods to lower surgical mortality.

The most frequent serious post-operative complications are coagulopathy requiring extensive use of blood products and clotting factors, re-exploration of the thorax due to bleeding/tamponade, haemodialysis, stroke, or cerebral haemorrhagic transformation of prior cerebrovascular lesions, low cardiac output syndrome, respiratory complications and tracheostomy, prolonged hospital stay, and need for a permanent pacemaker.<sup>515,585,586</sup> When mortality occurs, the cause of death is often multifactorial. Post-mortem examination is helpful for determining the cause of death, further understanding of disease process, teaching purposes at academic environments, and quality control.

## 10.6. Management of antithrombotic therapy after surgery

The management of antithrombotic therapy early after surgery for IE may need to be altered when compared with non-IE clinical scenarios (see also [Section 12.10](#)).<sup>128</sup> This is mainly due to known increased risk of intracranial haemorrhage after cerebral embolism. Restrictive or tailored use of antiplatelet and antithrombotic agents after surgery are key to avoid further complications,<sup>203,587</sup> which is more feasible in patients who received bioprosthetic valve prostheses or valve repair operations than after mechanical valve replacement surgery.

## 11. Outcome after discharge: follow-up and long-term prognosis

Following in-hospital treatment, patients should be followed-up for the occurrence of main post-discharge complications, including recurrence of infection, HF, need for valve surgery or additional intervention, stroke, need for renal replacement therapy, psychological complications, and death.<sup>86,588,589</sup>

### 11.1. Recurrences: relapses and reinfections


The risk of recurrence (which includes relapses and reinfections) among survivors of IE varies significantly between studies, ranging from 2% to 9% in more contemporary analyses.<sup>86,589–595</sup> However, it has been shown that reinfections have worse outcomes as compared with relapses.<sup>592</sup>

[Figure 12](#) illustrates the diagnostic paths to differentiate relapse from reinfection.<sup>596</sup>

Conceptually, relapse refers to a repeat episode of IE caused by the same microorganism and represents a failure of treatment due to insufficient duration of initial treatment, sub-optimal choice of initial antibiotics, or a persistent focus of infection.<sup>592</sup> Conversely, reinfection is related to patients' clinical and immunological profiles, describes an infection caused by a different microorganism usually more than 6 months after the initial episode,<sup>4,596</sup> and is associated with worse outcome.<sup>592</sup> The differentiation between relapse and reinfection needs to be interpreted with caution, however, as a long time period from initial infection suggests reinfection even in the presence of the same strain. Contemporary data report low rates of relapse,<sup>86</sup> most probably reflecting improved management of these patients. Relapse should be treated with i.v. antibiotics for an additional 4–6 weeks, depending on the causative microorganism and its antibiotic susceptibility, and cardiac surgery should be considered. It is also important to consider that antibiotic resistance may develop over time. Factors associated with an increased rate of relapse are listed in [Table 13](#).<sup>588,595,597</sup>

In surgically managed NVE, the risk of IE recurrence is no different when comparing valve replacement and valve repair.<sup>84,598</sup> Several previous studies have also reported no difference regarding the risk of recurrent IE between types of valve implanted.<sup>599–601</sup> However, the most recent Danish registry study reports increased risk of IE recurrence associated with biological vs. mechanical prostheses.<sup>84</sup>

Partial oral vs. i.v. antibiotic treatment of IE, as well as OPAT vs. hospital-based antibiotic treatment in select stable patients, is not associated with an increased risk of recurrent IE.<sup>43,396,399,602</sup> Notably, residual vegetation after treatment for IE also did not show increased association with recurrence of IE,<sup>602</sup> although this result should be interpreted with caution. Patients with relapse or reinfection IE should be managed as indicated in [Sections 7 and 8](#) (if complicated IE).



**Figure 12** Algorithm differentiating relapse from reinfection. Reproduced with permission from Chu et al.<sup>596</sup>

**Table 13 Factors associated with an increased rate of relapse of infective endocarditis**

Inadequate antibiotic treatment (i.e. agent, dose, duration)
Resistant microorganisms (i.e. <i>Brucella</i> spp., <i>Legionella</i> spp., <i>Chlamydia</i> spp., <i>Mycoplasma</i> spp., <i>Mycobacterium</i> spp., <i>Bartonella</i> spp., <i>C. Burnetii</i> , fungi)
Infective endocarditis caused by <i>S. aureus</i> and <i>Enterococcus</i> spp.
Polymicrobial infection in people who inject drugs
Periannular extension
Prosthetic valve endocarditis
Persistent metastatic foci of infection (abscesses)
Resistance to conventional antibiotic regimens
Positive valve culture
Persistence of fever at the 7th post-operative day
Chronic kidney disease, especially on dialysis
High-risk behaviour, inability to adhere to medical treatment
Poor oral hygiene

© ESC 2023

### 11.2. First year follow-up

Patients discharged after the first episode of IE should remain under close surveillance for potential long-term complications. A partnership between cardiologists, infectious disease specialists, cardiac surgeons, general practitioners, and dentists is encouraged to improve patient care and reinforce prophylaxis measures. In medically treated patients, residual valve dysfunction may worsen, or structural valve deterioration may progress, despite bacteriological cure. To monitor the risk of development of secondary HF, an initial clinical evaluation and baseline TTE should be performed at the completion of antimicrobial therapy and repeated if a change in the clinical condition occurs.

Clinical re-assessment should be performed one or more times in the first year and yearly thereafter depending on the individual risk profile. The need for late valve surgery is relatively low, ranging from 3% to 11%.<sup>27,588,592</sup> Blood testing for inflammatory markers (i.e. WBC, C-reactive protein, procalcitonin) should be performed early after finishing antimicrobial treatment and repeated thereafter when clinically indicated.<sup>592</sup> Due to the increased risk of relapse for virulent microorganisms, blood cultures are encouraged within the first week after finishing treatment.

The early period after discharge might be challenged by slow physical and mental recovery.<sup>603,604</sup> Patients' and families' concerns should be addressed during follow-up. Supporting the family may indirectly support the patient during recovery and reduce the psychological burden. Cardiac rehabilitation, including physical exercise training and patient education, may be beneficial, and has been shown to be safe and feasible in stable patients at a minimum of 2 weeks after surgery for left-sided IE.<sup>605</sup> Physical training should start as early as possible and can be adapted post-sternotomy with isolated lower-limb training. Adherence is improved if the delay to training is minimized, and rebuilding muscle mass and reducing frailty should be a priority.

Patients, and their caregivers, should be informed of their risk of IE recurrence and be educated on preventive measures and self-monitoring. In particular, patients should be educated that new onset of fever, chills, or other signs of infection mandate immediate evaluation, including procurement of blood cultures before empirical use of antibiotics, and that contact with the Heart Valve Centre is mandatory in case of suspected recurrent IE. Good oral health maintenance,

preventive dentistry, and advice about skin hygiene, including advice on tattoos and skin piercing, are mandatory. Deficiencies in dental surveillance contribute to the continuous gradual increase in the incidence of IE, which underlines the need for repeating the principles of IE prevention at each follow-up visit. In PWID patients, follow-up care should include a strategy for addiction treatment, involve relevant addiction specialists before hospital discharge, and possibly including medication for opioid-use disorder.<sup>606,607</sup>

**Recommendation Table 18 — Recommendations for post-discharge follow-up**

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>
Patient education on the risk of recurrence and preventive measures, with emphasis on dental health, and based on the individual risk profile, is recommended during follow-up. <sup>608</sup>	I	C
Addiction treatment for patients following PWID-related IE is recommended. <sup>606,607</sup>	I	C
Cardiac rehabilitation including physical exercise training should be considered in clinically stable patients based on an individual assessment. <sup>605,609</sup>	IIa	C
Psychosocial support may be considered to be integrated in follow-up care, including screening for anxiety and depression, and referral to relevant psychological treatment. <sup>605,609</sup>	IIb	C

IE, infective endocarditis; PWID, persons who inject drugs.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

### 11.3. Long-term prognosis

Contemporary long-term survival rates after the completion of IE treatment are estimated to be ~85–90% and 70–80% at 1 and 5 years, respectively.<sup>589,592–594,610,611</sup> Impact of referral bias, however, should be taken into consideration.<sup>612</sup> The main predictors of long-term mortality are age, co-morbidities, PWID, double valve infection, recurrences of IE, and HF, especially when cardiac surgery cannot be performed.<sup>588,589,592,593,613</sup> Compared with an age- and sex-matched general population, patients that survived a first episode of IE have significantly worse survival when suffering relapses or reinfections.<sup>589,614</sup>

This excess mortality is especially high within the first few years after hospital discharge and can be explained by late complications such as HF, risk of recurrences, and higher patient vulnerability.<sup>589,611</sup> In fact, most recurrences of IE and late cardiac surgeries occurred during this period of time.<sup>589,592,611</sup>

## 12. Management of specific situations

### 12.1. Prosthetic valve endocarditis

Prosthetic valve endocarditis is the most severe form of IE and occurs in 1–6% of patients with valve prostheses,<sup>615</sup> with an incidence of 0.3–1.2% per patient-year.<sup>5,420,616,617</sup> PVE accounts for 20–30% of all cases of IE,<sup>618</sup> and may be more common after biological than after mechanical valve replacement surgery.<sup>619,620</sup> PVE was observed in 21% of cases of IE in a French survey,<sup>618</sup> in 26% of cases in the Euro Heart Survey,<sup>419</sup> and in 20% of cases in the ICE-PCS.<sup>621</sup> Real-world

observational studies demonstrated stable rates of IE, but a remarkable increase in PVE between 1998 and 2013.<sup>80</sup> Recently, a further increase in PVE cases (31%) was observed in the EURO-ENDO registry.<sup>5</sup> PVE is still associated with difficulties in diagnosis, determination of the optimal therapeutic strategy, and poor prognosis.

### 12.1.1. Definition and pathophysiology

A distinction is commonly made between early PVE and late PVE based on the time since valve surgery, because of significant differences in the microbiological profiles between these two groups.<sup>622</sup> However, the time to IE onset is prognostically less important than the connection of IE to the peri-operative period or to specific pathogens. Prosthetic valve endocarditis with an onset in the peri-operative period involves mainly *S. aureus*, *Staphylococcus epidermidis*, or nosocomial microorganisms, such as Gram-negative pathogens or fungi. Late PVE more commonly mimics the pattern of NVE, which is mostly represented by streptococcal and staphylococcal infections.<sup>623</sup> *S. aureus* is more commonly observed in patients with mechanical valves, while alpha-haemolytic streptococci, enterococci, and CoNS are more common in patients with bioprosthetic valves.<sup>624</sup> PVE due to *Mycobacterium chimaera* is an uncommon form of nosocomial infection that can result from contaminated CPB heater-cooler systems. Such infections present many months after the index operation and can therefore be challenging to identify, and are associated with high mortality.<sup>625</sup>

The pathogenesis of PVE differs according to both the type of contamination and the type of prosthetic valve (see [Supplementary data online, Section S6.1](#)).

### 12.1.2. Diagnosis

Diagnosis is more difficult in PVE than in NVE. Clinical presentation is frequently atypical, particularly in the early post-operative period, in which fever and inflammatory syndromes are common in the absence of macroscopic alterations of the prosthesis on cardiac imaging. However, persistent fever should trigger the suspicion of PVE. As in NVE, diagnosis of PVE is based mainly on the results of echocardiography and blood cultures. However, both are associated with a sensitivity of only 60% for the definite diagnosis of endocarditis.<sup>212</sup>

Although TOE is mandatory in suspected PVE ([Figure 6](#)), its diagnostic value is lower than in NVE. Identification of a new periprosthetic leak is a major criterion of IE and urges additional imaging modality to confirm the diagnosis (see [Section 5](#)).<sup>533,626</sup> Recently, nuclear techniques, particularly [18F]FDG-PET/CT, have been shown to improve the diagnostic accuracy of the Duke criteria and increase sensitivity.<sup>34,209</sup> Combinations of different imaging techniques such as cardiac CT, nuclear imaging, and TOE, improve diagnostic accuracy and provide relevant information in terms of prognosis.<sup>33,627</sup> In select cases of suspected PVE, and non-diagnostic results for the above-listed exams, intracardiac echocardiography may be considered.

### 12.1.3. Prognosis and treatment

A high in-hospital mortality rate of 20–40% has been reported in PVE.<sup>628,629</sup> Compared with NVE, PVE is associated with increased in-hospital mortality and morbidity as well as reduced long-term survival.<sup>88,630</sup> Several factors have been associated with poor prognosis in PVE, including older age, diabetes mellitus, healthcare-associated infections, and early PVE.<sup>312</sup> Among the different causative organisms, staphylococcal or fungal infection seem to be more aggressive, whereas enterococcal infections are associated with similar mortality but higher recurrence rates.<sup>628</sup> Haemodynamic instability, multivalvular

involvement as well as involvement of the aortomitral fibrosa have been associated with worse outcomes. It is noteworthy that the most important risk factor for recurrent IE and mortality is withholding surgery despite an obvious indication.<sup>5</sup>

The best therapeutic option in PVE is still debated. Although surgery is generally considered the best option when PVE causes severe prosthetic dysfunction or HF, in the EURO-ENDO registry it was performed in only 73% of patients with PVE despite a clear indication for surgical treatment.<sup>5</sup> In a single-series study of 523 PVE patients, early surgery was a large independent predictor of early and 1-year survival.<sup>631</sup> Conversely, after adjustment for differences in clinical characteristics and survival bias, early valve replacement was not associated with lower mortality compared with medical therapy in a large international cohort.<sup>421</sup> In this series, however, surgery was beneficial in the subgroup of patients with the strongest indications for surgery including valve regurgitation, vegetation, and dehiscence or paravalvular abscess/fistula formation.<sup>421</sup> Therefore, a surgical strategy is recommended for PVE in high-risk subgroups identified by prognostic assessment, i.e. PVE complicated with HF, severe prosthetic dysfunction, abscess, or persistent fever. Conversely, patients with uncomplicated non-staphylococcal late PVE can be managed conservatively.<sup>632–634</sup> However, patients who are initially treated medically require close follow-up because of the risk of late events and the higher risk of relapse or valvular dysfunction.

Surgery for PVE follows the general principles outlined for NVE. However, the reoperation setting and the higher incidence of periprosthetic tissue destruction increase the complexity of the procedure. Meticulous and radical debridement of the infected material, including the original prosthesis, suture, and pledgets, is recommended. The type of valve substitute used for PVE follows the same recommendations as for NVE (see also [Section 10.3.1](#)).

Early PVE following valve replacement surgery is a separate entity associated with a high mortality rate, where conservative treatment with antibiotics is unlikely to lead to a cure and repeat surgery should be performed.<sup>621,635</sup> Staphylococci, Cutibacteria, or similar species are the usual causative organisms.<sup>622,636</sup>

### Recommendation Table 19 — Recommendations for prosthetic valve endocarditis

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>
Surgery is recommended for early PVE (within 6 months of valve surgery) with new valve replacement and complete debridement. <sup>621,635</sup>	I	C

PVE, prosthetic valve endocarditis.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

## 12.2. Endocarditis in the elderly

Characteristics of patients with IE have dramatically changed over recent decades, with an increasing prevalence and specific features of IE in the elderly population.<sup>25,145,637,638</sup> In this population, enterococci and *S. aureus* are reported to be the most frequent aetiological agents. In addition, the higher presence of intracardiac prosthetic devices (CIED and valvular prosthesis/repair including TAVI devices) and increased incidence of healthcare-associated IE episodes are observed.<sup>25,637</sup> Finally, a lower risk of embolic episodes has been observed in this subgroup.<sup>462,639–641</sup>

A number of studies have shown that cardiac surgery positively affects the clinical outcome of IE patients. Nevertheless, old age, co-morbidities, and previous non-cardiac and cardiac procedures lead to surgical hesitancy by referring physicians, surgeons, and patients themselves.<sup>642</sup> Moreover, these characteristics also influence the outcome of this fragile cohort.<sup>400,433</sup> As a result, less frequent performance of curative surgery and increased mortality are typical hallmarks of IE episodes in elderly as compared with the younger population.<sup>640</sup> In a recently published Swedish propensity analysis of IE patients from 2006 to 2017, the authors found that surgery was underused in the elderly and that 1-year mortality was significantly higher in elderly patients who did not undergo surgery.<sup>641</sup> In a sub-analysis of the ESC EORP EURO-ENDO registry, the indication for surgery was less often recognized (51% vs. 57%) and surgery was far less frequently performed when indicated (35% vs. 68%) in patients >80 vs. <80 years. However, mortality of surgically treated patients was remarkably similar in patients <80 and >80 years after propensity matching (19.7% vs. 20.0%). Age was also not demonstrated to be an independent predictor of mortality in this large prospective study.<sup>640,643</sup> These findings suggest that performance of surgery in well-selected elderly patients is underutilized and may increase their chance of survival.

In elderly IE patients, functional and nutritional status are important predictors of outcomes.<sup>400</sup> When considering cardiac surgery in elderly patients, functional and nutritional status, and their associated risks, should be accurately explored through a comprehensive assessment by geriatricians. In addition, the earliest possible discharge home to facilitate the patient's functional recovery should be considered in this subgroup of patients.

## 12.3. Transcatheter prosthetic valve endocarditis

### 12.3.1. Endocarditis following transcatheter aortic valve implantation

The incidence of IE post-TAVI ranges from 0.3 to 1.9 per 100 patient-years,<sup>94,623,644–648</sup> which is similar to that reported following surgical aortic valve replacement in both observational studies and RCTs.<sup>94,623,646,647</sup> One recent study, however, reported a lower incidence of PVE after TAVI compared with surgical prostheses.<sup>649</sup> The risk of IE is higher within the first year following the procedure, and particularly within the initial 3 months.<sup>644,645,648,650–652</sup> A modest decrease in the incidence of IE post-TAVI has been observed in recent years, particularly in the early period following the procedure, presumably related to multiple technical improvements, more streamlined procedures, and a reduction of periprocedural complications.<sup>650,652</sup> A similar IE rate has been reported irrespective of transcatheter valve type,<sup>653</sup> and predisposing factors, including younger age, male gender, renal dysfunction, and significant residual aortic regurgitation, have been identified.<sup>94,644–646,648,651,652</sup>

#### 12.3.1.1. Diagnosis

The diagnosis of IE post-TAVI is challenging. The stent frame of transcatheter valves, with a much higher amount of metal surrounding the valve leaflets compared with surgical prostheses, and the characteristics of TAVI patients (frequently elderly with multiple co-morbidities) may increase the diagnostic challenges in this population. The clinical presentation is frequently atypical, with fever lacking in 13–20% of patients.<sup>623,645,650</sup> Enterococci and *S. aureus* are the two most common microorganisms involved in IE post-TAVI, followed by streptococci and CoNS.<sup>644–646,650</sup>

Some important aspects should be considered regarding TOE in patients with suspected IE post-TAVI: (i) no vegetations are detected in

38–60% of cases,<sup>623,645,650,651</sup> (ii) vegetations are located in the stent frame of the transcatheter valve (and not on the valve leaflets) in 12% of cases, and this rate increases up to 19% in the presence of some self-expanding valve systems with a longer stent frame occupying the ascending aorta,<sup>653</sup> and (iii) the vegetations are located outside the transcatheter valve in about one-third of cases, mainly at the level of the mitral valve.<sup>645,650,651</sup> Nuclear imaging or CT have been useful to diagnose IE post-TAVI.<sup>654,655</sup> The addition of [18F]FDG-PET/CT and/or CTA to the diagnostic work-up of IE in TAVI changed the final clinical diagnosis in 33% of patients.<sup>655</sup> Intracardiac echocardiography may also be useful for detecting vegetations in patients with suspected IE after TAVI and negative TOE.<sup>165</sup>

#### 12.3.1.2. Prognosis and treatment

Prognosis and treatment of post-TAVI PVE is complicated by the fact that patients are older and have more co-morbidities than post-surgical PVE patients. About two-thirds of patients with IE post-TAVI exhibit at least one complication, with acute kidney injury and HF being the most frequent adverse events.<sup>645,646,656</sup> The in-hospital and 30-day mortality rates are very high, ranging from 16% to 36%,<sup>623,644–647,657</sup> and increase up to 41–59% at 1-year follow-up.<sup>644,645,652,657</sup> A higher patient risk profile, *S. aureus*, and the occurrence of IE complications have been identified as risk factors for increased mortality.<sup>645,652,657</sup>

Antimicrobial therapy for IE post-TAVI is similar to that of PVE (see [Section 7](#)). Similar to surgical PVE, cardiac surgery is considered the best option in the presence of IE complications, particularly severe prosthetic failure or HF, but is infrequently performed. Surgery is performed in ~20% of cases (ranging from 3.8% to 31.3%),<sup>645,652,656</sup> a much lower rate compared with NVE and surgical PVE. The characteristics of the TAVI population, with often advanced age and high or prohibitive surgical risk, along with the potential difficulties associated with the removal of some transcatheter valve systems (particularly those with a large amount of stent frame, frequently adherent to the ascending aorta after a few months following the TAVI procedure) may play a role in the low rate of surgical interventions.

To date, all studies but one failed to demonstrate the potential benefit of surgery in IE post-TAVI patients,<sup>442,645,652,656,658</sup> but the relatively small sample size of the studies and the multiplicity of potential confounders when comparing to those patients not receiving surgical treatment precludes definite conclusions. The only study showing a beneficial effect of surgical intervention focused on those patients who had a local extension of the infection (i.e. abscess or fistula).<sup>442</sup>

The decision to proceed with surgery in IE post-TAVI patients should be individualized, balancing the surgical risks and the prognosis of medical treatment alone. In cases with local extension of the infection, surgery may be recommended in the absence of a prohibitive surgical risk. In cases with healed IE and valve prosthesis dysfunction, repeat transcatheter therapy (valve-in-valve procedure) can be performed in select patients.<sup>659</sup> Such interventions should be performed at least 1–3 months after the healed endocarditis episode and following a negative follow-up TOE.

### 12.3.2. Endocarditis following transcatheter pulmonary valve implantation

The incidence of IE post-transcatheter pulmonary valve implantation (TPVI) ranges from 1.6 to 4.0 per 100 patient-years,<sup>93,660–667</sup> which seems to be higher than that reported following surgical pulmonary valve interventions (observational studies, no randomized data).<sup>662,663,667,668</sup> While some studies suggest a higher risk associated with the use of bovine jugular vein valves,<sup>662,667,669</sup> a recent large multi-centre study including different transcatheter valve systems did not

observe differences between valve types.<sup>665</sup> The most consistent factors associated with an increased risk of IE following TPVI have been younger age, a previous history of IE, and a higher transvalvular residual gradient.<sup>93,663,665</sup>

### 12.3.2.1. Diagnosis

The diagnosis of IE in TPVI recipients may be challenging, and the use of intracardiac echocardiography and [18F]FDG-PET/CT has been shown to be useful in cases with a clinical suspicion and negative TTE/TOE.<sup>34,93,210,660,665,670</sup> *S. aureus* and oral group streptococci species are the most common microorganisms causing IE post-TPVI.<sup>660,664–666</sup>

### 12.3.2.2. Prognosis and treatment

New moderate or severe prosthetic valve stenosis occurs much more frequently (one-third to one-half of patients) in post-TPVI PVE than in aortic PVE, and the rate of surgical valve replacement therapy ranges from 26% to 56%.<sup>93,660,661,664,665</sup> The possibility of a transcatheter therapy (valve-in-valve intervention) for treating severe prosthesis dysfunction in cases with healed endocarditis or as an urgent treatment (balloon dilatation) in severe valve stenosis cases has also been reported.<sup>660,665</sup> A valve-in-valve intervention should be delayed at least 1–3 months following antibiotic treatment of the endocarditis episode. The mortality rate related to the IE episode ranges from 0% to 11%.<sup>93,660,661,664,665</sup> This rate is much lower compared with TAVI patients, which is likely to be related to the younger and less co-morbid characteristics of the TPVI population.

## 12.4. Infective endocarditis affecting cardiac implantable electronic devices

Device-related infection is one of the most serious complications of CIED therapy and is associated with significant mortality and morbidity.<sup>671</sup>

### 12.4.1. Definitions of cardiac device infections

A recent EHRA consensus document has published criteria for CIED infection.<sup>130</sup> Localized infections may be either superficial incisional infections (acute infection without involvement of the pocket or hardware) or isolated pocket infections (limited to the hardware in the pocket), and can be either acute or chronic. Systemic CIED infections may occur with or without pocket infection, and with or without visible vegetations on the tricuspid or pulmonary valves or pacing leads. Cardiovascular implanted electronic device-related IE is defined as evidence of CIED infection with clinical signs of pocket infection and/or imaging findings (lead vegetations, positive FDG-PET on the generator/leads etc.) which fulfil the criteria for valvular IE (see [Section 5](#)).

### 12.4.2. Pathophysiology and microbiology

Cardiovascular implanted electronic device-related IE occurs by two mechanisms. Local infection usually results from bacterial flora from the patient's skin that is introduced into the pocket at the time of incision despite surgical preparation.<sup>672</sup> Seeding via bacteraemia from a distant focus is less frequent.<sup>673–676</sup>

Whereas CoNS are most frequently the cause of chronic pocket infection, the most frequent agents identified with bacteraemia in CIED infection are *S. aureus* and CoNS.<sup>677,678</sup> Other causative organisms are *Enterococcus* spp.,  $\beta$ -haemolytic streptococci, oral streptococci group, *Cutibacterium acnes*, and *Corynebacterium* spp.<sup>674,678,679</sup> More rarely, systemic infection is caused by Gram-negative (mainly *P. aeruginosa* or *Serratia marcescens*)<sup>680</sup> or polymicrobial agents, whereas systemic fungal infections (*Candida* spp. and *Aspergillus* spp.)<sup>681</sup> are exceptional.

### 12.4.3. Risk factors

Risk factors may be divided into patient-related, procedure-related, and device-related factors.<sup>118</sup> The PADIT (Previous procedure on same pocket; Age; Depressed renal function; Immunocompromised; Type of procedure) study randomized 19 603 patients undergoing CIED implantation to conventional treatment (pre-procedural cefazolin infusion) vs. different regimens of incremental treatment.<sup>682</sup> The primary outcome was 1-year hospitalization for device infection which was not significantly different between groups. A risk score for infection has been derived from the study (see [Supplementary data online, Table S11](#))<sup>683</sup> and has been validated externally.<sup>684</sup> A web-based calculator is available (<https://padit-calculator.ca>).<sup>683</sup>

### 12.4.4. Prophylaxis

Antibiotic prophylaxis to prevent CIED-related IE before interventions, such as dental, respiratory, gastrointestinal, or genitourinary procedures, is not warranted as the risk is very low.

Prevention of CIED infection at implantation hinges upon careful planning, pre-operative antibiotic prophylaxis, correction of modifiable risk factors, hygienic surgical environment and technique, ancillary measures in case of increased risk (e.g. use of an antibacterial envelope), and proper post-operative care.

Correction of modifiable risk factors includes general measures such as postponing the procedure in cases of fever or signs of infection and avoiding temporary pacing. Routine administration of prophylactic systemic antibiotics within 1 h of incision is the standard of care.<sup>118</sup> RCTs have used flucloxacillin (1–2 g i.v.)<sup>117</sup> and first-generation cephalosporins, such as cefazolin (1–2 g i.v.).<sup>116</sup> Vancomycin (1–2 g over 60–90 min) may be used in case of allergy to cephalosporins with other alternatives, including teicoplanin and clindamycin.<sup>117</sup> Coverage of MRSA should be guided by the prevalence in the implanting institution.


Haematoma is a major contributor to risk of infection, and all possible measures should be taken to avoid this complication.<sup>685,686</sup> Another major risk factor is a revision with re-opening of the pocket (e.g. for lead repositioning). Technical aspects have recently been covered in detail in an EHRA consensus document on CIED implantation.<sup>687</sup>

It is generally not recommended to wash the pocket with antibiotics, nor to administer antibiotic treatment post-operatively, as shown by the PADIT trial.<sup>682</sup> An antibiotic mesh envelope, which locally releases minocycline and rifampin for a minimum of 7 days and is fully absorbed in ~9 weeks, may, however, be useful to reduce risk of infection in selected patients. The Worldwide Randomized Antibiotic Envelope Infection Prevention Trial (WRAP-IT) showed that the mesh envelope significantly reduces the incidence of CIED infection in patients at increased risk (i.e. undergoing a pocket revision, generator replacement, system upgrade, or implantation of a cardiac resynchronization therapy [CRT]-implantable cardioverter defibrillator [ICD]).<sup>688</sup> The number needed to treat was, however, high at 200, but is ~50 in patients undergoing CRT reoperations (replacement/upgrade/revision) in a recent observational study.<sup>689</sup>

### 12.4.5. Diagnosis

Clinical presentation of CIED-associated IE is similar to valvular IE with patients frequently presenting with fever, chills, and embolic events. Signs of pocket infection (swelling, tenderness, erythema, purulent discharge etc.) may or may not be present.

The probability that a positive blood culture in a CIED recipient represents underlying device infection depends on the organism type and duration of bacteraemia. Suspicion of CIED-associated IE should be particularly high in the event of *S. aureus* bacteraemia.<sup>675</sup> CIED infection is less likely with Gram-negative bacteraemia, and in these instances, the pocket usually shows signs of infection.<sup>680,690,691</sup>



Downloaded from <https://academic.oup.com/eurheartj/article/44/39/3948/7243107> by Universiteit Leiden - LUMC user on 14 March 2024

**Figure 13** Management of cardiovascular implanted electronic device-related infective endocarditis. [18F]FDG-PET/CT, <sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomography; CIED, cardiovascular implanted electronic device; ESC, European Society of Cardiology; IE, infective endocarditis; MRSA, methicillin-resistant *S. aureus*; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography; WBC SPECT/CT, white blood cell single photon emission tomography/computed tomography. <sup>a</sup>If no signs of pocket infection and negative TOE. <sup>b</sup>Taking into account the identified pathogen, procedural risk, and requirement for valve surgery. <sup>c</sup>At a distant site and postponed as long as possible (until signs and symptoms of infection have resolved and blood cultures are negative for >72 h in the absence of vegetations and /or ‘ghosts’, or otherwise after >2 weeks of negative blood cultures).

Transthoracic echocardiography and TOE are both recommended in the case of suspected CIED-related IE.<sup>692–694</sup> Intracardiac echocardiography may also be used to visualize vegetations,<sup>695</sup> and may be useful in patients in whom TOE is not possible. However, the absence of vegetations does not rule out IE, as these may be present on extracardiac segments of the lead which cannot be visualized. Repeating TTE and/or TOE within 5–7 days is recommended in case of initially negative examination when clinical suspicion of CIED-related IE remains high. It is important to note that fibrinous lead masses may be observed in asymptomatic CIED patients, and do not predict CIED-related IE over long-term follow-up.<sup>696</sup>

Diagnosis of CIED-related endocarditis by [18F]FDG-PET/CT has good sensitivity and specificity,<sup>129</sup> and is particularly useful in the setting of possible CIED-related IE without signs of pocket infection.<sup>238</sup> Results should be interpreted with caution, however, if the CIED is recently implanted (<6 weeks).<sup>130</sup>

White blood cell SPECT/CT has also been used for diagnosing CIED infection but has limited availability.<sup>216,697</sup> A chest X-ray or CT should be performed in all patients to evaluate the presence of pulmonary complications.

#### 12.4.6. Antimicrobial therapy

Treatment of CIED infection involves early<sup>698,699</sup> and complete removal of all parts of the system, combined with initial empirical antibiotic therapy directed at MRSA and Gram-negative bacteria, while awaiting identification of the pathogen.<sup>130,700,701</sup> Antibiotic treatment follows the recommendations indicated in Section 7. In exceptional cases where complete device removal is not possible, i.v. antibiotics for 4–6 weeks may be administered followed by close follow-up after interruption of antibiotic therapy or, alternatively, individualized long-term suppressive oral therapy.

#### 12.4.7. Device extraction

When CIED and lead extraction is required, such procedures should be performed in centres with the corresponding expertise. Complete CIED removal is recommended for all patients with confirmed infection of the lead(s), as conservative treatment is associated with increased mortality.<sup>678,699</sup> In patients with left-sided prosthetic heart valves and CIED infection, complete CIED removal combined with prolonged (4–)6 week antibiotic therapy may prevent left-sided valve infection.<sup>130,702</sup> Complete CIED extraction should also be considered in case of valvular IE without definite lead involvement, taking into account the identified pathogens (*Staphylococcus* spp. infections may be more prone to seed the CIED),<sup>673,675,676</sup> procedural risk, and indication for valve surgery.

Complete device extraction should be considered even in the absence of vegetations in the setting of persistent or relapsing Gram-positive bacteraemia or fungaemia after a course of appropriate antibiotic therapy, if there is no other identified source (see Figure 13).<sup>681</sup> In all instances of lead extraction, procedural risk should be carefully evaluated taking into account lead dwell time, pacemaker dependency, patient frailty, and other co-morbidities within the process of shared decision-making.<sup>703</sup>

Lead extraction should be performed, without delay (i.e. within the first days of admission), as this has been shown to be associated with improved outcomes.<sup>698,699,704</sup> Percutaneous rather than surgical extraction is the preferred procedure, but requires specialized tools and should be performed in centres with expertise in this technique and with onsite surgical backup, due to the risk of life-threatening tamponade and vein laceration.

Large vegetations may be aspirated percutaneously before lead extraction to reduce risk associated with embolization.<sup>705</sup> Surgical lead

extraction should be considered in case of large vegetations (e.g. >20 mm)<sup>679</sup> and if aspiration is not available or is unsuccessful. Surgical removal is also the preferred technique if valve surgery is indicated. Hardware retrieved from extraction, especially the lead tip, should be cultured.<sup>706</sup> Sonication has been shown to increase diagnostic yield.<sup>707,708</sup>

#### 12.4.8. Device reimplantation

The indication for reimplantation should always be carefully evaluated and no part of the removed CIED system should be reimplanted. Quality of evidence regarding timing of reimplantation is poor.<sup>709</sup> Reimplantation should be performed at a site distant from that of the previous generator, and delayed until signs and symptoms of local and systemic infection have resolved and blood cultures are negative for at least 72 h after extraction in the absence of vegetations or 'ghosts' (fibrous remnants after lead extraction, which have been associated with death and reinfection),<sup>710</sup> or after 2 weeks of negative blood cultures if vegetations were visualized.<sup>701,711</sup>

For patients with a high risk of sudden cardiac death, a wearable defibrillator is an option as a bridge to reimplantation. In pacemaker-dependent patients, an active-fixation lead may be introduced via the internal jugular vein and connected to an external pacemaker for up to 4–6 weeks, thereby preserving the contralateral side for definitive device reimplantation.<sup>712</sup> As an alternative to delayed reimplantation in pacemaker-dependent patients, an epicardial pacemaker may be implanted before lead extraction, although this strategy has been associated with a higher risk of device re-intervention.<sup>713</sup> Alternative devices such as leadless pacemakers<sup>714</sup> or subcutaneous ICD<sup>715</sup> may be implanted in selected patients if the risk of new infection is deemed high.

#### Recommendation Table 20 — Recommendations for cardiovascular implanted electronic device-related infective endocarditis

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>
Antibiotic prophylaxis covering <i>S. aureus</i> is recommended for CIED implantation. <sup>118</sup>	I	A
TTE and TOE are both recommended in case of suspected CIED-related IE to identify vegetations. <sup>692–694</sup>	I	B
Complete system extraction without delay is recommended in patients with definite CIED-related IE under initial empirical antibiotic therapy. <sup>698,699</sup>	I	B
Obtaining at least three sets of blood cultures is recommended before prompt initiation of empirical antibiotic therapy for CIED infection, <sup>710</sup> covering methicillin-resistant staphylococci and Gram-negative bacteria.	I	C
If CIED reimplantation is indicated after extraction for CIED-related IE, it is recommended to be performed at a site distant from the previous generator, as late as possible, once signs and symptoms of infection have abated and until blood cultures are negative for at least 72 h in the absence of vegetations, and negative for at least 2 weeks if vegetations were visualized. <sup>701,711</sup>	I	C

Continued

Complete CIED extraction should be considered in case of valvular IE, even without definite lead involvement, taking into account the identified pathogen and requirement for valve surgery.	<b>IIa</b>	<b>C</b>
In cases of possible CIED-related IE with occult Gram-positive bacteraemia or fungaemia, complete system removal should be considered in case bacteraemia/fungaemia persists after a course of antimicrobial therapy. <sup>673–676</sup>	<b>IIa</b>	<b>C</b>
Extension of antibiotic treatment of CIED-related endocarditis to (4–6) weeks following device extraction should be considered in the presence of septic emboli or prosthetic valves. <sup>702</sup>	<b>IIa</b>	<b>C</b>
Use of an antibiotic envelope may be considered in select high-risk patients undergoing CIED reimplantation to reduce risk of infection. <sup>688,689</sup>	<b>IIb</b>	<b>B</b>
In cases of possible CIED-related IE with occult Gram-negative bacteraemia, complete system removal may be considered in case of persistent/relapsing bacteraemia after a course of antimicrobial therapy. <sup>680,690,691</sup>	<b>IIb</b>	<b>C</b>
In non- <i>S. aureus</i> CIED-related endocarditis without valve involvement or lead vegetations, and if follow-up blood cultures are negative without septic emboli, 2 weeks of antibiotic treatment may be considered following device extraction.	<b>IIb</b>	<b>C</b>
Removal of CIED after a single positive blood culture, with no other clinical evidence of infection, is not recommended. <sup>675</sup>	<b>III</b>	<b>C</b>

© ESC 2023

CIED, cardiovascular implanted electronic device; IE, infective endocarditis; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

## 12.5. Infective endocarditis in patients admitted to intensive care units

Infective endocarditis is frequently associated with severe life-threatening cardiac and/or systemic complications and the number of patients requiring intensive care unit (ICU) admission has steadily been growing in recent years, as shown in a large retrospective study.<sup>716</sup> The need for ICU admission, advanced monitoring, vasoactive treatment, and organ support is most commonly prompted by the occurrence of septic shock, acute HF, and cardiogenic shock leading to multiorgan failure. Moreover, in recent years, an increase in healthcare-associated IE, usually of staphylococcal origin, predominantly in older patients with an increased number of comorbidities, and more likely to lead to critical illness, has also been reported.<sup>29,717–719</sup> Any IE patient requiring ICU admission should be urgently discussed within the Endocarditis Team.

In the largest multicentre retrospective series, focusing on critically ill IE patients with organ failure requiring ICU admission in France over an 18-year period, overall in-hospital mortality was 32%.<sup>716</sup> Multivariate analysis showed age, Simplified Acute Physiology Score (SAPS) II score, organ failure, stroke, and *Staphylococcus* spp. to be associated with an increased risk of death. In contrast, cardiac surgery, CIED, male gender, and *Streptococcus* spp. as the causative microorganism of IE, were associated with a better survival.<sup>716</sup> In another

study that reported an even higher mortality (42%), four independent prognostic factors were identified: high SAPS II (>35 points) and Sequential Organ Failure Assessment (>8 points) scores, MRSA infection, and native valve IE.<sup>718</sup>

Right-sided IE, which is more commonly associated with PWID, accounts for <10% of IE cases but is associated with high mortality in patients needing ICU admission.<sup>717</sup>

### 12.5.1. Causative microorganisms

The majority of retrospective series in the ICU setting point to *Staphylococcus* spp. as the main causative agent of IE episodes. Indeed, *S. aureus* has emerged as the most feared aetiological agent with the highest rates of complications and mortality, being responsible for up to 56% of IE cases in one observational study.<sup>719</sup> *Streptococcus* spp., *Enterococcus* spp., Gram-negative bacilli, and *Candida* spp. are less frequently reported.<sup>718,719</sup> Identification of the infecting microorganism remains the mainstay of effective therapy in complicated IE cases. Hence, in patients with negative blood cultures, serological or molecular testing by PCR should be considered (see [Section 5.3](#)).

### 12.5.2. Diagnosis

The diverse nature, epidemiological profile, and presentation phenotype of IE in the ICU setting may hinder early diagnosis. In particular, pyrexial episodes suggestive of an alternative infective source and neurological manifestations, such as confusion, delirium, or focal symptoms may initially mislead the clinician from a diagnosis of IE.

The diagnosis of IE in ICUs follows the same modified criteria as in non-ICU patients (see [Section 5](#)). Transoesophageal echocardiography has a prominent role as a tool for diagnosis of IE and its complications in the ICU.<sup>720</sup>

### 12.5.3. Management

Antimicrobial therapy and indications for surgery in patients with IE are described in [Sections 7](#) and [10](#), respectively. Surgical therapy has been associated with an improved early and late outcome both in the general population and in patients admitted to ICUs. Although surgery is the treatment of choice in about one-half of patients, surgical therapy in ICU patients is characterized by more complex procedures with increased peri-operative mortality, as well as difficult post-operative care due to higher requirements of circulatory and pulmonary support. Five independent predictors of post-operative need for advanced circulatory support were found in one study of patients with IE: male sex, increased surgery duration, renal dysfunction (pre-operative estimated glomerular filtration <60 mL/min/m<sup>2</sup>), HF prior to surgery, and lower pre-operative platelet count.<sup>721</sup>

Extracorporeal membrane oxygenation is occasionally required in patients post-surgery but is associated with poor outcomes.<sup>722</sup>

Decision-making in ICU patients with IE should always be a product of consensus of the Endocarditis Team to determine the best management strategy. Pre-operative haemodynamic optimization and goal-directed therapy protocols including vasoactive drugs and mechanical circulatory support may be considered in these complex high-risk patients.<sup>721</sup>

## 12.6. Right-sided infective endocarditis

Right-sided IE accounts for ~5–10% of patients with IE,<sup>723</sup> but its frequency may be increasing as its risk factors are increasing in some countries.<sup>133,724</sup> Risk factors for right-sided IE include patients with CHD, indwelling catheters, and CIED, as well as immunocompromised and PWID patients. Of these, PWID is an increasingly common risk

factor,<sup>133,723</sup> while patients with indwelling vascular catheters have the worst prognosis.<sup>725</sup> IE of transcatheter pulmonary valves is covered in [Section 12.2](#), whereas CIED-related right-sided IE is covered in [Section 12.3](#).

The most common microorganism causing right-sided IE is *S. aureus*, accounting for the majority of patients.<sup>723,726</sup> The tricuspid valve is much more commonly infected than the pulmonary valve in patients with right-sided IE.<sup>723,727</sup> Right-sided IE may also involve non-functional embryonic remnants of the right atrium (e.g. Eustachian valve).<sup>723,727</sup> Right-sided IE rarely spreads to involve the left-sided cardiac structures, whereas spread from left- to right-sided structures is not uncommon.<sup>728</sup>

### 12.6.1. Diagnosis and complications

Right-sided IE patients present with fever, bacteraemia, and pulmonary complaints (i.e. cough, chest pain, or haemoptysis). Right-sided HF may also occur due to tricuspid or pulmonary regurgitation, or to pulmonary hypertension induced by multiple pulmonary septic emboli.<sup>133</sup>

Diagnosis is most frequently confirmed by echocardiographic findings of vegetations on the tricuspid valve or, less frequently, pulmonary valve. Adequate evaluation of the tricuspid valve may be performed with TTE, due to the anterior location of the valve and the large vegetations frequently observed in right-sided IE. Transoesophageal echocardiography is frequently required, however, particularly for evaluation of the pulmonary valve or in patients with indwelling venous catheters or intracardiac devices.<sup>729</sup> Intracardiac echocardiography may also be helpful in select patients. Vegetations may be challenging to identify on the pulmonary valve even with TOE, especially in patients with a prosthetic valve in the pulmonary position. [18]FDG-PET imaging may be very helpful in such patients.<sup>34,730</sup> Perivalvular abscess formation and invasion into surrounding structures is rarely seen in right-sided IE, unless it is a secondary consequence of left-sided IE.<sup>728</sup> CT is useful in order to identify concomitant pulmonary disease, including infarcts and abscess formation.

### 12.6.2. Endocarditis in people who inject drugs

Infective endocarditis in PWID is an increasing global phenomenon.<sup>10,132,133,141</sup> Repeat i.v. injections result in contaminated particles that reach the tricuspid valve and right-heart chambers and can also lead to infection of left-heart structures, which is associated with worse prognosis.<sup>614</sup> PWID patients also have an increased rate of human immunodeficiency virus (HIV) and hepatitis than other patients with right-sided IE.<sup>731</sup> The majority of right-sided IE in PWID can be treated successfully with antibiotic therapy. Mortality rates of PWID are relatively low, even when surgery is required, probably due to the young patient age.<sup>723</sup> However, PWID have a markedly increased rate of IE recurrence, particularly in the first 6 months post-surgery.<sup>133,614,723,732</sup>

### 12.6.3. Prognosis and treatment

Right-sided IE is generally a more benign clinical entity than left-sided IE and can be medically managed in ~90% of patients, with surgery reserved for those who fail medical therapy.<sup>733</sup> Patients with CIED-related right-sided IE have a worse prognosis as compared with non-CIED-related right-sided IE (see [Section 12.4](#)).<sup>723, 725</sup> Right-sided IE in immunocompromised patients, particularly fungal infections, carries a very poor prognosis.

#### 12.6.3.1. Antimicrobial therapy

*S. aureus* and CoNS are the cause of right-sided IE in a large proportion of cases, with *S. aureus* predominating in PWID and CoNS being more common in patients with indwelling devices.<sup>723,726</sup> MRSA rates may be

increasing over time, particularly in PWID.<sup>133</sup> Right-sided IE due to *Streptococcus* spp. is unusual but can be observed in alcoholics and diabetics. *P. aeruginosa* and other Gram-negative organisms are rare causes of right-sided IE, while *Candida albicans* is mostly seen in immunocompromised patients.

Empirical antimicrobial therapy depends on the suspected microorganism, the type of drug and solvent used by the PWID, and the infection location,<sup>734</sup> but *S. aureus* must be initially covered in all cases. Initial treatment consists of penicillinase-resistant penicillin, vancomycin, or daptomycin, depending on the local prevalence of MRSA,<sup>735</sup> in combination with gentamicin. If the patient is a pentazocine addict, an anti-*Pseudomonas* agent may also be required, as the use of recreational drugs may also entail infections with Gram-negative bacteria.<sup>735</sup> Very large vegetations and history of brown heroin use dissolved in lemon juice suggest infection for *Candida* spp. (not *C. albicans*), and therefore antifungal treatment should be added.<sup>736</sup> Antifungals may be necessary in selected PWID, particularly if immunocompromised.<sup>737</sup>

Once the causative organisms have been isolated, therapy has to be adjusted. An RCT demonstrated that a 2-week treatment course may be sufficient and that aminoglycosides may be unnecessary.<sup>738, 717</sup> Two-week treatment with oxacillin (or cloxacillin) without gentamicin is effective when:

- (i) MSSA is the causative organism;
- (ii) There is good clinical and microbiological response to treatment (>96 h);<sup>739</sup>
- (iii) The vegetation size is ≤20 mm; and
- (iv) There is an absence of metastatic sites of infection or empyema and cardiac or extracardiac complications,<sup>739,740</sup> prosthetic valve or left-sided valve infection,<sup>741</sup> and severe immunosuppression.<sup>742</sup>

Glycopeptides (vancomycin) should not be used in a 2-week treatment. The standard 4–6-week regimen should be used in the remaining patients or when therapy with antibiotics other than penicillinase-resistant penicillins are used.<sup>330,739–744</sup> When the conventional i.v. route therapy is not possible, *S. aureus* right-sided IE in PWID may also be treated with oral ciprofloxacin (750 mg twice a day) plus rifampin (300 mg twice a day) if the strain is susceptible to both drugs, the case is uncomplicated, and patient adherence is monitored carefully.<sup>745</sup> Partial oral antibiotic treatment may also be beneficial for PWID with IE.<sup>746</sup>

For organisms other than *S. aureus*, therapy in PWID does not differ from that in other patients.

#### 12.6.3.2. Surgery

The commonly accepted indications for surgical treatment of right-sided IE in patients who are receiving appropriate antibiotic therapy are (see Recommendation Table 19):

- Persistent bacteraemia after at least 1 week of appropriate antibiotic therapy.<sup>10</sup>
- Tight ventricular dysfunction secondary to acute severe tricuspid regurgitation non-responsive to diuretics.<sup>479</sup>
- Respiratory insufficiency requiring ventilatory support after recurrent pulmonary emboli.<sup>747</sup>
- Involvement of left-sided structures;<sup>748,749</sup> and
- Large residual tricuspid vegetations (>20 mm) after recurrent pulmonary emboli.<sup>145,471</sup>

Patients should be individually assessed by the Endocarditis Team. An isolated vegetation is not an indication for surgery. Patients with

residual large vegetations frequently present with right-heart and/or respiratory failure, as well as persistent sepsis.<sup>750</sup>

The common surgical strategies for tricuspid valve IE include valve repair, replacement and, less commonly, surgical valvectomy.<sup>751</sup> Tricuspid valve repair is more frequently performed than valve replacement in right-sided IE, although the extent of valve destruction may make repair impossible.<sup>725,752</sup> Tricuspid valve repair may also be associated with better short- and long-term outcomes than replacement for right-sided IE, particularly with regards to recurrent infection and need for repeat surgery.<sup>479,723</sup>

When valve replacement for right-sided IE is required, bioprostheses are frequently preferred due to concerns with the management and risks of lifelong anticoagulation, especially in PWID, and the risks of thrombo-embolism for mechanical valves in the right heart.<sup>726</sup>

Prophylactic placement of permanent epicardial leads should be performed at the time of tricuspid valve surgery for right-sided IE, particularly if heart block is present in the operating room to prevent damage of a replaced valve during subsequent transvenous lead displacement and to lower the risk of reinfection.<sup>733</sup>

Recently, interest has been generated in the extraction of large vegetations using percutaneous extracorporeal circuitry for aspiration.<sup>753</sup> The main goals have been debulking of septic intracardiac masses, reducing the infectious load, and achieving clinical stability.<sup>754</sup>

**Recommendation Table 21 — Recommendations for the surgical treatment of right-sided infective endocarditis**

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>
Surgery is recommended in patients with right-sided IE who are receiving appropriate antibiotic therapy for the following scenarios:		
Right ventricular dysfunction secondary to acute severe tricuspid regurgitation non-responsive to diuretics. <sup>479</sup>	I	B
Persistent vegetation with respiratory insufficiency requiring ventilatory support after recurrent pulmonary emboli. <sup>479,755</sup>	I	B
Large residual tricuspid vegetations (>20 mm) after recurrent septic pulmonary emboli. <sup>145,471</sup>	I	C
Patients with simultaneous involvement of left-heart structures. <sup>749</sup>	I	C
Tricuspid valve repair should be considered instead of valve replacement, when possible. <sup>479</sup>	IIa	B
Surgery should be considered in patients with right-sided IE who are receiving appropriate antibiotic therapy and present persistent bacteraemia/sepsis after at least 1 week of appropriate antibiotic therapy. <sup>436,755</sup>	IIa	C
Prophylactic placement of an epicardial pacing lead should be considered at the time of tricuspid valve surgical procedures. <sup>733</sup>	IIa	C
Debulking of right intra-atrial septic masses by aspiration may be considered in selected patients who are high risk for surgery. <sup>753</sup>	IIb	C

© ESC 2023

IE: infective endocarditis.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

**12.7. Infective endocarditis in congenital heart disease**

Although the incidence of CHD is relatively constant, the overall population with CHD is constantly increasing due to increased survival following CHD surgery in childhood and increased longevity of adults with CHD. The presence of CHD, even after repair, is recognized as a lifelong potential substrate for IE. Congenital heart disease predisposes to IE via several mechanisms including turbulent non-laminar blood flow causing shear stress and endothelial damage, the presence of intracardiac foreign material such as prosthetic valves or CIED, cyanosis, and recurrent exposure to cardiac procedures.<sup>98</sup>

There are marked variations in susceptibility to IE between CHD lesions. Some simple conditions, such as secundum atrial septal defect, patent ductus arteriosus, and pulmonary valve stenosis, carry a low risk of IE, while others, such as bicuspid aortic valve carry a somewhat increased risk.<sup>8</sup> However, CHD often presents with multiple cardiac lesions, each adding to the total risk of IE.<sup>8,756</sup> In general terms, IE is more common in CHD with multiple defects and in patients with more complex CHD.<sup>757</sup>

Specific high-risk conditions are prosthetic valves, including transcatheter valves, valve repair using a prosthetic ring, previous IE, any unrepaired cyanotic CHD, and any CHD repaired with prosthetic material for up to 6 months after the procedure, or lifelong if residual shunt or valvar regurgitation remains.<sup>758</sup> Contemporary studies confirm the relatively high risk of IE in CHD patients after valve surgery.<sup>8,47,90,759</sup> Specific awareness is needed after TPVI (see Section 12.3.2).<sup>566,759,760</sup>

The distribution of causative microorganisms does not differ from the pattern found in acquired heart disease, with *Streptococcus* spp. and *Staphylococcus* spp. being the most common strains.<sup>98,757,761,762</sup> As in other groups, the diagnosis of IE is often made late,<sup>757</sup> highlighting the need to consider the diagnosis of IE in any CHD patient presenting with persisting fever or other signs of ongoing infection. Multiple blood cultures are essential before starting antibiotic treatment. The principal symptoms, complications, and basis for diagnosis do not differ from IE in general. However, in CHD right-sided IE is more frequent than in non-CHD-acquired cardiac disease.

Transthoracic echocardiography is sufficient in many cases to image the infectious lesions and their complications. However, complex anatomy and the presence of artificial material may reduce the rate of vegetation detection and other features of IE, thus favouring the addition of TOE, particularly in adults and larger children. Despite the improved sensitivity of TOE for the detection of IE, TOE may only perform similarly to TTE for anterior structures of the heart, such as the right ventricular outflow tract, or infected sites at distal structures, such as stents or other prosthetic material within branch pulmonary arteries. Hence, a negative study does not exclude the diagnosis of IE. In patients with prosthetic material advanced imaging such as [18F]FDG-PET/CT and PET/CTA, can increase the diagnostic accuracy.<sup>223</sup>

In addition to the usual Endocarditis Team (see Section 4), multidisciplinary care of CHD patients with IE from diagnosis to treatment should be provided in specialized CHD centres with expertise in CHD cardiac imaging, CHD surgery, infectious disease, and intensive care. Surgical indications do not differ from those of acquired heart disease IE. Mortality rates in CHD vary from 6% to 15%.<sup>757,761–764</sup> This better prognosis compared with acquired heart disease IE may reflect the higher proportion of right-heart IE, younger overall patient age, or the comprehensive care in CHD centres.

Primary prevention of IE in CHD patients and corresponding patient education is essential (see Section 3).<sup>765</sup>

## 12.8. Infective endocarditis in rheumatic heart disease

Infective endocarditis is a known complication of RHD,<sup>766</sup> and acute rheumatic fever (the antecedent of RHD) may even present with concomitant IE.<sup>767</sup> Of the 3343 participants enrolled in The Global Rheumatic Heart Disease Registry (REMEDY),<sup>768</sup> 133 (2.4%) had a history of IE at enrolment,<sup>769</sup> and 20 (0.7%; 3.65 per 1000 patient-years) developed IE during the 27-month follow-up.<sup>770</sup> These participants were young with a median age of 28 years (interquartile range 18–40 years), 66.2% were women, and over 30% were children. The majority of the over 40 million patients with RHD<sup>771</sup> live in low- and middle-income countries and face socioeconomic and health-system barriers<sup>772</sup> to adequate prevention, early diagnosis, and advanced care and, therefore, are at particular risk of IE.<sup>773</sup>

Global access to surgery for RHD and RHD-associated complications is extremely limited.<sup>774</sup> RHD patients presenting with fever, changing or new murmurs should be investigated for IE. In studies from RHD-endemic regions, RHD is the most common underlying cardiac condition, with significant mortality and morbidity.<sup>775–784</sup> In those affected with oral bacteria-related IE linked to RHD, oral *Streptococcus* spp. was the main cause of IE associated with poor oral health status.<sup>785</sup> In RHD-endemic countries, IE in children is strongly linked to RHD,<sup>786–788</sup> and when causing HF, carries the highest case fatality rate.<sup>789</sup> IE is associated with enhanced risk of death among patients with RHD undergoing isolated mitral valve replacement (odds ratio 5.22, 95% confidence interval [CI], 1368–19 915;  $P = 0.008$ ).<sup>790</sup> Pregnancy is a particularly high-risk period for women with RHD, with an increased risk of developing IE.<sup>791,792</sup> However, high-income countries or countries with emerging economies are seeing less IE linked to RHD, as the incidence rates of RHD in these regions decrease.<sup>793–796</sup>

## 12.9. Infective endocarditis during pregnancy

Infective endocarditis in pregnancy is a rare but extremely serious condition with high maternal and foetal morbidity and mortality, and is estimated to complicate ~1 in 100 000 pregnancies.<sup>797–799</sup> Maternal mortality approaches 18%, with most deaths relating to HF or an embolic event, while pre-term birth is reported at 55.7% and foetal mortality at 29%.<sup>800</sup> Recurrent infective complications can occur in up to 27% of women post-partum.<sup>801</sup>

The diagnosis must be considered in pregnant women with unexplained fever and cardiac signs (especially tachycardia), new or changing cardiac murmurs, and peripheral signs of septic emboli.<sup>802</sup> Women with CHD, RHD,<sup>803</sup> and structural heart disease, together with those with prosthetic heart valves and with PWID are at particular risk.<sup>800,804–807</sup>

The gravity of the condition requires the inclusion of gynaecologists, obstetricians, and neonatologists in the Endocarditis Team in any suspected cases, and a diagnosis and treatment plan should be formulated without delay, as this is key to saving the lives of mothers and infants.<sup>799,808,809</sup> Management can be challenging, especially when the pregnant patient warrants a cardiac operation under CPB. Although this poses a considerable risk to the foetus, urgent surgery when indicated should not be delayed.<sup>799,810</sup>

## 12.10. Infective endocarditis in immunocompromised patients

### 12.10.1. Solid organ transplant recipients

The incidence of IE in recipients of solid organ transplantation (SOT) ranges between 1% and 2%.<sup>107</sup> SOT recipients with IE are younger

and have higher prevalence of co-morbidities (particularly renal and liver disease) compared with non-SOT patients with IE. Among the SOT patients with IE, the most common transplanted organ is the kidney (72%), followed by liver (17%), and pancreas (8%).<sup>811</sup> Similar to non-SOT patients, aortic followed by mitral IE are the most common forms of IE while right-sided IE is uncommon. Interestingly, SOT patients with IE more frequently have atrial or ventricular vegetations without valve involvement (mural IE).<sup>107</sup> In-hospital and healthcare-related IE are the most frequent causes of IE in recipients of SOT and the most frequent microorganism involved is *S. aureus* (34%), followed by *Enterococcus* spp. (17%), and *Streptococcus* spp. (11%).<sup>107,811</sup>

Surgical valve repair/replacement is less frequently performed in SOT patients with IE as compared with non-SOT patients. Interestingly, the outcomes of IE in patients with SOT do not differ from those of non-SOT with IE.<sup>107,811</sup> The reasons for the similar outcomes may rely on the younger age of the SOT patients, the frequent contact with the healthcare system which may lead to early diagnosis and treatment of IE, and the frequent involvement of infectious disease specialists in the care of hospitalized SOT patients. However, compared with SOT patients without IE, those who develop IE during the index transplant hospitalization have worse outcomes.<sup>811</sup> The high levels of immunosuppression probably negatively impact the IE course in these patients.

Heart transplant recipients represent 10% of SOT with IE patients.<sup>811</sup> Among 57 heart transplant recipients who developed IE, the most frequent organism was *S. aureus* (26%), followed by *A. fumigatus* (19%), and *E. faecalis* (12%).<sup>105</sup> The median time to IE presentation after heart transplant was 8 years and the mitral valve was the most frequently affected, followed by mural and tricuspid valve IE. All-cause mortality in this group of patients is high (45%), and fungal aetiology is associated with worse outcomes. Similar to other SOT recipients, heart transplant recipients were not frequently referred to surgery (35%).<sup>105</sup>

### 12.10.2. Patients with human immunodeficiency virus

The advent of combined antiretroviral treatment has led to a reduction in the risk of developing acquired immune deficiency syndrome (AIDS) but people living with HIV remain a vulnerable population for IE.<sup>812</sup> The incidence of IE in people living with HIV has decreased over the last two decades. A retrospective study from Spain has shown a reduction in the incidence of IE from 18.2 per 100 000 patient-years between 1997 and 1999 to 2.9 events per 100 000 patient-years between 2000 and 2014.<sup>813</sup> Similarly, a registry from the United States of America reported a reduction in the incidence of IE from 148 in 2007 to 112 in 2017.<sup>141</sup> Patients living with HIV and presenting with IE are becoming older, and have a higher percentage of substance abuse and co-morbidities.<sup>141,813</sup> Of importance, the number of patients living with HIV who are admitted with IE have higher frequency of CHD, prior valve surgery, CIED infection, and haemodialysis.<sup>141,813</sup> The most frequent microorganisms causing IE are *Staphylococcus* spp. (the majority of which is *S. aureus*), followed by *Streptococcus* spp., Gram-negative bacilli, and enterococci. It is important to note that over the last two decades, the frequency of CoNS as a cause of IE has decreased whereas the frequency of streptococci, Gram-negative bacilli, enterococci, and fungus has increased.<sup>813</sup> Community-acquired IE has become the most frequent form while healthcare-associated IE rates have significantly decreased over time.

The outcomes of IE in people living with HIV have improved over the years (from 23.9 to 5.5 deaths per 100 000 patient-years) and surgical

treatment should follow the same indications as in patients without HIV.<sup>813</sup>

**12.10.3. Patients with neutropaenia**

Neutropaenia is common in patients with haematological malignancies and in patients receiving chemotherapy for other malignancies, but is rare in patients presenting with IE.<sup>814</sup> Neutrophils play an important role in the pathogenesis of IE by producing layers of extracellular traps that entrap bacteria-platelet aggregates, leading to expansion of these aggregates, vegetation growth, and the destruction of tissues.<sup>814</sup> The diagnosis of IE can therefore be challenging in patients with neutropaenia, delaying the appropriate treatment, and worsening outcomes. Series reporting the clinical characteristics and outcomes of IE in patients with neutropaenia are anecdotal.<sup>814</sup> As in any other immunocompromised patient with IE, antibiotic and surgical treatment are the same as in patients without neutropaenia. It is important to take into consideration the side effects of some antibiotics which may worsen the neutropaenia, such as cloxacillin and ceftaroline.<sup>815,816</sup>

**12.11. Antithrombotic and anticoagulant therapy in infective endocarditis**

Infective endocarditis by itself is not an indication for antithrombotics or anticoagulants, and bleeding complications or stroke may in contrast justify discontinuation or interruption of such therapies. Indications for antithrombotic therapy or anticoagulants (e.g. atrial fibrillation, valve prostheses, ischaemic heart disease, prior stroke, etc.) are prevalent in the general population and, as a result, the clinician is often faced with the challenge of these therapies in patients presenting with IE, especially in cases where surgery is part of the treatment course. For patients with IE and stroke, thrombolytic therapy is not recommended (see Section 9.1). However, thrombectomy may be considered in selected cases with large vessel occlusion.

The level of evidence underlying the recommendations for antithrombotic and anticoagulant therapy in IE is low and should be discussed within the Endocarditis Team. Bridging with low-molecular-weight heparin/unfractionated heparin instead of oral anticoagulants should be considered early on in the IE course, especially for patients in whom surgery is indicated. To date, no data support initiation of either antithrombotics nor anticoagulants for treatment or prevention of stroke in IE.

**Recommendation Table 22 — Recommendations for the use of antithrombotic therapy in infective endocarditis**

Recommendation	Class <sup>a</sup>	Level <sup>b</sup>
Interruption of antiplatelet or anticoagulant therapy is recommended in the presence of major bleeding (including intracranial haemorrhage). <sup>482,483</sup>	I	C
In patients with intracranial haemorrhage and a mechanical valve, reinitiating unfractionated heparin should be considered as soon as possible following multidisciplinary discussion. <sup>817</sup>	IIa	C

Continued

In the absence of stroke, replacement of oral anticoagulant therapy by unfractionated heparin under close monitoring should be considered in cases where indication for surgery is likely (e.g. <i>S. aureus</i> IE). <sup>451,817</sup>	IIa	C
Thrombolytic therapy is not recommended in patients with IE. <sup>481,491</sup>	III	C

IE, infective endocarditis.  
<sup>a</sup>Class of recommendation.  
<sup>b</sup>Level of evidence.

**12.12. Non-bacterial thrombotic endocarditis**

Non-bacterial thrombotic endocarditis (NBTE) is a rare condition with an incidence varying from 1.1% to 1.6% in patient-series from autopsy studies.<sup>818,819</sup> Non-bacterial thrombotic endocarditis occurs in patients with a predisposing factor and/or a hypercoagulable state, such as systemic lupus erythematosus (SLE), APLs (Libman–Sacks endocarditis), cancer (marantic endocarditis), disseminated intravascular coagulation (DIC), or various other chronic diseases (tuberculosis or autoimmune disease).<sup>820,821</sup> Increased production of coagulation factors, of cytokines, and high tissue factor expression are potential mechanisms underlying NBTE in cancer patients.<sup>822</sup>

In a recent contemporary registry, 41% of NBTE patients had cancer, 33% SLE, and 36% APLs, with 21% of patients having both SLE and APLs.<sup>823</sup> Among the patients with malignancies, the three most frequent cancers were lung adenocarcinoma, breast, and pancreatic cancer. Stroke was the most frequent clinical presentation at admission (60%), while HF was observed in 21% and acute coronary syndrome in 7% of patients. Transthoracic echocardiography was able to confirm the diagnosis in 45% of patients. The mitral valve was more often affected (62%) than the aortic valve (24%).<sup>823</sup>

The diagnosis of NBTE remains challenging and should be suspected in patients presenting with systemic embolization and a predisposing factor (i.e. cancer, APLs, SLE). Laboratory findings of a hypercoagulable state (eg. lupus anticoagulant, anti-cardiolipin antibodies, and anti-β<sub>2</sub>-glycoprotein 1 antibodies or DIC) may be present, but are non-specific and may also be demonstrated in other IE patients with embolic events.<sup>162</sup>

Echocardiography diagnosis should attempt to differentiate non-bacterial thrombotic vegetation from IE, Lambl excrescences, or fibroelastoma, or other benign intracardiac masses/tumours.<sup>824</sup> Libman–Sacks vegetations may present with various shapes (sessile, tubular, or coalescent), various levels of echogenicity (heterogeneously or homogeneously), could be nodular or protuberant, are generally located near the leaflet’s edge of coaptation, and frequently have extensions to the mid and basal portions of the leaflet. They are rarely associated with valve dysfunction and never with valve perforation, which is an important method of differentiating from bacterial IE.<sup>824</sup> Compared with TOE, TTE has a lower sensitivity (63%), specificity (58%), negative predictive value (40%), and a moderate positive predictive value (78%) for the detection of NBTE.<sup>823,824</sup> Compared with two-dimensional TOE, three-dimensional TOE provides additional information and allows a better characterization of the vegetation.<sup>823</sup>

The treatment of the underlying cause (i.e. SLE or cancer) is crucial to prevent recurrent NBTE. Anticoagulant treatment should be considered in all patients and should be balanced against the individual

patient's bleeding risk.<sup>821</sup> Patients may be anticoagulated with low-molecular-weight heparin, vitamin K antagonists, or unfractionated heparin. There are no data to support the use of direct oral anticoagulants in NBTE. In a randomized open-label multicentre study comparing rivaroxaban and warfarin in patients with thrombotic APLs, the use of rivaroxaban was associated with an increased rate of thrombo-embolic events and major bleeding.<sup>825</sup> The role of surgery is controversial and remains to be clarified. However, surgery should be considered in patients with severe valve dysfunction or with large vegetations.<sup>823</sup>

### 12.13. Infective endocarditis and malignancy

There are limited data on the prevalence, clinical presentation, management, and outcome of IE in patients with malignancy. In a retrospective Japanese cohort study including 170 patients, 17.6% had active malignancy.<sup>826</sup> Compared with patients without malignancy, patients with malignancies were older, nosocomial IE was more frequent, and procedures before IE (non-dental, i.v. catheter insertion, invasive endoscopic, or genitourinary procedures) were more frequent.<sup>826</sup> Another recent study from the EURO-ENDO registry of 3085 patients with IE found a history of malignancy in 11.6% of patients.<sup>827</sup> Patients with a history of malignancy had a similar rate of theoretical indications for surgery, but surgery was performed less often in this group. Mortality was higher in the malignancy group with independent predictors for mortality being elevated creatinine >2 mg/dL, congestive HF, and unperformed cardiac surgery when indicated.<sup>827</sup> In IE patients with concomitant cancer, indications for valve surgery should be discussed within the Endocarditis Team, including a cardio-oncologist and the oncologist in charge of the patient, in order to take into account the risks and benefits of surgery and cancer prognosis.

## 13. Patient-centred care and shared decision-making in infective endocarditis

### 13.1. What is patient-centred care and shared decision-making and why is it important?

Patient-centred care encourages involvement and collaboration between patients, families, and healthcare providers during all stages of diagnosis, treatment, and recovery.<sup>828–831</sup> Core elements of patient-centred care include: involvement of family and caregivers, respect for patients' preferences and values, care co-ordination and continuity, information and education, as well as physical comfort and emotional support (Figure 14).<sup>828–830</sup>

Shared decision-making involves a bidirectional process where patients, family, and healthcare providers share information and discuss care options in the context of the patients' preferences, beliefs and values, and the best available evidence ensuring that the patient understands the risks,<sup>832,833</sup> benefits, and possible consequences of the different options.<sup>834–836</sup> The majority of patients prefer sharing decisions about their own health, if they are sufficiently informed and prepared.<sup>837,838</sup> Patient-centred care and shared decision-making have been shown to contribute to improved concordance between care providers and patients on treatment plans, as well as increased patient satisfaction, quality of life, and health outcomes.<sup>830,839–843</sup>

### 13.2. Patient-centred care and shared decision-making in infective endocarditis

The severity of IE, the complex and comprehensive diagnostics and treatment, as well as the long illness trajectory, put special emphasis on patient-centred care and shared decision-making in IE (Figure 14). Quality of life appears to be impaired in IE survivors, with a significant number of patients developing symptoms of anxiety, depression, or even post-traumatic stress disorder following IE treatment.<sup>604,844</sup>

The time of diagnosis is often emotionally distressing to the patient and family, as they face a life-threatening condition and lengthy treatment.<sup>845</sup>

During the diagnostic and active treatment phase, healthcare providers should make every effort to minimize patient discomfort (e.g. related to symptoms and diagnostic procedures), and alleviate distress in both patient and family by providing support and comprehensive and timely information about the patient's condition, therapeutic options, and prognosis. Independent of the therapeutic strategy (i.e. surgical vs. conservative), patient-centred care is key to ensure a good physical and mental outcome during a lengthy treatment and hospitalization associated with IE. Maintaining continuity of care, when possible, by minimizing the number of providers the patient encounters and minimizing transfers between and within units, is all part of a patient-centred care approach. Allowing family visits at any time and providing the opportunity to uphold personal integrity and autonomy are important issues for patients. National patient organizations and associations may be an option for offering information and support to patients and their families.


The role of outpatient antimicrobial treatment options in IE should be discussed using a shared decision-making approach, involving the patient's partner or family if possible. The outpatient treatment should be in concordance with the patient's and family's preferences, also considering transportation and self-care abilities. To monitor possible complications, it is important to inform and educate patients and caregivers about the signs and symptoms of disease progression or recurrence.

The early period after discharge can be challenging for patients and their families, and patients report slow physical and mental recovery after IE, often extending longer than anticipated.<sup>603,604,846,847</sup> Patient-centred care should therefore extend further than the clinical treatment at the hospital to ensure a good outcome after discharge. Though little research has explored patients' and families' needs for recovery and rehabilitation following IE, patients with heart disease report experiencing new and continuous challenges and a lack of knowledge and understanding after discharge, which should be addressed to optimize recovery.<sup>848</sup>

It is recommended that a recovery plan is developed in collaboration with the patient and their caregivers and that the plan is reviewed and potentially adjusted following a short period after discharge.<sup>849</sup>

Physical exercise should be recommended based on an individual assessment of functional capacity (guided by physicians and physiotherapists), and patient education and psychosocial support should address the main problems and concerns patients and families have. Importantly, patient education should also include information about the risk of recurrence and preventive measures described in Sections 3 and 11. Special consideration should be taken for patients with no close relatives. Self-support groups or mentors may be introduced to patients without support networks. Also, follow-up by telephone from the ward staff, until full recovery has been reached, may be an option.

A palliative approach aims to improve the quality of life of patients and their families who are facing problems associated with life-threatening illness, which is relevant for many patients with IE. This approach includes a holistic, needs-based perspective with the aims of



**Figure 14** Concept of patient-centred care in infective endocarditis.

assessing and improving symptom management, communication, advanced care planning, as well as psychosocial and spiritual needs.<sup>850</sup>

## 14. Sex differences

Female sex is less common in patients diagnosed with IE, being present in approximately one-third of cases; a finding that has been demonstrated in multiple IE patient subpopulations and across different regions.<sup>5,59,723,851,852</sup> The reason why female sex is observed less frequently in IE is unknown and deserves further investigation. Possible reasons include underdiagnosis of IE in women, referral bias in published studies, intrinsic protective mechanisms against IE in women, and decreased incidence of risk factors for IE in women (e.g.

bicuspid aortic valve disease, previous heart valve replacement surgery), among others. A recent nationwide population study of individual patient-level linkage data of 7513 patients hospitalized for IE in Scotland, however, demonstrated roughly equal proportions of male and female patients throughout the 25-year study period.<sup>27</sup>

Female patients with IE have been demonstrated to have a higher prevalence of several risk factors for IE in comparison to their male counterparts including older age, mitral valve involvement, *S. aureus* infection, neurological symptoms, and haemodialysis.<sup>853–856</sup> However, men have a higher prevalence of other important risk factors including previous prosthetic valve replacement, periannular complications, CAD, and liver cirrhosis.<sup>855</sup>

Some studies have demonstrated higher mortality rates for female patients with IE,<sup>856</sup> while others have demonstrated no differences in

early and 1-year mortality rates between males and females.<sup>853,855,857</sup> The abovementioned population study from Scotland showed lower mortality rates for women during the study period.<sup>27</sup>

Although surgery has been demonstrated to be protective against mortality in several clinical scenarios (see [Section 8](#)), surgery is performed less frequently in female patients with IE.<sup>855,856</sup> In a study using the National Inpatient Sample of 81 942 patients hospitalized for IE over an 11-year period, women were 43% less likely to undergo valve replacement surgery, a significant difference that remained after adjusting for confounding factors.<sup>855</sup> The reason for decreased surgery in female IE patients is unknown and requires further investigation.

Female sex has also been identified as an independent risk factor for mortality in prediction models for patients with IE undergoing surgery.<sup>416</sup> However, a single-centre study suggested that worse observed surgical outcomes in female patients with IE was related to their increased risk factors and severity of presentation, rather than gender per se.<sup>854</sup> In addition, a large multicentre registry of 4300 patients undergoing surgery for IE failed to identify female gender as an independent predictor of mortality.<sup>852</sup>

## 15. Key messages

### Prevention:

- Populations at high risk of IE include patients with previous IE, patients with surgical or transcatheter prosthetic valves or post-cardiac valve repair, and patients with untreated CHD and surgically corrected CHD.
- Prevention of IE comprise hygienic measures (including oral hygiene) for all individuals and antibiotic prophylaxis for patients at high risk of IE undergoing oro-dental procedures.

### The Endocarditis Team:

- The diagnosis and management of patients with IE should be discussed with the Endocarditis Team, which includes healthcare professionals with the expertise to diagnose and treat IE and its complications.
- Uncomplicated IE can be managed in a Referring Centre that remains in early and regular communication with the Endocarditis Team of the Heart Valve Centre.
- Patients with complicated IE should be treated in the Heart Valve Centre, which must offer a wide range of ancillary specialty support including onsite cardiac surgery expertise.

### Diagnosis:

- The diagnosis of IE is based on major criteria, which include positive blood cultures and valvular and perivalvular/periprosthetic anatomic and metabolic lesions detected on imaging, and on minor criteria which have been updated to include frequent embolic vascular dissemination including asymptomatic lesions detected by imaging only.
- Clear diagnostic algorithms have been established to diagnose NVE, PVE, and right-sided IE.

### Antimicrobial therapy – principles and methods:

- Successful treatment of IE relies on microbial eradication by antimicrobial drugs. Surgery contributes by removing infected material and draining abscesses.

- Antibiotic treatment of PVE should last longer ( $\geq 6$  weeks) than that of NVE (2–6 weeks).
- In both NVE and PVE, the duration of treatment is based on the first day of effective antibiotic therapy (negative blood culture in the case of initial positive blood culture), not on the day of surgery.
- The initial choice of empirical treatment depends on the use of previous antibiotic therapy, whether IE is NVE or PVE (and if so, when surgery was performed [early vs. late PVE]), the place where the infection took place (community, nosocomial, or non-nosocomial healthcare-associated IE), and knowledge of the local epidemiology.
- The antibiotic treatment of IE has two phases. The first phase consists of 2 weeks of in-hospital i.v. treatment. In this initial phase, cardiac surgery should be performed if indicated, infected foreign bodies should be removed, and cardiac as well as extracardiac abscesses should be drained. In the second phase, in selected patients, the antibiotic treatment can be completed within an outpatient parenteral or oral antibiotic programme for up to 6 weeks.
- Aminoglycosides are not recommended in staphylococcal NVE because their clinical benefits have not been demonstrated. In IE caused by other microorganisms in which aminoglycosides are indicated, they should be prescribed in a single daily dose to reduce nephrotoxicity.
- Rifampin should be used only in IE involving foreign material, such as PVE, after 3–5 days of effective antibiotic therapy.
- When daptomycin is indicated, it must be given at high doses (10 mg/kg once daily) and combined with a second antibiotic (beta-lactams or fosfomycin in beta-lactam allergic patients) to increase activity and avoid the development of resistance.
- OPAT can only start when a TOE shows absence of local progression and complications (e.g. severe valvular dysfunction).
- In the OPAT programme, patients continue with the same antibiotics administered in the acute phase, if possible.

### Indications for surgery and management of main infective endocarditis complications:

- There are three main reasons to undergo surgery in the setting of acute IE: HF, uncontrolled infection, and prevention of septic embolization.
- While surgery during the acute phase of IE is usually performed on an urgent basis (i.e. the patient undergoes surgery within 3–5 days), some cases require emergency surgery (i.e. within 24 h), irrespective of the pre-operative duration of antibiotic treatment.

### Other complications of infective endocarditis:

- Stroke may be the first presenting symptom in patients with IE. Unexplained fever accompanying a stroke in a patient with risk factors for IE should trigger the suspicion of IE.
- Epicardial pacemaker implantation should be considered in patients undergoing surgery for IE with complete AVB and other risk factors.
- MRI or PET/CT are indicated in patients with suspected spondylodiscitis and vertebral osteomyelitis complicating IE.

### Surgical therapy principles and methods:

- The indication to perform invasive coronary angiography or CTA prior to surgery for IE should be based on the presence of cardiovascular risk factors in patients with aortic valve IE.
- Surgery should not be delayed in patients with non-haemorrhagic stroke and clear indications for surgery. In patients with significant

pre-operative haemorrhagic stroke, a delay in operative management ( $\geq 4$  weeks) is generally recommended.

- The decision of not offering surgery when indicated should be made in the setting of an Endocarditis Team.

### Outcome after discharge – follow-up and long-term prognosis:

- Relapse is a repeat episode of IE caused by the same microorganism and represents a failure of treatment, and mandates a search for a persistent focus of infection and an evaluation towards surgical therapy.
- Reinfection is an infection caused by a different microorganism, usually more than 6 months after the initial episode.
- Once antibiotic treatment has been completed, blood cultures should be performed.
- Patients discharged after the first episode of IE should remain under close surveillance for potential long-term complications.

### Management of specific situations:

- Antibiotic prophylaxis to prevent CIED-related IE before dental and other non-cardiac interventions is not warranted.
- A single positive blood culture with no other clinical evidence of infection should not result in removal of the CIED. Complete CIED removal is recommended for all patients with confirmed infection of the lead(s).
- The indication for CIED reimplantation should always be re-evaluated and no part of the removed system should be reimplanted. In pacemaker-dependent patients, an active-fixation lead may be introduced and connected to an external pacemaker for up to 6 weeks.
- Surgical treatment of right-sided IE is indicated in patients with persistent bacteraemia, right ventricular dysfunction, recurrent septic pulmonary embolism and respiratory compromise, and involvement of left-sided structures.
- Multidisciplinary care of CHD patients with IE, from diagnosis to treatment, should be provided in specialized CHD centres with expertise in CHD cardiac imaging, CHD surgery, and intensive care.

### Patient-centred care and shared decision-making in infective endocarditis:

- In patients with IE, shared decision-making enables the integration of patients' preferences, values, and priorities to achieve a good treatment decision.
- In patients with IE and without support networks or severely impacted by social determinants, a recovery plan developed in collaboration with the patient should be established, highlighting the information about the risk of recurrence and preventive measures.

### Sex differences:

- Female sex is less common in patients diagnosed with IE, being present in approximately one-third of cases.

## 16. Gaps in evidence

- The majority of the recommendations with a level of evidence B are based on observational studies rather than single RCTs or meta-analyses from RCTs.

### Prevention:

- In the intermediate or unknown risk condition groups, there is no evidence to recommend antibiotic prophylaxis.
- There is currently no evidence to support the use of antibiotic prophylaxis after the implantation of a left atrial appendage occlusion device.

### Diagnosis:

- More data on the accuracy of diagnosis of culture-negative IE using molecular biology techniques, or the determination of bacterial/fungal cell-free DNA in blood samples, is required.
- Standardization of the methodology to assess the size of the vegetations has not been established.
- More data on the diagnostic performance of intracardiac echocardiography in PVE are needed.
- The role of [18F]FDG-PET/CT(A) in NVE needs to be established.
- Routine use of imaging tests to screen the presence of embolic events, especially brain imaging, is not well established.
- In fungal endocarditis, the role of molecular and biochemical indicators to establish the diagnosis is not well studied.

### Antimicrobial therapy – principles and methods:

- Clinical trials are needed to assess the efficacy and safety of recommended antimicrobial treatment regimens and new combinations or antimicrobials. Many recommendations come from clinical trials for bacteraemia and not for IE.
- Effective antibiotic treatment in patients with highly penicillin-resistant oral streptococci should be investigated.
- Randomized data to establish the best medical strategy in staphylococcal IE are required.
- Effective antibiotic treatments for patients with HLAR *E. faecalis* IE and hypersensitivity to beta-lactams need further research.
- Effective treatments for vancomycin-resistant enterococcal IE need further research.
- Randomized head-to-head comparisons of different antibiotics to better judge efficacy and toxicity (e.g. for aminoglycosides) are needed.
- The duration of antibiotic treatment has been established empirically and no randomized data have been published.
- The efficacy of combined antifungal therapy has not been studied.
- The empirical use of an aminoglycoside-sparing empirical combination regimen has not been extensively studied.
- More data on implementation of oral treatment in large studies are needed.

### Indications for surgery and management of main infective endocarditis complications:

- The indication of surgical treatment in patients with IE rely mainly on expert opinion based on observational studies.
- RCTs are required to establish the indication and timing of surgery in patients with:
  - Increased surgical risk.
  - Large vegetations but without other indications for surgery.
  - Cerebral emboli or bleeding.
  - Patients with uncontrolled infection.
- More data on the need and timing of coronary angiogram before endocarditis surgery.
- There is a lack of information on timing and sequence of interventions in patients with multiple septic sources.
- More data are needed on the efficacy and safety of vegetation extraction systems in right-sided IE.

**Other complications of infective endocarditis:**

- There is limited information on the safety and efficacy of mechanical thrombectomy in IE-related embolic strokes.
- There are no prospective data on the timing and safety of splenectomy for splenic abscess, complicating IE in relation to surgical valve treatment.

**Surgical therapy principles and methods:**

- There is a significant need for scores to predict futility of surgical management in very high-risk patients.
- There is a lack of data on the most appropriate anticoagulation regimen in patients with PVE complicated by haemorrhagic stroke.

**Outcome after discharge: follow-up and long-term prognosis:**

- Clinical trials are required to assess the efficacy of rehabilitation, including optimal timing, duration, methods, and components.
- Data on patient-reported outcomes during short- and long-term follow-up are needed.

**Management of specific situations:**

- Additional data on the incidence, characteristics, and outcomes of IE in patients treated with transcatheter valve therapies or left atrial appendage occluders are needed.

- There is an unmet clinical question on the efficacy and safety of surgical treatment of IE in patients previously treated with transcatheter valve therapies.
- Randomized data on the timing of CIED reimplantation after device removal after CIED infection are needed.
- There is a lack of evidence on whether or not CIED removal should be routinely performed in patients with left-sided IE.
- Randomized data on surgery in right-sided IE are required.

**Patient-centred care and shared decision-making in infective endocarditis:**

- As no disease-specific evidence exists, data on patient-centred care and shared decision-making in IE is needed.
- Data on how patient-centred care and shared decision-making in patients with social and mental health vulnerabilities can improve their outcomes are lacking.
- Data on the effect of patient-centred care and shared decision-making interventions are required to implement effective strategies.

**Sex differences:**

- Further data are required to determine why IE is less frequently observed, and why the outcomes are worse, in female patients.
- The reasons for lower referral to surgery in female patients with IE as compared with male patients need to be determined and addressed.

## 17. 'What to do' and 'What not to do' messages from the Guidelines

**Table 14** 'What to do' and 'What not to do'

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>
<b>Recommendations for antibiotic prophylaxis in patients with cardiovascular diseases undergoing oro-dental procedures at increased risk of infective endocarditis</b>		
Antibiotic prophylaxis is recommended in patients with previous IE.	I	B
General prevention measures are recommended in individuals at high and intermediate risk of IE.	I	C
Antibiotic prophylaxis is recommended in patients with surgically implanted prosthetic valves and with any material used for surgical cardiac valve repair.	I	C
Antibiotic prophylaxis is recommended in patients with transcatheter implanted aortic and pulmonary valvular prostheses.	I	C
Antibiotic prophylaxis is recommended in patients with untreated cyanotic CHD, and patients treated with surgery or transcatheter procedures with post-operative palliative shunts, conduits, or other prostheses. After surgical repair, in the absence of residual defects or valve prostheses, antibiotic prophylaxis is recommended only for the first 6 months after the procedure.	I	C
Antibiotic prophylaxis is recommended in patients with ventricular assist devices.	I	C
Antibiotic prophylaxis is not recommended in other patients at low risk of IE.	III	C
<b>Recommendations for infective endocarditis prevention in high-risk patients</b>		
Antibiotic prophylaxis is recommended in dental extractions, oral surgery procedures, and procedures requiring manipulation of the gingival or periapical region of the teeth.	I	B
<b>Recommendations for infective endocarditis prevention in cardiac procedures</b>		
Pre-operative screening for nasal carriage of <i>S. aureus</i> is recommended before elective cardiac surgery or transcatheter valve implantation to treat carriers.	I	A
Peri-operative antibiotic prophylaxis is recommended before placement of a CIED.	I	A
Optimal pre-procedural aseptic measures of the site of implantation are recommended to prevent CIED infections.	I	B
Periprocedural antibiotic prophylaxis is recommended in patients undergoing surgical or transcatheter implantation of a prosthetic valve, intravascular prosthetic, or other foreign material.	I	B

Continued

Surgical standard aseptic measures are recommended during the insertion and manipulation of catheters in the catheterization laboratory environment.	<b>I</b>	<b>C</b>	
Systematic skin or nasal decolonization without screening for <i>S. aureus</i> is not recommended.	<b>III</b>	<b>C</b>	
<b>Recommendations for the Endocarditis Team</b>			
Diagnosis and management of patients with complicated IE are recommended to be performed at an early stage in a Heart Valve Centre, with immediate surgical facilities and an 'Endocarditis Team' to improve the outcomes.	<b>I</b>	<b>B</b>	
For patients with uncomplicated IE managed in a Referring Centre, early and regular communication between the local and the Heart Valve Centre endocarditis teams is recommended to improve the outcomes of the patients.	<b>I</b>	<b>B</b>	
<b>Recommendations for the role of echocardiography in infective endocarditis</b>			
<b>A. Diagnosis</b>			
TTE is recommended as the first-line imaging modality in suspected IE.	<b>I</b>	<b>B</b>	
TOE is recommended in all patients with clinical suspicion of IE and a negative or non-diagnostic TTE.	<b>I</b>	<b>B</b>	
TOE is recommended in patients with clinical suspicion of IE, when a prosthetic heart valve or an intracardiac device is present.	<b>I</b>	<b>B</b>	
Repeating TTE and/or TOE within 5–7 days is recommended in cases of initially negative or inconclusive examination when clinical suspicion of IE remains high.	<b>I</b>	<b>C</b>	
TOE is recommended in patients with suspected IE, even in cases with positive TTE, except in isolated right-sided native valve IE with good quality TTE examination and unequivocal echocardiographic findings.	<b>I</b>	<b>C</b>	
<b>B. Follow-up under medical therapy</b>			
Repeating TTE and/or TOE is recommended as soon as a new complication of IE is suspected (new murmur, embolism, persisting fever and bacteraemia, HF, abscess, AVB).	<b>I</b>	<b>B</b>	
TOE is recommended when the patient is stable before switching from intravenous to oral antibiotic therapy.	<b>I</b>	<b>B</b>	
<b>C. Intra-operative echocardiography</b>			
Intra-operative echocardiography is recommended in all cases of IE requiring surgery.	<b>I</b>	<b>C</b>	
<b>D. Following completion of therapy</b>			
TTE and/or TOE are recommended at completion of antibiotic therapy for evaluation of cardiac and valve morphology and function in patients with IE who did not undergo heart valve surgery.	<b>I</b>	<b>C</b>	
<b>Recommendations for the role of computed tomography, nuclear imaging, and magnetic resonance in infective endocarditis</b>			
Cardiac CTA is recommended in patients with possible NVE to detect valvular lesions and confirm the diagnosis of IE.	<b>I</b>	<b>B</b>	
[18F]FDG-PET/CT(A) and cardiac CTA are recommended in possible PVE to detect valvular lesions and confirm the diagnosis of IE.	<b>I</b>	<b>B</b>	
Cardiac CTA is recommended in NVE and PVE to diagnose paravalvular or periprosthetic complications if echocardiography is inconclusive.	<b>I</b>	<b>B</b>	
Brain and whole-body imaging (CT, [18F]FDG-PET/CT, and/or MRI) are recommended in symptomatic patients with NVE and PVE to detect peripheral lesions or add minor diagnostic criteria.	<b>I</b>	<b>B</b>	
<b>Recommendations for antibiotic treatment of infective endocarditis due to oral streptococci and <i>Streptococcus gallolyticus</i> group</b>			
<b>Penicillin-susceptible oral streptococci and <i>Streptococcus gallolyticus</i> group</b>			
<b>Standard treatment: 4-week duration in NVE or 6-week duration in PVE</b>			
In patients with IE due to oral streptococci and <i>S. gallolyticus</i> group, penicillin G, amoxicillin, or ceftriaxone are recommended for 4 (in NVE) or 6 weeks (in PVE), using the following doses:	<b>I</b>	<b>B</b>	
<i>Adult antibiotic dosage and route</i>			
Penicillin G			12–18 million U/day i.v. either in 4–6 doses or continuously
Amoxicillin			100–200 mg/kg/day i.v. in 4–6 doses
Ceftriaxone			2 g/day i.v. in 1 dose
<i>Paediatric antibiotic dosage and route</i>			
Penicillin G			200 000 U/kg/day i.v. in 4–6 divided doses
Amoxicillin			100–200 mg/kg/day i.v. in 4–6 doses
Ceftriaxone			100 mg/kg/day i.v. in 1 dose
<b>Standard treatment: 2-week duration (not applicable to PVE)</b>			
2-week treatment with penicillin G, amoxicillin, ceftriaxone combined with gentamicin is recommended only for the treatment of non-complicated NVE due to oral streptococci and <i>S. gallolyticus</i> in patients with normal renal function using the following doses:	<b>I</b>	<b>B</b>	
<i>Adult antibiotic dosage and route</i>			
Penicillin G			12–18 million U/day i.v. either in 4–6 doses or continuously
Amoxicillin	100–200 mg/kg/day i.v. in 4–6 doses		

Continued

Ceftriaxone	2 g/day i.v. in 1 dose		
Gentamicin	3 mg/kg/day i.v. or i.m. in 1 dose		
<i>Paediatric antibiotic dosage and route</i>			
Penicillin G	200 000 U/kg/day i.v. in 4–6 divided doses		
Amoxicillin	100–200 mg/kg/day i.v. in 4–6 doses		
Ceftriaxone	100 mg/kg i.v. in 1 dose		
Gentamicin	3 mg/kg/day i.v. or i.m. in 1 dose or 3 equally divided doses		
<b>Allergy to beta-lactams</b>			
In patients allergic to beta-lactams and with IE due to oral streptococci and <i>S. gallolyticus</i> , vancomycin for 4 weeks in NVE or for 6 weeks in PVE is recommended using the following doses:		<b>I</b>	<b>C</b>
<i>Adult antibiotic dosage and route</i>			
Vancomycin	30 mg/kg/day i.v. in 2 doses		
<i>Paediatric antibiotic dosage and route</i>			
Vancomycin	30 mg/kg/day i.v. in 2 or 3 equally divided doses		
<b>Oral streptococci and <i>Streptococcus gallolyticus</i> group susceptible, increased exposure or resistant to penicillin</b>			
In patients with NVE due to oral streptococci and <i>S. gallolyticus</i> , penicillin G, amoxicillin, or ceftriaxone for 4 weeks in combination with gentamicin for 2 weeks is recommended using the following doses:		<b>I</b>	<b>B</b>
<i>Adult antibiotic dosage and route</i>			
Penicillin G	24 million U/day i.v. either in 4–6 doses or continuously		
Amoxicillin	12 g/day i.v. in 6 doses		
Gentamicin	3 mg/kg/day i.v. or i.m. in 1 dose		
In patients with PVE due to oral streptococci and <i>S. gallolyticus</i> , penicillin G, amoxicillin, or ceftriaxone for 6 weeks combined with gentamicin for 2 weeks is recommended using the following doses:		<b>I</b>	<b>B</b>
<i>Adult antibiotic dosage and route</i>			
Penicillin G	24 million U/day i.v. either in 4–6 doses or continuously		
Amoxicillin	12 g/day i.v. in 6 doses		
Gentamicin	3 mg/kg/day i.v. or i.m. in 1 dose		
<b>Allergy to beta-lactams</b>			
In patients with NVE due to oral streptococci and <i>S. gallolyticus</i> and who are allergic to beta-lactams, vancomycin for 4 weeks is recommended using the following doses:		<b>I</b>	<b>C</b>
<i>Adult antibiotic dosage and route</i>			
Vancomycin	30 mg/kg/day i.v. in 2 doses		
<i>Paediatric antibiotic dosage and route</i>			
Vancomycin	30 mg/kg/day i.v. in 2 doses		
In patients with PVE due to oral streptococci and <i>S. gallolyticus</i> and who are allergic to beta-lactams, vancomycin for 6 weeks combined with gentamicin for 2 weeks is recommended using the following doses:		<b>I</b>	<b>C</b>
<i>Adult antibiotic dosage and route</i>			
Vancomycin	30 mg/kg/day i.v. in 2 doses		
Gentamicin	3 mg/kg/day i.v. or i.m. in 1 dose		
<i>Paediatric antibiotic dosage and route</i>			
Vancomycin	30 mg/kg/day i.v. in 2 doses		
Gentamicin	3 mg/kg/day i.v. or i.m. in 1 dose		
<b>Recommendations for antibiotic treatment of infective endocarditis due to <i>Staphylococcus</i> spp.</b>			
<b>IE caused by methicillin-susceptible staphylococci</b>			
In patients with NVE due to methicillin-susceptible staphylococci, (flu)cloxacillin or cefazolin is recommended for 4–6 weeks using the following doses:		<b>I</b>	<b>B</b>
<i>Adult antibiotic dosage and route</i>			
(Flu)cloxacillin	12 g/day i.v. in 4–6 doses		
Cefazolin	6 g/day i.v. in 3 doses		
<i>Paediatric antibiotic dosage and route</i>			
(Flu)cloxacillin	200–300 mg/kg/day i.v. in 4–6 equally divided doses		
Cefazolin	300–600 mg/kg/day in 3–4 doses		

Continued

In patients with PVE due to methicillin-susceptible staphylococci, (flu)cloxacillin or cefazolin with rifampin for at least 6 weeks and gentamicin for 2 weeks is recommended using the following doses:		I	B
<i>Adult antibiotic dosage and route</i>			
(Flu)cloxacillin	12 g/day i.v. in 4–6 doses		
Cefazolin	6 g/day i.v. in 3 doses		
Rifampin	900 mg/day i.v. or orally in 3 equally divided doses		
Gentamicin	3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses		
<i>Paediatric antibiotic dosage and route</i>			
(Flu)cloxacillin	200–300 mg/kg/day i.v. in 4–6 equally divided doses		
Cefazolin	300–600 mg/kg/day in 3–4 doses		
Rifampin	20 mg/kg/day i.v. or orally in 3 equally divided doses		
Gentamicin	3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses		
<b>Allergy to beta-lactams</b>			
In patients with NVE due to methicillin-susceptible staphylococci who are allergic to penicillin, cefazolin for 4–6 weeks is recommended using the following doses:		I	B
<i>Adult antibiotic dosage and route</i>			
Cefazolin	6 g/day i.v. in 3 doses		
<i>Paediatric antibiotic dosage and route</i>			
Cefazolin	300–600 mg/kg/day in 3–4 doses		
In patients with PVE due to methicillin-susceptible staphylococci who are allergic to penicillin, cefazolin combined with rifampin for at least 6 weeks and gentamicin for 2 weeks is recommended using the following doses:		I	B
<i>Adult antibiotic dosage and route</i>			
Cefazolin	6 g/day i.v. in 3 doses		
Rifampin	900 mg/day i.v. or orally in 3 equally divided doses		
Gentamicin	3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses		
<i>Paediatric antibiotic dosage and route</i>			
Cefazolin	300–600 mg/kg/day in 3–4 doses		
Rifampin	20 mg/kg/day i.v. or orally in 3 equally divided doses		
Gentamicin	3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses		
<b>IE caused by methicillin-resistant staphylococci</b>			
In patients with NVE due to methicillin-resistant staphylococci, vancomycin is recommended for 4–6 weeks using the following doses:		I	B
<i>Adult antibiotic dosage and route</i>			
Vancomycin	30–60 mg/kg/day i.v. in 2–3 doses		
<i>Paediatric antibiotic dosage and route</i>			
Vancomycin	30 mg/kg/day i.v. in 2–3 equally divided doses		
In patients with PVE due to methicillin-resistant staphylococci, vancomycin with rifampin for at least 6 weeks and gentamicin for 2 weeks is recommended using the following doses:		I	B
<i>Adult antibiotic dosage and route</i>			
Vancomycin	30–60 mg/kg/day i.v. in 2–3 doses		
Rifampin	900–1200 mg/day i.v. or orally in 2 or 3 divided doses		
Gentamicin	3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses		
<i>Paediatric antibiotic dosage and route</i>			
Vancomycin	30 mg/kg/day i.v. in 2–3 equally divided doses		
Rifampin	20 mg/kg/day i.v. or orally in 2 or 3 divided doses		
Gentamicin	3 mg/kg/day i.v. or i.m. in 1 (preferred) or 2 doses		
<b>Recommendations for antibiotic treatment of infective endocarditis due to <i>Enterococcus</i> spp.</b>			
<b>Beta-lactam and gentamicin-susceptible strains</b>			
In patients with NVE due to non-HLAR <i>Enterococcus</i> spp., the combination of ampicillin or amoxicillin with ceftriaxone for 6 weeks or with gentamicin for 2 weeks is recommended using the following doses:		I	B
<i>Adult antibiotic dosage and route</i>			
Amoxicillin	200 mg/kg/day i.v. in 4–6 doses		
Ampicillin	12 g/day i.v. in 4–6 doses		

Continued

Ceftriaxone	4 g/day i.v. in 2 doses				
Gentamicin	3 mg/kg/day i.v. or i.m. in 1 dose				
<i>Paediatric antibiotic dosage and route</i>					
Ampicillin	300 mg/kg/day i.v. in 4–6 equally divided doses				
Ceftriaxone	100 mg/kg i.v. in 2 doses				
Gentamicin	3 mg/kg/day i.v. or i.m. in 3 equally divided doses				
In patients with PVE and patients with complicated NVE or >3 months of symptoms due to non-HLAR <i>Enterococcus</i> spp., the combination of ampicillin or amoxicillin with ceftriaxone for 6 weeks or with gentamicin for 2 weeks is recommended using the following doses:		I	B		
<i>Adult antibiotic dosage and route</i>					
Amoxicillin	200 mg/kg/day i.v. in 4–6 doses				
Ampicillin	12 g/day i.v. in 4–6 doses				
Ceftriaxone	4 g/day i.v. in 2 doses				
Gentamicin	3 mg/kg/day i.v. or i.m. in 1 dose				
<i>Paediatric antibiotic dosage and route</i>					
Ampicillin	300 mg/kg/day i.v. in 4–6 equally divided doses				
Amoxicillin	100–200 mg/kg/day i.v. in 4–6 doses				
Ceftriaxone	100 mg/kg/day i.v. in 2 doses				
Gentamicin	3 mg/kg/day i.v. or i.m. in 3 equally divided doses				
<b>High-level aminoglycoside resistance</b>					
In patients with NVE or PVE due to HLAR <i>Enterococcus</i> spp., the combination of ampicillin or amoxicillin and ceftriaxone for 6 weeks is recommended using the following doses:				I	B
<i>Adult antibiotic dosage and route</i>					
Ampicillin	12 g/day i.v. in 4–6 doses				
Amoxicillin	200 mg/kg/day i.v. in 4–6 doses				
Ceftriaxone	4 g/day i.v. or i.m. in 2 doses				
<i>Paediatric antibiotic dosage and route</i>					
Ampicillin	300 mg/kg/day i.v. in 4–6 equally divided doses				
Amoxicillin	100–200 mg/kg/day i.v. in 4–6 doses				
Ceftriaxone	100 mg/kg i.v. or i.m. in 2 doses				
<b>Beta-lactam-resistant <i>Enterococcus</i> spp. (<i>E. faecium</i>)</b>					
In patients with IE due to beta-lactam-resistant <i>Enterococcus</i> spp. ( <i>E. faecium</i> ), vancomycin for 6 weeks combined with gentamicin for 2 weeks is recommended using the following doses:		I	C		
<i>Adult antibiotic dosage and route</i>					
Vancomycin	30 mg/kg/day i.v. in 2 doses				
Gentamicin	3 mg/kg/day i.v. or i.m. in 1 dose				
<i>Paediatric antibiotic dosage and route</i>					
Vancomycin	30 mg/kg/day i.v. in 2–3 equally divided doses				
Gentamicin	3 mg/kg/day i.v. or i.m. in 1 dose				
<b>Vancomycin-resistant <i>Enterococcus</i> spp.</b>					
In patients with IE due to vancomycin-resistant <i>Enterococcus</i> spp., daptomycin combined with beta-lactams (ampicillin, ertapenem, or ceftaroline) or fosfomycin is recommended using the following doses:		I	C		
<i>Adult antibiotic dosage and route</i>					
Daptomycin	10–12 mg/kg/day i.v. in 1 dose				
Ampicillin	300 mg/kg/day i.v. in 4–6 equally divided doses				
Fosfomycin	12 g/day i.v. in 4 doses				
Ceftaroline	1800 mg/day i.v. in 3 doses				
Ertapenem	2 g/day i.v. or i.m. in 1 dose				
<i>Paediatric antibiotic dosage and route</i>					
Daptomycin	10–12 mg/kg/day i.v. in 1 dose (age-adjusted)				
Ampicillin	300 mg/kg/day i.v. in 4–6 equally divided doses				
Fosfomycin	2–3 g/day i.v. in 1 dose				
Ceftaroline	24–36 mg/kg/day in 3 doses				
Ertapenem	1 g/day i.v. or i.m. in 1 dose (if younger than 12 years, 15 mg/kg/dose [to a maximum of 500 mg] twice daily)				

Continued

<b>Recommendations for outpatient antibiotic treatment of infective endocarditis</b>		
Outpatient parenteral antibiotic treatment is not recommended in patients with IE caused by highly difficult-to-treat microorganisms, liver cirrhosis (Child–Pugh B or C), severe cerebral nervous system emboli, untreated large extracardiac abscesses, heart valve complications, or other severe conditions requiring surgery, severe post-surgical complications, and PWID-related IE.	III	C
<b>Recommendations for the main indications of surgery in infective endocarditis (native valve endocarditis and prosthetic valve endocarditis)</b>		
<b>(i) Heart failure</b>		
Emergency surgery is recommended in aortic or mitral NVE or PVE with severe acute regurgitation, obstruction, or fistula causing refractory pulmonary oedema or cardiogenic shock.	I	B
Urgent surgery is recommended in aortic or mitral NVE or PVE with severe acute regurgitation or obstruction causing symptoms of HF or echocardiographic signs of poor haemodynamic tolerance.	I	B
<b>(ii) Uncontrolled infection</b>		
Urgent surgery is recommended in locally uncontrolled infection (abscess, false aneurysm, fistula, enlarging vegetation, prosthetic dehiscence, new AVB).	I	B
Urgent or non-urgent surgery is recommended in IE caused by fungi or multiresistant organisms according to the haemodynamic condition of the patient.	I	C
<b>(iii) Prevention of embolism</b>		
Urgent surgery is recommended in aortic or mitral NVE or PVE with persistent vegetations $\geq 10$ mm after one or more embolic episodes despite appropriate antibiotic therapy.	I	B
Urgent surgery is recommended in IE with vegetation $\geq 10$ mm and other indications for surgery.	I	C
<b>Recommendations for the treatment of neurological complications of infective endocarditis</b>		
Brain CT or MRA is recommended in patients with IE and suspected infective cerebral aneurysms.	I	B
Neurosurgery or endovascular therapy is recommended for large aneurysms, those with continuous growth despite optimal antibiotic therapy, and ruptured intracranial infective cerebral aneurysms.	I	C
Thrombolytic therapy is not recommended in embolic stroke due to IE.	III	C
<b>Recommendations for patients with musculoskeletal manifestations of infective endocarditis</b>		
MRI or PET/CT is recommended in patients with suspected spondylodiscitis and vertebral osteomyelitis complicating IE.	I	C
TTE/TOE is recommended to rule out IE in patients with spondylodiscitis and/or septic arthritis with positive blood cultures for typical IE microorganisms.	I	C
<b>Recommendations for pre-operative coronary anatomy assessment in patients requiring surgery for infective endocarditis</b>		
In haemodynamically stable patients with aortic valve vegetations who require cardiac surgery and are high risk of CAD, a high-resolution multislice coronary CTA is recommended.	I	B
Invasive coronary angiography is recommended in patients requiring heart surgery who are high risk of CAD, in the absence of aortic valve vegetations.	I	C
<b>Indications and timing of cardiac surgery after neurological complications in active infective endocarditis</b>		
After a transient ischaemic attack, cardiac surgery, if indicated, is recommended without delay.	I	B
After a stroke, surgery is recommended without any delay in the presence of HF, uncontrolled infection, abscess, or persistent high embolic risk, as long as coma is absent and the presence of cerebral haemorrhage has been excluded by cranial CT or MRI.	I	B
<b>Recommendations for post-discharge follow-up</b>		
Patient education on the risk of recurrence and preventive measures, with emphasis on dental health, and based on the individual risk profile is recommended during follow-up.	I	C
Addition treatment for patients following PWID-related IE is recommended.	I	C
<b>Recommendations for prosthetic valve endocarditis</b>		
Surgery is recommended for early PVE (within 6 months of valve surgery) with new valve replacement and complete debridement.	I	C
<b>Recommendations for cardiovascular implanted electronic device-related infective endocarditis</b>		
Antibiotic prophylaxis covering <i>S. aureus</i> is recommended for CIED implantation.	I	A
TTE and TOE are both recommended in cases of suspected CIED-related IE to identify vegetations.	I	B
Complete system extraction without delay is recommended in patients with definite CIED-related IE under initial empirical antibiotic therapy.	I	B

Continued

Obtaining at least three sets of blood cultures is recommended before prompt initiation of empirical antibiotic therapy for CIED infection, covering methicillin-resistant staphylococci and Gram-negative bacteria.	I	C
If CIED reimplantation is indicated after extraction for CIED-related IE, it is recommended to be performed at a site distant from the previous generator, as late as possible, once signs and symptoms of infection have abated, and until blood cultures are negative for at least 72 h in the absence of vegetations, and negative for at least 2 weeks if vegetations were visualized.	I	C
Removal of CIED after a single positive blood culture, with no other clinical evidence of infection, is not recommended.	III	C
<b>Recommendations for the surgical treatment of right-sided infective endocarditis</b>		
Surgery is recommended in patients with right-sided IE who are receiving appropriate antibiotic therapy for the following scenarios:		
Right ventricular dysfunction secondary to acute severe tricuspid regurgitation non-responsive to diuretics.	I	B
Persistent vegetation with respiratory insufficiency requiring ventilatory support after recurrent pulmonary emboli.	I	B
Large residual tricuspid vegetations (>20 mm) after recurrent septic pulmonary emboli.	I	C
Patients with simultaneous involvement of left-heart structures.	I	C
<b>Recommendations for the use of antithrombotic therapy in infective endocarditis</b>		
Interruption of antiplatelet or anticoagulant therapy is recommended in the presence of major bleeding (including intracranial haemorrhage).	I	C
Thrombolytic therapy is not recommended in patients with IE.	III	C

© ESC 2023

[18F]FDG-PET, <sup>18</sup>F-fluorodeoxyglucose positron emission tomography; AVB, atrioventricular block; CAD, coronary artery disease; CHD, congenital heart disease; CIED, cardiovascular implanted electronic device; CT, computed tomography; CTA, computed tomography angiography; HF, heart failure; HLAR, high-level aminoglycoside resistance; IE, infective endocarditis; i.m., intramuscular; i.v., intravenous; MRA, magnetic resonance angiography; MRI, magnetic resonance imaging; NVE, native valve endocarditis; PET, positron emission tomography; PVE, prosthetic valve endocarditis; PWID, people who inject drugs; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

## 18. Supplementary data

Supplementary data are available at *European Heart Journal* online.

## 19. Data availability

No new data were generated or analysed in support of this research.

## 20. Author information

**Author/Task Force Member Affiliations:** **Nina Ajmone Marsan**, Leiden University Medical Center, Leiden, Netherlands; **Suzanne de Waha**, Heart Center Leipzig at University of Leipzig, Leipzig, Germany; **Nikolaos Bonaros**, Medical University of Innsbruck, Innsbruck, Austria and University Hospital Innsbruck, Innsbruck, Austria; **Margarita Brida**, Medical Faculty University of Rijeka, Rijeka, Croatia and Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton & Harefield Hospitals, London, United Kingdom; **Haran Burri**, University Hospital of Geneva, Geneva, Switzerland; **Stefano Caselli**, Hirslanden Klinik im Park, Zurich, Switzerland and University Heart Center, University Hospital Zurich, Zurich, Switzerland; **Torsten Doenst**, Friedrich-Schiller-University Jena, University Hospital, Jena, Germany; **Stephane Ederhy**, Hopital Saint-Antoine, Paris, France and Unité de cardio-oncologie, UNICO-GRECO, Hopital Saint-Antoine, Paris, France and Groupe de recherche clinique en cardio-oncologie, GRC n°27, Hopital Saint-Antoine, Paris, France; **Paola Anna Erba**, University of Milan Bicocca, Milan, Italy and Nuclear Medicine Department, ASST – Ospedale Papa Giovanni XXIII, Bergamo, Italy and Medical Imaging Center, Department of Nuclear Medicine & Molecular Imaging, University Medical Center Groningen, Groningen, Netherlands; **Dan Foldager**, ESC Patient Forum, Sophia Antipolis, France; **Emil L. Fosbøl**, University

Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark; **Jan Kovac**, University of Leicester, Leicester, United Kingdom and RRCV Glenfield, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom; **Carlos A. Mestres**, The University of the Free State, Bloemfontein, South Africa and Cardiac Surgery, University Hospital Zurich, Zurich, Switzerland; **Owen I. Miller**, Evelina London Children's Hospital, London, United Kingdom and Department of Women and Children's Health, Kings College London, London, United Kingdom; **Jose M. Miro**, Hospital Clinic - IDIBAPS, Barcelona, Spain and Faculty of Medicine, University of Barcelona, Barcelona, Spain and Centro de Investigación Biomédica en Red Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; **Michal Pazdernik**, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic; **Maria Nazarena Pizzi**, Vall d'Hebron University Hospital, Barcelona, Spain; **Eduard Quintana**, Hospital Clínic de Barcelona, Barcelona, Spain and Departament de Cirurgia i Especialitats Medicoquirúrgiques, Facultat de Medicina i Ciències de la Salut, University of Barcelona, Barcelona, Spain; **Trine Bernholdt Rasmussen**, Herlev and Gentofte University Hospital, Hellerup, Denmark and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; **Arsen D. Ristić**, University Clinical Center of Serbia, Belgrade, Serbia and Faculty of Medicine, University of Belgrade, Belgrade, Serbia; **Josep Rodés-Cabau**, Quebec Heart and Lung Institute, Laval University, Quebec, Canada and Research and Innovation, Clínic Barcelona, Barcelona, Spain; **Alessandro Sionis**, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain and Universitat Autònoma de Barcelona, Barcelona, Spain; **Liesel Joanna Zühlke**, Francie van Zijl Drive Parowallei, Cape Town; PO Box 19070, Cape Town, South Africa and Division of Paediatric Cardiology, Department of Paediatrics, Institute of Child Health, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.

## 21. Appendix

### ESC Society Scientific Document Group

Includes Document Reviewers and ESC National Cardiac Societies.

**Document Reviewers:** Bernard Iung (CPG Review Co-ordinator) (France), Bernard Prendergast (CPG Review Co-ordinator) (United Kingdom), Magdy Abdelhamid (Egypt), Marianna Adamo (Italy), Riccardo Asteggiano (Italy), Larry M. Baddour (United States of America), Jelena Čelutkienė (Lithuania), John Chambers (United Kingdom), Jean-Claude Deharo (France), Wolfram Doehner (Germany), Laura Dos Subira (Spain), Xavier Duval (France), Volkmar Falk (Germany), Laurent Fauchier (France), Nuria Fernandez-Hidalgo (Spain), Christian Giske (Sweden), Anežka Gombošová (Czechia), Gilbert Habib (France), Borja Ibanez (Spain), Tiny Jaarsma (Sweden), Lars Køber (Denmark), Konstantinos C. Koskinas (Switzerland), Dipak Kotecha (United Kingdom), Ulf Landmesser (Germany), Sandra B. Lauck (Canada), Basil S. Lewis (Israel), Maja-Lisa Løchen (Norway), John William McEvoy (Ireland), Borislava Mihaylova (United Kingdom), Richard Mindham (United Kingdom), Lis Neubeck (United Kingdom), Jens Cosedis Nielsen (Denmark), Jean-François Obadia (France), Agnes A. Pasquet (Belgium), Steffen Petersen (United Kingdom), Eva Prescott (Denmark), Susanna Price (United Kingdom), Amina Rakisheva (Kazakhstan), Archana Rao (United Kingdom), François Rouzet (France), Jonathan Sandoe (United Kingdom), Renate B. Schnabel (Germany), Christine Selton-Suty (France), Lars Sondergaard (Denmark), Martin Thornhill (United Kingdom), Konstantinos Toutouzas (Greece), Nico Van de Veire (Belgium), Isidre Vilacosta (Spain), Christiaan Vrints (Belgium), Olaf Wendler (United Kingdom).

**ESC National Cardiac Societies** actively involved in the review process of the 2023 Guidelines for the management of endocarditis.

**Algeria:** Algerian Society of Cardiology, Yasmina Benchabi; **Armenia:** Armenian Cardiologists Association, Aram Chilingaryan; **Austria:** Austrian Society of Cardiology, Sebastian J. Reinstadler; **Azerbaijan:** Azerbaijan Society of Cardiology, Fuad Samadov; **Belgium:** Belgian Society of Cardiology, Bernard Paelinck; **Bosnia and Herzegovina:** Association of Cardiologists of Bosnia and Herzegovina, Zumreta Kušljugić; **Bulgaria:** Bulgarian Society of Cardiology, Elena Kinova; **Croatia:** Croatian Cardiac Society, Maja Cikes; **Cyprus:** Cyprus Society of Cardiology, Ioannis Michaloliakos; **Czechia:** Czech Society of Cardiology, Martin Mates; **Denmark:** Danish Society of Cardiology, Jonas Agerlund Povlsen; **Egypt:** Egyptian Society of Cardiology, Mohammad Abdelghani; **Estonia:** Estonian Society of Cardiology, Liisi Küünal-Arge; **Finland:** Finnish Cardiac Society, Helena Rajala; **France:** French Society of Cardiology, Christine Selton-Suty; **Georgia:** Georgian Society of Cardiology, Zurab Pagava; **Germany:** German Cardiac Society, Marcus Franz; **Greece:** Hellenic Society of Cardiology, Alexandros Patrianakos; **Hungary:** Hungarian Society of Cardiology, Judit Barta; **Iceland:** Icelandic Society of Cardiology, Pórdís Jóna Hrafnkelsdóttir; **Ireland:** Irish Cardiac Society, David Moore; **Israel:** Israel Heart Society, Katia Orvin; **Italy:** Italian Federation of Cardiology, Fabrizio Oliva; **Kazakhstan:** Association of Cardiologists of Kazakhstan, Gynulnar Zhussupova; **Kosovo (Republic of):** Kosovo Society of Cardiology, Gani Bajraktari; **Kyrgyzstan:** Kyrgyz Society of Cardiology, Alina Kerimkulova; **Latvia:** Latvian Society of Cardiology, Ginta Kamzola; **Lebanon:** Lebanese Society of Cardiology, Pierrette Habib; **Lithuania:** Lithuanian Society of Cardiology, Vaida Mizarienė; **Luxembourg:** Luxembourg Society of Cardiology, Rouguatou Sow; **Malta:** Maltese Cardiac Society, Daniela Cassar Demarco; **Moldova**

**(Republic of):** Moldavian Society of Cardiology, Elena Panfile; **Morocco:** Moroccan Society of Cardiology, Laila Bendriss; **Netherlands:** Netherlands Society of Cardiology, Wilco Tanis; **North Macedonia:** The National Society of Cardiology of North Macedonia, Irena Mitevska; **Norway:** Norwegian Society of Cardiology, Erlend Aune; **Portugal:** Portuguese Society of Cardiology, Manuel Antunes; **Romania:** Romanian Society of Cardiology, Bogdan A. Popescu; **San Marino:** San Marino Society of Cardiology, Roberto Bini; **Serbia:** Cardiology Society of Serbia, Milorad Tesic; **Slovakia:** Slovak Society of Cardiology, Marek Orban; **Slovenia:** Slovenian Society of Cardiology, Mojca Bervar; **Spain:** Spanish Society of Cardiology, Isidre Vilacosta; **Sweden:** Swedish Society of Cardiology, Christina Christersson; **Switzerland:** Swiss Society of Cardiology, Michelle Frank; **Tunisia:** Tunisian Society of Cardiology and Cardiovascular Surgery, Lilia Zakhama; **Türkiye:** Turkish Society of Cardiology, Gamze Babur Guler; **Ukraine:** Ukrainian Association of Cardiology, Sergii Cherniuk; **United Kingdom of Great Britain and Northern Ireland:** British Cardiovascular Society, Simon Woldman; **Uzbekistan:** Association of Cardiologists of Uzbekistan, Nigora Srojidinova.

**ESC Clinical Practice Guidelines (CPG) Committee:** Eva Prescott (Chairperson) (Denmark), Stefan James (Co-Chairperson) (Sweden), Elena Arbelo (Spain), Colin Baigent (United Kingdom), Michael A. Borger (Germany), Sergio Buccheri (Sweden), Borja Ibanez (Spain), Lars Køber (Denmark), Konstantinos C. Koskinas (Switzerland), John William McEvoy (Ireland), Borislava Mihaylova (United Kingdom), Richard Mindham (United Kingdom), Lis Neubeck (United Kingdom), Jens Cosedis Nielsen (Denmark), Agnes A. Pasquet (Belgium), Amina Rakisheva (Kazakhstan), Bianca Rocca (Italy), Xavier Rossello (Spain), Ilonca Vaartjes (Netherlands), Christiaan Vrints (Belgium), Adam Witkowski (Poland), and Katja Zeppenfeld (Netherlands).

## 22. References

- Global Burden of Disease Metrics. *Institute for Health Metrics Evaluation*. University of Washington, Seattle. Available at: <https://vizhub.healthdata.org/gbd-compare/> (accessed October 2021).
- Momtazmanesh S, Saeedi Moghaddam S, Malakan Rad E, Azadnajafabad S, Ebrahimi N, Mohammadi E, et al. Global, regional, and national burden and quality of care index of endocarditis: the global burden of disease study 1990–2019. *Eur J Prev Cardiol* 2022;**29**: 1287–1297. <https://doi.org/10.1093/eurjpc/zwab211>
- Chen H, Zhan Y, Zhang K, Gao Y, Chen L, Zhan J, et al. The global, regional, and national burden and trends of infective endocarditis from 1990 to 2019: results from the global burden of disease study 2019. *Front Med (Lausanne)* 2022;**9**:774224. <https://doi.org/10.3389/fmed.2022.774224>
- Habib G, Lancellotti P, Antunes MJ, Bongioni MG, Casalta JP, Del Zotti F, et al. 2015 ESC guidelines for the management of infective endocarditis: the Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of nuclear medicine (EANM). *Eur Heart J* 2015;**36**: 3075–3128. <https://doi.org/10.1093/eurheartj/ehv319>
- Habib G, Erba PA, Iung B, Donal E, Cosyns B, Laroche C, et al. Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study. *Eur Heart J* 2019;**40**:3222–3232. <https://doi.org/10.1093/eurheartj/ehz620>
- Janszky I, Gemes K, Ahnve S, Asgeirsson H, Moller J. Invasive procedures associated with the development of infective endocarditis. *J Am Coll Cardiol* 2018;**71**: 2744–2752. <https://doi.org/10.1016/j.jacc.2018.03.532>
- Pericas JM, Llopis J, Jimenez-Exposito MJ, Kourany WM, Almirante B, Carosi G, et al. Infective endocarditis in patients on chronic hemodialysis. *J Am Coll Cardiol* 2021;**77**: 1629–1640. <https://doi.org/10.1016/j.jacc.2021.02.014>
- Kuijpers JM, Koolbergen DR, Groenink M, Peels KCH, Reichert CLA, Post MC, et al. Incidence, risk factors, and predictors of infective endocarditis in adult congenital heart disease: focus on the use of prosthetic material. *Eur Heart J* 2017;**38**:2048–2056. <https://doi.org/10.1093/eurheartj/ehw591>

9. Sanaia Y, Lyons R, Benharash P. Infective endocarditis in intravenous drug users. *Trends Cardiovasc Med* 2020;**30**:491–497. <https://doi.org/10.1016/j.tcm.2019.11.007>
10. Pericas JM, Llopis J, Athan E, Hernandez-Meneses M, Hannan MM, Murdoch DR, et al. Prospective cohort study of infective endocarditis in people who inject drugs. *J Am Coll Cardiol* 2021;**77**:544–555. <https://doi.org/10.1016/j.jacc.2020.11.062>
11. Thornhill MH, Crum A, Campbell R, Stone T, Lee EC, Bradburn M, et al. Temporal association between invasive procedures and infective endocarditis. *Heart* 2023;**109**:223–231. <https://doi.org/10.1136/heartjnl-2022-321519>
12. Maeda K, Hirai Y, Nashi M, Yamamoto S, Taniike N, Takenobu T. Clinical features and antimicrobial susceptibility of oral bacteria isolated from the blood cultures of patients with infective endocarditis. *J Dent Sci* 2022;**17**:870–875. <https://doi.org/10.1016/j.jds.2021.09.023>
13. Thornhill MH, Gibson TB, Cutler E, Dayer MJ, Chu VH, Lockhart PB, et al. Antibiotic prophylaxis and incidence of endocarditis before and after the 2007 AHA recommendations. *J Am Coll Cardiol* 2018;**72**:2443–2454. <https://doi.org/10.1016/j.jacc.2018.08.2178>
14. Thornhill MH, Dayer MJ, Nicholl J, Prendergast BD, Lockhart PB, Baddour LM. An alarming rise in incidence of infective endocarditis in England since 2009: why? *Lancet* 2020;**395**:1325–1327. [https://doi.org/10.1016/S0140-6736\(20\)30530-4](https://doi.org/10.1016/S0140-6736(20)30530-4)
15. Dayer MJ, Prendergast BD, Thornhill MH, Baddour LM. Why are we seeing an increasing incidence of infective endocarditis in the UK? *Br J Hosp Med (Lond)* 2020;**81**:1–4. <https://doi.org/10.12968/hmed.2020.0263>
16. Quan TP, Muller-Pebody B, Fawcett N, Young BC, Minaji M, Sandoe J, et al. Investigation of the impact of the NICE guidelines regarding antibiotic prophylaxis during invasive dental procedures on the incidence of infective endocarditis in England: an electronic health records study. *BMC Med* 2020;**18**:84. <https://doi.org/10.1186/s12916-020-01531-y>
17. Vahasarla N, Lund B, Ternhag A, Gotrick B, Olaison L, Hultin M, et al. Incidence of infective endocarditis caused by viridans group streptococci in Sweden – effect of cessation of antibiotic prophylaxis in dentistry for risk individuals. *J Oral Microbiol* 2020;**12**:1768342. <https://doi.org/10.1080/20002297.2020.1768342>
18. Williams ML, Doyle MP, McNamara N, Tardo D, Mathew M, Robinson B. Epidemiology of infective endocarditis before versus after change of international guidelines: a systematic review. *Ther Adv Cardiovasc Dis* 2021;**15**:17539447211002687. <https://doi.org/10.1177/17539447211002687>
19. Ostergaard L, Bruun NE, Voldstedlund M, Arpi M, Andersen CO, Schonheyder HC, et al. Prevalence of infective endocarditis in patients with positive blood cultures: a Danish nationwide study. *Eur Heart J* 2019;**40**:3237–3244. <https://doi.org/10.1093/eurheartj/ehz327>
20. Kim I-C, Chang S, Hong G-R, Lee SH, Lee S, Ha J-W, et al. Comparison of cardiac computed tomography with transesophageal echocardiography for identifying vegetation and intracardiac complications in patients with infective endocarditis in the era of 3-dimensional images. *Circ Cardiovasc Imaging* 2018;**11**:e006986. <https://doi.org/10.1161/CIRCIMAGING.117.006986>
21. Salaun E, Habib G. Beyond standard echocardiography in infective endocarditis: computed tomography, 3-dimensional imaging, and multi-imaging. *Circ Cardiovasc Imaging* 2018;**11**:e007626. <https://doi.org/10.1161/CIRCIMAGING.118.007626>
22. Pizzi MN, Roque A, Fernandez-Hidalgo N, Cuellar-Calabria H, Ferreira-Gonzalez I, Gonzalez-Alujas MT, et al. Improving the diagnosis of infective endocarditis in prosthetic valves and intracardiac devices with 18F-fluorodeoxyglucose positron emission tomography/computed tomography angiography: initial results at an infective endocarditis referral center. *Circulation* 2015;**132**:1113–1126. <https://doi.org/10.1161/CIRCULATIONAHA.115.015316>
23. DeSimone DC, Lahr BD, Anavekar NS, Sohail MR, Tleyjeh IM, Wilson WR, et al. Temporal trends of infective endocarditis in Olmsted County, Minnesota, between 1970 and 2018: a population-based analysis. *Open Forum Infect Dis* 2021;**8**:ofab038. <https://doi.org/10.1093/ofid/ofab038>
24. Giannitsioti E, Pefanis A, Gogos C, Lekkou A, Dalekos GN, Gatselis N, et al. Evolution of epidemiological characteristics of infective endocarditis in Greece. *Int J Infect Dis* 2021;**106**:213–220. <https://doi.org/10.1016/j.ijid.2021.03.009>
25. Jensen AD, Bundgaard H, Butt JH, Bruun NE, Voldstedlund M, Torp-Pedersen C, et al. Temporal changes in the incidence of infective endocarditis in Denmark 1997–2017: a nationwide study. *Int J Cardiol* 2021;**326**:145–152. <https://doi.org/10.1016/j.ijcard.2020.10.029>
26. Keller K, von Bardeleben RS, Ostad MA, Hobohm L, Munzel T, Konstantinides S, et al. Temporal trends in the prevalence of infective endocarditis in Germany between 2005 and 2014. *Am J Cardiol* 2017;**119**:317–322. <https://doi.org/10.1016/j.amjcard.2016.09.035>
27. Shah ASV, McAllister DA, Gallacher P, Astengo F, Rodriguez Perez JA, Hall J, et al. Incidence, microbiology, and outcomes in patients hospitalized with infective endocarditis. *Circulation* 2020;**141**:2067–2077. <https://doi.org/10.1161/CIRCULATIONAHA.119.044913>
28. Ortega-Loubon C, Munoz-Moreno MF, Andres-Garcia I, Alvarez FJ, Gomez-Sanchez E, Bustamante-Munguira J, et al. Nosocomial vs. community-acquired infective endocarditis in Spain: location, trends, clinical presentation, etiology, and survival in the 21st century. *J Clin Med* 2019;**8**:1755. <https://doi.org/10.3390/jcm8101755>
29. Olmos C, Vilacosta I, Fernandez-Perez C, Bernal JL, Ferrera C, Garcia-Arribas D, et al. The evolving nature of infective endocarditis in Spain: a population-based study (2003 to 2014). *J Am Coll Cardiol* 2017;**70**:2795–2804. <https://doi.org/10.1016/j.jacc.2017.10.005>
30. Altini C, Lavelli V, Niccoli-Asabella A, Sardaro A, Branca A, Santo G, et al. Comparison of the diagnostic value of MRI and whole body (18)F-FDG PET/CT in diagnosis of spondylodiscitis. *J Clin Med* 2020;**9**:1581. <https://doi.org/10.3390/jcm9051581>
31. Holle SLK, Andersen MH, Klein CF, Bruun NE, Tonder N, Haarmark C, et al. Clinical usefulness of FDG-PET/CT for identification of abnormal extra-cardiac foci in patients with infective endocarditis. *Int J Cardiovasc Imaging* 2020;**36**:939–946. <https://doi.org/10.1007/s10554-020-01787-8>
32. Kim S-J, Pak K, Kim K, Lee JS. Comparing the diagnostic accuracies of F-18 fluorodeoxyglucose positron emission tomography and magnetic resonance imaging for the detection of spondylodiscitis: a meta-analysis. *Spine (Phila Pa 1976)* 2019;**44**:E414–E422. <https://doi.org/10.1097/BRS.0000000000002861>
33. Sifaoui I, Oliver L, Tacher V, Fiore A, Lepeule R, Moussafeur A, et al. Diagnostic performance of transesophageal echocardiography and cardiac computed tomography in infective endocarditis. *J Am Soc Echocardiogr* 2020;**33**:1442–1453. <https://doi.org/10.1016/j.echo.2020.07.017>
34. Venet M, Jalal Z, Ly R, Malekzadeh-Milani S, Hascoet S, Fournier E, et al. Diagnostic value of (18)F-fluorodeoxyglucose positron emission tomography computed tomography in prosthetic pulmonary valve infective endocarditis. *JACC Cardiovasc Imaging* 2022;**15**:299–308. <https://doi.org/10.1016/j.jcmg.2021.07.015>
35. Wang TKM, Bin Saeedan M, Chan N, Obuchowski NA, Shrestha N, Xu B, et al. Complementary diagnostic and prognostic contributions of cardiac computed tomography for infective endocarditis surgery. *Circ Cardiovasc Imaging* 2020;**13**:e011126. <https://doi.org/10.1161/CIRCIMAGING.120.011126>
36. Camou F, Dijos M, Barandon L, Cornolle C, Greib C, Laine M, et al. Management of infective endocarditis and multidisciplinary approach. *Med Mal Infect* 2019;**49**:17–22. <https://doi.org/10.1016/j.medmal.2018.06.007>
37. El-Dalati S, Cronin D, Riddell JT, Shea M, Weinberg RL, Washer L, et al. The clinical impact of implementation of a multidisciplinary endocarditis team. *Ann Thorac Surg* 2022;**113**:118–124. <https://doi.org/10.1016/j.athoracsur.2021.02.027>
38. Elad B, Perl L, Hamdan A, Yahav D, Atamna A, Shaked H, et al. The clinical value of the endocarditis team: insights from before and after guidelines implementation strategy. *Infection* 2022;**50**:57–64. <https://doi.org/10.1007/s15010-021-01636-3>
39. Gibbons EF, Huang G, Aldea G, Koomalsingh K, Klein JW, Dhanireddy S, et al. A multidisciplinary pathway for the diagnosis and treatment of infectious endocarditis. *Crit Pathw Cardiol* 2020;**19**:187–194. <https://doi.org/10.1097/HPC.0000000000000224>
40. Kaura A, Byrne J, Fife A, Deshpande R, Baghai M, Gunning M, et al. Inception of the ‘endocarditis team’ is associated with improved survival in patients with infective endocarditis who are managed medically: findings from a before-and-after study. *Open Heart* 2017;**4**:e000699. <https://doi.org/10.1136/openhrt-2017-000699>
41. Ruch Y, Mazzucotelli JP, Lefebvre F, Martin A, Lefebvre N, Douiri N, et al. Impact of setting up an “endocarditis team” on the management of infective endocarditis. *Open Forum Infect Dis* 2019;**6**:ofz308. <https://doi.org/10.1093/ofid/ofz308>
42. European Committee on Antimicrobial Susceptibility Testing. *The European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 12.0, 2022.* <http://www.eucast.org>
43. Iversen K, Ihlemann N, Gill SU, Madsen T, Elming H, Jensen KT, et al. Partial oral versus intravenous antibiotic treatment of endocarditis. *N Engl J Med* 2019;**380**:415–424. <https://doi.org/10.1056/NEJMoa1808312>
44. Wildenthal JA, Atkinson A, Lewis S, Sayood S, Nolan NS, Cabrera NL, et al. Outcomes of partial oral antibiotic treatment for complicated *Staphylococcus aureus* bacteremia in people who inject drugs. *Clin Infect Dis* 2022;**76**:487–496. <https://doi.org/10.1093/cid/ciac714>
45. Pericas JM, Llopis J, Munoz P, Gonzalez-Ramallo V, Garcia-Leoni ME, de Alarcon A, et al. Outpatient parenteral antibiotic treatment vs hospitalization for infective endocarditis: validation of the OPAT-games criteria. *Open Forum Infect Dis* 2022;**9**:ofac442. <https://doi.org/10.1093/ofid/ofac442>
46. Fernandez-Galilea A, Estella A, Garcia-Garmendia JL, Loza A, Palacios-Garcia I, Sierra-Camerino R, et al. Clindamycin but not intravenous immunoglobulins reduces mortality in a retrospective cohort of critically ill patients with bacteremic group A streptococcal infections. *Rev Esp Quimioter* 2022;**35**:475–481. <https://doi.org/10.37201/req/030.2022>
47. Thornhill MH, Jones S, Prendergast B, Baddour LM, Chambers JB, Lockhart PB, et al. Quantifying infective endocarditis risk in patients with predisposing cardiac conditions. *Eur Heart J* 2018;**39**:586–595. <https://doi.org/10.1093/eurheartj/ehx655>
48. Duval X, Millot S, Chirouze C, Selton-Suty C, Moby V, Tattevin P, et al. Oral streptococcal endocarditis, oral hygiene habits, and recent dental procedures: a case-control study. *Clin Infect Dis* 2017;**64**:1678–1685. <https://doi.org/10.1093/cid/cix237>
49. Lockhart PB, Brennan MT, Thornhill M, Michalowicz BS, Noll J, Bahrani-Mougeot FK, et al. Poor oral hygiene as a risk factor for infective endocarditis-related bacteremia. *J Am Dent Assoc* 2009;**140**:1238–1244. <https://doi.org/10.14219/jada.archive.2009.0046>

50. Sy RW, Kritharides L. Health care exposure and age in infective endocarditis: results of a contemporary population-based profile of 1536 patients in Australia. *Eur Heart J* 2010;**31**:1890–1897. <https://doi.org/10.1093/eurheartj/ehq110>
51. Thornhill MH, Gibson TB, Yoon F, Dayer MJ, Prendergast BD, Lockhart PB, et al. Antibiotic prophylaxis against infective endocarditis before invasive dental procedures. *J Am Coll Cardiol* 2022;**80**:1029–1041. <https://doi.org/10.1016/j.jacc.2022.06.030>
52. Cahill TJ, Harrison JL, Jewell P, Onakpoya I, Chambers JB, Dayer M, et al. Antibiotic prophylaxis for infective endocarditis: a systematic review and meta-analysis. *Heart* 2017;**103**:937–944. <https://doi.org/10.1136/heartjnl-2015-309102>
53. Glauser MP, Francioli P. Relevance of animal models to the prophylaxis of infective endocarditis. *J Antimicrob Chemother* 1987;**20**(Suppl A):87–98. [https://doi.org/10.1093/jac/20.suppl\\_A.87](https://doi.org/10.1093/jac/20.suppl_A.87)
54. Lafaurie GI, Noriega LA, Torres CC, Castillo Y, Moscoso SB, Mosquera S, et al. Impact of antibiotic prophylaxis on the incidence, nature, magnitude, and duration of bacteremia associated with dental procedures: a systematic review. *J Am Dent Assoc* 2019;**150**:948–959.e4. <https://doi.org/10.1016/j.adaj.2019.06.017>
55. Overholser CD, Moreillon P, Glauser MP. Experimental bacterial endocarditis after dental extractions in rats with periodontitis. *J Infect Dis* 1987;**155**:107–112. <https://doi.org/10.1093/infdis/155.1.107>
56. Veloso TR, Amiguet M, Rousson V, Giddey M, Vouillamoz J, Moreillon P, et al. Induction of experimental endocarditis by continuous low-grade bacteremia mimicking spontaneous bacteremia in humans. *Infect Immun* 2011;**79**:2006–2011. <https://doi.org/10.1128/IAI.01208-10>
57. Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. *Circulation* 2007;**116**:1736–1754. <https://doi.org/10.1161/CIRCULATIONAHA.106.183095>
58. Richey R, Wray D, Stokes T; Guideline Development Group. Prophylaxis against infective endocarditis: summary of NICE guidance. *BMJ* 2008;**336**:770–771. <https://doi.org/10.1136/bmj.39510.423148.AD>
59. Dayer MJ, Jones S, Prendergast B, Baddour LM, Lockhart PB, Thornhill MH. Incidence of infective endocarditis in England, 2000–13: a secular trend, interrupted time-series analysis. *Lancet* 2015;**385**:1219–1228. [https://doi.org/10.1016/S0140-6736\(14\)62007-9](https://doi.org/10.1016/S0140-6736(14)62007-9)
60. Tubiana S, Duval X, Alla F, Selton-Suty C, Tattevin P, Delahaye F, et al. The VIRSTA score, a prediction score to estimate risk of infective endocarditis and determine priority for echocardiography in patients with *Staphylococcus aureus* bacteremia. *J Infect* 2016;**72**:544–553. <https://doi.org/10.1016/j.jinf.2016.02.003>
61. Thornhill MH, Lockhart PB, Prendergast B, Chambers JB, Shanson D. NICE and antibiotic prophylaxis to prevent endocarditis. *Br Dent J* 2015;**218**:619–621. <https://doi.org/10.1038/sj.bdj.2015.496>
62. Tubiana S, Blotiere PO, Hoen B, Lesclous P, Millot S, Rudant J, et al. Dental procedures, antibiotic prophylaxis, and endocarditis among people with prosthetic heart valves: nationwide population based cohort and a case crossover study. *BMJ* 2017;**358**:j3776. <https://doi.org/10.1136/bmj.j3776>
63. Cloitre A, Duval X, Tubiana S, Giraud P, Veyrac G, Nosbaum A, et al. Antibiotic prophylaxis for the prevention of infective endocarditis for dental procedures is not associated with fatal adverse drug reactions in France. *Med Oral Patol Oral Cir Bucal* 2019;**24**:e296–e304. <https://doi.org/10.4317/medoral.22818>
64. Gross AE, Suda KJ, Zhou J, Calip GS, Rowan SA, Hershov RC, et al. Serious antibiotic-related adverse effects following unnecessary dental prophylaxis in the United States. *Infect Control Hosp Epidemiol* 2021;**42**:110–112. <https://doi.org/10.1017/ice.2020.1261>
65. Khalil D, Hultin M, Rashid MU, Lund B. Oral microflora and selection of resistance after a single dose of amoxicillin. *Clin Microbiol Infect* 2016;**22**:949.e1–949.e4. <https://doi.org/10.1016/j.cmi.2016.08.008>
66. Woodman AJ, Vidic J, Newman HN, Marsh PD. Effect of repeated high dose prophylaxis with amoxicillin on the resident oral flora of adult volunteers. *J Med Microbiol* 1985;**19**:15–23. <https://doi.org/10.1099/00222615-19-1-15>
67. Habib G, Hoen B, Tornos P, Thuny F, Prendergast B, Vilacosta I, et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the prevention, diagnosis, and treatment of infective endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for infection and cancer. *Eur Heart J* 2009;**30**:2369–2413. <https://doi.org/10.1093/eurheartj/ehp285>
68. Bates KE, Hall M, Shah SS, Hill KD, Pasquali SK. Trends in infective endocarditis hospitalizations at United States children's hospitals from 2003 to 2014: impact of the 2007 American Heart Association antibiotic prophylaxis guidelines. *Cardiol Young* 2017;**27**:686–690. <https://doi.org/10.1017/S1047951116001086>
69. Bikdeli B, Wang Y, Kim N, Desai MM, Quagliarello V, Krumholz HM. Trends in hospitalization rates and outcomes of endocarditis among medicare beneficiaries. *J Am Coll Cardiol* 2013;**62**:2217–2226. <https://doi.org/10.1016/j.jacc.2013.07.071>
70. DeSimone DC, Tleyjeh IM, Correa de Sa DD, Anavekar NS, Lahr BD, Sohail MR, et al. Temporal trends in infective endocarditis epidemiology from 2007 to 2013 in Olmsted County, MN. *Am Heart J* 2015;**170**:830–836. <https://doi.org/10.1016/j.ahj.2015.07.007>
71. Desimone DC, Tleyjeh IM, Correa de Sa DD, Anavekar NS, Lahr BD, Sohail MR, et al. Incidence of infective endocarditis caused by viridans group streptococci before and after publication of the 2007 American Heart Association's endocarditis prevention guidelines. *Circulation* 2012;**126**:60–64. <https://doi.org/10.1161/CIRCULATIONAHA.112.095281>
72. Duval X, Delahaye F, Alla F, Tattevin P, Obadia JF, Le Moing V, et al. Temporal trends in infective endocarditis in the context of prophylaxis guideline modifications: three successive population-based surveys. *J Am Coll Cardiol* 2012;**59**:1968–1976. <https://doi.org/10.1016/j.jacc.2012.02.029>
73. Garg P, Ko DT, Bray Jenkyn KM, Li L, Shariff SZ. Infective endocarditis hospitalizations and antibiotic prophylaxis rates before and after the 2007 American Heart Association guideline revision. *Circulation* 2019;**140**:170–180. <https://doi.org/10.1161/CIRCULATIONAHA.118.037657>
74. Mackie AS, Liu W, Savu A, Marelli AJ, Kaul P. Infective endocarditis hospitalizations before and after the 2007 American Heart Association prophylaxis guidelines. *Can J Cardiol* 2016;**32**:942–948. <https://doi.org/10.1016/j.cjca.2015.09.021>
75. Pasquali SK, He X, Mohamad Z, McCrindle BW, Newburger JW, Li JS, et al. Trends in endocarditis hospitalizations at US children's hospitals: impact of the 2007 American Heart Association antibiotic prophylaxis guidelines. *Am Heart J* 2012;**163**:894–899. <https://doi.org/10.1016/j.ahj.2012.03.002>
76. Rogers AM, Schiller NB. Impact of the first nine months of revised infective endocarditis prophylaxis guidelines at a university hospital: so far so good. *J Am Soc Echocardiogr* 2008;**21**:775. <https://doi.org/10.1016/j.jecho.2008.04.001>
77. Thornhill MH, Dayer MJ, Forde JM, Corey GR, Chu VH, Couper DJ, et al. Impact of the NICE guideline recommending cessation of antibiotic prophylaxis for prevention of infective endocarditis: before and after study. *BMJ* 2011;**342**:d2392. <https://doi.org/10.1136/bmj.d2392>
78. Pant S, Patel NJ, Deshmukh A, Golwala H, Patel N, Badheka A, et al. Trends in infective endocarditis incidence, microbiology, and valve replacement in the United States from 2000 to 2011. *J Am Coll Cardiol* 2015;**65**:2070–2076. <https://doi.org/10.1016/j.jacc.2015.03.518>
79. Sakai Bizmark R, Chang RR, Tsugawa Y, Zangwill KM, Kawachi I. Impact of AHA's 2007 guideline change on incidence of infective endocarditis in infants and children. *Am Heart J* 2017;**189**:110–119. <https://doi.org/10.1016/j.ahj.2017.04.006>
80. Toyoda N, Chikwe J, Itagaki S, Gelinis AC, Adams DH, Egorova NN. Trends in infective endocarditis in California and New York State, 1998–2013. *JAMA* 2017;**317**:1652–1660. <https://doi.org/10.1001/jama.2017.4287>
81. van den Brink FS, Swaans MJ, Hoogendijk MG, Alipour A, Kelder JC, Jaarsma W, et al. Increased incidence of infective endocarditis after the 2009 European Society of Cardiology guideline update: a nationwide study in the Netherlands. *Eur Heart J Qual Care Clin Outcomes* 2017;**3**:141–147. <https://doi.org/10.1093/ehjqcco/qcw039>
82. Talha KM, Baddour LM, Thornhill MH, Arshad V, Tariq W, Tleyjeh IM, et al. Escalating incidence of infective endocarditis in Europe in the 21st century. *Open Heart* 2021;**8**:e001846. <https://doi.org/10.1136/openhrt-2021-001846>
83. Wilson WR, Gewitz M, Lockhart PB, Bolger AF, DeSimone DC, Kazi DS, et al. Prevention of viridans group streptococcal infective endocarditis: a scientific statement from the American Heart Association. *Circulation* 2021;**143**:e963–e978. <https://doi.org/10.1161/CIR.0000000000000969>
84. Havers-Borgersen E, Butt JH, Ostergaard L, Bundgaard H, Smerup M, Bruun NE, et al. Recurrent infective endocarditis versus first-time infective endocarditis after heart valve surgery. *Clin Res Cardiol* 2020;**109**:1342–1351. <https://doi.org/10.1007/s00392-020-01628-7>
85. Calderon-Parra J, Kestler M, Ramos-Martinez A, Bouza E, Valerio M, de Alarcon A, et al. Clinical factors associated with reinfection versus relapse in infective endocarditis: prospective cohort study. *J Clin Med* 2021;**10**:748. <https://doi.org/10.3390/jcm10040748>
86. Freitas-Ferraz AB, Tirado-Conte G, Vilacosta I, Olmos C, Saez C, Lopez J, et al. Contemporary epidemiology and outcomes in recurrent infective endocarditis. *Heart* 2020;**106**:596–602. <https://doi.org/10.1136/heartjnl-2019-315433>
87. Salem M, Friedrich C, Saad M, Frank D, Salem M, Puehler T, et al. Active infective native and prosthetic valve endocarditis: short- and long-term outcomes of patients after surgical treatment. *J Clin Med* 2021;**10**:1868. <https://doi.org/10.3390/jcm10091868>
88. Luehr M, Bauernschmitt N, Peterss S, Li Y, Heyn O, Dashkevich A, et al. Incidence and surgical outcomes of patients with native and prosthetic aortic valve endocarditis. *Ann Thorac Surg* 2020;**110**:93–101. <https://doi.org/10.1016/j.athoracsur.2019.10.029>
89. Anantha-Narayanan M, Reddy YNV, Sundaram V, Murad MH, Erwin PJ, Baddour LM, et al. Endocarditis risk with bioprosthetic and mechanical valves: systematic review and meta-analysis. *Heart* 2020;**106**:1413–1419. <https://doi.org/10.1136/heartjnl-2020-316718>
90. Ostergaard L, Valeur N, Ihlemann N, Smerup MH, Bundgaard H, Gislason G, et al. Incidence and factors associated with infective endocarditis in patients undergoing left-sided heart valve replacement. *Eur Heart J* 2018;**39**:2668–2675. <https://doi.org/10.1093/eurheartj/ehy153>

91. Alexis SL, Malik AH, George I, Hahn RT, Khaliq OK, Seetharam K, et al. Infective endocarditis after surgical and transcatheter aortic valve replacement: a state of the art review. *J Am Heart Assoc* 2020;**9**:e017347. <https://doi.org/10.1161/JAHA.120.017347>
92. Lehner A, Haas NA, Dietl M, Jakob A, Schulze-Neick I, Dalla Pozza R, et al. The risk of infective endocarditis following interventional pulmonary valve implantation: a meta-analysis. *J Cardiol* 2019;**74**:197–205. <https://doi.org/10.1016/j.jicc.2019.04.007>
93. McElhinney DB, Sondergaard L, Armstrong AK, Bergersen L, Padera RF, Balzer DT, et al. Endocarditis after transcatheter pulmonary valve replacement. *J Am Coll Cardiol* 2018;**72**:2717–2728. <https://doi.org/10.1016/j.jacc.2018.09.039>
94. Summers MR, Leon MB, Smith CR, Kodali SK, Thourani VH, Herrmann HC, et al. Prosthetic valve endocarditis after TAVR and SAVR: insights from the PARTNER trials. *Circulation* 2019;**140**:1984–1994. <https://doi.org/10.1161/CIRCULATIONAHA.119.041399>
95. Asmarats L, Rodriguez-Gabella T, Chamandi C, Bernier M, Beaudoin J, O'Connor K, et al. Infective endocarditis following transcatheter edge-to-edge mitral valve repair: a systematic review. *Catheter Cardiovasc Interv* 2018;**92**:583–591. <https://doi.org/10.1002/ccd.27632>
96. Diller GP, Baumgartner H. Endocarditis in adults with congenital heart disease: new answers—new questions. *Eur Heart J* 2017;**38**:2057–2059. <https://doi.org/10.1093/eurheartj/ehx044>
97. Ly R, Compain F, Gaye B, Pontnau F, Bouchard M, Mainardi JL, et al. Predictive factors of death associated with infective endocarditis in adult patients with congenital heart disease. *Eur Heart J Acute Cardiovasc Care* 2020. <https://doi.org/10.1177/2048872620901394>
98. Snygg-Martin U, Giang KW, Dellborg M, Robertson J, Mandalenakis Z. Cumulative incidence of infective endocarditis in patients with congenital heart disease: a nationwide, case-control study over nine decades. *Clin Infect Dis* 2021;**73**:1469–1475. <https://doi.org/10.1093/cid/ciab478>
99. Mylotte D, Rushani D, Therrien J, Guo L, Liu A, Guo K, et al. Incidence, predictors, and mortality of infective endocarditis in adults with congenital heart disease without prosthetic valves. *Am J Cardiol* 2017;**120**:2278–2283. <https://doi.org/10.1016/j.amjcard.2017.08.051>
100. Mandalenakis Z, Rosengren A, Skoglund K, Lappas G, Eriksson P, Dellborg M. Survivorship in children and young adults with congenital heart disease in Sweden. *JAMA Intern Med* 2017;**177**:224–230. <https://doi.org/10.1001/jamainternmed.2016.7765>
101. Rushani D, Kaufman JS, Ionescu-Iltu R, Mackie AS, Pilote L, Therrien J, et al. Infective endocarditis in children with congenital heart disease: cumulative incidence and predictors. *Circulation* 2013;**128**:1412–1419. <https://doi.org/10.1161/CIRCULATIONAHA.113.001827>
102. Patel S, Rizvi SSA, Choi JH, Horan DP, Weber MP, Maynes EJ, et al. Management and outcomes of left ventricular assist device-associated endocarditis: a systematic review. *Ann Cardiothorac Surg* 2019;**8**:600–609. <https://doi.org/10.21037/acs.2019.04.04>
103. Ostergaard L, Valeur N, Wang A, Bundgaard H, Aslam M, Gislason G, et al. Incidence of infective endocarditis in patients considered at moderate risk. *Eur Heart J* 2019;**40**:1355–1361. <https://doi.org/10.1093/eurheartj/ehy629>
104. Russell EA, Walsh WF, Costello B, McLellan AJA, Brown A, Reid CM, et al. Medical management of rheumatic heart disease: a systematic review of the evidence. *Cardiol Rev* 2018;**26**:187–195. <https://doi.org/10.1097/CRD.0000000000000185>
105. Jordan AM, Tatum R, Ahmad D, Patel SV, Maynes EJ, Weber MP, et al. Infective endocarditis following heart transplantation: a systematic review. *Transplant Rev (Orlando)* 2021;**36**:100672. <https://doi.org/10.1016/j.trre.2021.100672>
106. Chuang S, Shrestha NK, Brizendine KD. Matched retrospective study of infective endocarditis among solid organ transplant recipients compared to non-transplant: seven-year experience in a US referral center. *Transpl Infect Dis* 2020;**22**:e13368. <https://doi.org/10.1111/tid.13368>
107. Martinez-Selles M, Valerio-Minero M, Farinas MC, Rodriguez-Abella H, Rodriguez ML, de Alarcon A, et al. Infective endocarditis in patients with solid organ transplantation. A nationwide descriptive study. *Eur J Intern Med* 2021;**87**:59–65. <https://doi.org/10.1016/j.ejim.2021.02.017>
108. Duval X, Alla F, Hoen B, Danielou F, Larrieu S, Delahaye F, et al. Estimated risk of endocarditis in adults with predisposing cardiac conditions undergoing dental procedures with or without antibiotic prophylaxis. *Clin Infect Dis* 2006;**42**:e102–e107. <https://doi.org/10.1086/504385>
109. Findler M, Chackartchi T, Regev E. Dental implants in patients at high risk for infective endocarditis: a preliminary study. *Int J Oral Maxillofac Surg* 2014;**43**:1282–1285. <https://doi.org/10.1016/j.ijom.2014.04.015>
110. Thornhill MH, Dayer M, Lockhart PB, Prendergast B. Antibiotic prophylaxis of infective endocarditis. *Curr Infect Dis Rep* 2017;**19**:9. <https://doi.org/10.1007/s11908-017-0564-y>
111. Thornhill MH, Dayer MJ, Durkin MJ, Lockhart PB, Baddour LM. Risk of adverse reactions to oral antibiotics prescribed by dentists. *J Dent Res* 2019;**98**:1081–1087. <https://doi.org/10.1177/0022034519863645>
112. Thornhill MH, Dayer MJ, Prendergast B, Baddour LM, Jones S, Lockhart PB. Incidence and nature of adverse reactions to antibiotics used as endocarditis prophylaxis. *J Antimicrob Chemother* 2015;**70**:2382–2388. <https://doi.org/10.1093/jac/dkv115>
113. Verhoeven PO, Gagnaire J, Botelho-Nevers E, Grattard F, Carricajo A, Lucht F, et al. Detection and clinical relevance of *Staphylococcus aureus* nasal carriage: an update. *Expert Rev Anti Infect Ther* 2014;**12**:75–89. <https://doi.org/10.1586/14787210.2014.859985>
114. Bode LG, Kluytmans JA, Wertheim HF, Bogaers D, Vandenbroucke-Grauls CM, Roosendaal R, et al. Preventing surgical-site infections in nasal carriers of *Staphylococcus aureus*. *N Engl J Med* 2010;**362**:9–17. <https://doi.org/10.1056/NEJMoa0808939>
115. Friedman AJ, Cosby R, Boyko S, Hatton-Bauer J, Turnbull G. Effective teaching strategies and methods of delivery for patient education: a systematic review and practice guideline recommendations. *J Cancer Educ* 2011;**26**:12–21. <https://doi.org/10.1007/s13187-010-0183-x>
116. de Oliveira JC, Martinelli M, Nishioka SA, Varejao T, Uipe D, Pedrosa AA, et al. Efficacy of antibiotic prophylaxis before the implantation of pacemakers and cardioverter-defibrillators: results of a large, prospective, randomized, double-blinded, placebo-controlled trial. *Circ Arrhythm Electrophysiol* 2009;**2**:29–34. <https://doi.org/10.1161/CIRCEP.108.795906>
117. Mounsey JP, Griffith MJ, Tynan M, Gould FK, MacDermott AF, Gold RG, et al. Antibiotic prophylaxis in permanent pacemaker implantation: a prospective randomised trial. *Br Heart J* 1994;**72**:339–343. <https://doi.org/10.1136/hrt.72.4.339>
118. Polyzos KA, Konstantelias AA, Falagas ME. Risk factors for cardiac implantable electronic device infection: a systematic review and meta-analysis. *Europace* 2015;**17**:767–777. <https://doi.org/10.1093/eurpace/euv053>
119. Darouiche RO, Wall MJ Jr, Itani KM, Otterson MF, Webb AL, Carrick MM, et al. Chlorhexidine-alcohol versus povidone-iodine for surgical-site antisepsis. *N Engl J Med* 2010;**362**:18–26. <https://doi.org/10.1056/NEJMoa0810988>
120. Lador A, Nasir H, Mansur N, Sharoni E, Biderman P, Leibovici L, et al. Antibiotic prophylaxis in cardiac surgery: systematic review and meta-analysis. *J Antimicrob Chemother* 2012;**67**:541–550. <https://doi.org/10.1093/jac/dkr470>
121. Conen A, Stortecky S, Moreillon P, Hannan MM, Franzeck FC, Jeger R, et al. A review of recommendations for infective endocarditis prevention in patients undergoing transcatheter aortic valve implantation. *EuroIntervention* 2021;**16**:1135–1140. <https://doi.org/10.4244/EIJ-D-19-00993>
122. Botelho-Nevers E, Thuny F, Casalta JP, Richez H, Gouriet F, Collart F, et al. Dramatic reduction in infective endocarditis-related mortality with a management-based approach. *Arch Intern Med* 2009;**169**:1290–1298. <https://doi.org/10.1001/archinternmed.2009.192>
123. Carrasco-Chinchilla F, Sanchez-Espin G, Ruiz-Morales J, Rodriguez-Bailon I, Melero-Tejedor JM, Ivanova-Georgieva R, et al. Influence of a multidisciplinary alert strategy on mortality due to left-sided infective endocarditis. *Rev Esp Cardiol (Engl Ed)* 2014;**67**:380–386. <https://doi.org/10.1016/j.recsep.2013.09.012>
124. Cervera C, del Rio A, Garcia L, Sala M, Almela M, Moreno A, et al. Efficacy and safety of outpatient parenteral antibiotic therapy for infective endocarditis: a ten-year prospective study. *Enferm Infecc Microbiol Clin* 2011;**29**:587–592. <https://doi.org/10.1016/j.eimc.2011.05.007>
125. Chirillo F, Scotton P, Rocco F, Rigoli R, Borsatto F, Pedrocco A, et al. Impact of a multidisciplinary management strategy on the outcome of patients with native valve infective endocarditis. *Am J Cardiol* 2013;**112**:1171–1176. <https://doi.org/10.1016/j.amjcard.2013.05.060>
126. Okura T, Iwata K, Koyama T, Ebisawa K, Arakawa Y, Kusuki M, et al. Impact of infectious disease consultation on management and outcomes of infective endocarditis. *Ann Thorac Surg* 2021;**112**:1228–1234. <https://doi.org/10.1016/j.athoracsurg.2020.09.044>
127. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation* 2021;**143**:e72–e227. <https://doi.org/10.1161/CIR.0000000000000923>
128. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. *Eur Heart J* 2022;**43**:561–632. <https://doi.org/10.1093/eurheartj/ehab395>
129. Wang TKM, Sanchez-Nadales A, Igbinomwanhia E, Cremer P, Griffin B, Xu B. Diagnosis of infective endocarditis by subtype using (18)F-fluorodeoxyglucose positron emission tomography/computed tomography: a contemporary meta-analysis. *Circ Cardiovasc Imaging* 2020;**13**:e010600. <https://doi.org/10.1161/CIRCIMAGING.120.010600>
130. Blomstrom-Lundqvist C, Traykov V, Erba PA, Burri H, Nielsen JC, Bongiorno MG, et al. European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections—endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCID) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the

- European Association for Cardio-Thoracic Surgery (EACTS). *Eurpace* 2020;**22**: 515–549. <https://doi.org/10.1093/eurpace/euz246>
131. Tagliari AP, Steckert GV, da Silveira LMV, Kochi AN, Wender OCB. Infective endocarditis profile, prognostic factors and in-hospital mortality: 6-year trends from a tertiary university center in South America. *J Card Surg* 2020;**35**:1905–1911. <https://doi.org/10.1111/jocs.14787>
  132. Schranz AJ, Fleischauer A, Chu VH, Wu LT, Rosen DL. Trends in drug use-associated infective endocarditis and heart valve surgery, 2007 to 2017: a study of statewide discharge data. *Ann Intern Med* 2019;**170**:31–40. <https://doi.org/10.7326/M18-2124>
  133. Rudasill SE, Sanaiha Y, Mardock AL, Khoury H, Xing H, Antonios JW, et al. Clinical outcomes of infective endocarditis in injection drug users. *J Am Coll Cardiol* 2019;**73**: 559–570. <https://doi.org/10.1016/j.jacc.2018.10.082>
  134. Mori M, Brown KJ, Bin Mahmood SU, Geirsson A, Mangi AA. Trends in infective endocarditis hospitalizations, characteristics, and valve operations in patients with opioid use disorders in the United States: 2005–2014. *J Am Heart Assoc* 2020;**9**:e012465. <https://doi.org/10.1161/JAHA.119.012465>
  135. Geirsson A, Schranz A, Jawitz O, Mori M, Feng L, Zwischenberger BA, et al. The evolving burden of drug use associated infective endocarditis in the United States. *Ann Thorac Surg* 2020;**110**:1185–1192. <https://doi.org/10.1016/j.athoracsur.2020.03.089>
  136. Mestres CA, Pare JC, Miro JM; Working Group on Infective Endocarditis of the Hospital Clínic de Barcelona. Organization and functioning of a multidisciplinary team for the diagnosis and treatment of infective endocarditis: a 30-year perspective (1985–2014). *Rev Esp Cardiol (Engl Ed)* 2015;**68**:363–368. <https://doi.org/10.1016/j.recsep.2014.10.007>
  137. Erba PA, Lancellotti P, Vilacosta I, Gaemperli O, Rouzet F, Hacker M, et al. Recommendations on nuclear and multimodality imaging in IE and CIED infections. *Eur J Nucl Med Mol Imaging* 2018;**45**:1795–1815. <https://doi.org/10.1007/s00259-018-4025-0>
  138. Schwiebert R, Baig W, Wu J, Sandoe JAT. Diagnostic accuracy of splinter haemorrhages in patients referred for suspected infective endocarditis. *Heart* 2022. <https://doi.org/10.1136/heartjnl-2022-321052>
  139. Grable C, Yusuf SW, Song J, Viola GM, Ulhaq O, Banchs J, et al. Characteristics of infective endocarditis in a cancer population. *Open Heart* 2021;**8**:e001664. <https://doi.org/10.1136/openhrt-2021-001664>
  140. Perez de Isla L, Zamorano J, Lennie V, Vazquez J, Ribera JM, Macaya C. Negative blood culture infective endocarditis in the elderly: long-term follow-up. *Gerontology* 2007;**53**: 245–249. <https://doi.org/10.1159/000101691>
  141. Wong CY, Zhu W, Aurigemma GP, Furukawa N, Teshale EH, Huang YA, et al. Infective endocarditis among persons aged 18–64 years living with human immunodeficiency virus, hepatitis C infection, or opioid use disorder, United States, 2007–2017. *Clin Infect Dis* 2021;**72**:1767–1781. <https://doi.org/10.1093/cid/ciaa372>
  142. N'Guyen Y, Duval X, Revest M, Saada M, Erpelding ML, Selton-Suty C, et al. Time interval between infective endocarditis first symptoms and diagnosis: relationship to infective endocarditis characteristics, microorganisms and prognosis. *Ann Med* 2017;**49**: 117–125. <https://doi.org/10.1080/07853890.2016.1235282>
  143. Niederman MS, Baron RM, Bouadma L, Calandra T, Daneman N, DeWaele J, et al. Initial antimicrobial management of sepsis. *Crit Care* 2021;**25**:307. <https://doi.org/10.1186/s13054-021-03736-w>
  144. Snipsoy MG, Ludvigsen M, Petersen E, Wiggers H, Honore B. A systematic review of biomarkers in the diagnosis of infective endocarditis. *Int J Cardiol* 2016;**202**:564–570. <https://doi.org/10.1016/j.ijcard.2015.09.028>
  145. Murdoch DR, Corey GR, Hoen B, Miro JM, Fowler VG Jr, Bayer AS, et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis–prospective cohort study. *Arch Intern Med* 2009;**169**:463–473. <https://doi.org/10.1001/archinternmed.2008.603>
  146. Amat-Santos IJ, Messika-Zeitoun D, Eltchaninoff H, Kapadia S, Lerakis S, Cheema AN, et al. Infective endocarditis after transcatheter aortic valve implantation: results from a large multicenter registry. *Circulation* 2015;**131**:1566–1574. <https://doi.org/10.1161/CIRCULATIONAHA.114.014089>
  147. Olmos C, Vilacosta I, Fernandez C, Lopez J, Sarría C, Ferrera C, et al. Contemporary epidemiology and prognosis of septic shock in infective endocarditis. *Eur Heart J* 2013;**34**:1999–2006. <https://doi.org/10.1093/eurheartj/ehs336>
  148. Escola-Verge L, Fernandez-Hidalgo N, Larrosa MN, Fernandez-Galera R, Almirante B. Secular trends in the epidemiology and clinical characteristics of *Enterococcus faecalis* infective endocarditis at a referral center (2007–2018). *Eur J Clin Microbiol Infect Dis* 2021;**40**:1137–1148. <https://doi.org/10.1007/s10096-020-04117-x>
  149. Dahl A, Iversen K, Tonder N, Hoest N, Arpi M, Dalsgaard M, et al. Prevalence of infective endocarditis in *Enterococcus faecalis* bacteremia. *J Am Coll Cardiol* 2019;**74**: 193–201. <https://doi.org/10.1016/j.jacc.2019.04.059>
  150. Lamy B, Dargere S, Arendrup MC, Parienti JJ, Tattavin P. How to optimize the use of blood cultures for the diagnosis of bloodstream infections? A state-of-the-art. *Front Microbiol* 2016;**7**:697. <https://doi.org/10.3389/fmicb.2016.00697>
  151. Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG Jr, Ryan T, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. *Clin Infect Dis* 2000;**30**: 633–638. <https://doi.org/10.1086/313753>
  152. La Scola B, Raoult D. Direct identification of bacteria in positive blood culture bottles by matrix-assisted laser desorption ionisation time-of-flight mass spectrometry. *PLoS One* 2009;**4**:e8041. <https://doi.org/10.1371/journal.pone.0008041>
  153. Burckhardt I, Zimmermann S. Susceptibility testing of bacteria using MALDI-ToF mass spectrometry. *Front Microbiol* 2018;**9**:1744. <https://doi.org/10.3389/fmicb.2018.01744>
  154. Pecoraro AJK, Herbst PG, Pienaar C, Taljaard J, Prozesky H, Janson J, et al. Modified Duke/European Society of Cardiology 2015 clinical criteria for infective endocarditis: time for an update? *Open Heart* 2022;**9**:e001856. <https://doi.org/10.1136/openhrt-2021-001856>
  155. Kong WKF, Salsano A, Giacobbe DR, Popescu BA, Laroche C, Duval X, et al. Outcomes of culture-negative vs. culture-positive infective endocarditis: the ESC-EORP EURO-ENDO registry. *Eur Heart J* 2022;**43**:2770–2780. <https://doi.org/10.1093/eurheartj/ehac307>
  156. Fournier PE, Gouriet F, Casalta JP, Lepidi H, Chaudet H, Thuny F, et al. Blood culture-negative endocarditis: improving the diagnostic yield using new diagnostic tools. *Medicine (Baltimore)* 2017;**96**:e8392. <https://doi.org/10.1097/MD.00000000000008392>
  157. Gouriet F, Samson L, Delaage M, Mainardi JL, Meconi S, Drancourt M, et al. Multiplexed whole bacterial antigen microarray, a new format for the automation of serodiagnosis: the culture-negative endocarditis paradigm. *Clin Microbiol Infect* 2008;**14**:1112–1118. <https://doi.org/10.1111/j.1469-0691.2008.02094.x>
  158. Raoult D, Casalta JP, Richet H, Khan M, Bernit E, Rovey C, et al. Contribution of systematic serological testing in diagnosis of infective endocarditis. *J Clin Microbiol* 2005;**43**:5238–5242. <https://doi.org/10.1128/JCM.43.10.5238-5242.2005>
  159. Hajduczenia MM, Klefisch FR, Hopf AGM, Grubitzsch H, Stegemann MS, Pfafflin F, et al. New perspectives for prosthetic valve endocarditis – impact of molecular imaging by fishseq diagnostics. *Clin Infect Dis* 2023;**76**:1050–1058. <https://doi.org/10.1093/cid/ciac860>
  160. Liesman RM, Pritt BS, Maleszewski JJ, Patel R. Laboratory diagnosis of infective endocarditis. *J Clin Microbiol* 2017;**55**:2599–2608. <https://doi.org/10.1128/JCM.00635-17>
  161. Loyens M, Thuny F, Grisoli D, Fournier PE, Casalta J-P, Vitte J, et al. Link between endocarditis on porcine bioprosthetic valves and allergy to pork. *Int J Cardiol* 2013;**167**: 600–602. <https://doi.org/10.1016/j.ijcard.2012.09.233>
  162. Selton-Suty C, Maigrat CH, Devignes J, Goehringer F, Erpelding ML, Alla F, et al. Possible relationship between antiphospholipid antibodies and embolic events in infective endocarditis. *Heart* 2018;**104**:509–516. <https://doi.org/10.1136/heartjnl-2017-312359>
  163. Habib G, Badano L, Tribouilloy C, Vilacosta I, Zamorano JL, Galderisi M, et al. Recommendations for the practice of echocardiography in infective endocarditis. *Eur J Echocardiogr* 2010;**11**:202–219. <https://doi.org/10.1093/ejchocard/jeq004>
  164. Erba PA, Pizzi MN, Roque A, Salauñ E, Lancellotti P, Tornos P, et al. Multimodality imaging in infective endocarditis: an imaging team within the endocarditis team. *Circulation* 2019;**140**:1753–1765. <https://doi.org/10.1161/CIRCULATIONAHA.119.040228>
  165. Ostergaard L, Vejstrup N, Kober L, Fosbol EL, Sondergaard L, Ihlemann N. Diagnostic potential of intracardiac echocardiography in patients with suspected prosthetic valve endocarditis. *J Am Soc Echocardiogr* 2019;**32**:1558–1564.e3. <https://doi.org/10.1016/j.echo.2019.06.016>
  166. Bai AD, Steinberg M, Showler A, Burry L, Bhatia RS, Tomlinson GA, et al. Diagnostic accuracy of transthoracic echocardiography for infective endocarditis findings using transesophageal echocardiography as the reference standard: a meta-analysis. *J Am Soc Echocardiogr* 2017;**30**:639–646.e8. <https://doi.org/10.1016/j.echo.2017.03.007>
  167. Chambers J, Sandoe J, Ray S, Prendergast B, Taggart D, Westaby S, et al. The infective endocarditis team: recommendations from an international working group. *Heart* 2014;**100**:524–527. <https://doi.org/10.1136/heartjnl-2013-304354>
  168. Jain V, Wang TKM, Bansal A, Farwati M, Gad M, Montane B, et al. Diagnostic performance of cardiac computed tomography versus transesophageal echocardiography in infective endocarditis: a contemporary comparative meta-analysis. *J Cardiovasc Comput Tomogr* 2021;**15**:313–321. <https://doi.org/10.1016/j.jcct.2020.11.008>
  169. Oliveira M, Guittet L, Hamon M, Hamon M. Comparative value of cardiac CT and transesophageal echocardiography in infective endocarditis: a systematic review and meta-analysis. *Radiol Cardiothorac Imaging* 2020;**2**:e190189. <https://doi.org/10.1148/ryct.2020190189>
  170. Palraj BR, Baddour LM, Hess EP, Steckelberg JM, Wilson WR, Lahr BD, et al. Predicting Risk of Endocarditis Using a Clinical Tool (PREDICT): scoring system to guide use of echocardiography in the management of *Staphylococcus aureus* bacteremia. *Clin Infect Dis* 2015;**61**:18–28. <https://doi.org/10.1093/cid/civ235>
  171. Sunnerhagen T, Tornell A, Vikbrant M, Nilson B, Rasmussen M. HANDOC: a handy score to determine the need for echocardiography in non-beta-hemolytic streptococcal bacteremia. *Clin Infect Dis* 2018;**66**:693–698. <https://doi.org/10.1093/cid/cix880>
  172. Berge A, Krantz A, Ostlund H, Naucner P, Rasmussen M. The DENOVA score efficiently identifies patients with monomicrobial *Enterococcus faecalis* bacteremia where echocardiography is not necessary. *Infection* 2019;**47**:45–50. <https://doi.org/10.1007/s15010-018-1208-3>
  173. Bouza E, Kestler M, Beca T, Mariscal G, Rodriguez-Creixems M, Bermejo J, et al. The NOVA score: a proposal to reduce the need for transesophageal echocardiography in patients with enterococcal bacteremia. *Clin Infect Dis* 2015;**60**:528–535. <https://doi.org/10.1093/cid/ciu872>

174. Rasmussen RV, Host U, Arpi M, Hassager C, Johansen HK, Korup E, et al. Prevalence of infective endocarditis in patients with *Staphylococcus aureus* bacteraemia: the value of screening with echocardiography. *Eur J Echocardiogr* 2011;**12**:414–420. <https://doi.org/10.1093/ejehocard/jer023>
175. van der Vaart TW, Prins JM, Soetekouw R, van Twillert G, Veenstra J, Herpers BL, et al. Prediction rules for ruling out endocarditis in patients with *Staphylococcus aureus* bacteremia. *Clin Infect Dis* 2022;**74**:1442–1449. <https://doi.org/10.1093/cid/ciab632>
176. Showler A, Burry L, Bai AD, Steinberg M, Ricciuto DR, Fernandes T, et al. Use of trans-thoracic echocardiography in the management of low-risk *Staphylococcus aureus* bacteremia: results from a retrospective multicenter cohort study. *JACC Cardiovasc Imaging* 2015;**8**:924–931. <https://doi.org/10.1016/j.jcmg.2015.02.027>
177. Peinado-Acevedo JS, Hurtado-Guerra JJ, Hincapie C, Mesa-Abad J, Uribe-Delgado JR, Giraldo-Ramirez S, et al. Validation of VIRSTA and Predicting Risk of Endocarditis Using a Clinical Tool (PREDICT) scores to determine the priority of echocardiography in patients with *Staphylococcus aureus* bacteremia. *Clin Infect Dis* 2021;**73**:e1151–e1157. <https://doi.org/10.1093/cid/ciaa1844>
178. Chamat-Hedemand S, Bruun NE, Ostergaard L, Arpi M, Fosbol E, Boel J, et al. Proposal for the use of echocardiography in bloodstream infections due to different streptococcal species. *BMC Infect Dis* 2021;**21**:689. <https://doi.org/10.1186/s12879-021-06391-2>
179. Young WJ, Jeffery DA, Hua A, Primus C, Serafino Wani R, Das S, et al. Echocardiography in patients with infective endocarditis and the impact of diagnostic delays on clinical outcomes. *Am J Cardiol* 2018;**122**:650–655. <https://doi.org/10.1016/j.amjcard.2018.04.039>
180. Iversen K, Host N, Bruun NE, Elming H, Pump B, Christensen JJ, et al. Partial oral treatment of endocarditis. *Am Heart J* 2013;**165**:116–122. <https://doi.org/10.1016/j.ahj.2012.11.006>
181. MacKay EJ, Zhang B, Augoustides JG, Groeneveld PW, Desai ND. Association of intraoperative transesophageal echocardiography and clinical outcomes after open cardiac valve or proximal aortic surgery. *JAMA Netw Open* 2022;**5**:e2147820. <https://doi.org/10.1001/jamanetworkopen.2021.47820>
182. Gonzalez-Juanatey C, Gonzalez-Gay MA, Llorca J, Crespo F, Garcia-Porrúa C, Corredoira J, et al. Rheumatic manifestations of infective endocarditis in non-addicts. A 12-year study. *Medicine (Baltimore)* 2001;**80**:9–19. <https://doi.org/10.1097/00005792-200101000-00002>
183. Vallejo Camazon N, Cediél G, Nunez Aragon R, Mateu L, Llibre C, Sopena N, et al. Short- and long-term mortality in patients with left-sided infective endocarditis not undergoing surgery despite indication. *Rev Esp Cardiol (Engl Ed)* 2020;**73**:734–740. <https://doi.org/10.1016/j.rec.2019.09.011>
184. Vallejo Camazon N, Mateu L, Cediél G, Escola-Verge L, Fernandez-Hidalgo N, Gurgui Ferrer M, et al. Long-term antibiotic therapy in patients with surgery-indicated not undergoing surgery infective endocarditis. *Cardiol J* 2021;**28**:566–578. <https://doi.org/10.5603/CJ.a2021.0054>
185. Chaosuwannakit N, Makarawate P. Value of cardiac computed tomography angiography in pre-operative assessment of infective endocarditis. *J Cardiothorac Surg* 2019;**14**:56. <https://doi.org/10.1186/s13019-019-0880-4>
186. Fagman E, Flinck A, Snygg-Martin U, Olaison L, Bech-Hanssen O, Svensson G. Surgical decision-making in aortic prosthetic valve endocarditis: the influence of electrocardiogram-gated computed tomography. *Eur J Cardiothorac Surg* 2016;**50**:1165–1171. <https://doi.org/10.1093/ejcts/ezw177>
187. Abbara S, Blanke P, Maroules CD, Cheezum M, Choi AD, Han BK, et al. SCCT guidelines for the performance and acquisition of coronary computed tomographic angiography: a report of the Society of Cardiovascular Computed Tomography Guidelines Committee: endorsed by the North American Society for Cardiovascular Imaging (NASCI). *J Cardiovasc Comput Tomogr* 2016;**10**:435–449. <https://doi.org/10.1016/j.jcct.2016.10.002>
188. Parra JA, Hernandez L, Munoz P, Blanco G, Rodriguez-Alvarez R, Vilar DR, et al. Detection of spleen, kidney and liver infarcts by abdominal computed tomography does not affect the outcome in patients with left-side infective endocarditis. *Medicine (Baltimore)* 2018;**97**:e11952. <https://doi.org/10.1097/MD.00000000000011952>
189. Huang JS, Ho AS, Ahmed A, Bhalla S, Menias CO. Borne identity: CT imaging of vascular infections. *Emerg Radiol* 2011;**18**:335–343. <https://doi.org/10.1007/s10140-011-0946-7>
190. Tonolini M, Petulla M, Bianco R. Mycotic visceral aneurysm complicating infectious endocarditis: imaging diagnosis and follow-up. *J Emerg Trauma Shock* 2012;**5**:201–203. <https://doi.org/10.4103/0974-2700.96501>
191. Gonzalez I, Sarría C, Lopez J, Vilacosta I, San Roman A, Olmos C, et al. Symptomatic peripheral mycotic aneurysms due to infective endocarditis: a contemporary profile. *Medicine (Baltimore)* 2014;**93**:42–52. <https://doi.org/10.1097/MD.0000000000000014>
192. Goddard AJ, Tan G, Becker J. Computed tomography angiography for the detection and characterization of intra-cranial aneurysms: current status. *Clin Radiol* 2005;**60**:1221–1236. <https://doi.org/10.1016/j.crad.2005.06.007>
193. Hekimian G, Kim M, Passetort S, Duval X, Wolff M, Lepout C, et al. Preoperative use and safety of coronary angiography for acute aortic valve infective endocarditis. *Heart* 2010;**96**:696–700. <https://doi.org/10.1136/hrt.2009.183772>
194. Lecomte R, Issa N, Gaborit B, Le Turnier P, Deschanvres C, Asseray N, et al. Risk-benefit assessment of systematic thoracoabdominal-pelvic computed tomography in infective endocarditis. *Clin Infect Dis* 2019;**69**:1605–1612. <https://doi.org/10.1093/cid/ciz014>
195. Dursun M, Yilmaz S, Yilmaz E, Yilmaz R, Onur I, Ofllaz H, et al. The utility of cardiac MRI in diagnosis of infective endocarditis: preliminary results. *Diagn Interv Radiol* 2015;**21**:28–33. <https://doi.org/10.5152/dir.2014.14239>
196. El Ouazzani J, Jandou I, Christophe Thuaiere I. Thrombus or vegetation? Importance of cardiac MRI as a diagnostic tool based on case report and literature review. *Ann Med Surg (Lond)* 2020;**60**:690–694. <https://doi.org/10.1016/j.amsu.2020.12.007>
197. Snygg-Martin U, Gustafsson L, Rosengren L, Alsio A, Ackerholm P, Andersson R, et al. Cerebrovascular complications in patients with left-sided infective endocarditis are common: a prospective study using magnetic resonance imaging and neurochemical brain damage markers. *Clin Infect Dis* 2008;**47**:23–30. <https://doi.org/10.1086/588663>
198. Cooper HA, Thompson EC, Laureno R, Fuisz A, Mark AS, Lin M, et al. Subclinical brain embolization in left-sided infective endocarditis: results from the evaluation by MRI of the brains of patients with left-sided intracardiac solid masses (EMBOLISM) pilot study. *Circulation* 2009;**120**:585–591. <https://doi.org/10.1161/CIRCULATIONAHA.108.834432>
199. Chakraborty T, Scharf E, DeSimone D, El Rafei A, Brinjikji W, Baddour LM, et al. Variable significance of brain MRI findings in infective endocarditis and its effect on surgical decisions. *Mayo Clin Proc* 2019;**94**:1024–1032. <https://doi.org/10.1016/j.mayocp.2018.09.015>
200. Duval X, lung B, Klein I, Brochet E, Thabut G, Arnoult F, et al. Effect of early cerebral magnetic resonance imaging on clinical decisions in infective endocarditis: a prospective study. *Ann Intern Med* 2010;**152**:497–504, W175. <https://doi.org/10.7326/0003-4819-152-8-201004200-00006>
201. Sotero FD, Rosario M, Fonseca AC, Ferro JM. Neurological complications of infective endocarditis. *Curr Neurol Neurosci Rep* 2019;**19**:23. <https://doi.org/10.1007/s11910-019-0935-x>
202. Fujimoto T, Morofuji Y, Matsunaga Y, Horie N, Izumo T, Tateishi Y, et al. Early diagnosis of infective endocarditis by brain T2\*-weighted magnetic resonance imaging. *Circ J* 2018;**82**:464–468. <https://doi.org/10.1253/circj.CJ-17-0212>
203. Haller S, Vernooij MV, Kuijper JPA, Larsson EM, Jager HR, Barkhof F. Cerebral microbleeds: imaging and clinical significance. *Radiology* 2018;**287**:11–28. <https://doi.org/10.1148/radiol.2018170803>
204. Hess A, Klein I, lung B, Lavallee P, Ilic-Habensuss E, Dornic Q, et al. Brain MRI findings in neurologically asymptomatic patients with infective endocarditis. *AJNR Am J Neuroradiol* 2013;**34**:1579–1584. <https://doi.org/10.3174/ajnr.A3582>
205. lung B, Tubiana S, Klein I, Messika-Zeitoun D, Brochet E, Lepage L, et al. Determinants of cerebral lesions in endocarditis on systematic cerebral magnetic resonance imaging: a prospective study. *Stroke* 2013;**44**:3056–3062. <https://doi.org/10.1161/STROKEAHA.113.001470>
206. Foreman SC, Schwaiger BJ, Gempt J, Jungmann PM, Kehl V, Delbridge C, et al. MR and CT imaging to optimize CT-guided biopsies in suspected spondylodiscitis. *World Neurosurg* 2017;**99**:726–734.e7. <https://doi.org/10.1016/j.wneu.2016.11.017>
207. Dunbar JA, Sandoe JA, Rao AS, Crimmins DW, Baig W, Rankine JJ. The MRI appearances of early vertebral osteomyelitis and discitis. *Clin Radiol* 2010;**65**:974–981. <https://doi.org/10.1016/j.crad.2010.03.015>
208. Gomes A, Glaudemans A, Touw DJ, van Melle JP, Willems TP, Maass AH, et al. Diagnostic value of imaging in infective endocarditis: a systematic review. *Lancet Infect Dis* 2017;**17**:e1–e14. [https://doi.org/10.1016/S1473-3099\(16\)30141-4](https://doi.org/10.1016/S1473-3099(16)30141-4)
209. Saby L, Laas O, Habib G, Cammilleri S, Mancini J, Tessonier L, et al. Positron emission tomography/computed tomography for diagnosis of prosthetic valve endocarditis: increased valvular 18F-fluorodeoxyglucose uptake as a novel major criterion. *J Am Coll Cardiol* 2013;**61**:2374–2382. <https://doi.org/10.1016/j.jacc.2013.01.092>
210. Swart LE, Gomes A, Scholtens AM, Sinha B, Tanis VW, Lam M, et al. Improving the diagnostic performance of (18)F-fluorodeoxyglucose positron-emission tomography/computed tomography in prosthetic heart valve endocarditis. *Circulation* 2018;**138**:1412–1427. <https://doi.org/10.1161/CIRCULATIONAHA.118.035032>
211. Duval X, Le Moing V, Tubiana S, Esposito-Farese M, Ilic-Habensuss E, Leclercq F, et al. Impact of systematic whole-body 18F-fluorodeoxyglucose PET/CT on the management of patients suspected of infective endocarditis: the prospective multicenter tependo study. *Clin Infect Dis* 2021;**73**:393–403. <https://doi.org/10.1093/cid/ciaa666>
212. Philip M, Tessonier L, Mancini J, Mainardi JL, Fernandez-Gerlinger MP, Lussato D, et al. Comparison between ESC and Duke criteria for the diagnosis of prosthetic valve infective endocarditis. *JACC Cardiovasc Imaging* 2020;**13**:2605–2615. <https://doi.org/10.1016/j.jcmg.2020.04.011>
213. Erba PA, Conti U, Lazzeri E, Sollini M, Doria R, De Tommasi SM, et al. Added value of 99mTc-HMPAO-labeled leukocyte SPECT/CT in the characterization and management of patients with infectious endocarditis. *J Nucl Med* 2012;**53**:1235–1243. <https://doi.org/10.2967/jnumed.111.099424>
214. Rouzet F, Chequer R, Benali K, Lepage L, Ghodbane WV, Duval X, et al. Respective performance of 18F-FDG PET and radiolabeled leukocyte scintigraphy for the diagnosis of prosthetic valve endocarditis. *J Nucl Med* 2014;**55**:1980–1985. <https://doi.org/10.2967/jnumed.114.141895>

215. Hyafil F, Rouzet F, Lepage L, Benali K, Raffoul R, Duval X, et al. Role of radiolabelled leucocyte scintigraphy in patients with a suspicion of prosthetic valve endocarditis and inconclusive echocardiography. *Eur Heart J Cardiovasc Imaging* 2013;**14**:586–594. <https://doi.org/10.1093/ehjci/jet029>
216. Holcman K, Szot W, Rubis P, Lesniak-Sobelga A, Hlawaty M, Wisniowska-Smialek S, et al. <sup>99m</sup>Tc-HMPAO-labeled leukocyte SPECT/CT and transthoracic echocardiography diagnostic value in infective endocarditis. *Int J Cardiovasc Imaging* 2019;**35**:749–758. <https://doi.org/10.1007/s10554-018-1487-x>
217. Albano D, Dondi F, Gazzilli M, Giubbini R, Bertagna F. Meta-analysis of the diagnostic performance of (18)F-FDG-PET/CT imaging in native valve endocarditis. *JACC Cardiovasc Imaging* 2021;**14**:1063–1065. <https://doi.org/10.1016/j.jcmg.2020.09.021>
218. de Camargo RA, Sommer Bitencourt M, Meneghetti JC, Soares J, Goncalves LFT, Buchpiguel CA, et al. The role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the diagnosis of left-sided endocarditis: native vs prosthetic valves endocarditis. *Clin Infect Dis* 2020;**70**:583–594. <https://doi.org/10.1093/cid/ciz267>
219. Pelletier-Galarneau M, Abikhzer G, Harel F, Dilsizian V. Detection of native and prosthetic valve endocarditis: incremental attributes of functional FDG PET/CT over morphologic imaging. *Curr Cardiol Rep* 2020;**22**:93. <https://doi.org/10.1007/s11886-020-01334-w>
220. Pizzi MN, Fernandez-Hidalgo N. Optimizing the diagnostic workup of infective endocarditis: an urgent need for studies focused on defining the decision-making process. *J Nucl Cardiol* 2020;**27**:609–611. <https://doi.org/10.1007/s12350-018-1434-1>
221. Boursier C, Duval X, Bourdon A, Imbert L, Mahida B, Chevalier E, et al. ECG-gated cardiac FDG PET acquisitions significantly improve detectability of infective endocarditis. *JACC Cardiovasc Imaging* 2020;**13**:2691–2693. <https://doi.org/10.1016/j.jcmg.2020.06.036>
222. Ishikita A, Sakamoto I, Yamamura K, Umemoto S, Nagata H, Kitamura Y, et al. Usefulness of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the diagnosis of infective endocarditis in patients with adult congenital heart disease. *Circ J* 2021;**85**:1505–1513. <https://doi.org/10.1253/circj.CJ-20-1067>
223. Pizzi MN, Dos-Subira L, Roque A, Fernandez-Hidalgo N, Cuellar-Calabria H, Pijuan Domenech A, et al. (18)F-FDG-PET/CT angiography in the diagnosis of infective endocarditis and cardiac device infection in adult patients with congenital heart disease and prosthetic material. *Int J Cardiol* 2017;**248**:396–402. <https://doi.org/10.1016/j.ijcard.2017.08.008>
224. San S, Ravis E, Tessonier L, Philip M, Cammilleri S, Lavagna F, et al. Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in infective endocarditis. *J Am Coll Cardiol* 2019;**74**:1031–1040. <https://doi.org/10.1016/j.jacc.2019.06.050>
225. Mikail N, Benali K, Mahida B, Vigne J, Hyafil F, Rouzet F, et al. (18)F-FDG-PET/CT imaging to diagnose septic emboli and mycotic aneurysms in patients with endocarditis and cardiac device infections. *Curr Cardiol Rep* 2018;**20**:14. <https://doi.org/10.1007/s11886-018-0956-0>
226. Orvin K, Goldberg E, Bernstine H, Groshar D, Sagie A, Kornowski R, et al. The role of FDG-PET/CT imaging in early detection of extra-cardiac complications of infective endocarditis. *Clin Microbiol Infect* 2015;**21**:69–76. <https://doi.org/10.1016/j.cmi.2014.08.012>
227. Duval X, lung B. Extracardiac imaging of infective endocarditis. *Curr Infect Dis Rep* 2017;**19**:24. <https://doi.org/10.1007/s11908-017-0580-y>
228. Kouijzer IJ, Bleeker-Rovers CP, Oyen WJ. 18F-FDG PET/CT for the detection of septic embolisms in patients with infectious endocarditis. *J Nucl Med* 2014;**55**:1045–1046. <https://doi.org/10.2967/jnumed.114.140707>
229. Germaini M, Boursier C, Goehringer F, Selton-Suty C, Lefevre B, Roch V, et al. The detection of infectious endocarditis may be enhanced by a repeat FDG-PET while maintaining patients on a ketogenic diet. *J Nucl Cardiol* 2022;**29**:3256–3262. <https://doi.org/10.1007/s12350-022-02921-w>
230. Slart R, Glaudemans A, Gheysens O, Lubberink M, Kero T, Dweck MR, et al. Procedural recommendations of cardiac PET/CT imaging: standardization in inflammatory-, infective-, infiltrative-, and innervation (4Is)-related cardiovascular diseases: a joint collaboration of the EACVI and the EANM. *Eur J Nucl Med Mol Imaging* 2021;**48**:1016–1039. <https://doi.org/10.1007/s00259-020-05066-5>
231. Mathieu C, Mikail N, Benali K, lung B, Duval X, Nataf P, et al. Characterization of (18)F-fluorodeoxyglucose uptake pattern in noninfected prosthetic heart valves. *Circ Cardiovasc Imaging* 2017;**10**:e005585. <https://doi.org/10.1161/CIRCIMAGING.116.005585>
232. Mistry NP, AlShaheen M, Leung E, Chow B, Wiefels C. Previous biogluce repair mimicking cardiac infection with (18)F-FDG PET imaging. *J Nucl Cardiol* 2023;**30**:420–424. <https://doi.org/10.1007/s12350-021-02807-3>
233. Scholtens AM, Swart LE, Verberne HJ, Tanis W, Lam MG, Budde RP. Confounders in FDG-PET/CT imaging of suspected prosthetic valve endocarditis. *JACC Cardiovasc Imaging* 2016;**9**:1462–1465. <https://doi.org/10.1016/j.jcmg.2016.01.024>
234. Roque A, Pizzi MN, Cuellar-Calabria H, Aguade-Bruix S. (18)F-FDG-PET/CT angiography for the diagnosis of infective endocarditis. *Curr Cardiol Rep* 2017;**19**:15. <https://doi.org/10.1007/s11886-017-0824-3>
235. Swart LE, Scholtens AM, Tanis W, Nieman K, Bogers A, Verzijlbergen FJ, et al. 18F-fluorodeoxyglucose positron emission/computed tomography and computed tomography angiography in prosthetic heart valve endocarditis: from guidelines to clinical practice. *Eur Heart J* 2018;**39**:3739–3749. <https://doi.org/10.1093/eurheartj/ehx784>
236. Pizzi MN, Roque A, Cuellar-Calabria H, Fernandez-Hidalgo N, Ferreira-Gonzalez I, Gonzalez-Alujas MT, et al. (18)F-FDG-PET/CTA of prosthetic cardiac valves and valve-tube grafts: infective versus inflammatory patterns. *JACC Cardiovasc Imaging* 2016;**9**:1224–1227. <https://doi.org/10.1016/j.jcmg.2016.05.013>
237. Amraoui S, Tlili G, Sohal M, Berte B, Hindie E, Ritter P, et al. Contribution of PET imaging to the diagnosis of septic embolism in patients with pacing lead endocarditis. *JACC Cardiovasc Imaging* 2016;**9**:283–290. <https://doi.org/10.1016/j.jcmg.2015.09.014>
238. Calais J, Touati A, Grall N, Laouenan C, Benali K, Mahida B, et al. Diagnostic impact of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography and white blood cell SPECT/computed tomography in patients with suspected cardiac implantable electronic device chronic infection. *Circ Cardiovasc Imaging* 2019;**12**:e007188. <https://doi.org/10.1161/CIRCIMAGING.117.007188>
239. Chen W, Sajadi MM, Dilsizian V. Merits of FDG PET/CT and functional molecular imaging over anatomic imaging with echocardiography and CT angiography for the diagnosis of cardiac device infections. *JACC Cardiovasc Imaging* 2018;**11**:1679–1691. <https://doi.org/10.1016/j.jcmg.2018.08.026>
240. Okazaki S, Yoshioka D, Sakaguchi M, Sawa Y, Mochizuki H, Kitagawa K. Acute ischemic brain lesions in infective endocarditis: incidence, related factors, and postoperative outcome. *Cerebrovasc Dis* 2013;**35**:155–162. <https://doi.org/10.1159/000346101>
241. Kestler M, Munoz P, Rodriguez-Creixems M, Rotger A, Jimenez-Requena F, Mari A, et al. Role of (18)F-FDG PET in patients with infectious endocarditis. *J Nucl Med* 2014;**55**:1093–1098. <https://doi.org/10.2967/jnumed.113.134981>
242. Habib G, Derumeaux G, Avierinos JF, Casalta JP, Jamal F, Volot F, et al. Value and limitations of the Duke criteria for the diagnosis of infective endocarditis. *J Am Coll Cardiol* 1999;**33**:2023–2029. [https://doi.org/10.1016/S0735-1097\(99\)00116-3](https://doi.org/10.1016/S0735-1097(99)00116-3)
243. Vieira ML, Grinberg M, Pomerantzeff PM, Andrade JL, Mansur AJ. Repeated echocardiographic examinations of patients with suspected infective endocarditis. *Heart* 2004;**90**:1020–1024. <https://doi.org/10.1136/hrt.2003.025585>
244. Hill EE, Herijgers P, Claus P, Vanderschueren S, Peetermans WE, Herregods MC. Abscess in infective endocarditis: the value of transesophageal echocardiography and outcome: a 5-year study. *Am Heart J* 2007;**154**:923–928. <https://doi.org/10.1016/j.ahj.2007.06.028>
245. Dahl A, Fowler VG, Miro JM, Bruun NE. Sign of the times: updating infective endocarditis diagnostic criteria to recognize *Enterococcus faecalis* as a typical endocarditis bacterium. *Clin Infect Dis* 2022;**75**:1097–1102. <https://doi.org/10.1093/cid/ciac181>
246. Roque A, Pizzi MN, Fernandez-Hidalgo N, Permyer E, Cuellar-Calabria H, Romero-Farina G, et al. Morpho-metabolic post-surgical patterns of non-infected prosthetic heart valves by [18F]FDG PET/CTA: “normality” is a possible diagnosis. *Eur Heart J Cardiovasc Imaging* 2020;**21**:24–33. <https://doi.org/10.1093/ehjci/jez222>
247. Anis HK, Miller EM, George J, Shrestha NK, Klika AK, Kamath AF, et al. Incidence and characteristics of osteoarticular infections in patients with infective endocarditis. *Orthopedics* 2020;**43**:24–29. <https://doi.org/10.3928/01477447-20191031-02>
248. Carbone A, Lieu A, Mouhat B, Santelli F, Philip M, Bohbot Y, et al. Spondylodiscitis complicating infective endocarditis. *Heart* 2020;**106**:1914–1918. <https://doi.org/10.1136/heartjnl-2019-316492>
249. Arvieux C, Common H. New diagnostic tools for prosthetic joint infection. *Orthop Traumatol Surg Res* 2019;**105**:S23–S30. <https://doi.org/10.1016/j.otsr.2018.04.029>
250. Park LP, Chu VH, Peterson G, Skoutelis A, Lejko-Zupa T, Bouza E, et al. Validated risk score for predicting 6-month mortality in infective endocarditis. *J Am Heart Assoc* 2016;**5**:e003016. <https://doi.org/10.1161/JAHA.115.003016>
251. Sevilla T, Lopez J, Gomez I, Vilacosta I, Sarria C, Garcia-Granja PE, et al. Evolution of prognosis in left-sided infective endocarditis: a propensity score analysis of 2 decades. *J Am Coll Cardiol* 2017;**69**:111–112. <https://doi.org/10.1016/j.jacc.2016.10.052>
252. Chandrasekar PH, Levine DP, Price S, Rybak MJ. Comparative efficacies of imipenem-cilastatin and vancomycin in experimental aortic valve endocarditis due to methicillin resistant *Staphylococcus aureus*. *J Antimicrob Chemother* 1988;**21**:461–469. <https://doi.org/10.1093/jac/21.4.461>
253. Durack DT, Pelletier LL, Petersdorf RG. Chemotherapy of experimental streptococcal endocarditis. II. Synergism between penicillin and streptomycin against penicillin-sensitive streptococci. *J Clin Invest* 1974;**53**:829–833. <https://doi.org/10.1172/JCI107622>
254. Wilson WR, Geraci JE, Wilkowske CJ, Washington JA 2nd. Short-term intramuscular therapy with procaine penicillin plus streptomycin for infective endocarditis due to viridans streptococci. *Circulation* 1978;**57**:1158–1161. <https://doi.org/10.1161/01.CIR.57.6.1158>
255. Lebeaux D, Fernandez-Hidalgo N, Pilmis B, Tattevin P, Mainardi JL. Aminoglycosides for infective endocarditis: time to say goodbye? *Clin Microbiol Infect* 2020;**26**:723–728. <https://doi.org/10.1016/j.cmi.2019.10.017>
256. Fernandez-Felix BM, Barca LV, Garcia-Esquinas E, Correa-Perez A, Fernandez-Hidalgo N, Muriel A, et al. Prognostic models for mortality after cardiac surgery in patients with

- infective endocarditis: a systematic review and aggregation of prediction models. *Clin Microbiol Infect* 2021;**27**:1422–1430. <https://doi.org/10.1016/j.cmi.2021.05.051>
257. Hoiby N, Ciofu O, Johansen HK, Song Z-J, Moser C, Jensen PO, et al. The clinical impact of bacterial biofilms. *Int J Oral Sci* 2011;**3**:55–65. <https://doi.org/10.4248/IJOS11026>
  258. Funane K, Tanaka Y, Hosaka T, Murakami K, Miyazaki T, Shiwa Y, et al. Combined drug resistance mutations substantially enhance enzyme production in *paenibacillus agarivorans*. *J Bacteriol* 2018;**200**:e00188-18. <https://doi.org/10.1128/JB.00188-18>
  259. Knudsen GM, Ng Y, Gram L. Survival of bactericidal antibiotic treatment by a persister subpopulation of *Listeria monocytogenes*. *Appl Environ Microbiol* 2013;**79**:7390–7397. <https://doi.org/10.1128/AEM.02184-13>
  260. Le Bot A, Lecomte R, Gazeau P, Benezit F, Arvieux C, Ansart S, et al. Is rifampin use associated with better outcome in staphylococcal prosthetic valve endocarditis? A multicenter retrospective study. *Clin Infect Dis* 2021;**72**:e249–e255. <https://doi.org/10.1093/cid/ciaa1040>
  261. Shrestha NK, Shah SY, Wang H, Hussain ST, Pettersson GB, Nowacki AS, et al. Rifampin for surgically treated staphylococcal infective endocarditis: a propensity score-adjusted cohort study. *Ann Thorac Surg* 2016;**101**:2243–2250. <https://doi.org/10.1016/j.athoracsur.2015.11.015>
  262. Marti-Carvajal AJ, Dayer M, Conterno LO, Gonzalez Garay AG, Marti-Amarista CE. A comparison of different antibiotic regimens for the treatment of infective endocarditis. *Cochrane Database Syst Rev* 2020;**5**:CD009880. <https://doi.org/10.1002/14651858.CD009880.pub3>
  263. Tissot-Dupont H, Casalta JP, Gouriet F, Hubert S, Salaun E, Habib G, et al. International experts' practice in the antibiotic therapy of infective endocarditis is not following the guidelines. *Clin Microbiol Infect* 2017;**23**:736–739. <https://doi.org/10.1016/j.cmi.2017.03.007>
  264. Cosgrove SE, Vigianni GA, Fowler VG Jr, Abrutyn E, Corey GR, Levine DP, et al. Initial low-dose gentamicin for *Staphylococcus aureus* bacteremia and endocarditis is nephrotoxic. *Clin Infect Dis* 2009;**48**:713–721. <https://doi.org/10.1086/597031>
  265. Pericas JM, Nathavitharana R, Garcia-de-la-Maria C, Falces C, Ambrosioni J, Almela M, et al. Endocarditis caused by highly penicillin-resistant viridans group streptococci: still room for vancomycin-based regimens. *Antimicrob Agents Chemother* 2019;**63**:e00516-19. <https://doi.org/10.1128/AAC.00516-19>
  266. Dahl A, Rasmussen RV, Bundgaard H, Hassager C, Bruun LE, Lauridsen TK, et al. *Enterococcus faecalis* infective endocarditis: a pilot study of the relationship between duration of gentamicin treatment and outcome. *Circulation* 2013;**127**:1810–1817. <https://doi.org/10.1161/CIRCULATIONAHA.112.001170>
  267. Miro JM, Garcia-de-la-Maria C, Armero Y, Soy D, Moreno A, del Rio A, et al. Addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in treatment of experimental endocarditis due to methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother* 2009;**53**:4172–4177. <https://doi.org/10.1128/AAC.00051-09>
  268. Garrigos C, Murillo O, Lora-Tamayo J, Verdager R, Tubau F, Cabellos C, et al. Fosfomicin-daptomycin and other fosfomicin combinations as alternative therapies in experimental foreign-body infection by methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother* 2013;**57**:606–610. <https://doi.org/10.1128/AAC.01570-12>
  269. Peghin M, Russo A, Givone F, Ingani M, Graziano E, Bassetti M. Should high-dose daptomycin be an alternative treatment regimen for enterococcal endocarditis? *Infect Dis Ther* 2019;**8**:695–702. <https://doi.org/10.1007/s40121-019-00261-w>
  270. Kullar R, Casapao AM, Davis SL, Levine DP, Zhao JJ, Crank CW, et al. A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis. *J Antimicrob Chemother* 2013;**68**:2921–2926. <https://doi.org/10.1093/jac/dkt294>
  271. Carugati M, Bayer AS, Miro JM, Park LP, Guimaraes AC, Skoutelis A, et al. High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study from the international collaboration on endocarditis. *Antimicrob Agents Chemother* 2013;**57**:6213–6222. <https://doi.org/10.1128/AAC.01563-13>
  272. Pujol M, Miro JM, Shaw E, Aguado JM, San-Juan R, Puig-Asensio M, et al. Daptomycin plus fosfomicin versus daptomycin alone for methicillin-resistant *Staphylococcus aureus* bacteremia and endocarditis: a randomized clinical trial. *Clin Infect Dis* 2021;**72**:1517–1525. <https://doi.org/10.1093/cid/ciaa1081>
  273. West KA, Sheeti A, Tamura MacKay K, Forrest GN. Eosinophilic syndromes associated with daptomycin use: re-exposure hypersensitivity pneumonitis and prior peripheral eosinophilia. *Open Forum Infect Dis* 2022;**9**:ofac065. <https://doi.org/10.1093/ofid/ofac065>
  274. Hidalgo-Tenorio C, Vinuesa D, Plata A, Martin Davila P, Iftimie S, Sequera S, et al. DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by Gram-positive cocci. *Ann Clin Microbiol Antimicrob* 2019;**18**:30. <https://doi.org/10.1186/s12941-019-0329-6>
  275. Spaziante M, Franchi C, Taliani G, D'Avolio A, Pietropaolo V, Biliotti E, et al. Serum bactericidal activity levels monitor to guide intravenous dalbavancin chronic suppressive therapy of inoperable staphylococcal prosthetic valve endocarditis: a case report. *Open Forum Infect Dis* 2019;**6**:ofz427. <https://doi.org/10.1093/ofid/ofz427>
  276. Abranches J, Zeng L, Kafjasz JK, Palmer SR, Chakraborty B, Wen ZT, et al. Biology of oral streptococci. *Microbiol Spectr* 2018;**6**. <https://doi.org/10.1128/microbiolspec.GPP3-0042-2018>
  277. Westling K, Aufwerber E, Ekdahl C, Friman G, Gardlund B, Julander I, et al. Swedish guidelines for diagnosis and treatment of infective endocarditis. *Scand J Infect Dis* 2007;**39**:929–946. <https://doi.org/10.1080/00365540701534517>
  278. Gould FK, Denning DW, Elliott TS, Foweraker J, Perry JD, Prendergast BD, et al. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the working party of the British Society for Antimicrobial Chemotherapy. *J Antimicrob Chemother* 2012;**67**:269–289. <https://doi.org/10.1093/jac/dkr450>
  279. Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Tleyjeh IM, Rybak MJ, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. *Circulation* 2015;**132**:1435–1486. <https://doi.org/10.1161/CIR.0000000000000296>
  280. Francioli P, Etienne J, Hoigne R, Thys JP, Gerber A. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone sodium for 4 weeks. Efficacy and outpatient treatment feasibility. *JAMA* 1992;**267**:264–267. <https://doi.org/10.1001/jama.1992.03480020074034>
  281. Francioli P, Ruch W, Stamboulou D. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone and netilmicin for 14 days: a prospective multicenter study. *Clin Infect Dis* 1995;**21**:1406–1410. <https://doi.org/10.1093/clinids/21.6.1406>
  282. Sexton DJ, Tenenbaum MJ, Wilson WR, Steckelberg JM, Tice AD, Gilbert D, et al. Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococci. Endocarditis Treatment Consortium Group. *Clin Infect Dis* 1998;**27**:1470–1474. <https://doi.org/10.1086/515038>
  283. Cremieux AC, Maziere B, Vallois JM, Ottaviani M, Azancot A, Raffoul H, et al. Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography. *J Infect Dis* 1989;**159**:938–944. <https://doi.org/10.1093/infdis/159.5.938>
  284. Wilson AP, Gaya H. Treatment of endocarditis with teicoplanin: a retrospective analysis of 104 cases. *J Antimicrob Chemother* 1996;**38**:507–521. <https://doi.org/10.1093/jac/38.3.507>
  285. Moet GJ, Dowzicky MJ, Jones RN. Tigecycline (GAR-936) activity against *Streptococcus gallolyticus* (bovis) and viridans group streptococci. *Diagn Microbiol Infect Dis* 2007;**57**:333–336. <https://doi.org/10.1016/j.diagmicrobio.2006.08.001>
  286. Shelburne SA 3rd, Greenberg SB, Aslam S, Tweardy DJ. Successful ceftriaxone therapy of endocarditis due to penicillin non-susceptible viridans streptococci. *J Infect* 2007;**54**:e99–e101. <https://doi.org/10.1016/j.jinf.2006.05.010>
  287. Hsu RB, Lin FY. Effect of penicillin resistance on presentation and outcome of non-enterococcal streptococcal infective endocarditis. *Cardiology* 2006;**105**:234–239. <https://doi.org/10.1159/000091821>
  288. Knoll B, Tleyjeh IM, Steckelberg JM, Wilson WR, Baddour LM. Infective endocarditis due to penicillin-resistant viridans group streptococci. *Clin Infect Dis* 2007;**44**:1585–1592. <https://doi.org/10.1086/518174>
  289. Levy CS, Kogulan P, Gill VJ, Croxton MB, Kane JG, Lucey DR. Endocarditis caused by penicillin-resistant viridans streptococci: 2 cases and controversies in therapy. *Clin Infect Dis* 2001;**33**:577–579. <https://doi.org/10.1086/321910>
  290. Pilmis B, Lourtet-Hascoet J, Barraud O, Piau C, Isnard C, Hery-Arnaud G, et al. Be careful about MICs to amoxicillin for patients with streptococci-related infective endocarditis. *Int J Antimicrob Agents* 2019;**53**:850–854. <https://doi.org/10.1016/j.ijantimicag.2019.03.002>
  291. Matsuo T, Mori N, Sakurai A, Kanie T, Mikami Y, Uehara Y, et al. Effectiveness of daptomycin against infective endocarditis caused by highly penicillin-resistant viridans group streptococci. *IDCases* 2021;**24**:e01113. <https://doi.org/10.1016/j.idcr.2021.e01113>
  292. Hook EW 3rd, Johnson WD Jr. Vancomycin therapy of bacterial endocarditis. *Am J Med* 1978;**65**:411–415. [https://doi.org/10.1016/0002-9343\(78\)90766-0](https://doi.org/10.1016/0002-9343(78)90766-0)
  293. Beraud G, Tubiana S, Erpelding ML, Le Moing V, Chirouze C, Gorenne I, et al. Combined bacterial meningitis and infective endocarditis: when should we search for the other when either one is diagnosed? *Infect Dis Ther* 2022;**11**:1521–1540. <https://doi.org/10.1007/s40121-022-00651-7>
  294. de Egea V, Munoz P, Valerio M, de Alarcon A, Lepe JA, Miro JM, et al. Characteristics and outcome of *Streptococcus pneumoniae* endocarditis in the XXI century: a systematic review of 111 cases (2000–2013). *Medicine (Baltimore)* 2015;**94**:e1562. <https://doi.org/10.1097/MD.0000000000001562>
  295. Martinez E, Miro JM, Almirante B, Aguado JM, Fernandez-Viladrich P, Fernandez-Guerrero ML, et al. Effect of penicillin resistance of *Streptococcus pneumoniae* on the presentation, prognosis, and treatment of pneumococcal endocarditis in adults. *Clin Infect Dis* 2002;**35**:130–139. <https://doi.org/10.1086/341024>
  296. Perier A, Puyade M, Revest M, Tattevin P, Bernard L, Lemaigen A, et al. Prognosis of *Streptococcus pneumoniae* endocarditis in France, a multicenter observational study (2000–2015). *Int J Cardiol* 2019;**288**:102–106. <https://doi.org/10.1016/j.ijcard.2019.04.048>

297. Friedland IR, McCracken GH Jr. Management of infections caused by antibiotic-resistant *Streptococcus pneumoniae*. *N Engl J Med* 1994;**331**:377–382. <https://doi.org/10.1056/NEJM199408113310607>
298. van Ettehoven CN, van de Beek D, Brouwer MC. Update on community-acquired bacterial meningitis: guidance and challenges. *Clin Microbiol Infect* 2017;**23**:601–606. <https://doi.org/10.1016/j.cmi.2017.04.019>
299. Fernandez Hidalgo N, Gharamti AA, Aznar ML, Almirante B, Yasmin M, Fortes CQ, et al. Beta-hemolytic streptococcal infective endocarditis: characteristics and outcomes from a large, multinational cohort. *Open Forum Infect Dis* 2020;**7**:ofaa120. <https://doi.org/10.1093/ofid/ofaa120>
300. Lefort A, Lortholary O, Casassus P, Selson-Suty C, Guillevin L, Mainardi JL, et al. Comparison between adult endocarditis due to beta-hemolytic streptococci (serogroups A, B, C, and G) and *Streptococcus milleri*: a multicenter study in France. *Arch Intern Med* 2002;**162**:2450–2456. <https://doi.org/10.1001/archinte.162.21.2450>
301. Sambola A, Miro JM, Tornos MP, Almirante B, Moreno-Torrico A, Gurgui M, et al. *Streptococcus agalactiae* infective endocarditis: analysis of 30 cases and review of the literature, 1962–1998. *Clin Infect Dis* 2002;**34**:1576–1584. <https://doi.org/10.1086/340538>
302. Adam EL, Siciliano RF, Gualandro DM, Calderaro D, Issa VS, Rossi F, et al. Case series of infective endocarditis caused by *Granulicatella* species. *Int J Infect Dis* 2015;**31**:56–58. <https://doi.org/10.1016/j.ijid.2014.10.023>
303. Giuliano S, Caccese R, Carfagna P, Vena A, Falcone M, Venditti M. Endocarditis caused by nutritionally variant streptococci: a case report and literature review. *Infez Med* 2012;**20**:67–74.
304. Tellez A, Ambrosioni J, Hernandez-Meneses M, Llopis J, Ripa M, Chambers ST, et al. Clinical characteristics and outcome of infective endocarditis due to *Abiotrophia* and *Granulicatella* compared to *Vidans* group streptococci. *J Infect* 2022;**85**:137–146. <https://doi.org/10.1016/j.jinf.2022.05.023>
305. Fernandez-Hidalgo N, Ribera A, Larrosa MN, Viedma E, Origen J, de Alarcon A, et al. Impact of *Staphylococcus aureus* phenotype and genotype on the clinical characteristics and outcome of infective endocarditis. A multicentre, longitudinal, prospective, observational study. *Clin Microbiol Infect* 2018;**24**:985–991. <https://doi.org/10.1016/j.cmi.2017.12.002>
306. Sandoe JA, Kerr KG, Reynolds GVV, Jain S. *Staphylococcus capitis* endocarditis: two cases and review of the literature. *Heart* 1999;**82**:e1. <https://doi.org/10.1136/hrt.82.3.e1>
307. Cone LA, Sontz EM, Wilson JW, Mitruka SN. *Staphylococcus capitis* endocarditis due to a transvenous endocardial pacemaker infection: case report and review of *Staphylococcus capitis* endocarditis. *Int J Infect Dis* 2005;**9**:335–339. <https://doi.org/10.1016/j.ijid.2004.08.004>
308. Korzeniowski O, Sande MA. Combination antimicrobial therapy for *Staphylococcus aureus* endocarditis in patients addicted to parenteral drugs and in nonaddicts: a prospective study. *Ann Intern Med* 1982;**97**:496–503. <https://doi.org/10.7326/0003-4819-97-4-496>
309. Apellaniz G, Valdes M, Perez R, Martin-Luengo F, Garcia A, Soria F, et al. [Teicoplanin versus cloxacillin, cloxacillin-gentamycin and vancomycin in the treatment of experimental endocarditis caused by methicillin-sensitive *Staphylococcus aureus*]. *Enferm Infecc Microbiol Clin* 1991;**9**:208–210.
310. Huang C, Chen I, Lin L. Comparing the outcomes of ceftaroline plus vancomycin or daptomycin combination therapy versus vancomycin or daptomycin monotherapy in adults with methicillin-resistant *Staphylococcus aureus* bacteremia—a meta-analysis. *Antibiotics (Basel)* 2022;**11**:1104. <https://doi.org/10.3390/antibiotics11081104>
311. Veliev A, Nakipoglu Y. Investigation of *Staphylococcus lugdunensis* and selected coagulase negative staphylococci isolated from blood culture bottles and determination of their sensitivities to antibiotics. *Pak J Med Sci* 2022;**38**:657–662. <https://doi.org/10.12669/pjms.38.3.4738>
312. Chirouze C, Cabell CH, Fowler VG Jr, Khayat N, Olaison L, Miro JM, et al. Prognostic factors in 61 cases of *Staphylococcus aureus* prosthetic valve infective endocarditis from the International Collaboration on Endocarditis merged database. *Clin Infect Dis* 2004;**38**:1323–1327. <https://doi.org/10.1086/383035>
313. Oberbach A, Schlichting N, Hagl C, Lehmann S, Kullnick Y, Friedrich M, et al. Four decades of experience of prosthetic valve endocarditis reflect a high variety of diverse pathogens. *Cardiovasc Res* 2023;**119**:410–428. <https://doi.org/10.1093/cvr/cvac055>
314. Hassoun A. Treatment of *Staphylococcus aureus* prosthetic valve endocarditis. *Am J Med* 2007;**120**:e9, author reply e11. <https://doi.org/10.1016/j.amjmed.2006.02.021>
315. Marin M, Munoz P, Sanchez M, Del Rosal M, Alcalá L, Rodriguez-Creixems M, et al. Molecular diagnosis of infective endocarditis by real-time broad-range polymerase chain reaction (PCR) and sequencing directly from heart valve tissue. *Medicine (Baltimore)* 2007;**86**:195–202. <https://doi.org/10.1097/MD.0b013e31811f44ec>
316. Martinez-Selles M, Munoz P, Arnaiz A, Moreno M, Galvez J, Rodriguez-Roda J, et al. Valve surgery in active infective endocarditis: a simple score to predict in-hospital prognosis. *Int J Cardiol* 2014;**175**:133–137. <https://doi.org/10.1016/j.ijcard.2014.04.266>
317. Munoz P, Kestler M, De Alarcon A, Miro JM, Bermejo J, Rodriguez-Abella H, et al. Current epidemiology and outcome of infective endocarditis: a multicenter, prospective, cohort study. *Medicine (Baltimore)* 2015;**94**:e1816. <https://doi.org/10.1097/MD.0000000000001816>
318. Saginur R, Stdenis M, Ferris W, Aaron SD, Chan F, Lee C, et al. Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections. *Antimicrob Agents Chemother* 2006;**50**:55–61. <https://doi.org/10.1128/AAC.50.1.55-61.2006>
319. Saeed K, Bal AM, Gould IM, David MZ, Dryden M, Giannitsioti E, et al. An update on *Staphylococcus aureus* infective endocarditis from the International Society of Antimicrobial Chemotherapy (ISAC). *Int J Antimicrob Agents* 2019;**53**:9–15. <https://doi.org/10.1016/j.ijantimicag.2018.09.014>
320. Ramos-Martinez A, Munoz Serrano A, de Alarcon Gonzalez A, Munoz P, Fernandez-Cruz A, Valerio M, et al. Gentamicin may have no effect on mortality of staphylococcal prosthetic valve endocarditis. *J Infect Chemother* 2018;**24**:555–562. <https://doi.org/10.1016/j.jiac.2018.03.003>
321. Riedel DJ, Weekes E, Forrest GN. Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by *Staphylococcus aureus*. *Antimicrob Agents Chemother* 2008;**52**:2463–2467. <https://doi.org/10.1128/AAC.00300-08>
322. Sader HS, Carvalhaes CG, Mendes RE. Ceftaroline activity against *Staphylococcus aureus* isolated from patients with infective endocarditis, worldwide (2010–2019). *Int J Infect Dis* 2021;**102**:524–528. <https://doi.org/10.1016/j.ijid.2020.11.130>
323. Zasowski EJ, Trinh TD, Claeys KC, Lagnf AM, Bhatia S, Klinker KP, et al. Multicenter cohort study of ceftaroline versus daptomycin for treatment of methicillin-resistant *Staphylococcus aureus* bloodstream infection. *Open Forum Infect Dis* 2022;**9**:ofab606. <https://doi.org/10.1093/ofid/ofab606>
324. Sader HS, Mendes RE, Pfaller MA, Flamm RK. Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres. *J Antimicrob Chemother* 2019;**74**:1306–1310. <https://doi.org/10.1093/jac/dkz006>
325. Casapao AM, Davis SL, McRoberts JP, Lagnf AM, Patel S, Kullar R, et al. Evaluation of vancomycin population susceptibility analysis profile as a predictor of outcomes for patients with infective endocarditis due to methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother* 2014;**58**:4636–4641. <https://doi.org/10.1128/AAC.02820-13>
326. Ishaq H, Tariq W, Talha KM, Palraj BRV, Sohail MR, Baddour LM, et al. Association between high vancomycin minimum inhibitory concentration and clinical outcomes in patients with methicillin-resistant *Staphylococcus aureus* bacteremia: a meta-analysis. *Infection* 2021;**49**:803–811. <https://doi.org/10.1007/s15010-020-01568-4>
327. Maraolo AE, Giaccone A, Gentile I, Saracino A, Bavaro DF. Daptomycin versus vancomycin for the treatment of methicillin-resistant *Staphylococcus aureus* bloodstream infection with or without endocarditis: a systematic review and meta-analysis. *Antibiotics (Basel)* 2021;**10**:1014. <https://doi.org/10.3390/antibiotics10081014>
328. Tong SYC, Lye DC, Yahav D, Sud A, Robinson JO, Nelson J, et al. Effect of vancomycin or daptomycin with vs without an antistaphylococcal beta-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial. *JAMA* 2020;**323**:527–537. <https://doi.org/10.1001/jama.2020.0103>
329. Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant *Staphylococcus aureus* infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. *Clin Infect Dis* 2020;**71**:1361–1364. <https://doi.org/10.1093/cid/ciaa303>
330. Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AWW, Rupp ME, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by *Staphylococcus aureus*. *N Engl J Med* 2006;**355**:653–665. <https://doi.org/10.1056/NEJMoa053783>
331. Murray KP, Zhao JJ, Davis SL, Kullar R, Kaye KS, Lephart P, et al. Early use of daptomycin versus vancomycin for methicillin-resistant *Staphylococcus aureus* bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study. *Clin Infect Dis* 2013;**56**:1562–1569. <https://doi.org/10.1093/cid/cit112>
332. Moore CL, Osaki-Kiyan P, Haque NZ, Perri MB, Donabedian S, Zervos MJ. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant *Staphylococcus aureus* with a high vancomycin minimum inhibitory concentration: a case-control study. *Clin Infect Dis* 2012;**54**:51–58. <https://doi.org/10.1093/cid/cir764>
333. Gould IM, Miro JM, Rybak MJ. Daptomycin: the role of high-dose and combination therapy for Gram-positive infections. *Int J Antimicrob Agents* 2013;**42**:202–210. <https://doi.org/10.1016/j.ijantimicag.2013.05.005>
334. Dhand A, Bayer AS, Pogliano J, Yang SJ, Bolaris M, Nizet V, et al. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant *Staphylococcus aureus*: role of enhanced daptomycin binding. *Clin Infect Dis* 2011;**53**:158–163. <https://doi.org/10.1093/cid/cir340>
335. Miro JM, Entenza JM, Del Rio A, Velasco M, Castaneda X, Garcia de la Maria C, et al. High-dose daptomycin plus fosfomicin is safe and effective in treating methicillin-susceptible and methicillin-resistant *Staphylococcus aureus* endocarditis. *Antimicrob Agents Chemother* 2012;**56**:4511–4515. <https://doi.org/10.1128/AAC.06449-11>
336. del Rio A, Gasch O, Moreno A, Pena C, Cuquet J, Soy D, et al. Efficacy and safety of fosfomicin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant *Staphylococcus aureus*: a multicenter clinical trial. *Clin Infect Dis* 2014;**59**:1105–1112. <https://doi.org/10.1093/cid/ciu580>

337. Tattevin P, Boutoille D, Vitrat V, Van Grunderbeeck N, Revest M, Dupont M, et al. Salvage treatment of methicillin-resistant staphylococcal endocarditis with ceftaroline: a multicentre observational study. *J Antimicrob Chemother* 2014;**69**:2010–2013. <https://doi.org/10.1093/jac/dku085>
338. Vouillamoz J, Entenza JM, Feger C, Glauser MP, Moreillon P. Quinupristin-dalfopristin combined with beta-lactams for treatment of experimental endocarditis due to *Staphylococcus aureus* constitutively resistant to macrolide-lincosamide-streptogramin B antibiotics. *Antimicrob Agents Chemother* 2000;**44**:1789–1795. <https://doi.org/10.1128/AAC.44.7.1789-1795.2000>
339. Guignard B, Entenza JM, Moreillon P. Beta-lactams against methicillin-resistant *Staphylococcus aureus*. *Curr Opin Pharmacol* 2005;**5**:479–489. <https://doi.org/10.1016/j.coph.2005.06.002>
340. Jang H-C, Kim S-H, Kim KH, Kim CJ, Lee S, Song K-H, et al. Salvage treatment for persistent methicillin-resistant *Staphylococcus aureus* bacteremia: efficacy of linezolid with or without carbapenem. *Clin Infect Dis* 2009;**49**:395–401. <https://doi.org/10.1086/600295>
341. Perichon B, Courvalin P. Synergism between beta-lactams and glycopeptides against vana-type methicillin-resistant *Staphylococcus aureus* and heterologous expression of the vanA operon. *Antimicrob Agents Chemother* 2006;**50**:3622–3630. <https://doi.org/10.1128/AAC.00410-06>
342. Casalta JP, Zaratzian C, Hubert S, Thuny F, Gouriet F, Habib G, et al. Treatment of *Staphylococcus aureus* endocarditis with high doses of trimethoprim-sulfamethoxazole and clindamycin—preliminary report. *Int J Antimicrob Agents* 2013;**42**:190–191. <https://doi.org/10.1016/j.ijantimicag.2013.05.002>
343. Tissot-Dupont H, Gouriet F, Oliver L, Jamme M, Casalta JP, Jimeno MT, et al. High-dose trimethoprim-sulfamethoxazole and clindamycin for *Staphylococcus aureus* endocarditis. *Int J Antimicrob Agents* 2019;**54**:143–148. <https://doi.org/10.1016/j.ijantimicag.2019.06.006>
344. Lefevre B, Hoen B, Goehringer F, Sime WN, Aissa N, Alauzet C, et al. Antistaphylococcal penicillins vs. ceftarolin in the treatment of methicillin-susceptible *Staphylococcus aureus* infective endocarditis: a quasi-experimental monocentre study. *Eur J Clin Microbiol Infect Dis* 2021;**40**:2605–2616. <https://doi.org/10.1007/s10096-021-04313-3>
345. Jorgensen SCJ, Zasowski EJ, Trinh TD, Lagnf AM, Bhatia S, Sabagha N, et al. Daptomycin plus beta-lactam combination therapy for methicillin-resistant *Staphylococcus aureus* bloodstream infections: a retrospective, comparative cohort study. *Clin Infect Dis* 2020;**71**:1–10. <https://doi.org/10.1093/cid/ciz746>
346. Rand KH, Houck HJ. Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother* 2004;**48**:2871–2875. <https://doi.org/10.1128/AAC.48.8.2871-2875.2004>
347. Berti AD, Wergin JE, Girdaukas GG, Hetzel SJ, Sakoulas G, Rose WE. Altering the proclivity towards daptomycin resistance in methicillin-resistant *Staphylococcus aureus* using combinations with other antibiotics. *Antimicrob Agents Chemother* 2012;**56**:5046–5053. <https://doi.org/10.1128/AAC.00502-12>
348. Sakoulas G, Moise PA, Casapao AM, Nonejuie P, Olson J, Okumura CY, et al. Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. *Clin Ther* 2014;**36**:1317–1333. <https://doi.org/10.1016/j.clinthera.2014.05.061>
349. Rose WE, Schulz LT, Andes D, Striker R, Berti AD, Hutson PR, et al. Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible *Staphylococcus aureus* during therapy improves antibacterial activity. *Antimicrob Agents Chemother* 2012;**56**:5296–5302. <https://doi.org/10.1128/AAC.00797-12>
350. Chirouze C, Athan E, Alla F, Chu VH, Ralph Corey G, Selton-Suty C, et al. Enterococcal endocarditis in the beginning of the 21st century: analysis from the International Collaboration on Endocarditis-prospective cohort study. *Clin Microbiol Infect* 2013;**19**:1140–1147. <https://doi.org/10.1111/1469-0691.12166>
351. Prematunge C, MacDougall C, Johnstone J, Adomako K, Lam F, Robertson J, et al. Vre and vse bacteremia outcomes in the era of effective vre therapy: a systematic review and meta-analysis. *Infect Control Hosp Epidemiol* 2016;**37**:26–35. <https://doi.org/10.1017/ice.2015.228>
352. DiazGranados CA, Zimmer SM, Klein M, Jernigan JA. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. *Clin Infect Dis* 2005;**41**:327–333. <https://doi.org/10.1086/430909>
353. Lupia T, Roberto G, Scaglione L, Shbaklo N, De Benedetto I, Scabini S, et al. Clinical and microbiological characteristics of bloodstream infections caused by *Enterococcus* spp. within internal medicine wards: a two-year single-centre experience. *Intern Emerg Med* 2022;**17**:1129–1137. <https://doi.org/10.1007/s11739-022-02926-w>
354. Reynolds R, Potz N, Colman M, Williams A, Livermore D, MacGowan A, et al. Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001–2002: the BSAC bacteraemia resistance surveillance programme. *J Antimicrob Chemother* 2004;**53**:1018–1032. <https://doi.org/10.1093/jac/dkh232>
355. Pericas JM, Cervera C, del Rio A, Moreno A, Garcia de la Maria C, Almela M, et al. Changes in the treatment of *Enterococcus faecalis* infective endocarditis in Spain in the last 15 years: from ampicillin plus gentamicin to ampicillin plus ceftriaxone. *Clin Microbiol Infect* 2014;**20**:O1075–O1083. <https://doi.org/10.1111/1469-0691.12756>
356. Rottier WC, Pinholt M, van der Bij AK, Arpi M, Blank SN, Nabuurs-Franssen MH, et al. Attributable mortality of vancomycin resistance in ampicillin-resistant *Enterococcus faecium* bacteremia in Denmark and the Netherlands: a matched cohort study. *Infect Control Hosp Epidemiol* 2022;**43**:719–727. <https://doi.org/10.1017/ice.2021.216>
357. Pinholt M, Gumpert H, Bayliss S, Nielsen JB, Vorobieva V, Pedersen M, et al. Genomic analysis of 495 vancomycin-resistant enterococcus faecium reveals broad dissemination of a vanA plasmid in more than 19 clones from Copenhagen, Denmark. *J Antimicrob Chemother* 2017;**72**:40–47. <https://doi.org/10.1093/jac/dkw360>
358. Tajji A, Heidari H, Shahini-Shamsabadi M, Motamedifar M. High-level resistance to aminoglycosides among multidrug resistant non-faecalis and non-faecium enterococci. *Clin Lab* 2022;**68**. <https://doi.org/10.7754/Clin.Lab.2022.220222>
359. Manoharan H, Lalitha AKV, Mariappan S, Sekar U, Venkataramana GP. Molecular characterization of high-level aminoglycoside resistance among enterococcus species. *J Lab Physicians* 2022;**14**:290–294. <https://doi.org/10.1053/s-0042-1742423>
360. Fernandez-Hidalgo N, Almirante B, Gavalda J, Gurgui M, Pena C, de Alarcon A, et al. Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating *Enterococcus faecalis* infective endocarditis. *Clin Infect Dis* 2013;**56**:1261–1268. <https://doi.org/10.1093/cid/cit052>
361. Gavalda J, Len O, Miro JM, Munoz P, Montejo M, Alarcon A, et al. Brief communication: treatment of *Enterococcus faecalis* endocarditis with ampicillin plus ceftriaxone. *Ann Intern Med* 2007;**146**:574–579. <https://doi.org/10.7326/0003-4819-146-8-200704170-00008>
362. Miro JM, Pericas JM, del Rio A; Hospital Clinic Endocarditis Study Group. A new era for treating *Enterococcus faecalis* endocarditis: ampicillin plus short-course gentamicin or ampicillin plus ceftriaxone: that is the question!. *Circulation* 2013;**127**:1763–1766. <https://doi.org/10.1161/CIRCULATIONAHA.113.002431>
363. Olaison L, Schadowitz K; Swedish Society of Infectious Diseases Quality Assurance Study Group for Endocarditis. Enterococcal endocarditis in Sweden, 1995–1999: can shorter therapy with aminoglycosides be used? *Clin Infect Dis* 2002;**34**:159–166. <https://doi.org/10.1086/338233>
364. De Nadai T, Francois M, Sommet A, Dubois D, Metsu D, Grare M, et al. Efficacy of teicoplanin monotherapy following initial standard therapy in *Enterococcus faecalis* infective endocarditis: a retrospective cohort study. *Infection* 2019;**47**:463–469. <https://doi.org/10.1007/s15010-019-01290-w>
365. Escola-Verge L, Fernandez-Hidalgo N, Rodriguez-Pardo D, Pigrau C, Gonzalez-Lopez JJ, Bartolome R, et al. Teicoplanin for treating enterococcal infective endocarditis: a retrospective observational study from a referral centre in Spain. *Int J Antimicrob Agents* 2019;**53**:165–170. <https://doi.org/10.1016/j.ijantimicag.2018.10.003>
366. Herrera-Hidalgo L, Lomas-Cabezas JM, Lopez-Cortes LE, Luque-Marquez R, Lopez-Cortes LF, Martinez-Marcos FJ, et al. Ampicillin plus ceftriaxone combined therapy for *Enterococcus faecalis* infective endocarditis in OPAT. *J Clin Med* 2021;**11**:7. <https://doi.org/10.3390/jcm11010007>
367. Herrera-Hidalgo L, Lopez-Cortes LE, Luque-Marquez R, Galvez-Acebal J, de Alarcon A, Lopez-Cortes LF, et al. Ampicillin and ceftriaxone solution stability at different temperatures in outpatient parenteral antimicrobial therapy. *Antimicrob Agents Chemother* 2020;**64**:e00309-20. <https://doi.org/10.1128/AAC.00309-20>
368. Erlanson KM, Sun J, Iwen PC, Rupp ME. Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant enterococcus bacteremia. *Clin Infect Dis* 2008;**46**:30–36. <https://doi.org/10.1086/523588>
369. Wang JT, Yang CJ, Yang JL, Lin SW, Chuang YC, Sheng WH, et al. A high daptomycin dose is associated with better bacterial clearance in infections caused by vancomycin-resistant enterococcus faecium regardless of daptomycin minimum inhibitory concentration in a rat infective endocarditis model. *Microbiol Spectr* 2022;**10**:e0255122. <https://doi.org/10.1128/spectrum.02551-22>
370. Blackberg A, Morenius C, Olaison L, Berge A, Rasmussen M. Infective endocarditis caused by HACEK group bacteria—a registry-based comparative study. *Eur J Clin Microbiol Infect Dis* 2021;**40**:1919–1924. <https://doi.org/10.1007/s10096-021-04240-3>
371. Paturel L, Casalta JP, Habib G, Nezri M, Raoult D. Actinobacillus actinomycetemcomitans endocarditis. *Clin Microbiol Infect* 2004;**10**:98–118. <https://doi.org/10.1111/j.1469-0691.2004.00794.x>
372. Das M, Badley AD, Cockerill FR, Steckelberg JM, Wilson WR. Infective endocarditis caused by HACEK microorganisms. *Annu Rev Med* 1997;**48**:25–33. <https://doi.org/10.1146/annurev.med.48.1.25>
373. Chambers ST, Murdoch D, Morris A, Holland D, Pappas P, Almela M, et al. HACEK infective endocarditis: characteristics and outcomes from a large, multi-national cohort. *PLoS One* 2013;**8**:e63181. <https://doi.org/10.1371/journal.pone.0063181>
374. Morpeth S, Murdoch D, Cabell CH, Karchmer AV, Pappas P, Levine D, et al. Non-HACEK Gram-negative bacillus endocarditis. *Ann Intern Med* 2007;**147**:829–835. <https://doi.org/10.7326/0003-4819-147-12-200712180-00002>
375. Lorenz A, Sobhanie MME, Orzel L, Coe K, Wardlow L. Clinical outcomes of combination versus monotherapy for Gram negative non-HACEK infective endocarditis. *Diagn Microbiol Infect Dis* 2021;**101**:115504. <https://doi.org/10.1016/j.diagmicrobio.2021.115504>

376. Veve MP, McCurry ED, Cooksey GE, Shorman MA. Epidemiology and outcomes of non-HACEK infective endocarditis in the southeast United States. *PLoS One* 2020; **15**:e0230199. <https://doi.org/10.1371/journal.pone.0230199>
377. Tattevin P, Watt G, Revest M, Arvieux C, Fournier PE. Update on blood culture-negative endocarditis. *Med Mal Infect* 2015; **45**:1–8. <https://doi.org/10.1016/j.medmal.2014.11.003>
378. Houpiakian P, Raoult D. Blood culture-negative endocarditis in a reference center: etiologic diagnosis of 348 cases. *Medicine (Baltimore)* 2005; **84**:162–173. <https://doi.org/10.1097/01.md.0000165658.82869.17>
379. Raoult D, Fournier PE, Vandenesch F, Mainardi JL, Eykyn SJ, Nash J, et al. Outcome and treatment of Bartonella endocarditis. *Arch Intern Med* 2003; **163**:226–230. <https://doi.org/10.1001/archinte.163.2.226>
380. Dajani AS, Taubert KA, Wilson W, Bolger AF, Bayer A, Ferrieri P, et al. Prevention of bacterial endocarditis. Recommendations by the American Heart Association. *Circulation* 1997; **96**:358–366. <https://doi.org/10.1161/01.CIR.96.1.358>
381. Rolain JM, Brouqui P, Koehler JE, Maguina C, Dolan MJ, Raoult D. Recommendations for treatment of human infections caused by Bartonella species. *Antimicrob Agents Chemother* 2004; **48**:1921–33. <https://doi.org/10.1128/AAC.48.6.1921-1933.2004>
382. Ghigo E, Capo C, Arouze M, Tung CH, Gorvel JP, Raoult D, et al. Survival of *Tropheryma whippelii*, the agent of Whipple's disease, requires phagosomal acidification. *Infect Immun* 2002; **70**:1501–1506. <https://doi.org/10.1128/IAI.70.3.1501-1506.2002>
383. Brouqui P, Raoult D. Endocarditis due to rare and fastidious bacteria. *Clin Microbiol Rev* 2001; **14**:177–207. <https://doi.org/10.1128/CMR.14.1.177-207.2001>
384. Garcia-Alvarez L, Sanz MM, Marin M, Montejo M, Goikoetxea J, et al. Antimicrobial management of *Tropheryma whippelii* endocarditis: the Spanish collaboration on endocarditis (games) experience. *J Antimicrob Chemother* 2019; **74**:1713–1717. <https://doi.org/10.1093/jac/dkz059>
385. Calderon Parra J, De Castro-Campos D, Munoz Garcia P, Olmedo Samperio M, Marin Arriaza M, De Alarcon A, et al. Non-HACEK Gram negative bacilli endocarditis: analysis of a national prospective cohort. *Eur J Intern Med* 2021; **92**:71–78. <https://doi.org/10.1016/j.ejim.2021.04.021>
386. Tattevin P, Revest M, Lefort A, Michelet C, Lortholary O. Fungal endocarditis: current challenges. *Int J Antimicrob Agents* 2014; **44**:290–294. <https://doi.org/10.1016/j.ijantimicag.2014.07.003>
387. Smego RA Jr, Ahmad H. The role of fluconazole in the treatment of *Candida endocarditis*: a meta-analysis. *Medicine (Baltimore)* 2011; **90**:237–249. <https://doi.org/10.1097/MD.0b013e3182259d38>
388. Kalokhe AS, Roupael N, El Chami MF, Workowski KA, Ganesh G, Jacob JT. Aspergillus endocarditis: a review of the literature. *Int J Infect Dis* 2010; **14**:e1040–e1047. <https://doi.org/10.1016/j.ijid.2010.08.005>
389. Lye DC, Hughes A, O'Brien D, Athan E. *Candida glabrata* prosthetic valve endocarditis treated successfully with fluconazole plus caspofungin without surgery: a case report and literature review. *Eur J Clin Microbiol Infect Dis* 2005; **24**:753–755. <https://doi.org/10.1007/s10096-005-0038-2>
390. Valerio M, Camici M, Machado M, Galar A, Olmedo M, Sousa D, et al. Aspergillus endocarditis in the recent years, report of cases of a multicentric national cohort and literature review. *Mycoses* 2022; **65**:362–373. <https://doi.org/10.1111/myc.13415>
391. Lee A, Mirrett S, Reller LB, Weinstein MP. Detection of bloodstream infections in adults: how many blood cultures are needed? *J Clin Microbiol* 2007; **45**:3546–3548. <https://doi.org/10.1128/JCM.01555-07>
392. Paul M, Zemer-Wassercug N, Talker O, Lishtzinsky Y, Lev B, Samra Z, et al. Are all beta-lactams similarly effective in the treatment of methicillin-sensitive *Staphylococcus aureus* bacteraemia? *Clin Microbiol Infect* 2011; **17**:1581–1586. <https://doi.org/10.1111/j.1469-0691.2010.03425.x>
393. Braquet P, Alla F, Cornu C, Goehringer F, Piroth L, Chirouze C, et al. Factors associated with 12 week case-fatality in *Staphylococcus aureus* bacteraemia: a prospective cohort study. *Clin Microbiol Infect* 2016; **22**:948.e1–948.e7. <https://doi.org/10.1016/j.cmi.2016.07.034>
394. Willekens R, Puig-Asensio M, Suanzes P, Fernandez-Hidalgo N, Larrosa MN, Gonzalez-Lopez JJ, et al. Empirical use of beta-lactam/beta-lactamase inhibitor combinations does not increase mortality compared with cloxacillin and cefazolin in methicillin-susceptible *Staphylococcus aureus* bacteraemia: a propensity-weighted cohort study. *J Antimicrob Chemother* 2022; **77**:2288–2295. <https://doi.org/10.1093/jac/dkac152>
395. VanEperen AS, Segreti J. Empirical therapy in methicillin-resistant *Staphylococcus aureus* infections: an up-to-date approach. *J Infect Chemother* 2016; **22**:351–359. <https://doi.org/10.1016/j.jiac.2016.02.012>
396. Rezar R, Jirak P, Lichtenauer M, Jung C, Lauten A, Hoppe UC, et al. Partial oral antibiotic therapy is non-inferior to intravenous therapy in non-critically ill patients with infective endocarditis: review and meta-analysis. *Wien Klin Wochenschr* 2020; **132**:762–769. <https://doi.org/10.1007/s00508-020-01614-z>
397. Spellberg B, Chambers HF, Musher DM, Walsh TL, Bayer AS. Evaluation of a paradigm shift from intravenous antibiotics to oral step-down therapy for the treatment of infective endocarditis: a narrative review. *JAMA Intern Med* 2020; **180**:769–777. <https://doi.org/10.1001/jamainternmed.2020.0555>
398. Rajaratnam D, Rajaratnam R. Outpatient antimicrobial therapy for infective endocarditis is safe. *Heart Lung Circ* 2021; **30**:207–215. <https://doi.org/10.1016/j.hlc.2020.08.016>
399. Perica SJ, Llopis J, Gonzalez-Ramallo V, Goenaga MA, Munoz P, Garcia-Leoni ME, et al. Outpatient parenteral antibiotic treatment for infective endocarditis: a prospective cohort study from the games cohort. *Clin Infect Dis* 2019; **69**:1690–1700. <https://doi.org/10.1093/cid/ciz030>
400. Forestier E, Roubaud-Baudron C, Fraise T, Patry C, Gavazzi G, Hoen B, et al. Comprehensive geriatric assessment in older patients suffering from infective endocarditis. A prospective multicentric cohort study. *Clin Microbiol Infect* 2019; **25**:1246–1252. <https://doi.org/10.1016/j.cmi.2019.04.021>
401. Pries-Heje MM, Wiingard C, Ihlemann N, Gill SU, Bruun NE, Elming H, et al. Five-year outcomes of the partial oral treatment of endocarditis (POET) trial. *N Engl J Med* 2022; **386**:601–602. <https://doi.org/10.1056/NEJMc2114046>
402. Tobudic S, Forstner C, Burgmann H, Lagler H, Ramharter M, Steiningger C, et al. Dalbavancin as primary and sequential treatment for Gram-positive infective endocarditis: 2-year experience at the general hospital of Vienna. *Clin Infect Dis* 2018; **67**:795–798. <https://doi.org/10.1093/cid/ciy279>
403. lung B, Doco-Lecompte T, Chocron S, Strady C, Delahaye F, Le Moing V, et al. Cardiac surgery during the acute phase of infective endocarditis: discrepancies between European Society of Cardiology guidelines and practices. *Eur Heart J* 2016; **37**:840–848. <https://doi.org/10.1093/eurheartj/ehv650>
404. Ostergaard L, Oestergaard LB, Lauridsen TK, Dahl A, Chaudry M, Gislason G, et al. Long-term causes of death in patients with infective endocarditis who undergo medical therapy only or surgical treatment: a nationwide population-based study. *Eur J Cardiothorac Surg* 2018; **54**:860–866. <https://doi.org/10.1093/ejcts/ezy156>
405. Arminanzas C, Farinas-Alvarez C, Zarauza J, Munoz P, Gonzalez Ramallo V, Martinez Selles M, et al. Role of age and comorbidities in mortality of patients with infective endocarditis. *Eur J Intern Med* 2019; **64**:63–71. <https://doi.org/10.1016/j.ejim.2019.03.006>
406. Diab M, Sponholz C, von Loeffelholz C, Scheffel P, Bauer M, Kortgen A, et al. Impact of perioperative liver dysfunction on in-hospital mortality and long-term survival in infective endocarditis patients. *Infection* 2017; **45**:857–866. <https://doi.org/10.1007/s15010-017-1064-6>
407. Nashef SA, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR, et al. EuroSCORE II. *Eur J Cardiothorac Surg* 2012; **41**:734–744, discussion 744–745. <https://doi.org/10.1093/ejcts/ezs043>
408. Shahian DM, Jacobs JP, Badhwar V, Kurlansky PA, Furnary AP, Cleveland JC Jr, et al. The Society of Thoracic Surgeons 2018 adult cardiac surgery risk models: Part 1—background, design considerations, and model development. *Ann Thorac Surg* 2018; **105**:1411–1418. <https://doi.org/10.1016/j.athoracsur.2018.03.002>
409. Costa MA, Wollmann DR Jr, Campos AC, Cunha CL, Carvalho RG, Andrade DF, et al. Risk index for death by infective endocarditis: a multivariate logistic model. *Rev Bras Cir Cardiovasc* 2007; **22**:192–200. <https://doi.org/10.1590/s0102-76382007000200007>
410. De Feo M, Cotrufo M, Carozza A, De Santo LS, Amendolara F, Giordano S, et al. The need for a specific risk prediction system in native valve infective endocarditis surgery. *Sci World J* 2012; **2012**:307571. <https://doi.org/10.1100/2012/307571>
411. Di Mauro M, Dato GMA, Barili F, Gelsomino S, Sante P, Corte AD, et al. A predictive model for early mortality after surgical treatment of heart valve or prosthesis infective endocarditis. The endoscore. *Int J Cardiol* 2017; **241**:97–102. <https://doi.org/10.1016/j.ijcard.2017.03.148>
412. Fernandez-Hidalgo N, Ferreria-Gonzalez I, Marsal JR, Ribera A, Aznar ML, de Alarcon A, et al. A pragmatic approach for mortality prediction after surgery in infective endocarditis: optimizing and refining EuroSCORE. *Clin Microbiol Infect* 2018; **24**:1102.e7–1102.e15. <https://doi.org/10.1016/j.cmi.2018.01.019>
413. Gaca JG, Sheng S, Daneshmand MA, O'Brien S, Rankin JS, Brennan JM, et al. Outcomes for endocarditis surgery in North America: a simplified risk scoring system. *J Thorac Cardiovasc Surg* 2011; **141**:98–106.e2. <https://doi.org/10.1016/j.jtcvs.2010.09.016>
414. Gatti G, Perrotti A, Obadia JF, Duval X, lung B, Alla F, et al. Simple scoring system to predict in-hospital mortality after surgery for infective endocarditis. *J Am Heart Assoc* 2017; **6**:e004806. <https://doi.org/10.1161/JAHA.116.004806>
415. Chu VH, Park LP, Athan E, Delahaye F, Freiburger T, Lamas C, et al. Association between surgical indications, operative risk, and clinical outcome in infective endocarditis: a prospective study from the International Collaboration on Endocarditis. *Circulation* 2015; **131**:131–140. <https://doi.org/10.1161/CIRCULATIONAHA.114.012461>
416. Varela Barca L, Fernandez-Felix BM, Navas Elorza E, Mestres CA, Munoz P, Cuerdo-Caballero G, et al. Prognostic assessment of valvular surgery in active infective endocarditis: multicentric nationwide validation of a new score developed from a meta-analysis. *Eur J Cardiothorac Surg* 2020; **57**:724–731. <https://doi.org/10.1093/ejcts/ezz328>
417. Varela Barca L, Navas Elorza E, Fernandez-Hidalgo N, Moya Mur JL, Muriel Garcia A, Fernandez-Felix BM, et al. Prognostic factors of mortality after surgery in infective endocarditis: systematic review and meta-analysis. *Infection* 2019; **47**:879–895. <https://doi.org/10.1007/s15010-019-01338-x>
418. Fernandez-Cisneros A, Hernandez-Meneses M, Llopis J, Sandoval E, Pereda D, Alcocer J, et al. Risk scores' performance and their impact on operative decision-making in left-

- sided endocarditis: a cohort study. *Eur J Clin Microbiol Infect Dis* 2023;**42**:33–42. <https://doi.org/10.1007/s10096-022-04516-2>
419. Tornos P, lung B, Permyner-Miralda G, Baron G, Delahaye F, Gohlke-Barwolf C, et al. Infective endocarditis in Europe: lessons from the Euro heart survey. *Heart* 2005;**91**: 571–575. <https://doi.org/10.1136/hrt.2003.032128>
  420. Kiefer T, Park L, Tribouilloy C, Cortes C, Casillo R, Chu V, et al. Association between valvular surgery and mortality among patients with infective endocarditis complicated by heart failure. *JAMA* 2011;**306**:2239–2247. <https://doi.org/10.1001/jama.2011.1701>
  421. Lalani T, Chu VH, Park LP, Cecchi E, Corey GR, Durante-Mangoni E, et al. In-hospital and 1-year mortality in patients undergoing early surgery for prosthetic valve endocarditis. *JAMA Intern Med* 2013;**173**:1495–1504. <https://doi.org/10.1001/jamainternmed.2013.8203>
  422. Lopez J, Sevilla T, Vilacosta I, Garcia H, Sarria C, Pozo E, et al. Clinical significance of congestive heart failure in prosthetic valve endocarditis. A multicenter study with 257 patients. *Rev Esp Cardiol (Engl Ed)* 2013;**66**:384–390. <https://doi.org/10.1016/j.rec.2012.10.022>
  423. Nadji G, Rusinaru D, Remadi JP, Jau A, Sorel C, Tribouilloy C. Heart failure in left-sided native valve infective endocarditis: characteristics, prognosis, and results of surgical treatment. *Eur J Heart Fail* 2009;**11**:668–675. <https://doi.org/10.1093/eurjhf/hfp077>
  424. Pericas JM, Hernandez-Meneses M, Munoz P, Martinez-Selles M, Alvarez-Uria A, de Alarcon A, et al. Characteristics and outcome of acute heart failure in infective endocarditis: focus on cardiogenic shock. *Clin Infect Dis* 2021;**73**:765–774. <https://doi.org/10.1093/cid/ciab098>
  425. Mir T, Uddin M, Qureshi WT, Regmi N, Tleyjeh IM, Saydain G. Predictors of complications secondary to infective endocarditis and their associated outcomes: a large cohort study from the national emergency database (2016–2018). *Infect Dis Ther* 2022;**11**: 305–321. <https://doi.org/10.1007/s40121-021-00563-y>
  426. Aksoy O, Sexton DJ, Wang A, Pappas PA, Kourany W, Chu V, et al. Early surgery in patients with infective endocarditis: a propensity score analysis. *Clin Infect Dis* 2007;**44**:364–372. <https://doi.org/10.1086/510583>
  427. Habib G, Tribouilloy C, Thuny F, Giorgi R, Brahim A, Amazoum M, et al. Prosthetic valve endocarditis: who needs surgery? A multicentre study of 104 cases. *Heart* 2005;**91**: 954–959. <https://doi.org/10.1136/hrt.2004.046177>
  428. Nadji G, Goissen T, Brahim A, Covioux F, Lorgeron N, Tribouilloy C. Impact of early surgery on 6-month outcome in acute infective endocarditis. *Int J Cardiol* 2008;**129**: 227–232. <https://doi.org/10.1016/j.ijcard.2007.07.087>
  429. Thuny F, Beurtheret S, Mancini J, Gariboldi V, Casalta JP, Riberi A, et al. The timing of surgery influences mortality and morbidity in adults with severe complicated infective endocarditis: a propensity analysis. *Eur Heart J* 2011;**32**:2027–2033. <https://doi.org/10.1093/eurheartj/ehp089>
  430. Bohbot Y, Habib G, Laroche C, Stohr E, Chirouze C, Hernandez-Meneses M, et al. Characteristics, management, and outcomes of patients with left-sided infective endocarditis complicated by heart failure: a substudy of the ESC-EORP EURO-ENDO (European infective endocarditis) registry. *Eur J Heart Fail* 2022;**24**:1253–1265. <https://doi.org/10.1002/ehf.2525>
  431. Siciliano RF, Gualandro DM, Bittencourt MS, Paixao M, Marcondes-Braga F, Soeiro AM, et al. Biomarkers for prediction of mortality in left-sided infective endocarditis. *Int J Infect Dis* 2020;**96**:25–30. <https://doi.org/10.1016/j.ijid.2020.03.009>
  432. Wei X-B, Liu Y-H, He P-C, Yu D-Q, Zhou Y-L, Tan N, et al. Prognostic value of N-terminal prohormone brain natriuretic peptide for in-hospital and long-term outcomes in patients with infective endocarditis. *Eur J Prev Cardiol* 2017;**24**:676–684. <https://doi.org/10.1177/2047487316686436>
  433. Ostergaard L, Dahl A, Bruun NE, Oestergaard LB, Lauridsen TK, Torp-Pedersen C, et al. Valve regurgitation in patients surviving endocarditis and the subsequent risk of heart failure. *Heart* 2020;**106**:1015–1022. <https://doi.org/10.1136/heartjnl-2019-315715>
  434. Revilla A, Lopez J, Vilacosta I, Villacorta E, Rollan MJ, Echevarria JR, et al. Clinical and prognostic profile of patients with infective endocarditis who need urgent surgery. *Eur Heart J* 2007;**28**:65–71. <https://doi.org/10.1093/eurheartj/ehi315>
  435. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). *JAMA* 2016;**315**:801–810. <https://doi.org/10.1001/jama.2016.0287>
  436. Pericas JM, Hernandez-Meneses M, Munoz P, Alvarez-Uria A, Pinilla-Llorente B, de Alarcon A, et al. Outcomes and risk factors of septic shock in patients with infective endocarditis: a prospective cohort study. *Open Forum Infect Dis* 2021;**8**:ofab119. <https://doi.org/10.1093/ofid/ofab119>
  437. Lopez J, Sevilla T, Vilacosta I, Sarria C, Revilla A, Ortiz C, et al. Prognostic role of persistent positive blood cultures after initiation of antibiotic therapy in left-sided infective endocarditis. *Eur Heart J* 2013;**34**:1749–1754. <https://doi.org/10.1093/eurheartj/ehs379>
  438. Horstkotte D, Follath F, Gutschik E, Lengyel M, Oto A, Pavie A, et al. Guidelines on prevention, diagnosis and treatment of infective endocarditis executive summary: the task force on infective endocarditis of the European Society of Cardiology. *Eur Heart J* 2004;**25**:267–276. <https://doi.org/10.1016/j.ehj.2003.11.008>
  439. Ramanathan A, Witten JC, Gordon SM, Griffin BP, Pettersson GB, Shrestha NK. Factors associated with local invasion in infective endocarditis: a nested case-control study. *Clin Microbiol Infect* 2021;**27**:1011–1014. <https://doi.org/10.1016/j.cmi.2020.09.003>
  440. Kiyota Y, Della Corte A, Montiero Vieira V, Habchi K, Huang C-C, Della Ratta EE, et al. Risk and outcomes of aortic valve endocarditis among patients with bicuspid and tricuspid aortic valves. *Open Heart* 2017;**4**:e000545. <https://doi.org/10.1136/openhrt-2016-000545>
  441. Forteza A, Centeno J, Ospina V, Lunar IG, Sanchez V, Perez E, et al. Outcomes in aortic and mitral valve replacement with intervalvular fibrous body reconstruction. *Ann Thorac Surg* 2015;**99**:838–845. <https://doi.org/10.1016/j.athoracsur.2014.09.052>
  442. Panagides V, Del Val D, Abdel-Wahab M, Mangner N, Durand E, Ihlemann N, et al. Perivalvular extension of infective endocarditis after transcatheter aortic valve replacement. *Clin Infect Dis* 2022;**75**:638–646. <https://doi.org/10.1093/cid/ciab1004>
  443. Sordelli C, Fele N, Mocerino R, Weisz SH, Ascione L, Caso P, et al. Infective endocarditis: echocardiographic imaging and new imaging modalities. *J Cardiovasc Echogr* 2019;**29**:149–155. [https://doi.org/10.4103/jcecho.jcecho\\_53\\_19](https://doi.org/10.4103/jcecho.jcecho_53_19)
  444. Ramos-Martinez A, Calderon-Parra J, Miro JM, Munoz P, Rodriguez-Abella H, Valerio M, et al. Effect of the type of surgical indication on mortality in patients with infective endocarditis who are rejected for surgical intervention. *Int J Cardiol* 2019;**282**:24–30. <https://doi.org/10.1016/j.ijcard.2019.01.014>
  445. Anguera I, Miro JM, Vilacosta I, Almirante B, Anguita M, Munoz P, et al. Aorto-cavitary fistulous tract formation in infective endocarditis: clinical and echocardiographic features of 76 cases and risk factors for mortality. *Eur Heart J* 2005;**26**:288–297. <https://doi.org/10.1093/eurheartj/ehi034>
  446. Knosalla C, Weng Y, Yankah AC, Siniawski H, Hofmeister J, Hammerschmidt R, et al. Surgical treatment of active infective aortic valve endocarditis with associated perianular abscess—11 year results. *Eur Heart J* 2000;**21**:490–497. <https://doi.org/10.1053/ehj.1999.1877>
  447. Baddley JW, Benjamin DK Jr, Patel M, Miro J, Athan E, Barsic B, et al. Candida infective endocarditis. *Eur J Clin Microbiol Infect Dis* 2008;**27**:519–529. <https://doi.org/10.1007/s10096-008-0466-x>
  448. Ellis ME, Al-Abdely H, Sandridge A, Greer W, Ventura W. Fungal endocarditis: evidence in the world literature, 1965–1995. *Clin Infect Dis* 2001;**32**:50–62. <https://doi.org/10.1086/317550>
  449. Remadi JP, Habib G, Nadji G, Brahim A, Thuny F, Casalta JP, et al. Predictors of death and impact of surgery in *Staphylococcus aureus* infective endocarditis. *Ann Thorac Surg* 2007;**83**:1295–1302. <https://doi.org/10.1016/j.athoracsur.2006.09.093>
  450. Mamtani S, Aljanabi NM, Gupta Rauniyar RP, Acharya A, Malik BH. Candida endocarditis: a review of the pathogenesis, morphology, risk factors, and management of an emerging and serious condition. *Cureus* 2020;**12**:e6695. <https://doi.org/10.7759/cureus.6695>
  451. Garcia-Cabrera E, Fernandez-Hidalgo N, Almirante B, Ivanova-Georgieva R, Nouredine M, Plata A, et al. Neurological complications of infective endocarditis: risk factors, outcome, and impact of cardiac surgery: a multicenter observational study. *Circulation* 2013;**127**:2272–2284. <https://doi.org/10.1161/CIRCULATIONAHA.112.000813>
  452. Selton-Suty C, Delahaye F, Tattevin P, Federspiel C, Le Moing V, Chirouze C, et al. Symptomatic and asymptomatic neurological complications of infective endocarditis: impact on surgical management and prognosis. *PLoS One* 2016;**11**:e0158522. <https://doi.org/10.1371/journal.pone.0158522>
  453. Diab M, Guenther A, Sponholz C, Lehmann T, Faerber G, Matz A, et al. Pre-operative stroke and neurological disability do not independently affect short- and long-term mortality in infective endocarditis patients. *Clin Res Cardiol* 2016;**105**:847–857. <https://doi.org/10.1007/s00392-016-0993-x>
  454. Thuny F, Avierinos JF, Tribouilloy C, Giorgi R, Casalta JP, Milandre L, et al. Impact of cerebrovascular complications on mortality and neurologic outcome during infective endocarditis: a prospective multicentre study. *Eur Heart J* 2007;**28**:1155–1161. <https://doi.org/10.1093/eurheartj/ehm005>
  455. Vilacosta I, Graupner C, San Roman JA, Sarria C, Ronderos R, Fernandez C, et al. Risk of embolization after institution of antibiotic therapy for infective endocarditis. *J Am Coll Cardiol* 2002;**39**:1489–1495. [https://doi.org/10.1016/S0735-1097\(02\)01790-4](https://doi.org/10.1016/S0735-1097(02)01790-4)
  456. Dickerman SA, Abrutyn E, Barsic B, Bouza E, Cecchi E, Moreno A, et al. The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infective endocarditis: an analysis from the ICE prospective cohort study (ICE-PCS). *Am Heart J* 2007;**154**:1086–1094. <https://doi.org/10.1016/j.ahj.2007.07.023>
  457. Thuny F, Di Salvo G, Belliard O, Avierinos JF, Pergola V, Rosenberg V, et al. Risk of embolism and death in infective endocarditis: prognostic value of echocardiography: a prospective multicenter study. *Circulation* 2005;**112**:69–75. <https://doi.org/10.1161/CIRCULATIONAHA.104.493155>
  458. Cabell CH, Pond KK, Peterson GE, Durack DT, Corey GR, Anderson DJ, et al. The risk of stroke and death in patients with aortic and mitral valve endocarditis. *Am Heart J* 2001;**142**:75–80. <https://doi.org/10.1067/mhj.2001.115790>
  459. Kim D-H, Kang D-H, Lee M-Z, Yun S-C, Kim Y-J, Song J-M, et al. Impact of early surgery on embolic events in patients with infective endocarditis. *Circulation* 2010;**122**(11 Suppl):S17–S22. <https://doi.org/10.1161/CIRCULATIONAHA.109.927665>
  460. Mohanandey D, Mohadjer A, Pettersson G, Navia J, Gordon S, Shrestha N, et al. Association of vegetation size with embolic risk in patients with infective endocarditis:

- a systematic review and meta-analysis. *JAMA Intern Med* 2018;**178**:502–510. <https://doi.org/10.1001/jamainternmed.2017.8653>
461. Pergola V, Di Salvo G, Habib G, Avierinos JF, Philip E, Vailloud JM, et al. Comparison of clinical and echocardiographic characteristics of *Streptococcus bovis* endocarditis with that caused by other pathogens. *Am J Cardiol* 2001;**88**:871–875. [https://doi.org/10.1016/S0002-9149\(01\)01914-2](https://doi.org/10.1016/S0002-9149(01)01914-2)
  462. Durante Mangoni E, Adinolfi LE, Tripodi MF, Andreana A, Gambardella M, Ragone E, et al. Risk factors for “major” embolic events in hospitalized patients with infective endocarditis. *Am Heart J* 2003;**146**:311–316. [https://doi.org/10.1016/S0002-8703\(02\)94802-7](https://doi.org/10.1016/S0002-8703(02)94802-7)
  463. Young WJ, Hoare D, Bvekerwa I, Primus C, Wani RS, Das S, et al. Association of vegetation size with valve destruction, embolism and mortality. *Heart Lung Circ* 2021;**30**:854–860. <https://doi.org/10.1016/j.hlc.2020.10.028>
  464. Cabezon G, Lopez J, Vilacosta I, Saez C, Garcia-Granja PE, Olmos C, et al. Reassessment of vegetation size as a sole indication for surgery in left-sided infective endocarditis. *J Am Soc Echocardiogr* 2022;**35**:570–575. <https://doi.org/10.1016/j.echo.2021.12.013>
  465. Rizzi M, Ravasio V, Carobbio A, Mattucci I, Crapis M, Stellini R, et al. Predicting the occurrence of embolic events: an analysis of 1456 episodes of infective endocarditis from the Italian Study on Endocarditis (SEL). *BMC Infect Dis* 2014;**14**:230. <https://doi.org/10.1186/1471-2334-14-230>
  466. Scheggi V, Alterini B, Olivetto I, Del Pace S, Zoppetti N, Tomberli B, et al. Embolic risk stratification and prognostic impact of early surgery in left-sided infective endocarditis. *Eur J Intern Med* 2020;**78**:82–87. <https://doi.org/10.1016/j.ejim.2020.04.017>
  467. Shiue AB, Stancoven AB, Purcell JB, Pinkston K, Wang A, Khera A, et al. Relation of level of B-type natriuretic peptide with outcomes in patients with infective endocarditis. *Am J Cardiol* 2010;**106**:1011–1015. <https://doi.org/10.1016/j.amjcard.2010.05.034>
  468. Sorabella RA, Han SM, Grbic M, Wu YS, Takayama H, Kurlansky P, et al. Early operation for endocarditis complicated by preoperative cerebral emboli is not associated with worsened outcomes. *Ann Thorac Surg* 2015;**100**:501–508. <https://doi.org/10.1016/j.athoracsur.2015.03.078>
  469. Diab M, Franz M, Hagel S, Guenther A, Struve A, Musleh R, et al. Impact of an in-hospital endocarditis team and a state-wide endocarditis network on perioperative outcomes. *J Clin Med* 2021;**10**:4734. <https://doi.org/10.3390/jcm10204734>
  470. Hubert S, Thuny F, Resseguier N, Giorgi R, Tribouilloy C, Le Dolley Y, et al. Prediction of symptomatic embolism in infective endocarditis: construction and validation of a risk calculator in a multicenter cohort. *J Am Coll Cardiol* 2013;**62**:1384–1392. <https://doi.org/10.1016/j.jacc.2013.07.029>
  471. Kang D-H, Kim Y-J, Kim S-H, Sun BJ, Kim D-H, Yun S-C, et al. Early surgery versus conventional treatment for infective endocarditis. *N Engl J Med* 2012;**366**:2466–2473. <https://doi.org/10.1056/NEJMoa1112843>
  472. Ferrera C, Vilacosta I, Fernandez C, Lopez J, Sarria C, Olmos C, et al. Early surgery for acute-onset infective endocarditis. *Eur J Cardiothorac Surg* 2018;**54**:1060–1066. <https://doi.org/10.1093/ejcts/ezy208>
  473. Kim YK, Choi CG, Jung J, Yu SN, Lee JY, Chong YP, et al. Effect of cerebral embolus size on the timing of cardiac surgery for infective endocarditis in patients with neurological complications. *Eur J Clin Microbiol Infect Dis* 2018;**37**:545–553. <https://doi.org/10.1007/s10096-017-3148-8>
  474. Dashkevich A, Bratkov G, Li Y, Joskowiak D, Peterss S, Juchem G, et al. Impact of operative timing in infective endocarditis with cerebral embolism—the risk of intermediate deterioration. *J Clin Med* 2021;**10**:2136. <https://doi.org/10.3390/jcm10102136>
  475. Hill EE, Herregods MC, Vanderschueren S, Claus P, Peetermans WE, Herijgers P. Outcome of patients requiring valve surgery during active infective endocarditis. *Ann Thorac Surg* 2008;**85**:1564–1569. <https://doi.org/10.1016/j.athoracsur.2008.02.014>
  476. Anguera I, Miro JM, Cabell CH, Abrutyn E, Fowler VG Jr, Hoen B, et al. Clinical characteristics and outcome of aortic endocarditis with periannular abscess in the International Collaboration on Endocarditis merged database. *Am J Cardiol* 2005;**96**:976–981. <https://doi.org/10.1016/j.amjcard.2005.05.056>
  477. Handa K, Yoshioka D, Toda K, Yokoyama J-Y, Samura T, Suzuki K, et al. Surgical results for infective endocarditis complicated with cardiogenic shock. *Circ J* 2020;**84**:926–934. <https://doi.org/10.1253/circj.CJ-19-0583>
  478. Fosbol EL, Park LP, Chu VH, Athan E, Delahaye F, Freiburger T, et al. The association between vegetation size and surgical treatment on 6-month mortality in left-sided infective endocarditis. *Eur Heart J* 2019;**40**:2243–2251. <https://doi.org/10.1093/eurheartj/ehz204>
  479. Yanagawa B, Elbatarny M, Verma S, Hill S, Mazine A, Puskas JD, et al. Surgical management of tricuspid valve infective endocarditis: a systematic review and meta-analysis. *Ann Thorac Surg* 2018;**106**:708–714. <https://doi.org/10.1016/j.athoracsur.2018.04.012>
  480. Ruttman E, Willeit J, Ulmer H, Chevtchik O, Hofer D, Poewe W, et al. Neurological outcome of septic cardioembolic stroke after infective endocarditis. *Stroke* 2006;**37**:2094–2099. <https://doi.org/10.1161/01.STR.0000229894.28591.3f>
  481. Asaithambi G, Adi MM, Qureshi AI. Thrombolysis for ischemic stroke associated with infective endocarditis: results from the nationwide inpatient sample. *Stroke* 2013;**44**:2917–2919. <https://doi.org/10.1161/STROKEAHA.113.001602>
  482. Chan KL, Dumesnil JG, Cujec B, Sanfilippo AJ, Jue J, Turek MA, et al. A randomized trial of aspirin on the risk of embolic events in patients with infective endocarditis. *J Am Coll Cardiol* 2003;**42**:775–780. [https://doi.org/10.1016/S0735-1097\(03\)00829-5](https://doi.org/10.1016/S0735-1097(03)00829-5)
  483. Chan KL, Tam J, Dumesnil JG, Cujec B, Sanfilippo AJ, Jue J, et al. Effect of long-term aspirin use on embolic events in infective endocarditis. *Clin Infect Dis* 2008;**46**:37–41. <https://doi.org/10.1086/524021>
  484. Feil K, Kupper C, Tiedt S, Dimitriadis K, Herzberg M, Dorn F, et al. Safety and efficacy of mechanical thrombectomy in infective endocarditis: a matched case-control analysis from the German Stroke Registry-endovascular treatment. *Eur J Neurol* 2021;**28**:861–867. <https://doi.org/10.1111/ene.14686>
  485. Park W, Ahn JS, Park JC, Kwun BD, Lee DH. Treatment strategy based on experience of treating intracranial infectious aneurysms. *World Neurosurg* 2017;**97**:351–359. <https://doi.org/10.1016/j.wneu.2016.09.119>
  486. Davis KA, Huang G, Petty SA, Tan VA, Malaver D, Peacock JE Jr. The effect of pre-existing anticoagulation on cerebrovascular events in left-sided infective endocarditis. *Am J Med* 2020;**133**:360–369. <https://doi.org/10.1016/j.amjmed.2019.07.059>
  487. Alawieh A, Chaudry MI, Turner RD, Turk AS, Spiotta AM. Infectious intracranial aneurysms: a systematic review of epidemiology, management, and outcomes. *J Neurointerv Surg* 2018;**10**:708–716. <https://doi.org/10.1136/neurintsurg-2017-013603>
  488. Hui FK, Bain M, Obuchowski NA, Gordon S, Spiotta AM, Moskowitz S, et al. Mycotic aneurysm detection rates with cerebral angiography in patients with infective endocarditis. *J Neurointerv Surg* 2015;**7**:449–452. <https://doi.org/10.1136/neurintsurg-2014-011124>
  489. Goulenok T, Klein I, Mazighi M, Messika-Zeitoun D, Alexandra JF, Mourvillier B, et al. Infective endocarditis with symptomatic cerebral complications: contribution of cerebral magnetic resonance imaging. *Cerebrovasc Dis* 2013;**35**:327–336. <https://doi.org/10.1159/000348317>
  490. Walkoff L, Brinjikji W, Rouchaud A, Caroff J, Kallmes DF. Comparing magnetic resonance angiography (MRA) and computed tomography angiography (CTA) with conventional angiography in the detection of distal territory cerebral mycotic and oncotic aneurysms. *Interv Neuroradiol* 2016;**22**:524–528. <https://doi.org/10.1177/1591019916653247>
  491. Bettencourt S, Ferro JM. Acute ischemic stroke treatment in infective endocarditis: systematic review. *J Stroke Cerebrovasc Dis* 2020;**29**:104598. <https://doi.org/10.1016/j.jstrokecerebrovasdis.2019.104598>
  492. Meshaal MS, Kassem HH, Samir A, Zakaria A, Baghdady Y, Rizk HH. Impact of routine cerebral CT angiography on treatment decisions in infective endocarditis. *PLoS One* 2015;**10**:e0118616. <https://doi.org/10.1371/journal.pone.0118616>
  493. White PM, Teasdale EM, Wardlaw JM, Easton V. Intracranial aneurysms: CT angiography and MR angiography for detection prospective blinded comparison in a large patient cohort. *Radiology* 2001;**219**:739–749. <https://doi.org/10.1148/radiology.219.3.r01ma16739>
  494. Boukobza M, Duval X, Laissy JP. Utility of susceptibility-weighted angiography sequence in the diagnosis of ruptured infectious aneurysms. *World Neurosurg* 2021;**149**:171–173. <https://doi.org/10.1016/j.wneu.2021.02.103>
  495. Ragulojan R, Grupke S, Fraser JF. Systematic review of endovascular, surgical, and conservative options for infectious intracranial aneurysms and cardiac considerations. *J Stroke Cerebrovasc Dis* 2019;**28**:838–844. <https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.11.035>
  496. Shi H, Parikh NS, Esenwa C, Zampolin R, Shah H, Khasiyev F, et al. Neurological outcomes of patients with mycotic aneurysms in infective endocarditis. *Neurohospitalist* 2021;**11**:5–11. <https://doi.org/10.1177/1941874420931233>
  497. Singla A, Fargen K, Blackburn S, Neal D, Martin TD, Hess PJ, et al. National treatment practices in the management of infectious intracranial aneurysms and infective endocarditis. *J Neurointerv Surg* 2016;**8**:741–746. <https://doi.org/10.1136/neurintsurg-2015-011834>
  498. Ohtake M, Tateishi K, Ikegaya N, Iwata J, Yamanaka S, Murata H. Initial treatment strategy for intracranial mycotic aneurysms: 2 case reports and literature review. *World Neurosurg* 2017;**106**:1051.e9–1051.e16. <https://doi.org/10.1016/j.wneu.2017.07.016>
  499. Wilson WR, Bower TC, Creager MA, Amin-Hanjani S, O’Gara PT, Lockhart PB, et al. Vascular graft infections, mycotic aneurysms, and endovascular infections: a scientific statement from the American Heart Association. *Circulation* 2016;**134**:e412–e460. <https://doi.org/10.1161/CIR.0000000000000457>
  500. Ting W, Silverman NA, Arzouman DA, Levitsky S. Splenic septic emboli in endocarditis. *Circulation* 1990;**82**(5 Suppl):IV105–IV109.
  501. Robinson SL, Saxe JM, Lucas CE, Arbulu A, Ledgerwood AM, Lucas WF. Splenic abscess associated with endocarditis. *Surgery* 1992;**112**:781–786, discussion 786–787.
  502. Hasan LZ, Shrestha NK, Dang V, Unai S, Petterson G, El-Hayek K, et al. Surgical infective endocarditis and concurrent splenic abscess requiring splenectomy: a case series and review of the literature. *Diagn Microbiol Infect Dis* 2020;**97**:115082. <https://doi.org/10.1016/j.diagmicrobio.2020.115082>
  503. Elafar A, AlBaradai A, AlHarfi Z, Allassal M, Ghoneim A, AlGhofaili F. Splenic abscess associated with infective endocarditis; case series. *J Saudi Heart Assoc* 2015;**27**:210–215. <https://doi.org/10.1016/j.jsha.2015.02.001>
  504. Bonfiglioli R, Nanni C, Morigi JJ, Graziosi M, Trapani F, Bartoletti M, et al. (1)(8)F-FDG PET/CT diagnosis of unexpected extracardiac septic embolisms in patients with

- suspected cardiac endocarditis. *Eur J Nucl Med Mol Imaging* 2013;**40**:1190–1196. <https://doi.org/10.1007/s00259-013-2426-7>
505. Simsir SA, Cheeseman SH, Lancey RA, Vander Salm TJ, Gammie JS. Staged laparoscopic splenectomy and valve replacement in splenic abscess and infective endocarditis. *Ann Thorac Surg* 2003;**75**:1635–1637. [https://doi.org/10.1016/S0003-4975\(02\)04769-0](https://doi.org/10.1016/S0003-4975(02)04769-0)
  506. Akhyari P, Mehrabi A, Adhiwana A, Kamiya H, Nimptsch K, Minol JP, et al. Is simultaneous splenectomy an additive risk factor in surgical treatment for active endocarditis? *Langenbecks Arch Surg* 2012;**397**:1261–1266. <https://doi.org/10.1007/s00423-012-0931-y>
  507. Chou Y-H, Hsu C-C, Tiu C-M, Chang T. Splenic abscess: sonographic diagnosis and percutaneous drainage or aspiration. *Gastrointest Radiol* 1992;**17**:262–266. <https://doi.org/10.1007/BF01888563>
  508. Farres H, Felsher J, Banbury M, Brody F. Management of splenic abscess in a critically ill patient. *Surg Laparosc Endosc Percutan Tech* 2004;**14**:49–52. <https://doi.org/10.1097/10129689-200404000-00001>
  509. de la Cuerda F, Ceconi A, Martinez P, Cuesta J, Olivera MJ, Jimenez-Borreguero LJ, et al. Myocardial septal seeding secondary to infective endocarditis: diagnosis by cardiac magnetic resonance imaging. *Int J Cardiovasc Imaging* 2021;**37**:2545–2547. <https://doi.org/10.1007/s10554-021-02225-z>
  510. Reyalden R, Wahi S, Cole C, Kaye G, Law P, Cooper C, et al. Concurrent native valve infective endocarditis and myocarditis: the key role of (18)F-FDG PET/CT. *J Nucl Cardiol* 2021;**28**:1781–1784. <https://doi.org/10.1007/s12350-020-02108-1>
  511. Royston AP, Gosling OE. Patient with native valve infective endocarditis and concomitant bacterial myopericarditis. *BMJ Case Rep* 2018;**2018**:bcr2018224907. <https://doi.org/10.1136/bcr-2018-224907>
  512. Regueiro A, Falces C, Cervera C, Del Rio A, Pare JC, Mestres CA, et al. Risk factors for pericardial effusion in native valve infective endocarditis and its influence on outcome. *Am J Cardiol* 2013;**112**:1646–1651. <https://doi.org/10.1016/j.amjcard.2013.07.024>
  513. Regueiro A, Falces C, Pericas JM, Munoz P, Martinez-Selles M, Valerio M, et al. Risk factors of pericardial effusion in native valve infective endocarditis and its influence on outcome: a multicenter prospective cohort study. *Int J Cardiol* 2018;**273**:193–198. <https://doi.org/10.1016/j.ijcard.2018.08.010>
  514. Padala SK, Cabrera JA, Ellenbogen KA. Anatomy of the cardiac conduction system. *Pacing Clin Electrophysiol* 2021;**44**:15–25. <https://doi.org/10.1111/pace.14107>
  515. Hill TE, Kiehl EL, Shrestha NK, Gordon SM, Petterson GB, Mohan C, et al. Predictors of permanent pacemaker requirement after cardiac surgery for infective endocarditis. *Eur Heart J Acute Cardiovasc Care* 2021;**10**:329–334. <https://doi.org/10.1177/2048872619848661>
  516. Murillo O, Grau I, Gomez-Junyent J, Cabrera C, Ribera A, Tubau F, et al. Endocarditis associated with vertebral osteomyelitis and septic arthritis of the axial skeleton. *Infection* 2018;**46**:245–251. <https://doi.org/10.1007/s15010-018-1121-9>
  517. Del Pace S, Scheggi V, Virgili G, Cacioli S, Olivetto I, Zoppetti N, et al. Endocarditis with spondylodiscitis: clinical characteristics and prognosis. *BMC Cardiovasc Disord* 2021;**21**:186. <https://doi.org/10.1186/s12872-021-01991-x>
  518. Aguilar-Company J, Pigrau C, Fernandez-Hidalgo N, Rodriguez-Pardo D, Falco V, Lung M, et al. Native vertebral osteomyelitis in aged patients: distinctive features. An observational cohort study. *Infection* 2018;**46**:679–686. <https://doi.org/10.1007/s15010-018-1177-6>
  519. Koslow M, Kuperstein R, Eshed I, Perelman M, Maor E, Sidi Y. The unique clinical features and outcome of infectious endocarditis and vertebral osteomyelitis co-infection. *Am J Med* 2014;**127**:669.e9–669.e15. <https://doi.org/10.1016/j.amjmed.2014.02.023>
  520. Viezens L, Dreimann M, Strahl A, Heuer A, Koepke LG, Bay B, et al. Spontaneous spondylodiscitis and endocarditis: interdisciplinary experience from a tertiary institutional case series and proposal of a treatment algorithm. *Neurosurg Rev* 2022;**45**:1335–1342. <https://doi.org/10.1007/s10143-021-01640-z>
  521. Behmanesh B, Gessler F, Schoes K, Dubinski D, Won S-Y, Konczalla J, et al. Infective endocarditis in patients with pyogenic spondylodiscitis: implications for diagnosis and therapy. *Neurosurg Focus* 2019;**46**:E2. <https://doi.org/10.3171/2018.10.FOCUS18445>
  522. Tamura K. Clinical characteristics of infective endocarditis with vertebral osteomyelitis. *J Infect Chemother* 2010;**16**:260–265. <https://doi.org/10.1007/s10156-010-0046-8>
  523. Pigrau C, Almirante B, Flores X, Falco V, Rodriguez D, Gasser I, et al. Spontaneous pyogenic vertebral osteomyelitis and endocarditis: incidence, risk factors, and outcome. *Am J Med* 2005;**118**:1287. <https://doi.org/10.1016/j.amjmed.2005.02.027>
  524. Smids C, Kouijzer JJ, Vos FJ, Sprong T, Hosman AJ, de Rooy JW, et al. A comparison of the diagnostic value of MRI and (18)F-FDG-PET/CT in suspected spondylodiscitis. *Infection* 2017;**45**:41–49. <https://doi.org/10.1007/s15010-016-0914-y>
  525. Castagne B, Soubrier M, Prouteau J, Mrozek N, Lesens O, Tournadre A, et al. A six-week antibiotic treatment of endocarditis with spondylodiscitis is not associated with increased risk of relapse: a retrospective cohort study. *Infect Dis Now* 2021;**51**:253–259. <https://doi.org/10.1016/j.medmal.2020.10.026>
  526. Pola E, Taccari F, Autore G, Giovannenze F, Pambianco V, Cauda R, et al. Multidisciplinary management of pyogenic spondylodiscitis: epidemiological and clinical features, prognostic factors and long-term outcomes in 207 patients. *Eur Spine J* 2018;**27**(Suppl 2):229–236. <https://doi.org/10.1007/s00586-018-5598-9>
  527. Thomas P, Allal J, Bontoux D, Rossi F, Poupet JY, Petitalot JP, et al. Rheumatological manifestations of infective endocarditis. *Ann Rheum Dis* 1984;**43**:716–720. <https://doi.org/10.1136/ard.43.5.716>
  528. Ojeda J, Lopez-Lopez L, Gonzalez A, Vila LM. Infective endocarditis initially presenting with a dermatomyositis-like syndrome. *BMJ Case Rep* 2014;**2014**:bcr2013200865. <https://doi.org/10.1136/bcr-2013-200865>
  529. Mahr A, Batteux F, Tubiana S, Goulvestre C, Wolff M, Papo T, et al. Brief report: prevalence of antineutrophil cytoplasmic antibodies in infective endocarditis. *Arthritis Rheumatol* 2014;**66**:1672–1677. <https://doi.org/10.1002/art.38389>
  530. Lieber SB, Tishler O, Nasrullah K, Fowler ML, Shmerling RH, Paz Z. Clinical features of patients with septic arthritis and echocardiographic findings of infective endocarditis. *Infection* 2019;**47**:771–779. <https://doi.org/10.1007/s15010-019-01302-9>
  531. Tahon J, Geselle PJ, Vandenberg B, Hill EE, Peetermans WE, Herijgers P, et al. Long-term follow-up of patients with infective endocarditis in a tertiary referral center. *Int J Cardiol* 2021;**331**:176–182. <https://doi.org/10.1016/j.ijcard.2021.01.048>
  532. Ortiz-Soriano V, Donaldson K, Du G, Li Y, Lambert J, Cleland D, et al. Incidence and cost of acute kidney injury in hospitalized patients with infective endocarditis. *J Clin Med* 2019;**8**:927. <https://doi.org/10.3390/jcm8070927>
  533. Khan MZ, Munir MB, Khan MU, Khan SU, Vasudevan A, Balla S. Contemporary trends and outcomes of prosthetic valve infective endocarditis in the United States: insights from the nationwide inpatient sample. *Am J Med Sci* 2021;**362**:472–479. <https://doi.org/10.1016/j.amjms.2021.05.014>
  534. Gagneux-Brunon A, Pouvret A, Maillard N, Berthelot P, Lutz MF, Cazorla C, et al. Acute kidney injury in infective endocarditis: a retrospective analysis. *Med Mal Infect* 2019;**49**:527–533. <https://doi.org/10.1016/j.medmal.2019.03.015>
  535. Von Tokarski F, Lemaigen A, Portais A, Fauchier L, Hennekinne F, Sautenet B, et al. Risk factors and outcomes of early acute kidney injury in infective endocarditis: a retrospective cohort study. *Int J Infect Dis* 2020;**99**:421–427. <https://doi.org/10.1016/j.ijid.2020.08.022>
  536. Ritchie BM, Hirning BA, Stevens CA, Cohen SA, DeGrado JR. Risk factors for acute kidney injury associated with the treatment of bacterial endocarditis at a tertiary academic medical center. *J Chemother* 2017;**29**:292–298. <https://doi.org/10.1080/1120009X.2017.1296916>
  537. Petersen JK, Jensen AD, Bruun NE, Kamper AL, Butt JH, Havers-Borgersen E, et al. Outcome of dialysis-requiring acute kidney injury in patients with infective endocarditis: a nationwide study. *Clin Infect Dis* 2021;**72**:e232–e239. <https://doi.org/10.1093/cid/ciaa1017>
  538. Li J, Zhou L, Gong X, Wang Y, Yao D, Li H. Abiotrophia defectiva as a rare cause of mitral valve infective endocarditis with mesenteric arterial branch pseudoaneurysm, splenic infarction, and renal infarction: a case report. *Front Med (Lausanne)* 2022;**9**:780828. <https://doi.org/10.3389/fmed.2022.780828>
  539. Vasconcellos D, Weng B, Wu P, Thompson G, Sutjita M. *Staphylococcus hominis* infective endocarditis presenting with embolic splenic and renal infarcts and spinal discitis. *Case Rep Infect Dis* 2022;**2022**:7183049. <https://doi.org/10.1155/2022/7183049>
  540. Boils CL, Nasr SH, Walker PD, Couser WG, Larsen CP. Update on endocarditis-associated glomerulonephritis. *Kidney Int* 2015;**87**:1241–9. <https://doi.org/10.1038/ki.2014.424>
  541. Paul G, Michels G, Hohmann C, Pfister R, Mader N, Blanke L, et al. Contrast-enhanced ultrasound for the detection of abdominal complications in infective endocarditis: first experience from a prospective cohort. *Ultrasound Med Biol* 2020;**46**:2965–2971. <https://doi.org/10.1016/j.ultrasmedbio.2020.07.027>
  542. Knol WG, WAhadat AR, Roos-Hesselink JW, Van Mieghem NM, Tanis WW, Bogers A, et al. Screening for coronary artery disease in early surgical treatment of acute aortic valve infective endocarditis. *Interact Cardiovasc Thorac Surg* 2021;**32**:522–529. <https://doi.org/10.1093/icvts/ivaa313>
  543. Spanneut TA, Paquet P, Bauters C, Modine T, Richardson M, Bonello L, et al. Utility and safety of coronary angiography in patients with acute infective endocarditis who required surgery. *J Thorac Cardiovasc Surg* 2022;**164**:905–913.e19. <https://doi.org/10.1016/j.jtcvs.2020.08.117>
  544. Laperche C, Lairez O, Ferrieres J, Robin G, Gautier M, Lavie Badie Y, et al. Coronary angiography in the setting of acute infective endocarditis requiring surgical treatment. *Arch Cardiovasc Dis* 2020;**113**:50–58. <https://doi.org/10.1016/j.acvd.2019.09.007>
  545. Diab M, Lehmann T, Weber C, Petrov G, Luehr M, Akhyari P, et al. Role of concomitant coronary artery bypass grafting in valve surgery for infective endocarditis. *J Clin Med* 2021;**10**:2867. <https://doi.org/10.3390/jcm10132867>
  546. Ren X, Liu K, Zhang H, Meng Y, Li H, Sun X, et al. Coronary evaluation before heart valvular surgery by using coronary computed tomographic angiography versus invasive coronary angiography. *J Am Heart Assoc* 2021;**10**:e019531. <https://doi.org/10.1161/JAHA.120.019531>
  547. Shapira Y, Weisenberg DE, Vaturi M, Sharoni E, Raanani E, Sahar G, et al. The impact of intraoperative transesophageal echocardiography in infective endocarditis. *Isr Med Assoc J* 2007;**9**:299–302.
  548. Paruk F, Sime FB, Lipman J, Roberts JA. Dosing antibiotic prophylaxis during cardiopulmonary bypass—a higher level of complexity? A structured review. *Int J Antimicrob Agents* 2017;**49**:395–402. <https://doi.org/10.1016/j.ijantimicag.2016.12.014>

549. Datt V, Wadhwa R, Sharma V, Virmani S, Minhas HS, Malik S. Vasoplegic syndrome after cardiovascular surgery: a review of pathophysiology and outcome-oriented therapeutic management. *J Card Surg* 2021;**36**:3749–3760. <https://doi.org/10.1111/jocs.15805>
550. Grayling M, Deakin CD. Methylene blue during cardiopulmonary bypass to treat refractory hypotension in septic endocarditis. *J Thorac Cardiovasc Surg* 2003;**125**:426–427. <https://doi.org/10.1067/jtcv.2003.140>
551. Santer D, Miazza J, Koechlin L, Gahl B, Brahami B, Hollinger A, et al. Hemoadsorption during cardiopulmonary bypass in patients with endocarditis undergoing valve surgery: a retrospective single-center study. *J Clin Med* 2021;**10**:564. <https://doi.org/10.3390/jcm10040564>
552. Diab M, Lehmann T, Bothe W, Akhyari P, Platzer S, Wendt D, et al. Cytokine hemoadsorption during cardiac surgery versus standard surgical care for infective endocarditis (REMOVE): results from a multicenter randomized controlled trial. *Circulation* 2022;**145**:959–968. <https://doi.org/10.1161/CIRCULATIONAHA.121.056940>
553. Pettersson GB, Hussain ST, Shrestha NK, Gordon S, Fraser TG, Ibrahim KS, et al. Infective endocarditis: an atlas of disease progression for describing, staging, coding, and understanding the pathology. *J Thorac Cardiovasc Surg* 2014;**147**:1142–1149.e2. <https://doi.org/10.1016/j.jtcv.2013.11.031>
554. de Kerchove L, Vanoverschelde JL, Poncelet A, Glineur D, Rubay J, Zech F, et al. Reconstructive surgery in active mitral valve endocarditis: feasibility, safety and durability. *Eur J Cardiothorac Surg* 2007;**31**:592–599. <https://doi.org/10.1016/j.ejcts.2007.01.002>
555. Defauw RJ, Tomsic A, van Brakel TJ, Marsan NA, Klautz RJM, Palmen M. A structured approach to native mitral valve infective endocarditis: is repair better than replacement? *Eur J Cardiothorac Surg* 2020;**58**:544–550. <https://doi.org/10.1093/ejcts/ezaa079>
556. Toyoda N, Itagaki S, Egorova NN, Tannous H, Anyanwu AC, El-Eshmawi A, et al. Real-world outcomes of surgery for native mitral valve endocarditis. *J Thorac Cardiovasc Surg* 2017;**154**:1906–1912.e9. <https://doi.org/10.1016/j.jtcv.2017.07.077>
557. Witten JC, Houghtaling PL, Shrestha NK, Gordon SM, Jaber W, Blackstone EH, et al. Aortic allograft infection risk. *J Thorac Cardiovasc Surg* 2023;**165**:1303–1315.e9. <https://doi.org/10.1016/j.jtcv.2021.04.086>
558. Witten JC, Durbak E, Houghtaling PL, Unai S, Roselli EE, Bakaen FG, et al. Performance and durability of cryopreserved allograft aortic valve replacements. *Ann Thorac Surg* 2021;**111**:1893–1900. <https://doi.org/10.1016/j.athoracsur.2020.07.033>
559. Flynn CD, Curran NP, Chan S, Zegri-Reiriz I, Tauron M, Tian DH, et al. Systematic review and meta-analysis of surgical outcomes comparing mechanical valve replacement and bioprosthetic valve replacement in infective endocarditis. *Ann Cardiothorac Surg* 2019;**8**:587–599. <https://doi.org/10.21037/acs.2019.10.03>
560. Giambuzzi I, Bonalumi G, Di Mauro M, Roberto M, Corona S, Alamanni F, et al. Surgical aortic mitral curtain replacement: systematic review and metanalysis of early and long-term results. *J Clin Med* 2021;**10**:3163. <https://doi.org/10.3390/jcm10143163>
561. Murphy KM, Vikram HR. Heart transplantation for infective endocarditis: viable option for a limited few? *Transpl Infect Dis* 2019;**21**:e13006. <https://doi.org/10.1111/tid.13006>
562. Nappi F, Singh SSA, Spadaccio C, Acar C. Revisiting the guidelines and choice the ideal substitute for aortic valve endocarditis. *Ann Transl Med* 2020;**8**:952. <https://doi.org/10.21037/atm-20-1522>
563. Head SJ, Celik M, Kappetein AP. Mechanical versus bioprosthetic aortic valve replacement. *Eur Heart J* 2017;**38**:2183–2191. <https://doi.org/10.1093/eurheartj/ehx141>
564. AATS Surgical Treatment of Infective Endocarditis Consensus Guidelines Writing Committee Chairs; Pettersson GB, Coselli JS, Writing C, Pettersson GB, Coselli JS, et al. 2016 the American Association for thoracic surgery (AATS) consensus guidelines: surgical treatment of infective endocarditis: executive summary. *J Thorac Cardiovasc Surg* 2017;**153**:1241–1258.e29. <https://doi.org/10.1016/j.jtcv.2016.09.093>
565. Delahaye F, Chu VH, Altclas J, Barsic B, Delahaye A, Freiburger T, et al. One-year outcome following biological or mechanical valve replacement for infective endocarditis. *Int J Cardiol* 2015;**178**:117–123. <https://doi.org/10.1016/j.ijcard.2014.10.125>
566. Cahill TJ, Baddour LM, Habib G, Hoen B, Salaun E, Pettersson GB, et al. Challenges in infective endocarditis. *J Am Coll Cardiol* 2017;**69**:325–344. <https://doi.org/10.1016/j.jacc.2016.10.066>
567. Samura T, Yoshioka D, Toda K, Sakaniwa R, Yokoyama J, Suzuki K, et al. Emergency valve surgery improves clinical results in patients with infective endocarditis complicated with acute cerebral infarction: analysis using propensity score matching dagger. *Eur J Cardiothorac Surg* 2019;**56**:942–949. <https://doi.org/10.1093/ejcts/ezz100>
568. Bonaros N, Czerny M, Pfausler B, Muller S, Bartel T, Thielmann M, et al. Infective endocarditis and neurologic events: indications and timing for surgical interventions. *Eur Heart J Suppl* 2020;**22**(Suppl M):M19–M25. <https://doi.org/10.1093/eurheartj/suaa167>
569. Barsic B, Dickerman S, Krajcinovic V, Pappas P, Altclas J, Carosi G, et al. Influence of the timing of cardiac surgery on the outcome of patients with infective endocarditis and stroke. *Clin Infect Dis* 2013;**56**:209–217. <https://doi.org/10.1093/cid/cis878>
570. Suzuki M, Takanashi S, Ohshima Y, Nagatomo Y, Seki A, Takamisawa I, et al. Critical potential of early cardiac surgery for infective endocarditis with cardio-embolic strokes. *Int J Cardiol* 2017;**227**:222–224. <https://doi.org/10.1016/j.ijcard.2016.11.143>
571. Okita Y, Minakata K, Yasuno S, Uozumi R, Sato T, Ueshima K, et al. Optimal timing of surgery for active infective endocarditis with cerebral complications: a Japanese multicentre study. *Eur J Cardiothorac Surg* 2016;**50**:374–382. <https://doi.org/10.1093/ejcts/ezw035>
572. Arregle F, Martel H, Philip M, Gouriet F, Casalta JP, Riberi A, et al. Infective endocarditis with neurological complications: delaying cardiac surgery is associated with worse outcome. *Arch Cardiovasc Dis* 2021;**114**:527–536. <https://doi.org/10.1016/j.acvd.2021.01.004>
573. Matthews CR, Hartman T, Madison M, Vilelli NW, Namburi N, Colgate CL, et al. Preoperative stroke before cardiac surgery does not increase risk of postoperative stroke. *Sci Rep* 2021;**11**:9025. <https://doi.org/10.1038/s41598-021-88441-y>
574. Murai R, Kaji S, Kitai T, Kim K, Ota M, Koyama T, et al. The clinical significance of cerebral microbleeds in infective endocarditis patients. *Semin Thorac Cardiovasc Surg* 2019;**31**:51–58. <https://doi.org/10.1053/j.semtcvs.2018.09.020>
575. Ruttman E, Abfaltherer H, Wagner J, Grimm M, Muller L, Bates K, et al. Endocarditis-related stroke is not a contraindication for early cardiac surgery: an investigation among 440 patients with left-sided endocarditis. *Eur J Cardiothorac Surg* 2020;**58**:1161–1167. <https://doi.org/10.1093/ejcts/ezaa239>
576. Small CN, Laurent D, Lucke-Wold B, Goutnik MA, Yue S, Chalouhi N, et al. Timing surgery and hemorrhagic complications in endocarditis with concomitant cerebral complications. *Clin Neurol Neurosurg* 2022;**214**:107171. <https://doi.org/10.1016/j.clineuro.2022.107171>
577. Tam DY, Yanagawa B, Verma S, Ruel M, Fremes SE, Mazine A, et al. Early vs late surgery for patients with endocarditis and neurological injury: a systematic review and meta-analysis. *Can J Cardiol* 2018;**34**:1185–1199. <https://doi.org/10.1016/j.cjca.2018.05.010>
578. Zhang LQ, Cho S-M, Rice CJ, Khoury J, Marquardt RJ, Buletko AB, et al. Valve surgery for infective endocarditis complicated by stroke: surgical timing and perioperative neurological complications. *Eur J Neurol* 2020;**27**:2430–2438. <https://doi.org/10.1111/ene.14438>
579. Jiad E, Gill SK, Krutikov M, Turner D, Parkinson MH, Curtis C, et al. When the heart rules the head: ischaemic stroke and intracerebral haemorrhage complicating infective endocarditis. *Pract Neurol* 2017;**17**:28–34. <https://doi.org/10.1136/practneurol-2016-001469>
580. Misfeld M, Girschbach F, Eitz CD, Binner C, Aspern KV, Dohmen PM, et al. Surgery for infective endocarditis complicated by cerebral embolism: a consecutive series of 375 patients. *J Thorac Cardiovasc Surg* 2014;**147**:1837–1844. <https://doi.org/10.1016/j.jtcv.2013.10.076>
581. Kume Y, Fujita T, Fukushima S, Shimahara Y, Matsumoto Y, Yamashita K, et al. Intracranial mycotic aneurysm is associated with cerebral bleeding post-valve surgery for infective endocarditis. *Interact Cardiovasc Thorac Surg* 2018;**27**:635–641. <https://doi.org/10.1093/icvts/ivy126>
582. Salaun E, Touil A, Hubert S, Casalta JP, Gouriet F, Robinet-Borgomano E, et al. Intracranial haemorrhage in infective endocarditis. *Arch Cardiovasc Dis* 2018;**111**:712–721. <https://doi.org/10.1016/j.acvd.2018.03.009>
583. Musleh R, Schlattmann P, Caldonazo T, Kirov H, Witte OW, Doenst T, et al. Surgical timing in patients with infective endocarditis and with intracranial hemorrhage: a systematic review and meta-analysis. *J Am Heart Assoc* 2022;**11**:e024401. <https://doi.org/10.1161/JAHA.121.024401>
584. Yoshioka D, Toda K, Sakaguchi T, Okazaki S, Yamauchi T, Miyagawa S, et al. Valve surgery in active endocarditis patients complicated by intracranial haemorrhage: the influence of the timing of surgery on neurological outcomes. *Eur J Cardiothorac Surg* 2014;**45**:1082–1088. <https://doi.org/10.1093/ejcts/ezt507>
585. Manne MB, Shrestha NK, Lytle BV, Nowicki ER, Blackstone E, Gordon SM, et al. Outcomes after surgical treatment of native and prosthetic valve infective endocarditis. *Ann Thorac Surg* 2012;**93**:489–493. <https://doi.org/10.1016/j.athoracsur.2011.10.063>
586. Wang A, Chu VH, Athan E, Delahaye F, Freiburger T, Lamas C, et al. Association between the timing of surgery for complicated, left-sided infective endocarditis and survival. *Am Heart J* 2019;**210**:108–116. <https://doi.org/10.1016/j.ahj.2019.01.004>
587. Champey J, Pavese P, Bouvaist H, Kastler A, Krainik A, Francois P. Value of brain MRI in infective endocarditis: a narrative literature review. *Eur J Clin Microbiol Infect Dis* 2016;**35**:159–168. <https://doi.org/10.1007/s10096-015-2523-6>
588. Martinez-Selles M, Munoz P, Estevez A, del Castillo R, Garcia-Fernandez MA, Rodriguez-Creixems M, et al. Long-term outcome of infective endocarditis in non-intravenous drug users. *Mayo Clin Proc* 2008;**83**:1213–1217. <https://doi.org/10.4065/83.11.1213>
589. Thuny F, Giorgi R, Habachi R, Ansaldi S, Le Dolley Y, Casalta JP, et al. Excess mortality and morbidity in patients surviving infective endocarditis. *Am Heart J* 2012;**164**:94–101. <https://doi.org/10.1016/j.ahj.2012.04.003>
590. Agrawal A, Virk HUH, Riaz I, Jain D, Tripathi B, Krittanawong C, et al. Predictors of 30-day re-admissions in patients with infective endocarditis: a national population based cohort study. *Rev Cardiovasc Med* 2020;**21**:123–127. <https://doi.org/10.31083/j.rcm.2020.01.552>
591. Alagna L, Park LP, Nicholson BP, Keiger AJ, Strahilevitz J, Morris A, et al. Repeat endocarditis: analysis of risk factors based on the International Collaboration on Endocarditis – prospective cohort study. *Clin Microbiol Infect* 2014;**20**:566–575. <https://doi.org/10.1111/1469-0691.12395>

592. Fernandez-Hidalgo N, Almirante B, Tornos P, Gonzalez-Alujas MT, Planes AM, Galinanes M, et al. Immediate and long-term outcome of left-sided infective endocarditis. A 12-year prospective study from a contemporary cohort in a referral hospital. *Clin Microbiol Infect* 2012;**18**:E522–E530. <https://doi.org/10.1111/1469-0691.12033>
593. Scheggi V, Merilli I, Marcucci R, Del Pace S, Olivetto I, Zoppetti N, et al. Predictors of mortality and adverse events in patients with infective endocarditis: a retrospective real world study in a surgical centre. *BMC Cardiovasc Disord* 2021;**21**:28. <https://doi.org/10.1186/s12872-021-01853-6>
594. Yoshioka D, Toda K, Yokoyama JY, Matsuura R, Miyagawa S, Kainuma S, et al. Diabetes mellitus adversely affects mortality and recurrence after valve surgery for infective endocarditis. *J Thorac Cardiovasc Surg* 2018;**155**:1021–1029.e5. <https://doi.org/10.1016/j.jtcvs.2017.09.013>
595. Citro R, Chan KL, Miglioranza MH, Laroche C, Benvenga RM, Furnaz S, et al. Clinical profile and outcome of recurrent infective endocarditis. *Heart* 2022;**108**:1729–1736. <https://doi.org/10.1136/heartjnl-2021-320652>
596. Chu VH, Sexton DJ, Cabell CH, Reller LB, Pappas PA, Singh RK, et al. Repeat infective endocarditis: differentiating relapse from reinfection. *Clin Infect Dis* 2005;**41**:406–409. <https://doi.org/10.1086/431590>
597. Inagaki K, Lucar J, Blackshear C, Hobbs CV. Methicillin-susceptible and methicillin-resistant *Staphylococcus aureus* bacteremia: nationwide estimates of 30-day readmission, in-hospital mortality, length of stay, and cost in the United States. *Clin Infect Dis* 2019;**69**:2112–2118. <https://doi.org/10.1093/cid/ciz123>
598. David TE, Gavra G, Feindel CM, Regesta T, Armstrong S, Maganti MD. Surgical treatment of active infective endocarditis: a continued challenge. *J Thorac Cardiovasc Surg* 2007;**133**:144–9. <https://doi.org/10.1016/j.jtcvs.2006.08.060>
599. Fedoruk LM, Jamieson WR, Ling H, Macnab JS, Germann E, Karim SS, et al. Predictors of recurrence and reoperation for prosthetic valve endocarditis after valve replacement surgery for native valve endocarditis. *J Thorac Cardiovasc Surg* 2009;**137**:326–333. <https://doi.org/10.1016/j.jtcvs.2008.08.024>
600. Moon MR, Miller DC, Moore KA, Oyer PE, Mitchell RS, Robbins RC, et al. Treatment of endocarditis with valve replacement: the question of tissue versus mechanical prosthesis. *Ann Thorac Surg* 2001;**71**:1164–1171. [https://doi.org/10.1016/S0003-4975\(00\)02665-5](https://doi.org/10.1016/S0003-4975(00)02665-5)
601. Toyoda N, Itagaki S, Tannous H, Egorova NN, Chikwe J. Bioprosthetic versus mechanical valve replacement for infective endocarditis: focus on recurrence rates. *Ann Thorac Surg* 2018;**106**:99–106. <https://doi.org/10.1016/j.athoracsur.2017.12.046>
602. Ostergaard L, Dahl A, Fosbol E, Bruun NE, Oestergaard LB, Lauridsen TK, et al. Residual vegetation after treatment for left-sided infective endocarditis and subsequent risk of stroke and recurrence of endocarditis. *Int J Cardiol* 2019;**293**:67–72. <https://doi.org/10.1016/j.ijcard.2019.06.059>
603. Rasmussen TB, Zwisler AD, Moons P, Berg SK. Insufficient living: experiences of recovery after infective endocarditis. *J Cardiovasc Nurs* 2015;**30**:E11–E19. <https://doi.org/10.1097/JCN.0000000000000144>
604. Rasmussen TB, Zwisler AD, Thygesen LC, Bundgaard H, Moons P, Berg SK. High readmission rates and mental distress after infective endocarditis – results from the national population-based CopenHeart IE survey. *Int J Cardiol* 2017;**235**:133–140. <https://doi.org/10.1016/j.ijcard.2017.02.077>
605. Rasmussen TB, Zwisler AD, Risom SS, Sibiltz KL, Christensen J, Bundgaard H, et al. Comprehensive cardiac rehabilitation for patients following infective endocarditis: results of the randomized CopenHeartE trial. *Eur J Cardiovasc Nurs* 2022;**21**:261–270. <https://doi.org/10.1093/eurjcn/zvab047>
606. Price CN, Solomon DA, Johnson JA, Montgomery MW, Martin B, Suzuki J. Feasibility and safety of outpatient parenteral antimicrobial therapy in conjunction with addiction treatment for people who inject drugs. *J Infect Dis* 2020;**222**(Suppl 5):S494–S498. <https://doi.org/10.1093/infdis/jiaa025>
607. Kimmel SD, Walley AY, Li Y, Linas BP, Lodi S, Bernson D, et al. Association of treatment with medications for opioid use disorder with mortality after hospitalization for injection drug use-associated infective endocarditis. *JAMA Netw Open* 2020;**3**:e2016228. <https://doi.org/10.1001/jamanetworkopen.2020.16228>
608. Hays LH. Infective endocarditis: call for education of adults with CHD: review of the evidence. *Cardiol Young* 2016;**26**:426–430. <https://doi.org/10.1017/S1047951115002395>
609. Abraham LN, Sibiltz KL, Berg SK, Tang LH, Risom SS, Lindschou J, et al. Exercise-based cardiac rehabilitation for adults after heart valve surgery. *Cochrane Database Syst Rev* 2021;**5**:CD010876. <https://doi.org/10.1002/14651858.CD010876.pub3>
610. Abegaz TM, Bhagavathula AS, Gebreyohannes EA, Mekonnen AB, Abebe TB. Short- and long-term outcomes in infective endocarditis patients: a systematic review and meta-analysis. *BMC Cardiovasc Disord* 2017;**17**:291. <https://doi.org/10.1186/s12872-017-0729-5>
611. Ternhag A, Cederstrom A, Torner A, Westling K. A nationwide cohort study of mortality risk and long-term prognosis in infective endocarditis in Sweden. *PLoS One* 2013;**8**:e67519. <https://doi.org/10.1371/journal.pone.0067519>
612. Collonnaz M, Erpelding ML, Alla F, Goehringer F, Delahaye F, lung B, et al. Impact of referral bias on prognostic studies outcomes: insights from a population-based cohort study on infective endocarditis. *Ann Epidemiol* 2021;**54**:29–37. <https://doi.org/10.1016/j.jannepidem.2020.09.008>
613. Mokhles MM, Ciampichetti I, Head SJ, Takkenberg JJ, Bogers AJ. Survival of surgically treated infective endocarditis: a comparison with the general Dutch population. *Ann Thorac Surg* 2011;**91**:1407–1412. <https://doi.org/10.1016/j.athoracsur.2011.02.007>
614. Straw S, Baig MW, Gillott R, Wu J, Witte KK, O'Regan DJ, et al. Long-term outcomes are poor in intravenous drug users following infective endocarditis, even after surgery. *Clin Infect Dis* 2020;**71**:564–571. <https://doi.org/10.1093/cid/ciz869>
615. Vongpatanasin W, Hillis LD, Lange RA. Prosthetic heart valves. *N Engl J Med* 1996;**335**:407–416. <https://doi.org/10.1056/NEJM199608033350607>
616. Moreillon P, Que YA. Infective endocarditis. *Lancet* 2004;**363**:139–149. [https://doi.org/10.1016/S0140-6736\(03\)15266-X](https://doi.org/10.1016/S0140-6736(03)15266-X)
617. Hoen B, Alla F, Selson-Suty C, Beguinot I, Bouvet A, Briancon S, et al. Changing profile of infective endocarditis: results of a 1-year survey in France. *JAMA* 2002;**288**:75–81. <https://doi.org/10.1001/jama.288.1.75>
618. Selson-Suty C, Celard M, Le Moing V, Doco-Lecompte T, Chirouze C, lung B, et al. Preeminence of *Staphylococcus aureus* in infective endocarditis: a 1-year population-based survey. *Clin Infect Dis* 2012;**54**:1230–1239. <https://doi.org/10.1093/cid/cis199>
619. Anantha Narayanan M, Mahfood Haddad T, Kalil AC, Kanmanthareddy A, Suri RM, Mansour G, et al. Early versus late surgical intervention or medical management for infective endocarditis: a systematic review and meta-analysis. *Heart* 2016;**102**:950–957. <https://doi.org/10.1136/heartjnl-2015-308589>
620. Brennan JM, Edwards FH, Zhao Y, O'Brien S, Booth ME, Dokholyan RS, et al. Long-term safety and effectiveness of mechanical versus biologic aortic valve prostheses in older patients: results from the Society of Thoracic Surgeons adult cardiac surgery national database. *Circulation* 2013;**127**:1647–1655. <https://doi.org/10.1161/CIRCULATIONAHA.113.002003>
621. Wang A, Athan E, Pappas PA, Fowler VG Jr, Olaison L, Pare C, et al. Contemporary clinical profile and outcome of prosthetic valve endocarditis. *JAMA* 2007;**297**:1354–1361. <https://doi.org/10.1001/jama.297.12.1354>
622. Lopez J, Revilla A, Vilacosta I, Villacorta E, Gonzalez-Juanatey C, Gomez I, et al. Definition, clinical profile, microbiological spectrum, and prognostic factors of early-onset prosthetic valve endocarditis. *Eur Heart J* 2007;**28**:760–765. <https://doi.org/10.1093/eurheartj/ehl486>
623. Moriyama N, Laakso T, Biancari F, Raivio P, Jalava MP, Jaakkola J, et al. Prosthetic valve endocarditis after transcatheter or surgical aortic valve replacement with a bioprosthesis: results from the FinnValve registry. *EuroIntervention* 2019;**15**:e500–e507. <https://doi.org/10.4244/EIJ-D-19-00247>
624. Berisha B, Ragnarsson S, Olaison L, Rasmussen M. Microbiological etiology in prosthetic valve endocarditis: a nationwide registry study. *J Intern Med* 2022;**292**:428–437. <https://doi.org/10.1111/joim.13491>
625. Kohler P, Kuster SP, Bloemberg G, Schulthess B, Frank M, Tanner FC, et al. Healthcare-associated prosthetic heart valve, aortic vascular graft, and disseminated *Mycobacterium chimaera* infections subsequent to open heart surgery. *Eur Heart J* 2015;**36**:2745–2753. <https://doi.org/10.1093/eurheartj/ehv342>
626. Chamat-Hedemand S, Dahl A, Ostergaard L, Arpi M, Fosbol E, Boel J, et al. Prevalence of infective endocarditis in streptococcal bloodstream infections is dependent on streptococcal species. *Circulation* 2020;**142**:720–730. <https://doi.org/10.1161/CIRCULATIONAHA.120.046723>
627. Expert Panel on Cardiac Imaging; Malik SB, Hsu JY, Hurwitz Koweek LM, Ghoshhajra BB, Beache GM, et al. ACR appropriateness criteria(r) infective endocarditis. *J Am Coll Radiol* 2021;**18**:S52–S61. <https://doi.org/10.1016/j.jacr.2021.01.010>
628. Luciani N, Mossuto E, Ricci D, Luciani M, Russo M, Salsano A, et al. Prosthetic valve endocarditis: predictors of early outcome of surgical therapy. A multicentric study. *Eur J Cardiothorac Surg* 2017;**52**:768–774. <https://doi.org/10.1093/ejcts/ezx169>
629. Glaser N, Jackson V, Holzmann MJ, Franco-Cereceda A, Sartipy U. Prosthetic valve endocarditis after surgical aortic valve replacement. *Circulation* 2017;**136**:329–331. <https://doi.org/10.1161/CIRCULATIONAHA.117.028783>
630. Erdem H, Puca E, Ruch Y, Santos L, Ghanem-Zoubi N, Argemi X, et al. Portraying infective endocarditis: results of multinational ID-IRI study. *Eur J Clin Microbiol Infect Dis* 2019;**38**:1753–1763. <https://doi.org/10.1007/s10096-019-03607-x>
631. Shrestha NK, Shah SY, Hussain ST, Pettersson GB, Griffin BP, Nowacki AS, et al. Association of surgical treatment with survival in patients with prosthetic valve endocarditis. *Ann Thorac Surg* 2020;**109**:1834–1843. <https://doi.org/10.1016/j.athoracsur.2019.09.015>
632. Truninger K, Attenhofer Jost CH, Seifert B, Vogt PR, Follath F, Schaffner A, et al. Long term follow up of prosthetic valve endocarditis: what characteristics identify patients who were treated successfully with antibiotics alone? *Heart* 1999;**82**:714–720. <https://doi.org/10.1136/hrt.82.6.714>
633. Tornos P, Almirante B, Olona M, Permyer G, Gonzalez T, Carballo J, et al. Clinical outcome and long-term prognosis of late prosthetic valve endocarditis: a 20-year experience. *Clin Infect Dis* 1997;**24**:381–386. <https://doi.org/10.1093/clinids/24.3.381>
634. Arnold CJ, Johnson M, Bayer AS, Bradley S, Giannitsioti E, Miro JM, et al. Candida infective endocarditis: an observational cohort study with a focus on therapy. *Antimicrob Agents Chemother* 2015;**59**:2365–2373. <https://doi.org/10.1128/AAC.04867-14>
635. Castillo JC, Anguita MP, Torres F, Mesa D, Franco M, Gonzalez E, et al. Long-term prognosis of early and late prosthetic valve endocarditis. *Am J Cardiol* 2004;**93**:1185–1187. <https://doi.org/10.1016/j.amjcard.2004.01.056>

636. Chu VH, Miro JM, Hoen B, Cabell CH, Pappas PA, Jones P, et al. Coagulase-negative staphylococcal prosthetic valve endocarditis—a contemporary update based on the International Collaboration on Endocarditis: prospective cohort study. *Heart* 2009; **95**:570–576. <https://doi.org/10.1136/hrt.2008.152975>
637. Jensen AD, Ostergaard L, Petersen JK, Graversen PL, Butt JH, Hadji-Turdeghal K, et al. Temporal trends of mortality in patients with infective endocarditis: a nationwide study. *Eur Heart J Qual Care Clin Outcomes* 2022; **9**:24–33. <https://doi.org/10.1093/ehjqcco/qcac011>
638. Slipczuk L, Cocolosa JN, Davila CD, Romero-Corral A, Yun J, Pressman GS, et al. Infective endocarditis epidemiology over five decades: a systematic review. *PLoS One* 2013; **8**:e82665. <https://doi.org/10.1371/journal.pone.0082665>
639. Oliver L, Lavoute C, Giorgi R, Salaun E, Hubert S, Casalta JP, et al. Infective endocarditis in octogenarians. *Heart* 2017; **103**:1602–1609. <https://doi.org/10.1136/heartjnl-2016-310853>
640. Pazardernik M, lung B, Mutlu B, Alla F, Riezebos R, Kong W, et al. Surgery and outcome of infective endocarditis in octogenarians: prospective data from the ESC EORP EURO-ENDO registry. *Infection* 2022; **50**:1191–1202. <https://doi.org/10.1007/s15010-022-01792-0>
641. Ragnarsson S, Salto-Alejandro S, Strom A, Olaison L, Rasmussen M. Surgery is under-used in elderly patients with left-sided infective endocarditis: a nationwide registry study. *J Am Heart Assoc* 2021; **10**:e020221. <https://doi.org/10.1161/JAHA.120.020221>
642. Ghanta RK, Pettersson GB. Surgical treatment of infective endocarditis in elderly patients: the importance of shared decision making. *J Am Heart Assoc* 2021; **10**:e022186. <https://doi.org/10.1161/JAHA.121.022186>
643. Lopez J, Revilla A, Vilacosta I, Sevilla T, Villacorta E, Sarria C, et al. Age-dependent profile of left-sided infective endocarditis: a 3-center experience. *Circulation* 2010; **121**:892–897. <https://doi.org/10.1161/CIRCULATIONAHA.109.877365>
644. Storteky S, Heg D, Tueller D, Pilgrim T, Muller O, Noble S, et al. Infective endocarditis after transcatheter aortic valve replacement. *J Am Coll Cardiol* 2020; **75**:3020–3030. <https://doi.org/10.1016/j.jacc.2020.04.044>
645. Regueiro A, Linke A, Latib A, Ihlemann N, Urena M, Walther T, et al. Association between transcatheter aortic valve replacement and subsequent infective endocarditis and in-hospital death. *JAMA* 2016; **316**:1083–1092. <https://doi.org/10.1001/jama.2016.12347>
646. Kolte D, Goldsweig A, Kennedy KF, Abbott JD, Gordon PC, Sellke FW, et al. Comparison of incidence, predictors, and outcomes of early infective endocarditis after transcatheter aortic valve implantation versus surgical aortic valve replacement in the United States. *Am J Cardiol* 2018; **122**:2112–2119. <https://doi.org/10.1016/j.amjcard.2018.08.054>
647. Fauchier L, Bisson A, Herbert J, Lacour T, Bourguignon T, Etienne CS, et al. Incidence and outcomes of infective endocarditis after transcatheter aortic valve implantation versus surgical aortic valve replacement. *Clin Microbiol Infect* 2020; **26**:1368–1374. <https://doi.org/10.1016/j.cmi.2020.01.036>
648. Butt JH, Ihlemann N, De Backer O, Sondergaard L, Havers-Borgersen E, Gislason GH, et al. Long-term risk of infective endocarditis after transcatheter aortic valve replacement. *J Am Coll Cardiol* 2019; **73**:1646–1655. <https://doi.org/10.1016/j.jacc.2018.12.078>
649. Cahill TJ, Raby J, Jewell PD, Brennan PF, Banning AP, Byrne J, et al. Risk of infective endocarditis after surgical and transcatheter aortic valve replacement. *Heart* 2022; **108**:639–647. <https://doi.org/10.1136/heartjnl-2021-320080>
650. Del Val D, Abdel-Wahab M, Linke A, Durand E, Ihlemann N, Urena M, et al. Temporal trends, characteristics, and outcomes of infective endocarditis after transcatheter aortic valve replacement. *Clin Infect Dis* 2021; **73**:e3750–e3758. <https://doi.org/10.1093/cid/ciaa1941>
651. Bjursten H, Rasmussen M, Nozohoor S, Gotberg M, Olaison L, Ruck A, et al. Infective endocarditis after transcatheter aortic valve implantation: a nationwide study. *Eur Heart J* 2019; **40**:3263–3269. <https://doi.org/10.1093/eurheartj/ehz588>
652. Mentias A, Girotra S, Desai MY, Horwitz PA, Rossen JD, Saad M, et al. Incidence, predictors, and outcomes of endocarditis after transcatheter aortic valve replacement in the United States. *JACC Cardiovasc Interv* 2020; **13**:1973–1982. <https://doi.org/10.1016/j.jcin.2020.05.012>
653. Regueiro A, Linke A, Latib A, Ihlemann N, Urena M, Walther T, et al. Infective endocarditis following transcatheter aortic valve replacement: comparison of balloon- versus self-expandable valves. *Circ Cardiovasc Interv* 2019; **12**:e007938. <https://doi.org/10.1161/CIRCINTERVENTIONS.119.007938>
654. Salaun E, Sportouch L, Barral PA, Hubert S, Lavoute C, Casalta AC, et al. Diagnosis of infective endocarditis after TAVR: value of a multimodality imaging approach. *JACC Cardiovasc Imaging* 2018; **11**:143–146. <https://doi.org/10.1016/j.jcmg.2017.05.016>
655. Wahadat AR, Tanis W, Swart LE, Scholtens A, Krestin GP, van Mieghem N, et al. Added value of (18)F-FDG-PET/CT and cardiac CTA in suspected transcatheter aortic valve endocarditis. *J Nucl Cardiol* 2021; **28**:2072–2082. <https://doi.org/10.1007/s12350-019-01963-x>
656. Mangner N, Leontyev S, Woitek FJ, Kiefer P, Haussig S, Binner C, et al. Cardiac surgery compared with antibiotics only in patients developing infective endocarditis after transcatheter aortic valve replacement. *J Am Heart Assoc* 2018; **7**:e010027. <https://doi.org/10.1161/JAHA.118.010027>
657. Del Val D, Trottier M, Alperi A, Muntane-Carol G, Faroux L, Delarochelliere R, et al. (18)F-fluorodeoxyglucose uptake pattern in noninfected transcatheter aortic valves. *Circ Cardiovasc Imaging* 2020; **13**:e011749. <https://doi.org/10.1161/CIRCIMAGING.120.011749>
658. Mangner N, del Val D, Abdel-Wahab M, Crusius L, Durand E, Ihlemann N. Surgical treatment of patients with infective endocarditis after transcatheter aortic valve implantation. *J Am Coll Cardiol* 2022; **79**:772–785. <https://doi.org/10.1016/j.jacc.2021.11.056>
659. Santos-Martinez S, Alkhodair A, Nombela-Franco L, Saia F, Munoz-Garcia AJ, Gutierrez E, et al. Transcatheter aortic valve replacement for residual lesion of the aortic valve following “healed” infective endocarditis. *JACC Cardiovasc Interv* 2020; **13**:1983–1996. <https://doi.org/10.1016/j.jcin.2020.05.033>
660. Bos D, De Wolf D, Cools B, Eyskens B, Hubrechts J, Boshoff D, et al. Infective endocarditis in patients after percutaneous pulmonary valve implantation with the stent-mounted bovine jugular vein valve: clinical experience and evaluation of the modified Duke criteria. *Int J Cardiol* 2021; **323**:40–46. <https://doi.org/10.1016/j.ijcard.2020.08.058>
661. Georgiev S, Ewert P, Eicken A, Hager A, Horer J, Cleuziou J, et al. Munich comparative study: prospective long-term outcome of the transcatheter melody valve versus surgical pulmonary bioprosthesis with up to 12 years of follow-up. *Circ Cardiovasc Interv* 2020; **13**:e008963. <https://doi.org/10.1161/CIRCINTERVENTIONS.119.008963>
662. Groning M, Tahri NB, Sondergaard L, Helvind M, Ersboll MK, Orbaek Andersen H. Infective endocarditis in right ventricular outflow tract conduits: a register-based comparison of homografts, conegra grafts and melody transcatheter valves. *Eur J Cardiothorac Surg* 2019; **56**:87–93. <https://doi.org/10.1093/ejcts/ezy478>
663. Lluri G, Levi DS, Miller E, Hageman A, Sinha S, Sadeghi S, et al. Incidence and outcome of infective endocarditis following percutaneous versus surgical pulmonary valve replacement. *Catheter Cardiovasc Interv* 2018; **91**:277–284. <https://doi.org/10.1002/ccd.27312>
664. Malekzadeh-Milani S, Houeijeh A, Jalal Z, Hascoet S, Baklouf M, Aldebert P, et al. French national survey on infective endocarditis and the melody valve in percutaneous pulmonary valve implantation. *Arch Cardiovasc Dis* 2018; **111**:497–506. <https://doi.org/10.1016/j.jacvd.2017.10.007>
665. McElhinney DB, Zhang Y, Aboulhosn JA, Morray BH, Biernacka EK, Qureshi AM, et al. Multicenter study of endocarditis after transcatheter pulmonary valve replacement. *J Am Coll Cardiol* 2021; **78**:575–589. <https://doi.org/10.1016/j.jacc.2021.05.044>
666. Nordmeyer J, Ewert P, Gewillig M, AlJufan M, Carminati M, Kretschmar O, et al. Acute and midterm outcomes of the post-approval MELODY registry: a multicentre registry of transcatheter pulmonary valve implantation. *Eur Heart J* 2019; **40**:2255–2264. <https://doi.org/10.1093/eurheartj/ehz201>
667. O'Donnell C, Holloway R, Tilton J, Finucane K, Wilson N. Infective endocarditis following melody valve implantation: comparison with a surgical cohort. *Cardiol Young* 2017; **27**:294–301. <https://doi.org/10.1017/S1047951116000494>
668. Van Dijk I, Budts W, Cools B, Eyskens B, Boshoff DE, Heying R, et al. Infective endocarditis of a transcatheter pulmonary valve in comparison with surgical implants. *Heart* 2015; **101**:788–793. <https://doi.org/10.1136/heartjnl-2014-306761>
669. Stammnitz C, Huscher D, Bauer UMM, Urban A, Nordmeyer J, Schubert S, et al. Nationwide registry-based analysis of infective endocarditis risk after pulmonary valve replacement. *J Am Heart Assoc* 2022; **11**:e022231. <https://doi.org/10.1161/JAHA.121.022231>
670. Cheung G, Vejstrup N, Ihlemann N, Arnous S, Franzen O, Bundgaard H, et al. Infective endocarditis following percutaneous pulmonary valve replacement: diagnostic challenges and application of intra-cardiac echocardiography. *Int J Cardiol* 2013; **169**:425–429. <https://doi.org/10.1016/j.ijcard.2013.10.016>
671. Olsen T, Jorgensen OD, Nielsen JC, Thogersen AM, Philbert BT, Johansen JB. Incidence of device-related infection in 97 750 patients: clinical data from the complete Danish device-cohort (1982–2018). *Eur Heart J* 2019; **40**:1862–1869. <https://doi.org/10.1093/eurheartj/ehz316>
672. Da Costa A, Lelievre H, Kirkorian G, Celard M, Chevalier P, Vandenesch F, et al. Role of the preaxillary flora in pacemaker infections: a prospective study. *Circulation* 1998; **97**:1791–1795. <https://doi.org/10.1161/01.CIR.97.18.1791>
673. Chamis AL, Peterson GE, Cabell CH, Corey GR, Sorrentino RA, Greenfield RA, et al. *Staphylococcus aureus* bacteremia in patients with permanent pacemakers or implantable cardioverter-defibrillators. *Circulation* 2001; **104**:1029–1033. <https://doi.org/10.1161/hc3401.095097>
674. Madhavan M, Sohail MR, Friedman PA, Hayes DL, Steckelberg JM, Wilson WR, et al. Outcomes in patients with cardiovascular implantable electronic devices and bacteremia caused by Gram-positive cocci other than *Staphylococcus aureus*. *Circ Arrhythm Electrophysiol* 2010; **3**:639–645. <https://doi.org/10.1161/CIRCEP.110.957514>
675. Sohail MR, Palraj BR, Khalid S, Uslan DZ, Al-Saffar F, Friedman PA, et al. Predicting risk of endovascular device infection in patients with *Staphylococcus aureus* bacteremia (PREDICT-SAB). *Circ Arrhythm Electrophysiol* 2015; **8**:137–144. <https://doi.org/10.1161/CIRCEP.114.002199>
676. Uslan DZ, Dowsley TF, Sohail MR, Hayes DL, Friedman PA, Wilson WR, et al. Cardiovascular implantable electronic device infection in patients with

- Staphylococcus aureus* bacteremia. *Pacing Clin Electrophysiol* 2010;**33**:407–413. <https://doi.org/10.1111/j.1540-8159.2009.02565.x>
677. Hussein AA, Baghdy Y, Wazni OM, Brunner MP, Kabbach G, Shao M, et al. Microbiology of cardiac implantable electronic device infections. *JACC Clin Electrophysiol* 2016;**2**:498–505. <https://doi.org/10.1016/j.jacep.2016.01.019>
  678. Mateos Gaitan R, Boix-Palop L, Munoz Garcia P, Mestres CA, Marin Arriaza M, Pedraz Prieto A, et al. Infective endocarditis in patients with cardiac implantable electronic devices: a nationwide study. *Europace* 2020;**22**:1062–1070. <https://doi.org/10.1093/europace/euaa076>
  679. Arora Y, Perez AA, Carrillo RG. Influence of vegetation shape on outcomes in transvenous lead extractions: does shape matter? *Heart Rhythm* 2020;**17**:646–653. <https://doi.org/10.1016/j.hrthm.2019.11.015>
  680. Esquer Garrigos Z, George MP, Vijayvargiya P, Tan EM, Farid S, Abu Saleh OM, et al. Clinical presentation, management, and outcomes of cardiovascular implantable electronic device infections due to Gram-negative versus Gram-positive bacteria. *Mayo Clin Proc* 2019;**94**:1268–1277. <https://doi.org/10.1016/j.jmayocp.2018.11.029>
  681. Baman JR, Medhekar AN, Jain SK, Knight BP, Harrison LH, Smith B, et al. Management of systemic fungal infections in the presence of a cardiac implantable electronic device: a systematic review. *Pacing Clin Electrophysiol* 2021;**44**:159–166. <https://doi.org/10.1111/pace.14090>
  682. Krahn AD, Longtin Y, Philippon F, Birnie DH, Manlucu J, Angaran P, et al. Prevention of arrhythmia device infection trial: the PADIT trial. *J Am Coll Cardiol* 2018;**72**:3098–3109. <https://doi.org/10.1016/j.jacc.2018.09.068>
  683. Birnie DH, Wang J, Alings M, Philippon F, Parkash R, Manlucu J, et al. Risk factors for infections involving cardiac implanted electronic devices. *J Am Coll Cardiol* 2019;**74**:2845–2854. <https://doi.org/10.1016/j.jacc.2019.09.060>
  684. Ahmed FZ, Blomstrom-Lundqvist C, Bloom H, Cooper C, Ellis C, Goette A, et al. Use of healthcare claims to validate the prevention of arrhythmia device infection trial cardiac implantable electronic device infection risk score. *Europace* 2021;**23**:1446–1455. <https://doi.org/10.1093/europace/euab028>
  685. Birnie DH, Healey JS, Wells GA, Ayala-Paredes F, Coutu B, Sumner GL, et al. Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2). *Eur Heart J* 2018;**39**:3973–3979. <https://doi.org/10.1093/eurheartj/ehy413>
  686. Birnie DH, Healey JS, Wells GA, Verma A, Tang AS, Krahn AD, et al. Pacemaker or defibrillator surgery without interruption of anticoagulation. *N Engl J Med* 2013;**368**:2084–2093. <https://doi.org/10.1056/NEJMoa1302946>
  687. Burri H, Starck C, Auricchio A, Biffi M, Burri M, D'Avila A, et al. EHRA expert consensus statement and practical guide on optimal implantation technique for conventional pacemakers and implantable cardioverter-defibrillators: endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), and the Latin-American Heart Rhythm Society (LAHRS). *Europace* 2021;**23**:983–1008. <https://doi.org/10.1093/europace/euab367>
  688. Tarakji KG, Mittal S, Kennergren C, Corey R, Poole JE, Schloss E, et al. Antibacterial envelope to prevent cardiac implantable device infection. *N Engl J Med* 2019;**380**:1895–1905. <https://doi.org/10.1056/NEJMoa1901111>
  689. Frausing M, Nielsen JC, Johansen JB, Jorgensen OD, Gerdes C, Olsen T, et al. Rate of device-related infections using an antibacterial envelope in patients undergoing cardiac resynchronization therapy reoperations. *Europace* 2022;**24**:421–429. <https://doi.org/10.1093/europace/euab207>
  690. Uslan DZ, Sohail MR, Friedman PA, Hayes DL, Wilson WR, Steckelberg JM, et al. Frequency of permanent pacemaker or implantable cardioverter-defibrillator infection in patients with Gram-negative bacteremia. *Clin Infect Dis* 2006;**43**:731–736. <https://doi.org/10.1086/506942>
  691. Uslan DZ, Sohail MR, St Sauver JL, Friedman PA, Hayes DL, Stoner SM, et al. Permanent pacemaker and implantable cardioverter defibrillator infection: a population-based study. *Arch Intern Med* 2007;**167**:669–675. <https://doi.org/10.1001/archinte.167.7.669>
  692. Fowler VG Jr, Li J, Corey GR, Boley J, Marr KA, Gopal AK, et al. Role of echocardiography in evaluation of patients with *Staphylococcus aureus* bacteremia: experience in 103 patients. *J Am Coll Cardiol* 1997;**30**:1072–1078. [https://doi.org/10.1016/S0735-1097\(97\)00250-7](https://doi.org/10.1016/S0735-1097(97)00250-7)
  693. Victor F, De Place C, Camus C, Le Breton H, Leclercq C, Pavin D, et al. Pacemaker lead infection: echocardiographic features, management, and outcome. *Heart* 1999;**81**:82–87. <https://doi.org/10.1136/hrt.81.1.82>
  694. Vilacosta I, Sarría C, San Roman JA, Jimenez J, Castillo JA, Iturralde E, et al. Usefulness of transesophageal echocardiography for diagnosis of infected transvenous permanent pacemakers. *Circulation* 1994;**89**:2684–2687. <https://doi.org/10.1161/01.CIR.89.6.2684>
  695. Narducci ML, Pelargonio G, Russo E, Marinaccio L, Di Monaco A, Perna F, et al. Usefulness of intracardiac echocardiography for the diagnosis of cardiovascular implantable electronic device-related endocarditis. *J Am Coll Cardiol* 2013;**61**:1398–1405. <https://doi.org/10.1016/j.jacc.2012.12.041>
  696. Golzio PG, Errigo D, Peyracchia M, Gallo E, Frea S, Castagno D, et al. Prevalence and prognosis of lead masses in patients with cardiac implantable electronic devices without infection. *J Cardiovasc Med (Hagerstown)* 2019;**20**:372–378. <https://doi.org/10.2459/JCM.0000000000000797>
  697. Erba PA, Sollini M, Conti U, Bandera F, Tascini C, De Tommasi SM, et al. Radiolabeled WBC scintigraphy in the diagnostic workup of patients with suspected device-related infections. *JACC Cardiovasc Imaging* 2013;**6**:1075–1086. <https://doi.org/10.1016/j.jcmg.2013.08.001>
  698. Lin AY, Saul T, Aldaas OM, Lupercio F, Ho G, Pollema T, et al. Early versus delayed lead extraction in patients with infected cardiovascular implantable electronic devices. *JACC Clin Electrophysiol* 2021;**7**:755–763. <https://doi.org/10.1016/j.jacep.2020.11.003>
  699. Le KY, Sohail MR, Friedman PA, Uslan DZ, Cha SS, Hayes DL, et al. Impact of timing of device removal on mortality in patients with cardiovascular implantable electronic device infections. *Heart Rhythm* 2011;**8**:1678–1685. <https://doi.org/10.1016/j.hrthm.2011.05.015>
  700. Durante-Mangoni E, Casillo R, Bernardo M, Caianiello C, Mattucci I, Pinto D, et al. High-dose daptomycin for cardiac implantable electronic device-related infective endocarditis. *Clin Infect Dis* 2012;**54**:347–354. <https://doi.org/10.1093/cid/cir805>
  701. Sohail MR, Uslan DZ, Khan AH, Friedman PA, Hayes DL, Wilson WR, et al. Management and outcome of permanent pacemaker and implantable cardioverter-defibrillator infections. *J Am Coll Cardiol* 2007;**49**:1851–1859. <https://doi.org/10.1016/j.jacc.2007.01.072>
  702. Huang X-M, Fu H-X, Zhong L, Cao J, Asirvatham SJ, Baddour LM, et al. Outcomes of transvenous lead extraction for cardiovascular implantable electronic device infections in patients with prosthetic heart valves. *Circ Arrhythm Electrophysiol* 2016;**9**:e004188. <https://doi.org/10.1161/CIRCEP.116.004188>
  703. De Ciancio G, Erpelding ML, Filippetti L, Goehringer F, Blangy H, Huttin O, et al. Adherence to diagnostic and therapeutic practice guidelines for suspected cardiac implantable electronic device infections. *Arch Cardiovasc Dis* 2021;**114**:634–646. <https://doi.org/10.1016/j.acvd.2021.06.010>
  704. Viganego F, O'Donoghue S, Eldadah Z, Shah MH, Rastogi M, Mazel JA, et al. Effect of early diagnosis and treatment with percutaneous lead extraction on survival in patients with cardiac device infections. *Am J Cardiol* 2012;**109**:1466–1471. <https://doi.org/10.1016/j.amjcard.2012.01.360>
  705. Starck CT, Schaefer RHM, Breitenstein A, Najibi S, Conrad J, Berend J, et al. Transcatheter aspiration of large pacemaker and implantable cardioverter-defibrillator lead vegetations facilitating safe transvenous lead extraction. *Europace* 2020;**22**:133–138. <https://doi.org/10.1093/europace/euz283>
  706. Golzio PG, Vinci M, Anselmino M, Comoglio C, Rinaldi M, Trevi GP, et al. Accuracy of swabs, tissue specimens, and lead samples in diagnosis of cardiac rhythm management device infections. *Pacing Clin Electrophysiol* 2009;**32**(Suppl 1):S76–S80. <https://doi.org/10.1111/j.1540-8159.2008.02257.x>
  707. Nagpal A, Patel R, Greenwood-Quaintance KE, Baddour LM, Lynch DT, Lahr BD, et al. Usefulness of sonication of cardiovascular implantable electronic devices to enhance microbial detection. *Am J Cardiol* 2015;**115**:912–917. <https://doi.org/10.1016/j.amjcard.2015.01.017>
  708. Rohacek M, Erne P, Kobza R, Pfyffer GE, Frei R, Weisser M. Infection of cardiovascular implantable electronic devices: detection with sonication, swab cultures, and blood cultures. *Pacing Clin Electrophysiol* 2015;**38**:247–253. <https://doi.org/10.1111/pace.12529>
  709. Chew D, Somayaji R, Conly J, Exner D, Rennert-May E. Timing of device reimplantation and reinfection rates following cardiac implantable electronic device infection: a systematic review and meta-analysis. *BMJ Open* 2019;**9**:e029537. <https://doi.org/10.1136/bmjopen-2019-029537>
  710. Diemberger I, Biffi M, Lorenzetti S, Martignani C, Raffaelli E, Ziacchi M, et al. Predictors of long-term survival free from relapses after extraction of infected CIED. *Europace* 2018;**20**:1018–1027. <https://doi.org/10.1093/europace/eux121>
  711. Chua JD, Wilkoff BL, Lee I, Juratli N, Longworth DL, Gordon SM. Diagnosis and management of infections involving implantable electrophysiologic cardiac devices. *Ann Intern Med* 2000;**133**:604–608. <https://doi.org/10.7326/0003-4819-133-8-200010170-00011>
  712. Kawata H, Pretorius V, Phan H, Mulpuru S, Gadiyaram V, Patel J, et al. Utility and safety of temporary pacing using active fixation leads and externalized re-usable permanent pacemakers after lead extraction. *Europace* 2013;**15**:1287–1291. <https://doi.org/10.1093/europace/eut045>
  713. Perrin T, Maille B, Lemoine C, Resseguier N, Franceschi F, Koutbi L, et al. Comparison of epicardial vs. endocardial reimplantation in pacemaker-dependent patients with device infection. *Europace* 2018;**20**:e42–e50. <https://doi.org/10.1093/europace/eux111>
  714. Zucchelli G, Barletta V, Della Tommasina V, Viani S, Parollo M, Mazzocchetti L, et al. Micra pacemaker implant after cardiac implantable electronic device extraction: feasibility and long-term outcomes. *Europace* 2019;**21**:1229–1236. <https://doi.org/10.1093/europace/euz160>
  715. Chung DU, Tauber J, Kaiser L, Schlichting A, Pecha S, Sinning C, et al. Performance and outcome of the subcutaneous implantable cardioverter-defibrillator after transvenous lead extraction. *Pacing Clin Electrophysiol* 2021;**44**:247–257. <https://doi.org/10.1111/pace.14157>

716. Joffre J, Dumas G, Aegerter P, Dubee V, Bige N, Preda G, et al. Epidemiology of infective endocarditis in French intensive care units over the 1997–2014 period-from CUB-rea network. *Crit Care* 2019;**23**:143. <https://doi.org/10.1186/s13054-019-2387-8>
717. Georges H, Leroy O, Airapetian N, Lamblin N, Zogheib E, Devos P, et al. Outcome and prognostic factors of patients with right-sided infective endocarditis requiring intensive care unit admission. *BMC Infect Dis* 2018;**18**:85. <https://doi.org/10.1186/s12879-018-2989-9>
718. Leroy O, Georges H, Devos P, Bitton S, De Sa N, Dedrie C, et al. Infective endocarditis requiring ICU admission: epidemiology and prognosis. *Ann Intensive Care* 2015;**5**:45. <https://doi.org/10.1186/s13613-015-0091-7>
719. Samol A, Kaese S, Bloch J, Gorlich D, Peters G, Waltenberger J, et al. Infective endocarditis on ICU: risk factors, outcome and long-term follow-up. *Infection* 2015;**43**:287–295. <https://doi.org/10.1007/s15010-014-0715-0>
720. Arntfield R, Lau V, Landry Y, Priestap F, Ball I. Impact of critical care transesophageal echocardiography in medical-surgical ICU patients: characteristics and results from 274 consecutive examinations. *J Intensive Care Med* 2020;**35**:896–902. <https://doi.org/10.1177/0885066618797271>
721. Belletti A, Jacobs S, Affronti G, Mladenow A, Landoni G, Falk V, et al. Incidence and predictors of postoperative need for high-dose inotropic support in patients undergoing cardiac surgery for infective endocarditis. *J Cardiothorac Vasc Anesth* 2018;**32**:2528–2536. <https://doi.org/10.1053/j.jvca.2017.12.015>
722. van den Brink FS, van Tooren R, Sonker U, Klein P, Waanders F, Zivelonghi C, et al. Venous arterial-extra corporal membrane oxygenation for the treatment of cardiac failure in patients with infective endocarditis. *Perfusion* 2019;**34**:613–617. <https://doi.org/10.1177/0267659119842807>
723. Lassen H, Nielsen SL, Gill SUA, Johansen IS. The epidemiology of infective endocarditis with focus on non-device related right-sided infective endocarditis: a retrospective register-based study in the region of southern Denmark. *Int J Infect Dis* 2020;**95**:224–230. <https://doi.org/10.1016/j.ijid.2020.04.011>
724. Sridhar AR, Lavu M, Yarlagadda V, Reddy M, Gunda S, Afzal R, et al. Cardiac implantable electronic device-related infection and extraction trends in the U.S. *Pacing Clin Electrophysiol* 2017;**40**:286–293. <https://doi.org/10.1111/pace.13009>
725. Witten JC, Hussain ST, Shrestha NK, Gordon SM, Houghtaling PL, Bakaeen FG, et al. Surgical treatment of right-sided infective endocarditis. *J Thorac Cardiovasc Surg* 2019;**157**:1418–1427.e14. <https://doi.org/10.1016/j.jtcvs.2018.07.112>
726. Pfanmueller B, Kahmann M, Davierwala P, Misfeld M, Bakhtiari F, Binner C, et al. Tricuspid valve surgery in patients with isolated tricuspid valve endocarditis: analysis of perioperative parameters and long-term outcomes. *Thorac Cardiovasc Surg* 2017;**65**:626–633. <https://doi.org/10.1055/s-0035-1564926>
727. Isaza N, Shrestha NK, Gordon S, Pettersson GB, Unai S, Vega Brizneda M, et al. Contemporary outcomes of pulmonary valve endocarditis: a 16-year single centre experience. *Heart Lung Circ* 2020;**29**:1799–1807. <https://doi.org/10.1016/j.hlc.2020.04.015>
728. Hussain ST, Shrestha NK, Witten J, Gordon SM, Houghtaling PL, Tingleff J, et al. Rarity of invasiveness in right-sided infective endocarditis. *J Thorac Cardiovasc Surg* 2018;**155**:54–61.e1. <https://doi.org/10.1016/j.jtcvs.2017.07.068>
729. San Roman JA, Vilacosta I, Lopez J, Revilla A, Arnold R, Sevilla T, et al. Role of transthoracic and transesophageal echocardiography in right-sided endocarditis: one echocardiographic modality does not fit all. *J Am Soc Echocardiogr* 2012;**25**:807–814. <https://doi.org/10.1016/j.echo.2012.05.016>
730. Anton-Vazquez V, Cannata A, Amin-Youssef G, Watson S, Fife A, Mulholland N, et al. Diagnostic value of (18)F-FDG PET/CT in infective endocarditis. *Clin Res Cardiol* 2022;**111**:673–679. <https://doi.org/10.1007/s00392-021-01975-z>
731. Weber C, Gassa A, Eghbalzadeh K, Merkle J, Djordjevic I, Maier J, et al. Characteristics and outcomes of patients with right-sided endocarditis undergoing cardiac surgery. *Ann Cardiothorac Surg* 2019;**8**:645–653. <https://doi.org/10.21037/acs.2019.08.02>
732. Shrestha NK, Jue J, Hussain ST, Jerry JM, Pettersson GB, Menon V, et al. Injection drug use and outcomes after surgical intervention for infective endocarditis. *Ann Thorac Surg* 2015;**100**:875–882. <https://doi.org/10.1016/j.athoracsur.2015.03.019>
733. Hussain ST, Witten J, Shrestha NK, Blackstone EH, Pettersson GB. Tricuspid valve endocarditis. *Ann Cardiothorac Surg* 2017;**6**:255–261. <https://doi.org/10.21037/acs.2017.03.09>
734. Marks LR, Nolan NS, Liang SY, Durkin MJ, Weimer MB. Infectious complications of injection drug use. *Med Clin North Am* 2022;**106**:187–200. <https://doi.org/10.1016/j.mcna.2021.08.006>
735. Kelly MC, Yeager SD, Shorman MA, Wright LR, Veve MP. Incidence and predictors of Gram-negative bacilli in hospitalized people who inject drugs with injection drug use-attributable infections. *Antimicrob Agents Chemother* 2021;**65**:e0092521. <https://doi.org/10.1128/AAC.00925-21>
736. Bisbe J, Miro JM, Latorre X, Moreno A, Mallolas J, Gatell JM, et al. Disseminated candidiasis in addicts who use brown heroin: report of 83 cases and review. *Clin Infect Dis* 1992;**15**:910–923. <https://doi.org/10.1093/clind/15.6.910>
737. Meena DS, Kumar D, Agarwal M, Bohra GK, Choudhary R, Samantaray S, et al. Clinical features, diagnosis and treatment outcome of fungal endocarditis: a systematic review of reported cases. *Mycoses* 2022;**65**:294–302. <https://doi.org/10.1111/myc.13398>
738. Ribera E, Gomez-Jimenez J, Cortes E, del Valle O, Planes A, Gonzalez-Alujas T, et al. Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-sided *Staphylococcus aureus* endocarditis. A randomized, controlled trial. *Ann Intern Med* 1996;**125**:969–974. <https://doi.org/10.7326/0003-4819-125-12-199612150-00005>
739. Cahill TJ, Prendergast BD. Infective endocarditis. *Lancet* 2016;**387**:882–893. [https://doi.org/10.1016/S0140-6736\(15\)00067-7](https://doi.org/10.1016/S0140-6736(15)00067-7)
740. Chong CZ, Cherian R, Ng P, Yeo TC, Ling LH, Soo WM, et al. Clinical outcomes of severe tricuspid valve infective endocarditis related to intravenous drug abuse – a case series. *Acta Cardiol* 2022;**77**:884–889. <https://doi.org/10.1080/00015385.2021.1976448>
741. Syed IM, Yanagawa B, Jeyaganth S, Verma S, Cheema AN. Injection drug use endocarditis: an inner-city hospital experience. *CJC Open* 2021;**3**:896–903. <https://doi.org/10.1016/j.cjco.2021.02.015>
742. Chahoud J, Sharif Yakan A, Saad H, Kanj SS. Right-sided infective endocarditis and pulmonary infiltrates: an update. *Cardiol Rev* 2016;**24**:230–237. <https://doi.org/10.1097/CRD.0000000000000095>
743. Damlin A, Westling K. Patients with infective endocarditis and history of injection drug use in a Swedish referral hospital during 10 years. *BMC Infect Dis* 2021;**21**:236. <https://doi.org/10.1186/s12879-021-05914-1>
744. Rose WE, Leonard SN, Sakoulas G, Kaatz GW, Zervos MJ, Sheth A, et al. Daptomycin activity against *Staphylococcus aureus* following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations. *Antimicrob Agents Chemother* 2008;**52**:831–836. <https://doi.org/10.1128/AAC.00869-07>
745. Al-Omari A, Cameron DW, Lee C, Corrales-Medina VF. Oral antibiotic therapy for the treatment of infective endocarditis: a systematic review. *BMC Infect Dis* 2014;**14**:140. <https://doi.org/10.1186/1471-2334-14-140>
746. Marks LR, Liang SY, Muthulingam D, Schwarz ES, Liss DB, Munigala S, et al. Evaluation of partial oral antibiotic treatment for persons who inject drugs and are hospitalized with invasive infections. *Clin Infect Dis* 2020;**71**:e650–e656. <https://doi.org/10.1093/cid/ciaa365>
747. Slaughter MS, Badhwar V, Ising M, Ganzel BL, Sell-Dottin K, Jawitz OK, et al. Optimum surgical treatment for tricuspid valve infective endocarditis: an analysis of the Society of Thoracic Surgeons national database. *J Thorac Cardiovasc Surg* 2021;**161**:1227–1235.e1. <https://doi.org/10.1016/j.jtcvs.2019.10.124>
748. Misfeld M, Davierwala PM, Borger MA, Bakhtiari F. The “UFO” procedure. *Ann Cardiothorac Surg* 2019;**8**:691–698. <https://doi.org/10.21037/acs.2019.11.05>
749. Navia JL, Elgharably H, Hakim AH, Witten JC, Haupt MJ, Germano E, et al. Long-term outcomes of surgery for invasive valvular endocarditis involving the aortomitral fibrosa. *Ann Thorac Surg* 2019;**108**:1314–1323. <https://doi.org/10.1016/j.athoracsur.2019.04.119>
750. Nappi F, Spadaccio C, Mihos C, Shaikhreza K, Acar C, Moon MR. The quest for the optimal surgical management of tricuspid valve endocarditis in the current era: a narrative review. *Ann Transl Med* 2020;**8**:1628. <https://doi.org/10.21037/atm-20-4685>
751. Arbulu A, Holmes RJ, Asfaw I. Surgical treatment of intractable right-sided infective endocarditis in drug addicts: 25 years experience. *J Heart Valve Dis* 1993;**2**:129–137, discussion 138–139.
752. Brescia AA, Watt TMF, Williams AM, Romano MA, Bolling SF. Tricuspid valve leaflet repair and augmentation for infective endocarditis. *Oper Tech Thorac Cardiovasc Surg* 2019;**24**:206–218. <https://doi.org/10.1053/j.optechstcvs.2019.09.002>
753. Randhawa VK, Rajani R. Novel frontiers for managing tricuspid valve endocarditis: tales of percutaneous extracorporeal circuitry. *JACC Case Rep* 2021;**3**:1350–1353. <https://doi.org/10.1016/j.jaccas.2021.06.026>
754. Starck CT, Dreizler T, Falk V. The AngioVac system as a bail-out option in infective valve endocarditis. *Ann Cardiothorac Surg* 2019;**8**:675–677. <https://doi.org/10.21037/acs.2019.11.04>
755. Luc JGY, Choi J-H, Kodja K, Weber MP, Horan DP, Maynes EJ, et al. Valvectomy versus replacement for the surgical treatment of infective tricuspid valve endocarditis: a systematic review and meta-analysis. *Ann Cardiothorac Surg* 2019;**8**:610–620. <https://doi.org/10.21037/acs.2019.11.06>
756. Gabriel HM, Heger M, Innerhofer P, Zehetgruber M, Mundigler G, Wimmer M, et al. Long-term outcome of patients with ventricular septal defect considered not to require surgical closure during childhood. *J Am Coll Cardiol* 2002;**39**:1066–1071. [https://doi.org/10.1016/S0735-1097\(02\)01706-0](https://doi.org/10.1016/S0735-1097(02)01706-0)
757. Moore B, Cao J, Kotchetkova I, Celermajer DS. Incidence, predictors and outcomes of infective endocarditis in a contemporary adult congenital heart disease population. *Int J Cardiol* 2017;**249**:161–165. <https://doi.org/10.1016/j.ijcard.2017.08.035>
758. Baumgartner H, De Backer J, Babu-Narayan SV, Budts W, Chessa M, Diller GP, et al. 2020 ESC Guidelines for the management of adult congenital heart disease. *Eur Heart J* 2021;**42**:563–645. <https://doi.org/10.1093/eurheartj/ehaa554>
759. Haas NA, Bach S, Vcasna R, Laser KT, Sandica E, Blanz U, et al. The risk of bacterial endocarditis after percutaneous and surgical biological pulmonary valve implantation. *Int J Cardiol* 2018;**268**:55–60. <https://doi.org/10.1016/j.ijcard.2018.04.138>
760. Hribernik I, Thomson J, Ho A, English K, Van Doorn C, Jaber O, et al. Comparative analysis of surgical and percutaneous pulmonary valve implants over a 20-year period. *Eur J Cardiothorac Surg* 2022;**61**:572–579. <https://doi.org/10.1093/ejcts/ezab368>

761. Dolgner SJ, Arya B, Kronman MP, Chan T. Effect of congenital heart disease status on trends in pediatric infective endocarditis hospitalizations in the United States between 2000 and 2012. *Pediatr Cardiol* 2019;**40**:319–329. <https://doi.org/10.1007/s00246-018-2020-7>
762. Jortveit J, Klcovansky J, Eskedal L, Birkeland S, Dohlen G, Holmstrom H. Endocarditis in children and adolescents with congenital heart defects: a Norwegian nationwide register-based cohort study. *Arch Dis Child* 2018;**103**:670–674. <https://doi.org/10.1136/archdischild-2017-313917>
763. Cahill TJ, Jewell PD, Denne L, Franklin RC, Frigiola A, Orchard E, et al. Contemporary epidemiology of infective endocarditis in patients with congenital heart disease: a UK prospective study. *Am Heart J* 2019;**215**:70–77. <https://doi.org/10.1016/j.ahj.2019.05.014>
764. Tutarel O, Alonso-Gonzalez R, Montanaro C, Schiff R, Uribarri A, Kempny A, et al. Infective endocarditis in adults with congenital heart disease remains a lethal disease. *Heart* 2018;**104**:161–165. <https://doi.org/10.1136/heartjnl-2017-311650>
765. Bauer UMM, Helm PC, Diller GP, Asfour B, Schlensak C, Schmitt K, et al. Are adults with congenital heart disease informed about their risk for infective endocarditis and treated in accordance to current guidelines? *Int J Cardiol* 2017;**245**:105–108. <https://doi.org/10.1016/j.ijcard.2017.07.040>
766. Watkins DA, Beaton AZ, Carapetis JR, Karthikeyan G, Mayosi BM, Wyber R, et al. Rheumatic heart disease worldwide: JACC Scientific Expert Panel. *J Am Coll Cardiol* 2018;**72**:1397–1416. <https://doi.org/10.1016/j.jacc.2018.06.063>
767. Bajracharya S, Khanal B, Siwakoti S, Singh RR, Sharma SK. Microbiological and clinico-epidemiological profile of a series of patients with infective endocarditis at a center in Eastern Nepal. *Can J Infect Dis Med Microbiol* 2021;**2021**:9980465. <https://doi.org/10.1155/2021/9980465>
768. Karthikeyan G, Zuhlke L, Engel M, Rangarajan S, Yusuf S, Teo K, et al. Rationale and design of a Global Rheumatic Heart Disease Registry: the REMEDY study. *Am Heart J* 2012;**163**:535–540.e1. <https://doi.org/10.1016/j.ahj.2012.01.003>
769. Zuhlke L, Engel ME, Karthikeyan G, Rangarajan S, Mackie P, Cupido B, et al. Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study). *Eur Heart J* 2015;**36**:1115–1122a. <https://doi.org/10.1093/eurheartj/ehu449>
770. Zuhlke L, Karthikeyan G, Engel ME, Rangarajan S, Mackie P, Cupido-Katya Mauff B, et al. Clinical outcomes in 3343 children and adults with rheumatic heart disease from 14 low- and middle-income countries: two-year follow-up of the Global Rheumatic Heart Disease Registry (the REMEDY study). *Circulation* 2016;**134**:1456–1466. <https://doi.org/10.1161/CIRCULATIONAHA.116.024769>
771. Rohn V, Laca B, Horn M, Vlk L, Antonova P, Mosna F. Surgery in drug use-associated infective endocarditis: long-term survival is negatively affected by recurrence. *Interact Cardiovasc Thorac Surg* 2020;**30**:528–534. <https://doi.org/10.1093/icvts/ivz302>
772. Kumar RK, Antunes MJ, Beaton A, Mirabel M, Nkomo VT, Okello E, et al. Contemporary diagnosis and management of rheumatic heart diseases: implications for closing the gap: a scientific statement from the American Heart Association. *Circulation* 2020;**142**:e337–e357. <https://doi.org/10.1161/CIR.0000000000000921>
773. Coates MM, Sliwa K, Watkins DA, Zuhlke L, Perel P, Berteletti F, et al. An investment case for the prevention and management of rheumatic heart disease in the African Union 2021–30: a modelling study. *Lancet Glob Health* 2021;**9**:e957–e966. [https://doi.org/10.1016/S2214-109X\(21\)00199-6](https://doi.org/10.1016/S2214-109X(21)00199-6)
774. Zilla P, Yacoub M, Zuhlke L, Beyersdorff F, Sliwa K, Khubulava G, et al. Global unmet needs in cardiac surgery. *Glob Heart* 2018;**13**:293–303. <https://doi.org/10.1016/j.heart.2018.08.002>
775. Mirabel M, Andre R, Barsoum P, Colboc H, Lacassin F, Noel B, et al. Ethnic disparities in the incidence of infective endocarditis in the Pacific. *Int J Cardiol* 2015;**186**:43–44. <https://doi.org/10.1016/j.ijcard.2015.03.243>
776. Mirabel M, Andre R, Barsoum Mikhail P, Colboc H, Lacassin F, Noel B, et al. Infective endocarditis in the Pacific: clinical characteristics, treatment and long-term outcomes. *Open Heart* 2015;**2**:e000183. <https://doi.org/10.1136/openhrt-2014-000183>
777. Kingue S, Ba SA, Balde D, Diarra MB, Anzouan-Kacou JB, Anisubia B, et al. The valvular study: a registry of rheumatic heart disease in Western and Central Africa. *Arch Cardiovasc Dis* 2016;**109**:321–329. <https://doi.org/10.1016/j.acvd.2015.12.004>
778. Subbaraju P, Rai S, Morakhia J, Midha G, Kamath A, Saravu K. Clinical – microbiological characterization and risk factors of mortality in infective endocarditis from a tertiary care academic hospital in southern India. *Indian Heart J* 2018;**70**:259–265. <https://doi.org/10.1016/j.ihj.2017.08.007>
779. Rwebembera J, Manyilira W, Zhu ZW, Nabbaale J, Namuyonga J, Ssinabulya I, et al. Prevalence and characteristics of primary left-sided valve disease in a cohort of 15,000 patients undergoing echocardiography studies in a tertiary hospital in Uganda. *BMC Cardiovasc Disord* 2018;**18**:82. <https://doi.org/10.1186/s12872-018-0813-5>
780. Pecoraro AJ, Doubell AF. Infective endocarditis in South Africa. *Cardiovasc Diagn Ther* 2020;**10**:252–261. <https://doi.org/10.21037/cdt.2019.06.03>
781. Hajsadeghi S, Hassanzadeh M, Hajahmadi M, Kadivar M. Concurrent diagnosis of infective endocarditis and acute rheumatic fever: a case report. *J Cardiol Cases* 2018;**17**:147–150. <https://doi.org/10.1016/j.jccase.2017.12.011>
782. Gouriet F, Chaudet H, Gautret P, Pellegrin L, de Santi VP, Savini H, et al. Endocarditis in the Mediterranean Basin. *New Microbes New Infect* 2018;**26**:S43–S51. <https://doi.org/10.1016/j.nmni.2018.05.004>
783. Dhar M, Kaeley N, Bhatt N, Ahmad S. Profile of newly diagnosed adult patients with rheumatic heart disease in sub-Himalayan region – a 5-year analysis. *J Family Med Prim Care* 2019;**8**:2933–2936. [https://doi.org/10.4103/jfmpc.jfmpc\\_363\\_19](https://doi.org/10.4103/jfmpc.jfmpc_363_19)
784. Blanchard V, Pagis B, Richaud R, Moronval F, Lutinier R, Gallais K, et al. Infective endocarditis in French Polynesia: epidemiology, treatments and outcomes. *Arch Cardiovasc Dis* 2020;**113**:252–262. <https://doi.org/10.1016/j.acvd.2019.12.007>
785. Montano TCP, Wanderley MIA, Sampaio RO, Alves CGB, Neves ILL, Lopes MA, et al. Demographic, cardiologic, microbiologic, and dental profiles of Brazilian patients who developed oral bacteria-related endocarditis. *Oral Surg Oral Med Oral Pathol Oral Radiol* 2021;**132**:418–425. <https://doi.org/10.1016/j.oooo.2021.07.007>
786. Jomaa VW, Ben Ali I, Abid D, Hajri Ernez S, Abid L, Triki F, et al. Clinical features and prognosis of infective endocarditis in children: insights from a Tunisian multicentre registry. *Arch Cardiovasc Dis* 2017;**110**:676–681. <https://doi.org/10.1016/j.acvd.2016.12.018>
787. Mahony M, Lean D, Pham L, Horvath R, Suna J, Ward C, et al. Infective endocarditis in children in Queensland, Australia: epidemiology, clinical features and outcome. *Pediatr Infect Dis J* 2021;**40**:617–622. <https://doi.org/10.1097/INF.0000000000003110>
788. Willoughby ML, Basera W, Perkins SR, Comitis GAM, Fourie B, Lawrenson JB, et al. Infective endocarditis in infants and children in the Western Cape, South Africa: a retrospective analysis. *Cardiol Young* 2019;**29**:1282–1286. <https://doi.org/10.1017/S1047951119002154>
789. Nigussie B, Tadele H. Heart failure in Ethiopian children: mirroring the unmet cardiac services. *Ethiop J Health Sci* 2019;**29**:811–818. <https://doi.org/10.4314/ejhs.v29i1.2>
790. Moreira JL, Barletta P, Baucia JA. Morbidity and mortality in patients undergoing mitral valve replacement at a cardiovascular surgery referral service: a retrospective analysis. *Braz J Cardiovasc Surg* 2021;**36**:183–191. <https://doi.org/10.21470/1678-9741-2019-0440>
791. Mocumbi AO, Jamal KK, Mbakwem A, Shung-King M, Sliwa K. The Pan-African Society of Cardiology position paper on reproductive healthcare for women with rheumatic heart disease. *Cardiovasc J Afr* 2018;**29**:394–403. <https://doi.org/10.5830/CVJA-2018-044>
792. Roos-Hesseling J, Baris L, Johnson M, De Backer J, Otto C, Marelli A, et al. Pregnancy outcomes in women with cardiovascular disease: evolving trends over 10 years in the ESC registry of pregnancy and cardiac disease (ROPAC). *Eur Heart J* 2019;**40**:3848–3855. <https://doi.org/10.1093/eurheartj/ehz136>
793. De Villiers MC, Viljoen CA, Manning K, Van der Westhuizen C, Seedat A, Rath M, et al. The changing landscape of infective endocarditis in South Africa. *S Afr Med J* 2019;**109**:592–596. <https://doi.org/10.7196/SAMJ.2019.v109i8.13888>
794. Sadeghpour A, Maleki M, Movassaghi M, Rezvani L, Noohi F, Boudagh S, et al. Iranian Registry of Infective Endocarditis (IRIE): time to relook at the guideline, regarding to regional differences. *Int J Cardiol Heart Vasc* 2020;**26**:100433. <https://doi.org/10.1016/j.ijcha.2019.100433>
795. Wu Z, Chen Y, Xiao T, Niu T, Shi Q, Xiao Y. Epidemiology and risk factors of infective endocarditis in a tertiary hospital in China from 2007 to 2016. *BMC Infect Dis* 2020;**20**:428. <https://doi.org/10.1186/s12879-020-05153-w>
796. Xu H, Cai S, Dai H. Characteristics of infective endocarditis in a tertiary hospital in east China. *PLoS One* 2016;**11**:e0166764. <https://doi.org/10.1371/journal.pone.0166764>
797. Connolly C, O'Donoghue K, Doran H, McCarthy FP. Infective endocarditis in pregnancy: case report and review of the literature. *Obstet Med* 2015;**8**:102–104. <https://doi.org/10.1177/1753495X15572857>
798. Yuan SM. Infective endocarditis during pregnancy. *J Coll Physicians Surg Pak* 2015;**25**:134–139.
799. Escola-Verge L, Rello P, Declercq C, Dubee V, Rouleau F, Duval X, et al. Infective endocarditis in pregnant women without intravenous drug use: a multicentre retrospective case series. *J Antimicrob Chemother* 2022;**77**:2701–2705. <https://doi.org/10.1093/jac/dkac258>
800. Dagher MM, Eichenberger EM, Addae-Konadu KL, Dotters-Katz SK, Kohler CL, Fowler VG, et al. Maternal and fetal outcomes associated with infective endocarditis in pregnancy. *Clin Infect Dis* 2021;**73**:1571–1579. <https://doi.org/10.1093/cid/ciab533>
801. Morelli MK, Veve MP, Shorman MA. Maternal bacteremia caused by *Staphylococcus aureus* with a focus on infective endocarditis. *Open Forum Infect Dis* 2020;**7**:ofaa239. <https://doi.org/10.1093/ofid/ofaa239>
802. English N, Weston P. Multivalvular infective endocarditis in pregnancy presenting with septic pulmonary emboli. *BMJ Case Rep* 2015;**2015**:bcr2014209131. <https://doi.org/10.1136/bcr-2014-209131>
803. Khanna R, Chandrad D, Yadav S, Sahu A, Singh N, Kumar S, et al. Maternal and fetal outcomes in pregnant females with rheumatic heart disease. *Indian Heart J* 2021;**73**:185–189. <https://doi.org/10.1016/j.ihj.2021.01.012>
804. Adesomo A, Gonzalez-Brown V, Rood KM. Infective endocarditis as a complication of intravenous drug use in pregnancy: a retrospective case series and literature review. *AJP Rep* 2020;**10**:e288–e293. <https://doi.org/10.1055/s-0040-1716732>

805. Dahshan D, Suliman M, Rahman EU, Curtis Z, Thompson E. Intravenous drug use-associated infective endocarditis in pregnant patients at a hospital in West Virginia. *Cureus* 2021;**13**:e17218. <https://doi.org/10.7759/cureus.17218>
806. Lin D, Mullan CW, Deshmukh U, Bahtiyar MO, Hosier H, Lipkind H, et al. Drug use associated tricuspid valve infective endocarditis in pregnancy. *J Card Surg* 2020;**35**:2392–2395. <https://doi.org/10.1111/jocs.14888>
807. Pfaller B, Sathananthan G, Grewal J, Mason J, D'Souza R, Spears D, et al. Preventing complications in pregnant women with cardiac disease. *J Am Coll Cardiol* 2020;**75**:1443–1452. <https://doi.org/10.1016/j.jacc.2020.01.039>
808. Botea R, Porterie J, Marcheix B, Breleur FO, Lavie-Badie Y. Infective endocarditis in a third trimester pregnant woman: team work is the best option. *JACC Case Rep* 2020;**2**:521–525. <https://doi.org/10.1016/j.jaccas.2020.02.017>
809. Wang J, Wang A, Cui Y, Wang C, Zhang J. Diagnosis and treatment of infective endocarditis in pregnancy: a case report. *J Cardiothorac Surg* 2020;**15**:109. <https://doi.org/10.1186/s13019-020-01147-6>
810. Liu Y, Han F, Zhuang J, Liu X, Chen J, Huang H, et al. Cardiac operation under cardiopulmonary bypass during pregnancy. *J Cardiothorac Surg* 2020;**15**:92. <https://doi.org/10.1186/s13019-020-01136-9>
811. Eichenberger EM, Dagher M, Sinclair MR, Maskarinec SA, Fowler VG Jr, Federspiel JJ. Infective endocarditis and solid organ transplantation: only worse outcomes during initial transplantation hospitalization. *Am Heart J* 2021;**240**:63–72. <https://doi.org/10.1016/j.ahj.2021.06.007>
812. Deeks SG, Overbaugh J, Phillips A, Buchbinder S. HIV infection. *Nat Rev Dis Primers* 2015;**1**:15035. <https://doi.org/10.1038/nrdp.2015.35>
813. Munoz-Moreno MF, Ryan P, Alvaro-Meca A, Valencia J, Tamayo E, Resino S. National temporal trend analysis of infective endocarditis among patients infected with HIV in Spain (1997–2014): a retrospective study. *J Clin Med* 2019;**8**:1167. <https://doi.org/10.3390/jcm8081167>
814. Beteille E, Guarana M, Nucci M. Infective endocarditis in neutropenic patients with viridans streptococci bacteraemia. *Clin Microbiol Infect* 2018;**24**:916–917. <https://doi.org/10.1016/j.cmi.2018.03.012>
815. Veve MP, Stuart M, Davis SL. Comparison of neutropenia associated with ceftazolin or ceftriaxone in patients receiving at least 7 days of therapy for severe infections. *Pharmacotherapy* 2019;**39**:809–815. <https://doi.org/10.1002/phar.2301>
816. Mani SSR, Iyyadurai R. Cloxacillin induced agranulocytosis: a rare adverse event of a commonly used antibiotic. *Int J Immunopathol Pharmacol* 2017;**30**:297–301. <https://doi.org/10.1177/0394632017724320>
817. Tornos P, Almirante B, Mirabet S, Permanyer G, Pahissa A, Soler-Soler J. Infective endocarditis due to *Staphylococcus aureus*: deleterious effect of anticoagulant therapy. *Arch Intern Med* 1999;**159**:473–475. <https://doi.org/10.1001/archinte.159.5.473>
818. Deppisch LM, Fayemi AO. Non-bacterial thrombotic endocarditis: clinicopathologic correlations. *Am Heart J* 1976;**92**:723–729. [https://doi.org/10.1016/S0002-8703\(76\)80008-7](https://doi.org/10.1016/S0002-8703(76)80008-7)
819. Llenas-Garcia J, Guerra-Vales JM, Montes-Moreno S, Lopez-Rios F, Castelbon-Fernandez FJ, Chimen-Garcia J. [Nonbacterial thrombotic endocarditis: clinicopathologic study of a necropsy series]. *Rev Esp Cardiol* 2007;**60**:493–500. [https://doi.org/10.1016/S1885-5857\(07\)60190-X](https://doi.org/10.1016/S1885-5857(07)60190-X)
820. Lopez JA, Ross RS, Fishbein MC, Siegel RJ. Nonbacterial thrombotic endocarditis: a review. *Am Heart J* 1987;**113**:773–784. [https://doi.org/10.1016/0002-8703\(87\)90719-8](https://doi.org/10.1016/0002-8703(87)90719-8)
821. Quintero-Martinez JA, Hindy JR, El Zein S, Michelenia HI, Nkomo VT, DeSimone DC, et al. Contemporary demographics, diagnostics and outcomes in non-bacterial thrombotic endocarditis. *Heart* 2022. <https://doi.org/10.1136/heartjnl-2022-320970>
822. el-Shami K, Griffiths E, Streiff M. Nonbacterial thrombotic endocarditis in cancer patients: pathogenesis, diagnosis, and treatment. *Oncologist* 2007;**12**:518–523. <https://doi.org/10.1634/theoncologist.12-5-518>
823. Zmaili MA, Alzubi JM, Kocyyigit D, Bansal A, Samra GS, Grimm R, et al. A contemporary 20-year Cleveland clinic experience of nonbacterial thrombotic endocarditis: etiology, echocardiographic imaging, management, and outcomes. *Am J Med* 2021;**134**:361–369. <https://doi.org/10.1016/j.amjmed.2020.06.047>
824. Roldan CA, Tolstrup K, Macias L, Qualls CR, Maynard D, Charlton G, et al. Libman-sacks endocarditis: detection, characterization, and clinical correlates by three-dimensional transesophageal echocardiography. *J Am Soc Echocardiogr* 2015;**28**:770–779. <https://doi.org/10.1016/j.echo.2015.02.011>
825. Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffatti A, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. *Blood* 2018;**132**:1365–1371. <https://doi.org/10.1182/blood-2018-04-848333>
826. Kim K, Kim D, Lee S-E, Cho IJ, Shim CY, Hong G-R, et al. Infective endocarditis in cancer patients – causative organisms, predisposing procedures, and prognosis differ from infective endocarditis in non-cancer patients. *Circ J* 2019;**83**:452–460. <https://doi.org/10.1253/circj.CJ-18-0609>
827. Cosyns B, Roosens B, Lancellotti P, Laroche C, Dulgheru R, Scheggi V, et al. Cancer and infective endocarditis: characteristics and prognostic impact. *Front Cardiovasc Med* 2021;**8**:766996. <https://doi.org/10.3389/fcvm.2021.766996>
828. Kitson A, Marshall A, Bassett K, Zeitz K. What are the core elements of patient-centred care? A narrative review and synthesis of the literature from health policy, medicine and nursing. *J Adv Nurs* 2013;**69**:4–15. <https://doi.org/10.1111/j.1365-2648.2012.06064.x>
829. Giusti A, Nkhoma K, Petrus R, Petersen I, Gwyther L, Farrant L, et al. The empirical evidence underpinning the concept and practice of person-centred care for serious illness: a systematic review. *BMJ Glob Health* 2020;**5**:e003330. <https://doi.org/10.1136/bmjgh-2020-003330>
830. Ekman I, Swedberg K, Taft C, Lindseth A, Norberg A, Brink E, et al. Person-centered care—ready for prime time. *Eur J Cardiovasc Nurs* 2011;**10**:248–251. <https://doi.org/10.1016/j.ejcnurse.2011.06.008>
831. NEJM Catalyst. What is patient-centered care? *New Engl J Med* 2017;**3**.
832. Lauck SB, Lewis KB, Borregaard B, de Sousa I. “What is the right decision for me?” Integrating patient perspectives through shared decision-making for valvular heart disease therapy. *Can J Cardiol* 2021;**37**:1054–1063. <https://doi.org/10.1016/j.cjca.2021.02.022>
833. Oshima Lee E, Emanuel EJ. Shared decision making to improve care and reduce costs. *N Engl J Med* 2013;**368**:6–8. <https://doi.org/10.1056/NEJMp1209500>
834. Stacey D, Legare F, Lewis K, Barry MJ, Bennett CL, Eden KB, et al. Decision aids for people facing health treatment or screening decisions. *Cochrane Database Syst Rev* 2017;**4**:CD001431. <https://doi.org/10.1002/14651858.CD001431.pub5>
835. R EGAT. *Shared Decision Making in Health Care: Achieving Evidence-Based Patient Choice*. 3rd ed. Oxford University Press, 2016.
836. Carmona C, Crutwell J, Burnham M, Polak L, Guideline C. Shared decision-making: summary of NICE guidance. *BMJ* 2021;**373**:n1430. <https://doi.org/10.1136/bmj.n1430>
837. van de Pol MH, Fluit CR, Lagro J, Slaats YH, Olde Rikkert MG, Lagro-Janssen AL. Expert and patient consensus on a dynamic model for shared decision-making in frail older patients. *Patient Educ Couns* 2016;**99**:1069–1077. <https://doi.org/10.1016/j.pec.2015.12.014>
838. Chewning B, Bylund CL, Shah B, Arora NK, Gueguen JA, Makoul G. Patient preferences for shared decisions: a systematic review. *Patient Educ Couns* 2012;**86**:9–18. <https://doi.org/10.1016/j.pec.2011.02.004>
839. White DB, Angus DC, Shields AM, Buddadhumaruk P, Pidro C, Paner C, et al. A randomized trial of a family-support intervention in intensive care units. *N Engl J Med* 2018;**378**:2365–2375. <https://doi.org/10.1056/NEJMoa1802637>
840. Shay LA, Lafata JE. Where is the evidence? A systematic review of shared decision making and patient outcomes. *Med Decis Making* 2015;**35**:114–131. <https://doi.org/10.1177/0272989X14551638>
841. McMillan SS, Kendall E, Sav A, King MA, Whitty JA, Kelly F, et al. Patient-centered approaches to health care: a systematic review of randomized controlled trials. *Med Care Res Rev* 2013;**70**:567–596. <https://doi.org/10.1177/1077558713496318>
842. Hibbard JH, Greene J. What the evidence shows about patient activation: better health outcomes and care experiences; fewer data on costs. *Health Aff (Millwood)* 2013;**32**:207–214. <https://doi.org/10.1377/hlthaff.2012.1061>
843. Dwamena F, Holmes-Rovner M, Gauden CM, Jorgenson S, Sadigh G, Sikorskii A, et al. Interventions for providers to promote a patient-centred approach in clinical consultations. *Cochrane Database Syst Rev* 2012;**12**:CD003267. <https://doi.org/10.1002/14651858.CD003267.pub2>
844. Verhagen DW, Hermanides J, Korevaar JC, Bossuyt PM, van den Brink RB, Speelman P, et al. Health-related quality of life and posttraumatic stress disorder among survivors of left-sided native valve endocarditis. *Clin Infect Dis* 2009;**48**:1559–1565. <https://doi.org/10.1086/598930>
845. Berg SK, Preisler P, Pedersen BD. Patients perspective on endocarditis—an intermezzo in life. *Eur J Cardiovasc Nurs* 2010;**9**:126–131. <https://doi.org/10.1016/j.ejcnurse.2009.11.007>
846. Butt JH, Kragholm K, Dalager-Pedersen M, Rorth R, Kristensen SL, Chaudry MS, et al. Return to the workforce following infective endocarditis—a nationwide cohort study. *Am Heart J* 2018;**195**:130–138. <https://doi.org/10.1016/j.ahj.2017.09.009>
847. Havers-Borgersen E, Fosbol EL, Rorth R, Kragholm K, Kristensen SL, Bundgaard H, et al. Nursing home admission and initiation of domiciliary care following infective endocarditis. *Glob Heart* 2019;**14**:41–46.e2. <https://doi.org/10.1016/j.gheart.2019.01.002>
848. Wattel R. ESC involving patients: purpose & priorities. *Eur Heart J* 2018;**39**:3681. <https://doi.org/10.1093/eurheartj/ehy644>
849. Ulin K, Olsson LE, Wolf A, Ekman I. Person-centred care – an approach that improves the discharge process. *Eur J Cardiovasc Nurs* 2016;**15**:e19–e26. <https://doi.org/10.1177/1474515115569945>
850. Hill L, Prager Geller T, Baruah R, Beattie JM, Boyne J, de Stoutz N, et al. Integration of a palliative approach into heart failure care: a European Society of Cardiology Heart Failure Association position paper. *Eur J Heart Fail* 2020;**22**:2327–2339. <https://doi.org/10.1002/ehfj.1994>
851. D'Alto M, Budts W, Diller GP, Mulder B, Egidy Assenza G, Oretto L, et al. Does gender affect the prognosis and risk of complications in patients with congenital heart disease in the modern era? *Int J Cardiol* 2019;**290**:156–161. <https://doi.org/10.1016/j.ijcard.2019.05.010>
852. Weber C, Petrov G, Luehr M, Aubin H, Tugtekin SM, Borger MA, et al. Surgical results for prosthetic versus native valve endocarditis: a multicenter analysis. *J Thorac Cardiovasc Surg* 2021;**161**:609–619.e10. <https://doi.org/10.1016/j.jtcvs.2019.09.186>

853. Curlier E, Hoen B, Alla F, Selton-Suty C, Schubel L, Doco-Lecompte T, et al. Relationships between sex, early valve surgery and mortality in patients with left-sided infective endocarditis analysed in a population-based cohort study. *Heart* 2014;**100**: 1173–1178. <https://doi.org/10.1136/heartjnl-2013-304916>
854. Weber C, Gassa A, Rokohl A, Sabashnikov A, Deppe AC, Eghbalzadeh K, et al. Severity of presentation, not sex, increases risk of surgery for infective endocarditis. *Ann Thorac Surg* 2019;**107**:1111–1117. <https://doi.org/10.1016/j.athoracsur.2018.10.033>
855. Bansal A, Cremer PC, Jaber WA, Rampersad P, Menon V. Sex differences in the utilization and outcomes of cardiac valve replacement surgery for infective endocarditis: insights from the national inpatient sample. *J Am Heart Assoc* 2021;**10**:e020095. <https://doi.org/10.1161/JAHA.120.020095>
856. Varela Barca L, Vidal-Bonnet L, Farinas MC, Munoz P, Valerio Minero M, de Alarcon A, et al. Analysis of sex differences in the clinical presentation, management and prognosis of infective endocarditis in Spain. *Heart* 2021;**107**:1717–1724. <https://doi.org/10.1136/heartjnl-2021-319254>
857. Ahtela E, Oksi J, Porela P, Ekstrom T, Rautava P, Kyto V. Trends in occurrence and 30-day mortality of infective endocarditis in adults: population-based registry study in Finland. *BMJ Open* 2019;**9**:e026811. <https://doi.org/10.1136/bmjopen-2018-026811>